White	O
coat	O
effect	O
detected	O
using	O
self-monitoring	Physical
of	Physical
blood	Physical
pressure	Physical
at	Physical
home	Physical
:	O
comparison	O
with	O
ambulatory	O
blood	O
pressure	O
.	O

The	O
objective	O
of	O
the	O
study	O
was	O
to	O
investigate	O
whether	O
home	Physical
blood	Physical
pressure	Physical
(	Physical
HBP	Physical
)	Physical
is	O
a	O
reliable	O
alternative	O
to	O
ambulatory	Physical
blood	Physical
pressure	Physical
(	Physical
ABP	Physical
)	Physical
for	O
the	O
detection	O
of	O
the	O
white	O
coat	O
effect	O
(	O
WCE	O
)	O
.	O

Hypertensive	O
patients	O
were	O
randomized	O
to	O
measure	O
HBP	Physical
for	O
2	O
weeks	O
or	O
ABP	Physical
for	O
24	O
h.	O
The	O
alternative	O
measurement	O
was	O
then	O
performed	O
.	O

Clinic	O
blood	O
pressure	O
(	O
CBP	O
)	O
was	O
measured	O
in	O
the	O
beginning	O
and	O
end	O
of	O
the	O
study	O
.	O

Subjects	O
with	O
a	O
difference	O
of	O
>	O
or	O
=	O
20	O
mm	O
Hg	O
systolic	O
or	O
>	O
or	O
=	O
10	O
mm	O
Hg	O
diastolic	O
BP	O
between	O
CBP	O
and	O
awake	O
ABP	Physical
or	O
CBP	O
and	O
HBP	Physical
,	O
were	O
classified	O
as	O
clinic	O
reactors	O
.	O

A	O
total	O
of	O
189	O
patients	O
completed	O
the	O
study	O
(	O
79	O
on	O
stable	O
antihypertensive	O
treatment	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
magnitude	O
of	O
WCE	O
assessed	O
using	O
the	O
ABP	Physical
or	O
the	O
HBP	Physical
method	O
(	O
mean	O
discrepancy	O
,	O
systolic	O
BP	O
:	O
-1.5	O
+/-	O
11.7	O
mm	O
Hg	O
,	O
95	O
%	O
CI	O
-3.2	O
,	O
0.2	O
;	O
diastolic	O
BP	O
:	O
0.9	O
+/-	O
7.0	O
,	O
95	O
%	O
CI	O
-0.1	O
,	O
1.9	O
)	O
.	O

A	O
strong	O
association	O
existed	O
between	O
WCE	O
calculated	O
using	O
the	O
HBP	O
or	O
the	O
ABP	Physical
method	O
(	O
r	O
=	O
0.64/0.59	O
systolic/diastolic	O
,	O
P	O
<	O
.001	O
)	O
.	O

The	O
proportion	O
of	O
patients	O
classified	O
as	O
clinic	O
reactors	O
was	O
identical	O
using	O
the	O
HBP	Physical
or	O
the	O
ABP	Physical
method	O
(	O
25.9	O
%	O
)	O
.	O

Agreement	O
between	O
methods	O
in	O
the	O
classification	O
of	O
clinic	O
reactors	O
was	O
found	O
in	O
147	O
patients	O
(	O
78	O
%	O
)	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
HBP	Physical
method	O
to	O
classify	O
correctly	O
clinic	O
reactors	O
(	O
ABP	Physical
method	O
used	O
as	O
the	O
standard	O
)	O
were	O
57	O
%	O
and	O
85	O
%	O
,	O
respectively	O
,	O
whereas	O
its	O
positive	O
and	O
negative	O
predictive	O
value	O
were	O
57	O
%	O
and	O
85	O
%	O
.	O

These	O
results	O
indicate	O
that	O
HBP	Physical
is	O
not	O
appropriate	O
as	O
an	O
alternative	O
to	O
ABP	Physical
diagnostic	O
testing	O
in	O
the	O
detection	O
of	O
WCE	O
.	O

Nevertheless	O
,	O
HBP	Physical
appears	O
useful	O
as	O
a	O
screening	O
test	O
for	O
the	O
detection	O
of	O
this	O
phenomenon	O
.	O

Optimization	O
of	O
acid	O
suppression	O
for	O
patients	O
with	O
peptic	O
ulcer	O
bleeding	O
:	O
an	O
intragastric	O
pH-metry	O
study	O
with	O
omeprazole	Pharmacological
.	Pharmacological

OBJECTIVE	O
To	O
study	O
whether	O
an	O
intravenous	O
infusion	O
dose	O
of	O
omeprazole	Pharmacological
(	O
80	O
mg	O
+	O
8	O
mg/h	O
)	O
during	O
24	O
h	O
can	O
be	O
subsequently	O
reduced	O
with	O
maintained	O
effect	O
.	O

Second	O
,	O
to	O
study	O
the	O
effect	O
of	O
oral	O
omeprazole	Pharmacological
20	O
mg	O
given	O
once	O
or	O
twice	O
daily	O
up	O
to	O
day	O
10	O
,	O
after	O
cessation	O
of	O
a	O
3-day	O
intravenous	O
infusion	O
(	O
80	O
mg	O
+	O
8	O
mg/h	O
)	O
.	O

DESIGN	O
Prospective	O
,	O
randomized	O
,	O
partly	O
blinded	O
study	O
.	O

METHODS	O
Twelve	O
Helicobacter	O
pylori	O
(	O
+	O
)	O
patients	O
and	O
12	O
H.	O
pylori	O
(	O
-	O
)	O
subjects	O
were	O
included	O
.	O

In	O
part	O
I	O
the	O
patients	O
received	O
omeprazole	Pharmacological
,	O
80	O
mg	O
+	O
8	O
mg/h	O
,	O
during	O
24	O
h	O
followed	O
by	O
8	O
,	O
4	O
or	O
2	O
mg/h	O
.	O

In	O
part	O
II	O
the	O
subjects	O
received	O
80	O
mg	O
+	O
8	O
mg/h	O
during	O
3	O
days	O
followed	O
by	O
20	O
mg	O
omeprazole	Pharmacological
orally	O
,	O
once	O
or	O
twice	O
daily	O
until	O
day	O
10	O
.	O

Intragastric	O
pH	O
was	O
measured	O
.	O

RESULTS	O
All	O
H.	O
pylori	O
(	O
+	O
)	O
patients	O
showed	O
a	O
rapid	O
increase	O
of	O
intragastric	O
pH	O
with	O
a	O
mean	O
intragastric	O
pH	O
of	O
6.7	O
during	O
the	O
second	O
half	O
of	O
the	O
first	O
day	O
.	O

After	O
the	O
subsequent	O
dose	O
reduction	O
,	O
the	O
mean	O
pH	O
decreased	O
to	O
6.1-6.2	O
.	O

Patients	O
continuing	O
on	O
8	O
mg/h	O
showed	O
the	O
best	O
results	O
.	O

Likewise	O
,	O
all	O
H.	O
pylori	O
(	O
-	O
)	O
subjects	O
showed	O
a	O
rapid	O
and	O
sustained	O
reduction	O
of	O
intragastric	O
acidity	O
during	O
the	O
infusion	O
.	O

Subsequent	O
dose	O
reduction	O
to	O
20	O
mg	O
once	O
daily	O
led	O
to	O
a	O
stable	O
fraction	O
of	O
time	O
with	O
pH	O
>	O
3	O
of	O
72	O
%	O
.	O

CONCLUSIONS	O
Omeprazole	Pharmacological
given	O
as	O
a	O
continuous	O
infusion	O
of	O
80	O
mg	O
+	O
8	O
mg/h	O
for	O
72	O
h	O
followed	O
by	O
omeprazole	Pharmacological
20	O
mg	O
once	O
daily	O
raised	O
the	O
intragastric	O
pH	O
to	O
and	O
above	O
levels	O
alleged	O
to	O
allow	O
haemostasis	O
in	O
patients	O
with	O
peptic	O
ulcer	O
bleeding	O
and	O
subsequent	O
healing	O
of	O
the	O
ulcer	O
.	O

Learning	O
about	O
the	O
equal	O
sign	O
:	O
does	O
comparing	O
with	O
inequality	O
symbols	O
help	O
?	O
This	O
study	O
investigated	O
whether	O
instruction	Other
that	Other
involves	Other
comparing	Other
the	Other
equal	Psychological
sign	Psychological
with	Other
other	Other
relational	Other
symbols	Other
is	O
more	O
effective	O
at	O
imparting	O
a	O
relational	O
interpretation	O
of	O
the	O
equal	Psychological
sign	Psychological
than	O
instruction	Other
about	Other
the	Other
equal	Psychological
sign	Psychological
alone	Other
.	O

Third-	O
and	O
fourth-grade	O
students	O
in	O
a	O
comparing	Educational
symbols	Educational
group	Educational
learned	Educational
about	Educational
the	Educational
greater	Educational
than	Educational
,	Educational
less	Educational
than	Educational
,	Educational
and	Educational
equal	Psychological
signs	Psychological
and	Educational
had	Educational
the	Educational
opportunity	Educational
to	Educational
compare	Educational
the	Educational
inequality	Educational
symbols	Educational
with	Educational
the	Educational
equal	Psychological
sign	Psychological
.	O

Students	O
in	O
an	O
equal	Psychological
sign	Psychological
group	Educational
learned	Educational
about	Educational
the	Educational
equal	Psychological
sign	Psychological
only	Educational
.	Educational

A	O
third	O
group	O
of	O
students	O
served	O
as	O
a	O
control	Control
group	Control
.	O

Three	O
aspects	O
of	O
students	O
'	O
knowledge	O
were	O
assessed	O
before	O
and	O
after	O
the	O
lesson	O
:	O
(	O
a	O
)	O
conceptual	O
understanding	O
of	O
the	O
equal	O
sign	O
,	O
(	O
b	O
)	O
equation	O
encoding	O
,	O
and	O
(	O
c	O
)	O
problem	O
solving	O
.	O

Students	O
in	O
the	O
comparing	O
symbols	O
group	O
showed	O
greater	O
gains	O
in	O
conceptual	O
understanding	O
from	O
pretest	O
to	O
posttest	O
than	O
students	O
in	O
the	O
other	O
two	O
groups	O
,	O
and	O
students	O
in	O
the	O
comparing	O
symbols	O
group	O
also	O
scored	O
higher	O
on	O
a	O
posttest	O
that	O
assessed	O
knowledge	O
about	O
inequality	O
symbols	O
and	O
inequality	O
problem	O
solving	O
.	O

Thus	O
,	O
they	O
learned	O
about	O
three	O
symbols	O
in	O
the	O
same	O
amount	O
of	O
time	O
as	O
other	O
students	O
learned	O
about	O
the	O
equal	O
sign	O
alone	O
or	O
not	O
at	O
all	O
.	O

Therefore	O
,	O
an	O
instructional	O
approach	O
involving	O
comparison	O
can	O
be	O
an	O
effective	O
tool	O
for	O
learning	O
about	O
concepts	O
in	O
mathematics	O
.	O

Shorter	O
treatment	O
for	O
vaginal	O
candidosis	O
:	O
comparison	O
between	O
single-dose	O
oral	O
fluconazole	Pharmacological
and	O
three-day	O
treatment	O
with	O
local	O
miconazole	Pharmacological
.	Pharmacological

Fluconazole	Pharmacological
is	O
an	O
effective	O
,	O
simple	O
and	O
safe	O
,	O
although	O
slightly	O
expensive	O
,	O
agent	O
for	O
the	O
treatment	O
of	O
vaginal	O
candidosis	O
.	O

Single-dose	O
fluconazole	Pharmacological
(	O
150	O
mg	O
)	O
administered	O
orally	O
in	O
capsule	O
form	O
was	O
compared	O
with	O
three-day	O
local	O
treatment	O
with	O
miconazole	Pharmacological
pessaries	O
in	O
the	O
treatment	O
of	O
vaginal	O
candidosis	O
in	O
a	O
randomized	O
study	O
in	O
Finland	O
.	O

Cure	O
rates	O
were	O
good	O
(	O
>	O
80	O
%	O
)	O
in	O
randomized	O
patient	O
groups	O
assessed	O
both	O
clinically	O
and	O
by	O
the	O
results	O
of	O
yeast	O
cultures	O
.	O

Oral	O
administration	O
was	O
preferred	O
to	O
local	O
therapy	O
by	O
patients	O
in	O
both	O
the	O
miconazole	Pharmacological
and	O
fluconazole	Pharmacological
groups	O
.	O

For	O
the	O
time	O
being	O
,	O
fluconazole	Pharmacological
is	O
not	O
recommended	O
for	O
use	O
during	O
pregnancy	O
or	O
lactation	O
.	O

Maternal	O
breast-milk	O
and	O
intestinal	O
bifidobacteria	O
guide	O
the	O
compositional	O
development	O
of	O
the	O
Bifidobacterium	O
microbiota	O
in	O
infants	O
at	O
risk	O
of	O
allergic	O
disease	O
.	O

BACKGROUND	O
The	O
sources	O
and	O
the	O
impact	O
of	O
maternal	O
bacteria	O
on	O
the	O
initial	O
inoculum	O
of	O
the	O
intestinal	O
microflora	O
of	O
newborn	O
infants	O
remain	O
elusive	O
.	O

OBJECTIVE	O
To	O
assess	O
the	O
association	O
between	O
maternal	O
breast-milk	O
and	O
fecal	O
bifidobacteria	O
and	O
infants	O
'	O
fecal	O
bifidobacteria	O
.	O

METHODS	O
Sixty-one	O
mother-infant	O
pairs	O
were	O
included	O
,	O
special	O
emphasis	O
being	O
placed	O
on	O
the	O
maternal	O
allergic	O
status	O
.	O

Bifidobacteria	O
were	O
analysed	O
by	O
a	O
direct	O
PCR	O
method	O
in	O
fecal	O
samples	O
from	O
mothers	O
at	O
30-35	O
weeks	O
of	O
gestation	O
and	O
from	O
infants	O
at	O
1	O
month	O
of	O
age	O
and	O
from	O
breast-milk	Physical
samples	Physical
1	O
month	O
post-partum	O
.	O

RESULTS	O
Fecal	O
Bifidobacterium	O
adolescentis	O
and	O
Bifidobacterium	O
bifidum	O
colonization	O
frequencies	O
and	O
counts	O
among	O
mother-infant	O
pairs	O
correlated	O
significantly	O
(	O
P=0.005	O
and	O
0.02	O
for	O
frequencies	O
,	O
respectively	O
,	O
and	O
P=0.002	O
and	O
0.01	O
for	O
counts	O
,	O
respectively	O
)	O
.	O

Only	O
infants	O
of	O
allergic	O
,	O
atopic	O
mothers	O
were	O
colonized	O
with	O
B.	O
adolescentis	O
.	O

Each	O
of	O
the	O
breast-milk	O
samples	O
contained	O
bifidobacteria	O
[	O
median	O
1.4	O
x	O
10	O
(	O
3	O
)	O
bacterial	O
cells/mL	O
;	O
interquartile	O
range	O
(	O
IQR	O
)	O
48.7-3.8	O
x	O
10	O
(	O
3	O
)	O
]	O
.	O

Bifidobacterium	O
longum	O
was	O
the	O
most	O
frequently	O
detected	O
species	O
in	O
breast-milk	O
.	O

Allergic	O
mothers	O
had	O
significantly	O
lower	O
amounts	O
of	O
bifidobacteria	O
in	O
breast-milk	O
compared	O
with	O
non-allergic	O
mothers	O
[	O
median	O
1.3	O
x	O
10	O
(	O
3	O
)	O
bacterial	O
cells/mL	O
(	O
IQR	O
22.4-3.0	O
x	O
10	O
(	O
3	O
)	O
)	O
vs.	O
5.6	O
x	O
10	O
(	O
3	O
)	O
bacterial	O
cells/mL	O
(	O
1.8	O
x	O
10	O
(	O
3	O
)	O
-1.8	O
x	O
10	O
(	O
4	O
)	O
)	O
,	O
respectively	O
,	O
(	O
P=0.004	O
)	O
]	O
,	O
and	O
their	O
infants	O
had	O
concurrently	O
lower	O
counts	O
of	O
bifidobacteria	O
in	O
feces	O
[	O
3.9	O
x	O
10	O
(	O
8	O
)	O
bacterial	O
cells/g	O
(	O
IQR	O
6.5	O
x	O
10	O
(	O
6	O
)	O
-1.5	O
x	O
10	O
(	O
9	O
)	O
)	O
in	O
infants	O
of	O
allergic	O
mothers	O
,	O
vs.	O
2.5	O
x	O
10	O
(	O
9	O
)	O
bacterial	O
cells/g	O
(	O
6.5	O
x	O
10	O
(	O
8	O
)	O
-3.2	O
x	O
10	O
(	O
10	O
)	O
)	O
in	O
infants	O
of	O
non-allergic	O
mothers	O
,	O
P=0.013	O
]	O
.	O

CONCLUSIONS	O
Breast-milk	O
contains	O
significant	O
numbers	O
of	O
bifidobacteria	O
and	O
the	O
maternal	O
allergic	O
status	O
further	O
deranges	O
the	O
counts	O
of	O
bifidobacteria	O
in	O
breast-milk	O
.	O

Maternal	O
fecal	O
and	O
breast-milk	O
bifidobacterial	O
counts	O
impacted	O
on	O
the	O
infants	O
'	O
fecal	O
Bifidobacterium	O
levels	O
.	O

Breast-milk	O
bacteria	O
should	O
thus	O
be	O
considered	O
an	O
important	O
source	O
of	O
bacteria	O
in	O
the	O
establishment	O
of	O
infantile	O
intestinal	O
microbiota	O
.	O

Hydrogen	Pharmacological
peroxide	Pharmacological
mouth	Pharmacological
rinse	Pharmacological
:	O
an	O
analgesic	O
post-tonsillectomy	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
analgesic	O
efficacy	O
of	O
hydrogen	Pharmacological
peroxide	Pharmacological
(	Pharmacological
H2O2	Pharmacological
)	Pharmacological
mouth	Pharmacological
rinse	Pharmacological
with	O
control	Control
for	O
post-tonsillectomy	O
pain	O
management	O
.	O

DESIGN	O
Double-blinded	O
,	O
prospective	O
,	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
.	O

PATIENTS	O
AND	O
METHODS	O
Thirty-seven	O
patients	O
from	O
5	O
to	O
14	O
years	O
old	O
undergoing	O
electrocautery	Surgical
tonsillectomy	Surgical
were	O
randomized	O
to	O
either	O
the	O
H2O2	Pharmacological
mouth	Pharmacological
rinse	Pharmacological
or	O
the	O
water	Control
rinse	Control
(	Control
control	Control
)	Control
group	Control
.	O

For	O
14	O
days	O
,	O
patients	O
recorded	O
pain	O
levels	O
twice	O
daily	O
using	O
a	O
visual	O
analogue	O
scale	O
.	O

Analgesic	O
uses	O
,	O
as	O
well	O
as	O
any	O
complications	O
,	O
were	O
also	O
noted	O
by	O
the	O
patients	O
.	O

RESULTS	O
Thirty-seven	O
patients	O
completed	O
the	O
study	O
,	O
21	O
in	O
the	O
treatment	O
group	O
and	O
16	O
in	O
the	O
control	O
group	O
.	O

Mean	O
postoperative	O
days	O
of	O
pain	O
were	O
10.3	O
and	O
8.3	O
,	O
respectively	O
,	O
and	O
differed	O
significantly	O
(	O
p	O
=	O
.008	O
)	O
.	O

Mean	O
postoperative	O
days	O
of	O
analgesic	O
use	O
were	O
9.0	O
and	O
6.7	O
,	O
respectively	O
,	O
and	O
differed	O
significantly	O
(	O
p	O
=	O
.005	O
)	O
.	O

Only	O
one	O
incidence	O
of	O
postoperative	O
hemorrhage	O
occurred	O
in	O
the	O
study	O
group	O
.	O

CONCLUSION	O
In	O
our	O
study	O
,	O
the	O
H2O2	Pharmacological
mouth	Pharmacological
rinse	Pharmacological
does	O
not	O
provide	O
a	O
better	O
analgesic	O
effect	O
than	O
the	O
water	O
rinse	O
for	O
post-tonsillectomy	O
pain	O
relief	O
.	O

Oral	O
health	O
impacts	O
on	O
daily	O
living	O
related	O
to	O
four	O
different	O
treatment	O
protocols	O
for	O
chronic	O
periodontitis	O
.	O

BACKGROUND	O
The	O
aims	O
of	O
this	O
study	O
were	O
to	O
evaluate	O
the	O
oral	O
health	O
impacts	O
perceived	O
by	O
patients	O
submitted	O
to	O
different	O
treatments	O
of	O
chronic	O
periodontitis	O
and	O
their	O
association	O
with	O
clinical	O
parameters	O
.	O

METHODS	O
Sixty	O
patients	O
were	O
assigned	O
to	O
one	O
of	O
the	O
following	O
therapeutic	O
groups	O
:	O
control	O
,	O
treated	O
with	O
full-mouth	Physical
scaling	Physical
and	O
root	Physical
planing	Physical
(	Physical
SRP	Physical
)	Physical
;	O
test	O
1	O
,	O
treated	O
with	O
SRP	Surgical
and	O
400	O
mg	O
systemically	O
administered	O
metronidazole	Pharmacological
(	O
MET	O
)	O
three	O
times	O
per	O
day	O
for	O
10	O
days	O
;	O
test	O
2	O
,	O
treated	O
with	O
SRP	Physical
and	O
professional	Physical
supragingival	Physical
plaque	Physical
removal	Physical
(	Physical
PP	Physical
)	Physical
every	O
week	O
for	O
3	O
months	O
;	O
and	O
test	O
3	O
,	O
treated	O
with	O
SRP	Surgical
and	O
MET	Pharmacological
plus	O
PP	O
.	O

Clinical	O
periodontal	O
measurements	O
and	O
data	O
regarding	O
patients	O
'	O
oral	O
health	O
impacts	O
(	O
perceived	O
impacts	O
on	O
bleeding	O
gums	O
,	O
gingival	O
recession	O
,	O
sensitivity	O
to	O
cold	O
,	O
packing	O
foods	O
,	O
aesthetics	O
,	O
bad	O
breath	O
,	O
and	O
tooth	O
mobility	O
)	O
were	O
collected	O
at	O
baseline	O
and	O
3	O
months	O
after	O
therapy	O
.	O

RESULTS	O
All	O
groups	O
presented	O
significant	O
improvement	O
in	O
oral	O
health	O
perceived	O
impacts	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
the	O
improvement	O
of	O
oral	O
health	O
impacts	O
among	O
groups	O
subjected	O
to	O
different	O
treatments	O
.	O

The	O
clinical	O
data	O
of	O
percentage	O
of	O
deep	O
probing	O
depth	O
,	O
deep	O
clinical	O
attachment	O
level	O
,	O
and	O
bleeding	O
on	O
probing	O
were	O
found	O
to	O
be	O
correlated	O
significantly	O
with	O
oral	O
health	O
impacts	O
.	O

CONCLUSIONS	O
Periodontal	Physical
treatment	Physical
leads	O
to	O
a	O
significant	O
reduction	O
of	O
self-perceived	O
impacts	O
regardless	O
of	O
the	O
non-surgical	O
treatment	O
protocol	O
employed	O
.	O

Most	O
of	O
the	O
clinical	O
data	O
were	O
associated	O
with	O
oral	O
health	O
impacts	O
.	O

Randomized	O
trial	O
of	O
fenretinide	Pharmacological
in	O
superficial	O
bladder	O
cancer	O
using	O
DNA	O
flow	O
cytometry	O
as	O
an	O
intermediate	O
end	O
point	O
.	O

Retinoids	O
have	O
shown	O
a	O
potential	O
activity	O
in	O
preventing	O
tumor	O
recurrence	O
in	O
superficial	O
bladder	O
cancer	O
.	O

We	O
assessed	O
the	O
activity	O
of	O
the	O
synthetic	Pharmacological
retinoid	Pharmacological
fenretinide	Pharmacological
in	O
superficial	O
bladder	O
cancer	O
using	O
DNA	O
flow	O
cytometry	O
and	O
conventional	O
cytology	O
as	O
surrogate	O
biomarkers	O
.	O

A	O
total	O
of	O
99	O
subjects	O
with	O
resected	O
superficial	O
bladder	O
cancer	O
(	O
pTa	O
,	O
pT1	O
)	O
were	O
randomized	O
to	O
either	O
fenretinide	Pharmacological
(	O
200	O
mg	O
day	O
p.o	O
.	O

for	O
24	O
months	O
)	O
or	O
no	Control
intervention	Control
.	O

Cystoscopy	O
and	O
bladder	O
washing	O
for	O
DNA	O
flow	O
cytometry	O
end	O
points	O
(	O
proportion	O
of	O
DNA	O
aneuploid	O
histograms	O
,	O
hyperdiploid	O
fraction	O
,	O
and	O
percentage	O
of	O
apoptotic	O
cells	O
)	O
and	O
proportion	O
of	O
abnormal	O
cytological	O
examinations	O
were	O
repeated	O
every	O
4	O
months	O
for	O
up	O
to	O
36	O
months	O
.	O

The	O
primary	O
study	O
end	O
point	O
was	O
the	O
proportion	O
of	O
DNA	O
aneuploid	O
histograms	O
after	O
12	O
months	O
.	O

This	O
figure	O
was	O
48.9	O
%	O
in	O
the	O
fenretinide	Pharmacological
arm	O
and	O
41.9	O
%	O
in	O
the	O
control	O
arm	O
(	O
odds	O
ratio	O
,	O
1.16	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.44-3.07	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
any	O
other	O
response	O
biomarker	O
between	O
the	O
two	O
groups	O
up	O
to	O
36	O
months	O
,	O
nor	O
was	O
any	O
biomarker	O
able	O
to	O
predict	O
recurrence	O
risk	O
.	O

Recurrence-free	O
survival	O
was	O
comparable	O
between	O
the	O
arms	O
(	O
27	O
events	O
in	O
the	O
fenretinide	O
arm	O
versus	O
21	O
in	O
the	O
control	O
arm	O
;	O
P	O
=	O
0.36	O
)	O
.	O

Twelve	O
subjects	O
in	O
the	O
fenretinide	O
arm	O
complained	O
of	O
diminished	O
dark	O
adaptability	O
,	O
and	O
nine	O
subjects	O
in	O
the	O
fenretinide	O
arm	O
versus	O
one	O
control	O
subject	O
had	O
mild	O
dermatological	O
alterations	O
.	O

We	O
conclude	O
that	O
fenretinide	O
showed	O
a	O
lack	O
of	O
effect	O
on	O
the	O
DNA	O
content	O
distribution	O
and	O
the	O
morphology	O
of	O
urothelial	O
cells	O
obtained	O
in	O
serial	O
bladder	O
washings	O
.	O

Recurrence-free	O
survival	O
was	O
comparable	O
between	O
groups	O
.	O

Because	O
our	O
data	O
are	O
hampered	O
by	O
the	O
lack	O
of	O
predictivity	O
of	O
the	O
selected	O
biomarkers	O
,	O
additional	O
studies	O
are	O
necessary	O
to	O
assess	O
the	O
activity	O
of	O
fenretinide	O
in	O
preventing	O
bladder	O
cancer	O
.	O

Partial	O
depletion	O
of	O
tissue	O
factor	O
pathway	O
inhibitor	O
during	O
subcutaneous	O
administration	O
of	O
unfractionated	O
heparin	Pharmacological
,	O
but	O
not	O
with	O
two	O
low	O
molecular	O
weight	O
heparins	O
.	O

Tissue	O
factor	O
pathway	O
inhibitor	O
(	O
TFPI	O
)	O
is	O
released	O
to	O
circulating	O
blood	O
after	O
intravenous	O
(	O
i.v	O
.	O

)	O
and	O
subcutaneous	O
(	O
s.c.	O
)	O
injections	O
of	O
heparins	O
,	O
and	O
may	O
thus	O
contribute	O
to	O
the	O
antithrombotic	O
effect	O
of	O
heparins	O
.	O

We	O
have	O
recently	O
shown	O
that	O
total	O
TFPI	O
activity	O
,	O
plasma	O
free	O
TFPI	O
antigen	O
,	O
and	O
heparin	O
releasable	O
TFPI	O
were	O
partially	O
depleted	O
during	O
repeated	O
and	O
continuous	O
i.v	O
.	O

infusion	O
of	O
unfractionated	Pharmacological
heparin	Pharmacological
(	O
UFH	O
)	O
,	O
but	O
not	O
during	O
s.c.	O
treatment	O
with	O
a	O
low	O
molecular	O
weight	O
heparin	O
(	O
LMWH	O
)	O
.	O

The	O
difference	O
may	O
be	O
attributed	O
to	O
a	O
different	O
mode	O
of	O
action	O
or	O
the	O
different	O
mode	O
of	O
administration	O
.	O

In	O
the	O
present	O
randomized	O
cross-over	O
study	O
,	O
s.c.	O
administration	O
of	O
therapeutic	O
doses	O
of	O
UFH	Pharmacological
was	O
compared	O
with	O
s.c.	O
administration	O
of	O
two	O
LMWHs	Pharmacological
.	O

12	O
healthy	O
male	O
volunteers	O
were	O
treated	O
for	O
3	O
d	O
with	O
UFH	Pharmacological
,	O
250	O
U/kg	O
twice	O
daily	O
,	O
dalteparin	Pharmacological
,	O
200	O
U/kg	O
once	O
daily	O
,	O
and	O
enoxaparin	Pharmacological
,	O
1.5	O
mg/kg	O
once	O
daily	O
.	O

Six	O
participants	O
were	O
also	O
treated	O
with	O
UFH	Pharmacological
,	O
300	O
U/kg	O
once	O
daily	O
.	O

On	O
day	O
5	O
a	O
single	O
dose	O
of	O
either	O
drug	O
was	O
given	O
.	O

Peak	O
levels	O
of	O
total	O
TFPI	O
activity	O
and	O
free	O
TFPI	O
antigen	O
were	O
detected	O
1	O
h	O
after	O
injection	O
,	O
whereas	O
maximal	O
prolongation	O
of	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
APTT	O
)	O
and	O
peak	O
levels	O
of	O
anti-factor	O
Xa	O
activity	O
and	O
anti-factor	O
IIa	O
activity	O
were	O
detected	O
after	O
4	O
h.	O
On	O
UFH	Pharmacological
administered	O
twice	O
daily	O
,	O
free	O
TFPI	O
antigen	O
decreased	O
by	O
44	O
%	O
from	O
baseline	O
level	O
before	O
the	O
first	O
injection	O
on	O
day	O
1	O
to	O
pre-injection	O
level	O
on	O
day	O
5	O
.	O

On	O
UFH	Pharmacological
administered	O
once	O
daily	O
,	O
basal	O
free	O
TFPI	O
antigen	O
decreased	O
by	O
50	O
%	O
,	O
56	O
%	O
and	O
27	O
%	O
on	O
day	O
2	O
,	O
3	O
and	O
5	O
respectively	O
,	O
compared	O
with	O
day	O
1	O
.	O

Minimal	O
depletion	O
of	O
TFPI	O
was	O
detected	O
during	O
treatment	O
with	O
LMWHs	O
.	O

The	O
study	O
demonstrates	O
the	O
different	O
modes	O
of	O
action	O
of	O
LMWHs	Pharmacological
and	O
UFH	Pharmacological
and	O
may	O
help	O
to	O
explain	O
the	O
superior	O
antithrombotic	O
efficacy	O
of	O
LMWHs	O
.	O

Hip	Physical
protectors	Physical
improve	O
falls	O
self-efficacy	O
.	O

OBJECTIVES	O
To	O
investigate	O
the	O
effect	O
of	O
use	O
of	O
external	Physical
hip	Physical
protectors	Physical
on	O
subjects	O
'	O
fear	O
of	O
falling	O
and	O
falls	O
self-efficacy	O
(	O
belief	O
in	O
their	O
own	O
ability	O
to	O
avoid	O
falling	O
)	O
.	O

DESIGN	O
Randomized	O
controlled	O
trial	O
.	O

SETTING	O
Aged-care	O
health	O
services	O
in	O
Sydney	O
,	O
Australia	O
.	O

PARTICIPANTS	O
131	O
women	O
aged	O
75	O
years	O
or	O
older	O
,	O
who	O
had	O
two	O
or	O
more	O
falls	O
or	O
one	O
fall	O
requiring	O
hospital	O
admission	O
in	O
the	O
previous	O
year	O
and	O
who	O
live	O
at	O
home	O
.	O

Sixty-one	O
subjects	O
were	O
in	O
the	O
intervention	O
group	O
and	O
70	O
in	O
the	O
control	Control
group	O
.	O

INTERVENTION	O
Use	O
of	O
external	Physical
hip	Physical
protectors	Physical
and	O
encouragement	Physical
to	Physical
use	Physical
the	Physical
protectors	Physical
by	Physical
an	Physical
adherence	Physical
nurse	Physical
.	O

MEASUREMENTS	O
At	O
the	O
time	O
of	O
enrolment	O
into	O
a	O
wider	O
study	O
examining	O
the	O
effect	O
of	O
hip	Physical
protectors	Physical
on	O
hip	O
fractures	O
,	O
participants	O
recruited	O
at	O
home	O
completed	O
an	O
assessment	O
of	O
fear	O
of	O
falling	O
and	O
falls	O
efficacy	O
as	O
measured	O
by	O
the	O
Falls	O
Efficacy	O
Scale	O
and	O
the	O
Modified	O
Falls	O
Efficacy	O
Scale	O
.	O

At	O
4-month	O
follow-up	O
,	O
these	O
scales	O
were	O
readministered	O
by	O
an	O
observer	O
who	O
was	O
not	O
aware	O
of	O
the	O
allocation	O
of	O
the	O
participant	O
to	O
intervention	O
or	O
control	O
groups	O
.	O

RESULTS	O
Fear	O
of	O
falling	O
and	O
falls	O
self-efficacy	O
,	O
as	O
measured	O
by	O
the	O
Falls	O
Efficacy	O
and	O
Modified	O
Falls	O
Efficacy	O
Scales	O
,	O
were	O
similar	O
at	O
baseline	O
in	O
both	O
groups	O
.	O

Fear	O
of	O
falling	O
was	O
present	O
at	O
follow-up	O
in	O
43	O
%	O
of	O
subjects	O
using	O
hip	O
protectors	O
and	O
57	O
%	O
of	O
the	O
control	O
group	O
(	O
chi2	O
=	O
2.58	O
,	O
P	O
=	O
0.11	O
)	O
.	O

Hip	Physical
protector	Physical
users	O
had	O
greater	O
improvement	O
in	O
falls	O
self-efficacy	O
at	O
follow-up	O
as	O
measured	O
by	O
the	O
Falls	O
Efficacy	O
Scale	O
(	O
t	O
=	O
2.44	O
,	O
P	O
=	O
0.016	O
)	O
and	O
the	O
Modified	O
Falls	O
Efficacy	O
Scale	O
(	O
t	O
=	O
2.08	O
,	O
P	O
=	O
0.039	O
)	O
.	O

CONCLUSION	O
Hip	Physical
protectors	Physical
improve	O
falls	O
self-efficacy	O
.	O

As	O
users	O
of	O
hip	Physical
protectors	Physical
feel	O
more	O
confident	O
that	O
they	O
can	O
complete	O
tasks	O
safely	O
,	O
they	O
may	O
become	O
more	O
physically	O
active	O
and	O
require	O
less	O
assistance	O
with	O
activities	O
of	O
daily	O
living	O
.	O

Relation	O
of	O
total	O
homocysteine	O
and	O
lipid	O
levels	O
in	O
children	O
to	O
premature	O
cardiovascular	O
death	O
in	O
male	O
relatives	O
.	O

We	O
assessed	O
the	O
relative	O
importance	O
of	O
lipid	O
,	O
apo	O
B	O
,	O
lipoprotein	O
(	O
a	O
)	O
[	O
Lp	O
(	O
a	O
)	O
]	O
,	O
and	O
total	O
homocysteine	O
(	O
tHcy	O
)	O
levels	O
in	O
children	O
in	O
relation	O
to	O
premature	O
cardiovascular	O
disease	O
in	O
family	O
members	O
.	O

Parents	O
of	O
381	O
girls	O
and	O
375	O
boys	O
age	O
8-12	O
y	O
completed	O
family	Other
history	Other
questionnaires	Other
.	Other

Nonfasting	O
serum	O
lipid	O
and	O
lipoproteins	O
and	O
plasma	O
tHcy	O
and	O
cysteine	O
levels	O
were	O
measured	O
in	O
the	O
children	O
.	O

Serum	O
folate	O
and	O
vitamin	O
B12	O
levels	O
were	O
determined	O
in	O
a	O
random	O
subsample	O
of	O
23	O
%	O
of	O
the	O
children	O
,	O
who	O
participated	O
in	O
a	O
food	O
frequency	O
interview	O
.	O

Children	O
whose	O
parents	O
reported	O
hypercholesterolemia	O
had	O
higher	O
total	O
and	O
non-HDL	O
cholesterol	O
and	O
apo	O
B	O
levels	O
than	O
the	O
rest	O
,	O
but	O
these	O
levels	O
were	O
not	O
associated	O
with	O
cardiovascular	O
disease	O
.	O

tHcy	O
levels	O
were	O
similar	O
in	O
girls	O
and	O
boys	O
.	O

tHcy	O
was	O
higher	O
in	O
children	O
whose	O
father	O
,	O
grandfather	O
,	O
or	O
uncle	O
died	O
at	O
age	O
<	O
or	O
=	O
55	O
y	O
of	O
myocardial	O
infarction	O
or	O
sudden	O
cardiac	O
arrest	O
(	O
n	O
=	O
42	O
)	O
than	O
in	O
control	O
children	O
[	O
5.92	O
mumol/L	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
of	O
5.47-6.36	O
)	O
versus	O
5.25	O
mumol/L	O
(	O
95	O
%	O
CI	O
,	O
5.16-5.34	O
)	O
]	O
,	O
also	O
after	O
adjustment	O
for	O
socioeconomic	O
group	O
.	O

Intake	O
and	O
serum	O
levels	O
of	O
vitamin	O
B12	O
and	O
folate	O
were	O
within	O
recommended	O
or	O
reference	O
ranges	O
.	O

In	O
a	O
stepwise	O
multiple	O
regression	O
analysis	O
,	O
serum	O
folate	O
(	O
negative	O
correlation	O
)	O
,	O
plasma	O
creatinine	O
,	O
and	O
sugar	O
intake	O
as	O
percent	O
of	O
dietary	O
energy	O
(	O
positive	O
correlations	O
)	O
were	O
significantly	O
associated	O
with	O
tHcy	O
(	O
multiple	O
r	O
=	O
0.44	O
,	O
adjusted	O
r2	O
=	O
18	O
%	O
;	O
95	O
%	O
CI	O
,	O
5-30	O
%	O
)	O
.	O

Our	O
data	O
show	O
that	O
a	O
modest	O
elevation	O
in	O
tHcy	O
in	O
children	O
was	O
related	O
to	O
premature	O
cardiovascular	O
death	O
in	O
their	O
male	O
relatives	O
and	O
may	O
partly	O
account	O
for	O
the	O
contribution	O
of	O
family	O
history	O
to	O
risk	O
of	O
cardiovascular	O
disease	O
.	O

tHcy	O
may	O
be	O
modifiable	O
through	O
the	O
diet	O
,	O
even	O
in	O
children	O
with	O
apparently	O
adequate	O
vitamin	O
nutriture	O
.	O

Ten-year	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
prognosis	O
after	O
infarction	O
.	O

Department	O
of	O
Veterans	O
Affairs	O
Cooperative	O
Study	O
of	O
Coronary	O
Artery	O
Bypass	O
Surgery	O
.	O

BACKGROUND	O
The	O
10-year	O
incidence	O
of	O
myocardial	O
infarction	O
(	O
fatal	O
and	O
nonfatal	O
)	O
and	O
the	O
prognosis	O
after	O
infarction	O
were	O
evaluated	O
in	O
686	O
patients	O
with	O
stable	O
angina	O
who	O
were	O
randomly	O
assigned	O
to	O
medical	Pharmacological
or	O
surgical	Surgical
treatment	O
in	O
the	O
Veterans	O
Administration	O
Cooperative	O
Study	O
of	O
Coronary	O
Artery	O
Bypass	O
Surgery	O
.	O

METHODS	O
AND	O
RESULTS	O
Myocardial	O
infarction	O
was	O
defined	O
by	O
either	O
new	O
Q	O
wave	O
findings	O
or	O
clinical	O
symptoms	O
compatible	O
with	O
myocardial	O
infarction	O
accompanied	O
by	O
serum	O
enzyme	O
elevations	O
with	O
or	O
without	O
electrocardiographic	O
findings	O
.	O

Treatment	O
comparisons	O
were	O
made	O
according	O
to	O
original	O
treatment	O
assignment	O
;	O
35	O
%	O
of	O
the	O
medical	O
cohort	O
had	O
bypass	Surgical
surgery	Surgical
during	O
the	O
10-year	O
follow-up	O
period	O
.	O

The	O
overall	O
cumulative	O
infarction	O
rate	O
was	O
somewhat	O
higher	O
in	O
patients	O
assigned	O
to	O
surgery	Surgical
(	O
36	O
%	O
)	O
than	O
in	O
medical	O
patients	O
(	O
31	O
%	O
)	O
(	O
p	O
=	O
0.13	O
)	O
due	O
to	O
perioperative	O
infarctions	O
(	O
13	O
%	O
)	O
and	O
an	O
accelerated	O
infarction	O
rate	O
after	O
the	O
fifth	O
year	O
of	O
follow-up	O
(	O
average	O
,	O
2.4	O
%	O
/yr	O
in	O
the	O
surgical	O
group	O
versus	O
1.4	O
%	O
/yr	O
in	O
the	O
medical	O
group	O
)	O
.	O

The	O
10-year	O
cumulative	O
incidence	O
of	O
death	O
or	O
myocardial	O
infarction	O
was	O
also	O
higher	O
in	O
surgical	O
(	O
54	O
%	O
)	O
than	O
in	O
medical	O
(	O
49	O
%	O
)	O
patients	O
(	O
p	O
=	O
0.20	O
)	O
.	O

According	O
to	O
the	O
Cox	O
model	O
,	O
the	O
estimated	O
risk	O
of	O
death	O
after	O
infarction	O
was	O
59	O
%	O
lower	O
in	O
surgical	O
than	O
in	O
medical	O
patients	O
(	O
p	O
less	O
than	O
0.0001	O
)	O
.	O

The	O
reduction	O
in	O
postinfarction	O
mortality	O
with	O
surgery	O
was	O
most	O
striking	O
in	O
the	O
first	O
month	O
after	O
the	O
event	O
:	O
99	O
%	O
in	O
the	O
first	O
month	O
(	O
p	O
less	O
than	O
0.0001	O
)	O
and	O
49	O
%	O
subsequently	O
(	O
p	O
less	O
than	O
0.0001	O
)	O
.	O

The	O
estimated	O
risk	O
of	O
death	O
in	O
the	O
absence	O
of	O
infarction	O
was	O
nearly	O
identical	O
regardless	O
of	O
treatment	O
(	O
p	O
=	O
0.75	O
)	O
.	O

Exclusion	O
of	O
perioperative	O
infarctions	O
did	O
not	O
alter	O
the	O
findings	O
.	O

CONCLUSIONS	O
Although	O
surgery	O
does	O
not	O
reduce	O
the	O
incidence	O
of	O
myocardial	O
infarction	O
overall	O
,	O
it	O
does	O
reduce	O
the	O
risk	O
of	O
mortality	O
after	O
infarction	O
,	O
particularly	O
in	O
the	O
first	O
30	O
days	O
after	O
the	O
event	O
(	O
fatal	O
infarctions	O
)	O
.	O

Step-down	O
approach	O
using	O
either	O
cyclosporin	Pharmacological
A	Pharmacological
or	O
methotrexate	Pharmacological
as	O
maintenance	O
therapy	O
in	O
early	O
rheumatoid	O
arthritis	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
feasibility	O
and	O
outcome	O
of	O
the	O
step-down	O
approach	O
using	O
either	O
cyclosporin	Pharmacological
A	Pharmacological
(	Pharmacological
CSA	Pharmacological
)	Pharmacological
or	O
methotrexate	Pharmacological
(	Pharmacological
MTX	Pharmacological
)	Pharmacological
as	O
maintenance	O
therapy	O
following	O
6	O
months	O
treatment	O
with	O
these	O
2	O
agents	O
in	O
combination	O
in	O
early	O
,	O
nonerosive	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

METHODS	O
Fifty-seven	O
patients	O
younger	O
than	O
65	O
years	O
with	O
early	O
,	O
nonerosive	O
RA	O
were	O
first	O
treated	O
with	O
CSA	Pharmacological
and	O
MTX	Pharmacological
in	O
combination	O
for	O
6	O
months	O
.	O

They	O
were	O
then	O
randomly	O
stepped	O
down	O
to	O
single-agent	O
maintenance	O
treatment	O
for	O
another	O
18	O
months	O
.	O

Safety	O
,	O
clinical	O
efficacy	O
,	O
survival	O
on	O
treatment	O
,	O
and	O
radiographic	O
progression	O
were	O
evaluated	O
.	O

RESULTS	O
When	O
being	O
treated	O
with	O
combination	O
therapy	O
,	O
7	O
of	O
the	O
57	O
patients	O
(	O
12.3	O
%	O
)	O
withdrew	O
because	O
of	O
adverse	O
events	O
.	O

Of	O
the	O
remaining	O
50	O
patients	O
,	O
42	O
(	O
84.0	O
%	O
)	O
were	O
American	O
College	O
of	O
Rheumatology	O
(	O
ACR	O
)	O
20	O
%	O
responders	O
,	O
30	O
(	O
60.0	O
%	O
)	O
were	O
ACR	O
50	O
%	O
responders	O
,	O
and	O
23	O
(	O
46.0	O
%	O
)	O
were	O
ACR	O
70	O
%	O
responders	O
.	O

At	O
month	O
6	O
,	O
22	O
patients	O
were	O
randomized	O
to	O
CSA	Pharmacological
and	O
27	O
to	O
MTX	Pharmacological
.	Pharmacological

During	O
this	O
trial	O
period	O
,	O
the	O
treatment	O
was	O
discontinued	O
by	O
16	O
patients	O
taking	O
CSA	Pharmacological
(	O
mainly	O
because	O
of	O
loss	O
of	O
efficacy	O
)	O
and	O
by	O
4	O
taking	O
MTX	Pharmacological
.	Pharmacological

At	O
month	O
24	O
,	O
the	O
probability	O
(	O
+/-	O
SEM	O
)	O
of	O
survival	O
on	O
treatment	O
was	O
0.273	O
+/-	O
0.09	O
for	O
CSA	Pharmacological
and	O
0.852	O
+/-	O
0.07	O
for	O
MTX	Pharmacological
.	Pharmacological

Of	O
the	O
6	O
CSA	O
patients	O
who	O
completed	O
the	O
trial	O
,	O
4	O
(	O
66.7	O
%	O
)	O
were	O
ACR	O
20	O
%	O
responders	O
,	O
and	O
3	O
(	O
50	O
%	O
)	O
were	O
both	O
ACR	O
50	O
%	O
and	O
ACR	O
70	O
%	O
responders	O
.	O

Of	O
the	O
23	O
completers	O
in	O
the	O
MTX	Pharmacological
arm	O
,	O
21	O
(	O
91.3	O
%	O
)	O
were	O
ACR	O
20	O
%	O
responders	O
,	O
18	O
(	O
78.3	O
%	O
)	O
were	O
ACR	O
50	O
%	O
,	O
and	O
10	O
(	O
43.5	O
%	O
)	O
were	O
ACR	O
70	O
%	O
responders	O
.	O

The	O
treatment	O
was	O
not	O
responsible	O
for	O
severe	O
adverse	O
events	O
.	O

Radiography	O
showed	O
a	O
slow	O
progression	O
in	O
the	O
damage	O
score	O
and	O
number	O
of	O
eroded	O
joints	O
in	O
both	O
treatment	O
groups	O
.	O

CONCLUSION	O
Stepping	O
down	O
to	O
single	O
agent	O
maintenance	O
therapy	O
following	O
6	O
months	O
of	O
combination	O
treatment	O
with	O
CSA	Pharmacological
and	O
MTX	Pharmacological
in	O
early	O
RA	O
was	O
only	O
successful	O
with	O
MTX	Pharmacological
.	Pharmacological

Because	O
this	O
treatment	O
did	O
not	O
prevent	O
some	O
radiographic	O
progression	O
,	O
other	O
approaches	O
(	O
e.g.	O
,	O
step-up	O
approach	O
)	O
may	O
be	O
more	O
appropriate	O
in	O
early	O
RA	O
.	O

0.1	O
%	O
bupivacaine	Pharmacological
does	O
not	O
reduce	O
the	O
requirement	O
for	O
epidural	O
fentanyl	O
infusion	O
after	O
major	O
abdominal	O
surgery	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
Although	O
local	O
anesthesia	O
has	O
been	O
demonstrated	O
to	O
potentiate	O
spinal	O
morphine	O
analgesia	O
in	O
animal	O
studies	O
,	O
results	O
comparing	O
epidural	O
local	O
anesthesia/opioid	O
mixtures	O
with	O
opioid	O
alone	O
are	O
contradictory	O
in	O
clinical	O
studies	O
.	O

The	O
hypothesis	O
was	O
that	O
,	O
although	O
the	O
concentration	O
of	O
bupivacaine	Pharmacological
(	O
0.1	O
%	O
)	O
was	O
low	O
to	O
minimize	O
its	O
adverse	O
effects	O
,	O
if	O
the	O
infusion	O
rate	O
of	O
a	O
fentanyl/bupivacaine	Pharmacological
solution	O
was	O
closely	O
adjusted	O
according	O
to	O
need	O
,	O
the	O
presence	O
bupivacaine	O
would	O
reduce	O
the	O
requirement	O
for	O
epidural	O
fentanyl	O
.	O

METHODS	O
Forty	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
fentanyl	Pharmacological
(	O
10	O
micrograms/mL	O
)	O
or	O
a	O
fentanyl/bupivacaine	Pharmacological
(	O
0.1	O
%	O
)	O
mixture	O
epidurally	O
corresponding	O
to	O
the	O
dermatome	O
of	O
the	O
surgical	O
incision	O
in	O
a	O
double-blind	O
fashion	O
for	O
the	O
first	O
18	O
hours	O
after	O
major	O
abdominal	O
surgery	O
.	O

The	O
infusion	O
was	O
titrated	O
for	O
each	O
patient	O
to	O
the	O
rate	O
required	O
for	O
pain	O
relief	O
during	O
forced	O
inspiration	O
(	O
pain	O
score	O
<	O
or	O
=	O
2	O
,	O
maximum	O
10	O
)	O
.	O

Pain	O
scores	O
,	O
the	O
fentanyl	O
doses	O
required	O
,	O
plasma	O
concentrations	O
of	O
fentanyl	O
at	O
18	O
hours	O
,	O
and	O
the	O
incidence	O
and	O
severity	O
of	O
adverse	O
effects	O
were	O
recorded	O
.	O

RESULTS	O
Patients	O
reported	O
similar	O
median	O
pain	O
scores	O
and	O
were	O
equally	O
satisfied	O
with	O
pain	O
relief	O
in	O
both	O
groups	O
.	O

The	O
mean	O
required	O
post-operative	O
fentanyl	O
infusion	O
rate	O
(	O
57.7	O
+/-	O
19.5	O
micrograms/h	O
)	O
and	O
the	O
plasma	O
concentrations	O
(	O
0.84	O
+/-	O
0.36	O
ng/mL	O
)	O
in	O
the	O
fentanyl	O
group	O
were	O
comparable	O
to	O
the	O
infusion	O
rate	O
(	O
54.4	O
+/-	O
19.2	O
micrograms/h	O
)	O
and	O
the	O
plasma	O
concentrations	O
(	O
0.86	O
+/-	O
0.36	O
ng/mL	O
)	O
in	O
the	O
fentanyl/bupivacaine	O
group	O
.	O

Respiratory	O
and	O
cardiovascular	O
functions	O
were	O
preserved	O
,	O
and	O
the	O
incidence	O
of	O
nausea	O
,	O
pruritus	O
,	O
and	O
periods	O
of	O
drowsiness	O
or	O
sleep	O
were	O
similar	O
in	O
both	O
groups	O
.	O

CONCLUSIONS	O
In	O
low	O
concentrations	O
(	O
0.1	O
%	O
)	O
,	O
bupivacaine	Pharmacological
did	O
not	O
reduce	O
the	O
titrated	O
dose	O
of	O
epidural	O
fentanyl	O
required	O
for	O
adequate	O
pain	O
relief	O
during	O
forced	O
inspiration	O
after	O
major	O
abdominal	O
surgery	O
.	O

The	O
incidence	O
and	O
severity	O
of	O
adverse	O
effects	O
were	O
also	O
comparable	O
whether	O
or	O
not	O
low-dose	O
bupivacaine	Pharmacological
infusion	O
was	O
used	O
.	O

The	O
ScanBrit	O
randomised	O
,	O
controlled	O
,	O
single-blind	O
study	O
of	O
a	O
gluten-	Other
and	Other
casein-free	Other
dietary	Other
intervention	Other
for	O
children	O
with	O
autism	O
spectrum	O
disorders	O
.	O

There	O
is	O
increasing	O
interest	O
in	O
the	O
use	O
of	O
gluten-	Other
and	Other
casein-free	Other
diets	Other
for	O
children	O
with	O
autism	O
spectrum	O
disorders	O
(	O
ASDs	O
)	O
.	O

We	O
report	O
results	O
from	O
a	O
two-stage	O
,	O
24-month	O
,	O
randomised	O
,	O
controlled	O
trial	O
incorporating	O
an	O
adaptive	O
'catch-up	O
'	O
design	O
and	O
interim	O
analysis	O
.	O

Stage	O
1	O
of	O
the	O
trial	O
saw	O
72	O
Danish	O
children	O
(	O
aged	O
4	O
years	O
to	O
10	O
years	O
11	O
months	O
)	O
assigned	O
to	O
diet	O
(	O
A	O
)	O
or	O
non-diet	Control
(	O
B	O
)	O
groups	O
by	O
stratified	O
randomisation	O
.	O

Autism	O
Diagnostic	O
Observation	O
Schedule	O
(	O
ADOS	O
)	O
and	O
the	O
Gilliam	O
Autism	O
Rating	O
Scale	O
(	O
GARS	O
)	O
were	O
used	O
to	O
assess	O
core	O
autism	O
behaviours	O
,	O
Vineland	O
Adaptive	O
Behaviour	O
Scales	O
(	O
VABS	O
)	O
to	O
ascertain	O
developmental	O
level	O
,	O
and	O
Attention-Deficit	O
Hyperactivity	O
Disorder	O
-	O
IV	O
scale	O
(	O
ADHD-IV	O
)	O
to	O
determine	O
inattention	O
and	O
hyperactivity	O
.	O

Participants	O
were	O
tested	O
at	O
baseline	O
,	O
8	O
,	O
and	O
12	O
months	O
.	O

Based	O
on	O
per	O
protocol	O
repeated	O
measures	O
analysis	O
,	O
data	O
for	O
26	O
diet	O
children	O
and	O
29	O
controls	O
were	O
available	O
at	O
12	O
months	O
.	O

At	O
this	O
point	O
,	O
there	O
was	O
a	O
significant	O
improvement	O
to	O
mean	O
diet	O
group	O
scores	O
(	O
time*treatment	O
interaction	O
)	O
on	O
sub-domains	O
of	O
ADOS	O
,	O
GARS	O
and	O
ADHD-IV	O
measures	O
.	O

Surpassing	O
of	O
predefined	O
statistical	O
thresholds	O
as	O
evidence	O
of	O
improvement	O
in	O
group	O
A	O
at	O
12	O
months	O
sanctioned	O
the	O
re-assignment	O
of	O
group	O
B	O
participants	O
to	O
active	O
dietary	O
treatment	O
.	O

Stage	O
2	O
data	O
for	O
18	O
group	O
A	O
and	O
17	O
group	O
B	O
participants	O
were	O
available	O
at	O
24	O
months	O
.	O

Multiple	O
scenario	O
analysis	O
based	O
on	O
inter-	O
and	O
intra-group	O
comparisons	O
showed	O
some	O
evidence	O
of	O
sustained	O
clinical	O
group	O
improvements	O
although	O
possibly	O
indicative	O
of	O
a	O
plateau	O
effect	O
for	O
intervention	O
.	O

Our	O
results	O
suggest	O
that	O
dietary	Other
intervention	Other
may	O
positively	O
affect	O
developmental	O
outcome	O
for	O
some	O
children	O
diagnosed	O
with	O
ASD	O
.	O

In	O
the	O
absence	O
of	O
a	O
placebo	Control
condition	O
to	O
the	O
current	O
investigation	O
,	O
we	O
are	O
,	O
however	O
,	O
unable	O
to	O
disqualify	O
potential	O
effects	O
derived	O
from	O
intervention	O
outside	O
of	O
dietary	O
changes	O
.	O

Further	O
studies	O
are	O
required	O
to	O
ascertain	O
potential	O
best-	O
and	O
non-responders	O
to	O
intervention	O
.	O

The	O
study	O
was	O
registered	O
with	O
ClincialTrials.gov	O
,	O
number	O
NCT00614198	O
.	O

Niacin	Pharmacological
revisited	O
.	O

A	O
randomized	O
,	O
controlled	O
trial	O
of	O
wax-matrix	O
sustained-release	O
niacin	Pharmacological
in	O
hypercholesterolemia	O
.	O

Two	O
hundred	O
one	O
male	O
and	O
female	O
subjects	O
,	O
aged	O
20	O
to	O
70	O
years	O
,	O
with	O
elevated	O
low-density	O
lipoprotein	O
cholesterol	O
values	O
(	O
in	O
the	O
75th	O
to	O
95th	O
percentiles	O
)	O
,	O
participated	O
in	O
a	O
randomized	O
,	O
controlled	O
,	O
double-blind	O
study	O
using	O
a	O
new	O
form	O
of	O
niacin	Pharmacological
(	Pharmacological
Enduracin	Pharmacological
)	Pharmacological
,	O
which	O
employs	O
a	O
wax-matrix	O
vehicle	O
for	O
sustained	O
release	O
.	O

Four	O
niacin	Pharmacological
treatment	O
groups	O
(	O
daily	O
doses	O
of	O
2000	O
,	O
1500	O
,	O
1250	O
,	O
and	O
1000	O
mg	O
)	O
were	O
compared	O
with	O
placebo-	Control
and	O
diet-treated	Control
controls	Control
to	O
determine	O
side-effect	O
profile	O
and	O
optimal	O
range	O
of	O
efficacy	O
.	O

The	O
groups	O
given	O
2000	O
and	O
1500	O
mg	O
demonstrated	O
significant	O
reductions	O
in	O
values	O
of	O
low-density	O
lipoprotein	O
cholesterol	O
(	O
-26	O
%	O
and	O
-19.3	O
%	O
,	O
respectively	O
)	O
,	O
total	O
cholesterol	O
(	O
-18.4	O
%	O
and	O
-13.3	O
%	O
)	O
,	O
and	O
total	O
cholesterol-high-density	O
lipoprotein	O
cholesterol	O
ratio	O
(	O
-20.4	O
%	O
and	O
-19.4	O
%	O
)	O
when	O
compared	O
with	O
diet-	O
and	O
placebo-treated	O
controls	O
.	O

Smaller	O
improvements	O
were	O
seen	O
in	O
high-density	O
lipoprotein	O
cholesterol	O
and	O
triglyceride	O
levels	O
.	O

Blood	O
chemistry	O
monitoring	O
indicated	O
that	O
reduction	O
in	O
low-density	O
lipoprotein	O
cholesterol	O
level	O
strongly	O
correlated	O
with	O
an	O
increase	O
in	O
baseline	O
levels	O
of	O
some	O
enzymes	O
for	O
niacin-treated	O
subjects	O
.	O

The	O
improved	O
side-effect	O
profile	O
of	O
the	O
wax-matrix	O
form	O
of	O
niacin	Pharmacological
was	O
particularly	O
notable	O
.	O

The	O
dropout	O
rate	O
due	O
to	O
side	O
effects	O
was	O
only	O
3.4	O
%	O
and	O
was	O
coupled	O
with	O
good	O
medication	O
compliance	O
.	O

Aminocaproic	Pharmacological
acid	Pharmacological
versus	O
prednisone	Pharmacological
for	O
the	O
treatment	O
of	O
traumatic	O
hyphema	O
.	O

A	O
randomized	O
clinical	O
trial	O
.	O

One	O
hundred	O
twelve	O
patients	O
who	O
sustained	O
hyphema	O
after	O
blunt	O
trauma	O
were	O
enrolled	O
in	O
a	O
double-blind	O
randomized	O
clinical	O
trial	O
to	O
determine	O
the	O
relative	O
efficacies	O
of	O
aminocaproic	Pharmacological
acid	Pharmacological
(	Pharmacological
Amicar	Pharmacological
)	Pharmacological
and	O
systemic	Pharmacological
prednisone	Pharmacological
for	O
reducing	O
the	O
rate	O
of	O
secondary	O
hemorrhage	O
.	O

Fifty-six	O
patients	O
received	O
an	O
oral	O
dosage	O
of	O
50	O
mg/kg	O
of	O
aminocaproic	Pharmacological
acid	Pharmacological
every	O
4	O
hours	O
for	O
5	O
days	O
,	O
up	O
to	O
a	O
maximum	O
of	O
30	O
g	O
daily	O
,	O
and	O
56	O
patients	O
received	O
an	O
oral	O
dosage	O
of	O
40	O
mg	O
of	O
prednisone	Pharmacological
daily	O
(	O
adjusted	O
for	O
weight	O
)	O
in	O
two	O
divided	O
doses	O
.	O

Placebo	Control
pills	O
and	O
liquids	O
were	O
given	O
to	O
each	O
patient	O
to	O
mask	O
the	O
treatment	O
schedules	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
patient	O
populations	O
for	O
any	O
demographic	O
or	O
clinical	O
characteristic	O
(	O
e.g.	O
,	O
visual	O
acuity	O
,	O
intraocular	O
pressure	O
[	O
IOP	O
]	O
,	O
initial	O
hyphema	O
size	O
)	O
measured	O
in	O
the	O
study	O
.	O

Blacks	O
comprised	O
53	O
%	O
of	O
the	O
study	O
population	O
,	O
and	O
the	O
mean	O
age	O
of	O
the	O
patients	O
was	O
23.5	O
years	O
.	O

Four	O
patients	O
in	O
each	O
of	O
the	O
treatment	O
groups	O
experienced	O
a	O
secondary	O
hemorrhage	O
;	O
the	O
rebleed	O
rate	O
was	O
7.1	O
%	O
in	O
each	O
group	O
.	O

Lactobacillus	Pharmacological
plantarum	Pharmacological
CECT7315	Pharmacological
and	Pharmacological
CECT7316	Pharmacological
stimulate	O
immunoglobulin	O
production	O
after	O
influenza	Pharmacological
vaccination	Pharmacological
in	O
elderly	O
.	O

OBJECTIVE	O
The	O
effectiveness	O
of	O
influenza	Pharmacological
vaccination	Pharmacological
in	O
preventing	O
illness	O
is	O
lower	O
in	O
the	O
elderly	O
;	O
this	O
is	O
why	O
the	O
ability	O
of	O
Lactobacillus	Pharmacological
plantarum	Pharmacological
CECT	Pharmacological
7315/7316	Pharmacological
to	O
stimulate	O
the	O
response	O
to	O
influenza	Pharmacological
vaccination	Pharmacological
in	O
elderly	O
was	O
evaluated	O
.	O

RESEARCH	O
METHODS	O
AND	O
PROCEDURES	O
A	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	Control
human	O
trial	O
including	O
60	O
institutionalized	O
volunteers	O
aged	O
65-85	O
years	O
was	O
performed	O
.	O

All	O
the	O
volunteers	O
were	O
vaccinated	O
with	O
a	O
trivalent	Pharmacological
influenza	Pharmacological
vaccine	Pharmacological
(	Pharmacological
A/Wisconsin/67/2005	Pharmacological
NYMC	Pharmacological
X-161B	Pharmacological
(	Pharmacological
H3N2	Pharmacological
)	Pharmacological
,	Pharmacological
A/Solomon	Pharmacological
Islands/3/2006	Pharmacological
(	Pharmacological
H1N1	Pharmacological
)	Pharmacological
and	Pharmacological
B/Malaysia/2506/2004	Pharmacological
)	Pharmacological
for	O
the	O
Spanish	O
vaccine	O
campaign	O
2006/2007	O
.	O

The	O
consumption	O
of	O
the	O
probiotic	O
began	O
between	O
three	O
and	O
four	O
months	O
after	O
the	O
vaccination	O
.	O

Volunteers	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
following	O
groups	O
:	O
group	O
A	O
(	O
receiving	O
5*10	O
(	O
9	O
)	O
cfu/day	O
of	O
L.	Pharmacological
plantarum	Pharmacological
CECT	Pharmacological
7315/7316	Pharmacological
in	O
20	O
g	O
powdered	O
skim	O
milk	O
)	O
,	O
group	O
B	O
(	O
receiving	O
5*10	O
(	O
8	O
)	O
cfu/day	O
of	O
L.	Pharmacological
plantarum	Pharmacological
CECT	Pharmacological
7315/7316	Pharmacological
in	O
20	O
g	O
powdered	O
skim	O
milk	O
)	O
and	O
group	O
C	O
or	O
placebo	Control
(	O
20	O
g	O
powered	Control
skim	Control
milk	Control
)	Control
.	Control

The	O
participants	O
consumed	O
the	O
probiotic	O
during	O
3	O
months	O
.	O

RESULTS	O
The	O
consumption	O
of	O
L.	Pharmacological
plantarum	Pharmacological
CECT	Pharmacological
7315/7316	Pharmacological
during	O
3	O
months	O
after	O
influenza	Pharmacological
vaccination	Pharmacological
increased	O
the	O
levels	O
of	O
influenza-specific	O
IgA	O
and	O
IgG	O
antibodies	O
.	O

Moreover	O
,	O
a	O
trend	O
towards	O
an	O
increase	O
in	O
influenza-specific	O
IgM	O
antibodies	O
was	O
also	O
observed	O
.	O

CONCLUSION	O
L.	Pharmacological
plantarum	Pharmacological
CECT7315/7316	Pharmacological
has	O
an	O
immunostimulating	O
effect	O
and	O
could	O
be	O
used	O
to	O
improve	O
the	O
response	O
to	O
influenza	Pharmacological
vaccination	Pharmacological
in	O
elderly	O
.	O

Effect	O
of	O
ranolazine	Pharmacological
on	O
A1C	O
and	O
glucose	O
levels	O
in	O
hyperglycemic	O
patients	O
with	O
non-ST	O
elevation	O
acute	O
coronary	O
syndrome	O
.	O

OBJECTIVE	O
We	O
determined	O
the	O
relationships	O
between	O
glycemia	O
at	O
randomization	O
,	O
concurrent	Pharmacological
antidiabetic	Pharmacological
therapy	Pharmacological
,	O
and	O
change	O
in	O
A1C	O
and	O
fasting	O
plasma	O
glucose	O
(	O
FPG	O
)	O
in	O
patients	O
with	O
diabetes	O
receiving	O
standard	O
treatment	O
for	O
diabetes	O
and	O
randomized	O
to	O
ranolazine	Pharmacological
or	O
placebo	Control
within	O
the	O
MERLIN-TIMI-36	O
(	O
MERLIN	O
)	O
study	O
.	O

Ranolazine	Pharmacological
is	O
a	O
novel	O
first-in-class	O
drug	O
approved	O
for	O
treating	O
angina	O
pectoris	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
Randomization	O
and	O
4-month	O
glycemic	O
and	O
antidiabetes	Pharmacological
drug	Pharmacological
usage	O
data	O
from	O
MERLIN	O
were	O
analyzed	O
using	O
Spotfire	O
and	O
SAS	O
version	O
9.1	O
software	O
.	O

RESULTS	O
In	O
patients	O
with	O
diabetes	O
and	O
A1C	O
of	O
>	O
or=8-10	O
%	O
at	O
randomization	O
(	O
n	O
=	O
171	O
)	O
,	O
there	O
was	O
an	O
absolute	O
A1C	O
reduction	O
in	O
the	O
ranolazine	Pharmacological
group	O
of	O
1.2	O
%	O
(	O
95	O
%	O
CI	O
-1.4	O
to	O
-1.0	O
)	O
,	O
and	O
the	O
placebo-adjusted	Control
(	O
n	O
=	O
182	O
)	O
decrease	O
in	O
A1C	O
by	O
ranolazine	O
was	O
0.59	O
%	O
(	O
95	O
%	O
CI	O
-0.99	O
to	O
-0.20	O
,	O
P	O
<	O
0.001	O
)	O
.	O

In	O
patients	O
with	O
FPG	O
of	O
150-400	O
mg/dl	O
at	O
randomization	O
,	O
ranolazine	Pharmacological
(	O
n	O
=	O
131	O
)	O
compared	O
with	O
placebo	Control
(	O
n	O
=	O
147	O
)	O
reduced	O
FPG	O
by	O
25.7	O
mg/dl	O
(	O
95	O
%	O
CI	O
-43.3	O
to	O
-8.1	O
,	O
P	O
=	O
0.001	O
)	O
.	O

When	O
changes	O
in	O
either	O
A1C	O
or	O
FPG	O
were	O
correlated	O
to	O
A1C	O
or	O
FPG	O
at	O
randomization	O
,	O
the	O
slopes	O
were	O
significantly	O
steeper	O
for	O
ranolazine	Pharmacological
than	O
placebo	Control
(	O
A1C	O
,	O
P	O
=	O
0.046	O
;	O
FPG	O
,	O
P	O
<	O
0.001	O
)	O
,	O
indicating	O
that	O
lowering	O
of	O
A1C	O
and	O
FPG	O
by	O
ranolazine	Pharmacological
is	O
related	O
to	O
hyperglycemia	O
at	O
randomization	O
.	O

Ranolazine	O
,	O
compared	O
with	O
placebo	O
,	O
was	O
not	O
associated	O
with	O
serious	O
hypoglycemic	O
events	O
,	O
associated	O
with	O
significant	O
changes	O
in	O
concurrent	O
antidiabetic	Pharmacological
therapy	Pharmacological
,	O
or	O
dependent	O
on	O
a	O
history	O
of	O
angina	O
.	O

CONCLUSIONS	O
Ranolazine	Pharmacological
,	O
when	O
added	O
to	O
concurrent	O
antidiabetes	O
treatment	O
,	O
lowers	O
FPG	O
and	O
A1C	O
in	O
patients	O
with	O
cardiovascular	O
disease	O
and	O
poorly	O
controlled	O
diabetes	O
.	O

Hyperbaric	Pharmacological
oxygen	Pharmacological
attenuation	O
of	O
lipopolysaccharide-induced	O
acute	O
lung	O
injury	O
involves	O
heme	O
oxygenase-1	O
.	O

BACKGROUND	O
Hyperbaric	Pharmacological
oxygen	Pharmacological
(	Pharmacological
HBO	Pharmacological
)	Pharmacological
attenuates	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
acute	O
lung	O
injury	O
.	O

This	O
beneficial	O
effect	O
of	O
HBO	O
involves	O
inhibition	O
of	O
inducible	O
nitric	O
oxide	O
synthase	O
(	O
iNOS	O
)	O
expression	O
and	O
subsequent	O
nitric	O
oxide	O
(	O
NO	O
)	O
biosynthesis	O
.	O

We	O
sought	O
to	O
investigate	O
the	O
role	O
of	O
heme	O
oxygenase-1	O
(	O
HO-1	O
)	O
on	O
this	O
HBO	O
inhibition	O
of	O
iNOS	O
induction	O
and	O
acute	O
lung	O
injury	O
in	O
septic	O
rat	O
lungs	O
.	O

METHODS	O
Before	O
the	O
experiment	O
,	O
72	O
rats	O
were	O
randomly	O
allocated	O
to	O
receive	O
HBO	Pharmacological
or	O
air	Pharmacological
treatment	Pharmacological
.	O

With	O
or	O
without	O
HBO	Pharmacological
pre-treatment	O
,	O
the	O
rats	O
were	O
further	O
divided	O
into	O
the	O
following	O
subgroups	O
(	O
n	O
=	O
6	O
)	O
:	O
(	O
i	O
)	O
LPS	Pharmacological
injection	Pharmacological
,	O
(	O
ii	O
)	O
normal	Control
saline	Control
(	Control
N/S	Control
)	Control
injection	Control
,	O
(	O
iii	O
)	O
hemin	Pharmacological
(	Pharmacological
a	Pharmacological
HO-1	Pharmacological
inducer	Pharmacological
)	Pharmacological
plus	Pharmacological
LPS	Pharmacological
,	O
(	O
iv	O
)	O
hemin	Pharmacological
alone	O
,	O
(	O
v	O
)	O
tin	Pharmacological
protoporphyrin	Pharmacological
(	Pharmacological
SnPP	Pharmacological
;	Pharmacological
a	Pharmacological
HO-1	Pharmacological
inhibitor	Pharmacological
)	Pharmacological
plus	Pharmacological
LPS	Pharmacological
,	O
and	O
(	O
vi	O
)	O
SnPP	Pharmacological
alone	O
.	O

All	O
rats	O
were	O
maintained	O
for	O
6	O
h	O
and	O
then	O
sacrificed	O
with	O
a	O
high-dose	Pharmacological
pentobarbital	Pharmacological
injection	Pharmacological
.	Pharmacological

Lung	O
injuries	O
and	O
relevant	O
enzymes	O
expression	O
were	O
thus	O
assayed	O
.	O

RESULTS	O
Histological	O
analysis	O
,	O
PMNs/alveoli	O
ratio	O
,	O
and	O
wet/dry	O
weight	O
ratio	O
measurements	O
demonstrated	O
that	O
LPS	O
caused	O
significant	O
lung	O
injury	O
and	O
HBO	O
and/or	O
hemin	O
significantly	O
attenuated	O
this	O
LPS-induced	O
lung	O
injury	O
.	O

Increased	O
pulmonary	O
iNOS	O
expression	O
and	O
NO	O
production	O
were	O
associated	O
with	O
lung	O
injury	O
.	O

Induction	O
of	O
HO-1	O
,	O
by	O
HBO	O
and/or	O
hemin	O
,	O
significantly	O
attenuated	O
this	O
LPS-induced	O
iNOS	O
expression	O
and	O
acute	O
lung	O
injury	O
.	O

SnPP	O
,	O
on	O
the	O
contrary	O
,	O
offset	O
the	O
effects	O
of	O
HBO	Pharmacological
and	O
worsened	O
the	O
LPS-induced	O
lung	O
injury	O
.	O

CONCLUSIONS	O
HBO	Pharmacological
may	O
act	O
through	O
inhibiting	O
pulmonary	O
iNOS	O
expression	O
to	O
attenuate	O
LPS-induced	O
acute	O
lung	O
injury	O
in	O
septic	O
rats	O
.	O

Furthermore	O
,	O
this	O
HBO	Pharmacological
attenuation	O
of	O
iNOS	O
expression	O
involves	O
HO-1	O
induction	O
.	O

Does	O
temporary	Surgical
clamping	Surgical
of	Surgical
drains	Surgical
following	O
knee	O
arthroplasty	O
reduce	O
blood	O
loss	O
?	O
A	O
randomised	O
controlled	O
trial	O
.	O

In	O
a	O
randomised	O
,	O
blinded	O
study	O
76	O
patients	O
undergoing	O
primary	O
total	O
knee	O
arthroplasty	O
were	O
assigned	O
to	O
either	O
immediate	Surgical
drain	Surgical
opening	Surgical
(	O
n	O
=	O
45	O
)	O
or	O
drains	Surgical
opened	Surgical
at	Surgical
2	Surgical
h	Surgical
(	O
n	O
=	O
31	O
)	O
.	O

No	O
significant	O
differences	O
were	O
found	O
between	O
the	O
groups	O
for	O
the	O
volume	O
of	O
drained	O
blood	O
,	O
transfusion	O
requirements	O
,	O
knee	O
motion	O
or	O
wound	O
status	O
.	O

The	O
authors	O
conclude	O
that	O
the	O
practice	O
of	O
clamping	Surgical
drains	Surgical
has	O
no	O
benefit	O
in	O
routine	O
knee	O
arthroplasty	O
.	O

However	O
,	O
when	O
faced	O
with	O
immediate	O
brisk	O
blood	O
loss	O
,	O
the	O
results	O
suggest	O
that	O
drains	Surgical
can	O
be	O
clamped	O
without	O
any	O
excess	O
morbidity	O
.	O

In-hospital	O
costs	O
of	O
self-expanding	Surgical
nitinol	Surgical
stent	Surgical
implantation	Surgical
versus	O
balloon	Surgical
angioplasty	Surgical
in	O
the	O
femoropopliteal	O
artery	O
(	O
the	O
VascuCoil	O
Trial	O
)	O
.	O

PURPOSE	O
Although	O
several	O
prospective	O
studies	O
have	O
examined	O
the	O
safety	O
and	O
efficacy	O
of	O
stent	Surgical
placement	Surgical
for	O
femoropopliteal	O
arterial	O
disease	O
,	O
the	O
current	O
cost	O
of	O
these	O
procedures	O
is	O
unknown	O
.	O

To	O
estimate	O
and	O
compare	O
hospital	O
costs	O
associated	O
with	O
conventional	Surgical
balloon	Surgical
angioplasty	Surgical
(	Surgical
percutaneous	Surgical
transluminal	Surgical
angioplasty	Surgical
[	Surgical
PTA	Surgical
]	Surgical
)	Surgical
and	O
stent	Surgical
placement	Surgical
for	O
patients	O
with	O
symptomatic	O
peripheral	O
arterial	O
disease	O
,	O
the	O
authors	O
performed	O
a	O
prospective	O
economic	O
evaluation	O
in	O
conjunction	O
with	O
the	O
Intracoil	O
Femoropopliteal	O
Stent	O
Trial	O
(	O
VascuCoil	O
)	O
.	O

MATERIALS	O
AND	O
METHODS	O
Between	O
May	O
1997	O
and	O
December	O
1999	O
,	O
266	O
patients	O
with	O
stenotic	O
or	O
occluded	O
superficial	O
femoral	O
or	O
popliteal	O
arteries	O
were	O
prospectively	O
randomized	O
to	O
treatment	O
with	O
the	O
IntraCoil	Surgical
stent	Surgical
or	O
PTA	Surgical
.	Surgical

Detailed	O
resource	O
use	O
and	O
cost	O
data	O
for	O
each	O
patient	O
's	O
initial	O
revascularization	O
procedure	O
and	O
ensuing	O
hospitalization	O
were	O
collected	O
and	O
analyzed	O
on	O
an	O
intention-to-treat	O
basis	O
.	O

RESULTS	O
Compared	O
with	O
conventional	Surgical
balloon	Surgical
angioplasty	Surgical
,	O
stent	Surgical
placement	Surgical
did	O
not	O
improve	O
clinical	O
outcomes	O
but	O
increased	O
procedure	O
duration	O
,	O
equipment	O
costs	O
,	O
and	O
physician	O
services	O
.	O

As	O
a	O
result	O
,	O
initial	O
hospital	O
costs	O
were	O
approximately	O
3,500	O
dollars	O
higher	O
for	O
patients	O
randomized	O
to	O
the	O
IntraCoil	Surgical
stent	Surgical
,	O
compared	O
with	O
PTA	Surgical
(	O
8,435	O
dollars	O
vs	O
4,980	O
dollars	O
;	O
P	O
<	O
.001	O
)	O
.	O

CONCLUSIONS	O
As	O
performed	O
in	O
the	O
VascuCoil	O
trial	O
,	O
primary	O
stent	O
placement	O
for	O
femoropopliteal	O
disease	O
did	O
not	O
improve	O
clinical	O
outcomes	O
but	O
increased	O
initial	O
treatment	O
costs	O
by	O
more	O
than	O
3,000	O
dollars	O
.	O

Because	O
there	O
were	O
no	O
substantial	O
differences	O
in	O
subsequent	O
clinical	O
outcomes	O
between	O
the	O
two	O
treatments	O
,	O
it	O
is	O
unlikely	O
that	O
these	O
increased	O
initial	O
costs	O
would	O
be	O
offset	O
by	O
savings	O
in	O
follow-up	O
costs	O
.	O

These	O
findings	O
suggest	O
that	O
a	O
strategy	O
of	O
routine	O
stent	Physical
implantation	O
for	O
patients	O
undergoing	O
femoropopliteal	O
PTA	Physical
is	O
not	O
optimal	O
on	O
economic	O
grounds	O
and	O
that	O
PTA	Physical
with	O
provisional	Physical
stent	Physical
implantation	Physical
is	O
preferred	O
.	O

Long-term	O
prospective	O
,	O
randomized	O
,	O
controlled	O
study	O
using	O
repetitive	O
education	O
at	O
six-month	O
intervals	O
and	O
monitoring	O
for	O
adherence	O
in	O
heart	O
failure	O
outpatients	O
:	O
the	O
REMADHE	O
trial	O
.	O

BACKGROUND	O
The	O
effectiveness	O
of	O
heart	O
failure	O
disease	O
management	O
programs	O
in	O
patients	O
under	O
cardiologists	O
'	O
care	O
over	O
long-term	O
follow-up	O
is	O
not	O
established	O
.	O

METHODS	O
AND	O
RESULTS	O
We	O
investigated	O
the	O
effects	O
of	O
a	O
disease	Other
management	Other
program	Other
with	Other
repetitive	Other
education	Other
and	O
telephone	Other
monitoring	Other
on	O
primary	O
(	O
combined	O
death	O
or	O
unplanned	O
first	O
hospitalization	O
and	O
quality-of-life	O
changes	O
)	O
and	O
secondary	O
end	O
points	O
(	O
hospitalization	O
,	O
death	O
,	O
and	O
adherence	O
)	O
.	O

The	O
REMADHE	O
[	O
Repetitive	O
Education	Other
and	Other
Monitoring	Other
for	O
ADherence	O
for	O
Heart	O
Failure	O
]	O
trial	O
is	O
a	O
long-term	O
randomized	O
,	O
prospective	O
,	O
parallel	O
trial	O
designed	O
to	O
compare	O
intervention	O
with	O
control	Control
.	Control

One	O
hundred	O
seventeen	O
patients	O
were	O
randomized	O
to	O
usual	O
care	O
,	O
and	O
233	O
to	O
additional	O
intervention	O
.	O

The	O
mean	O
follow-up	O
was	O
2.47+/-1.75	O
years	O
,	O
with	O
54	O
%	O
adherence	O
to	O
the	O
program	O
.	O

In	O
the	O
intervention	O
group	O
,	O
the	O
primary	O
end	O
point	O
composite	O
of	O
death	O
or	O
unplanned	O
hospitalization	O
was	O
reduced	O
(	O
hazard	O
ratio	O
,	O
0.64	O
;	O
confidence	O
interval	O
,	O
0.43	O
to	O
0.88	O
;	O
P=0.008	O
)	O
,	O
driven	O
by	O
reduction	O
in	O
hospitalization	O
.	O

The	O
quality-of-life	O
questionnaire	O
score	O
improved	O
only	O
in	O
the	O
intervention	O
group	O
(	O
P	O
<	O
0.003	O
)	O
.	O

Mortality	O
was	O
similar	O
in	O
both	O
groups	O
.	O

Number	O
of	O
hospitalizations	O
(	O
1.3+/-1.7	O
versus	O
0.8+/-1.3	O
,	O
P	O
<	O
0.0001	O
)	O
,	O
total	O
hospital	O
days	O
during	O
the	O
follow-up	O
(	O
19.9+/-51	O
versus	O
11.1+/-24	O
days	O
,	O
P	O
<	O
0.0001	O
)	O
,	O
and	O
the	O
need	O
for	O
emergency	O
visits	O
(	O
4.5+/-10.6	O
versus	O
1.6+/-2.4	O
,	O
P	O
<	O
0.0001	O
)	O
were	O
lower	O
in	O
the	O
intervention	O
group	O
.	O

Beneficial	O
effects	O
were	O
homogeneous	O
for	O
sex	O
,	O
race	O
,	O
diabetes	O
and	O
no	O
diabetes	O
,	O
age	O
,	O
functional	O
class	O
,	O
and	O
etiology	O
.	O

CONCLUSIONS	O
For	O
a	O
longer	O
follow-up	O
period	O
than	O
in	O
previous	O
studies	O
,	O
this	O
heart	O
failure	O
disease	O
management	O
program	O
model	O
of	O
patients	O
under	O
the	O
supervision	O
of	O
a	O
cardiologist	O
is	O
associated	O
with	O
a	O
reduction	O
in	O
unplanned	O
hospitalization	O
,	O
a	O
reduction	O
of	O
total	O
hospital	O
days	O
,	O
and	O
a	O
reduced	O
need	O
for	O
emergency	O
care	O
,	O
as	O
well	O
as	O
improved	O
quality	O
of	O
life	O
,	O
despite	O
modest	O
program	O
adherence	O
over	O
time	O
.	O

A	O
prospective	O
randomised	O
comparison	O
of	O
sublingual	Pharmacological
and	Pharmacological
vaginal	Pharmacological
misoprostol	Pharmacological
in	O
second	O
trimester	O
termination	O
of	O
pregnancy	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
efficacy	O
,	O
side	O
effects	O
and	O
acceptability	O
of	O
sublingual	Pharmacological
and	Pharmacological
vaginal	Pharmacological
misoprostol	Pharmacological
for	O
second	O
trimester	O
medical	O
abortion	O
.	O

DESIGN	O
Prospective	O
randomised	O
controlled	O
trial	O
.	O

SETTING	O
Tertiary	O
referral	O
unit	O
and	O
a	O
teaching	O
hospital	O
.	O

POPULATION	O
Two	O
hundred	O
and	O
twenty-four	O
women	O
at	O
12	O
to	O
20	O
weeks	O
of	O
gestation	O
.	O

METHODS	O
The	O
women	O
were	O
randomised	O
to	O
receive	O
either	O
sublingual	Pharmacological
or	Pharmacological
vaginal	Pharmacological
misoprostol	Pharmacological
400	Pharmacological
microg	Pharmacological
every	O
3	O
hours	O
for	O
a	O
maximum	O
of	O
five	O
doses	O
.	O

The	O
course	O
of	O
misoprostol	Pharmacological
was	O
repeated	O
if	O
the	O
woman	O
did	O
not	O
abort	O
within	O
24	O
hours	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
The	O
success	O
rate	O
at	O
48	O
hours	O
,	O
induction-to-abortion	O
interval	O
and	O
the	O
side	O
effects	O
.	O

RESULTS	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
success	O
rate	O
at	O
48	O
hours	O
(	O
sublingual	O
:	O
91	O
%	O
;	O
vaginal	O
:	O
95	O
%	O
)	O
.	O

However	O
,	O
the	O
success	O
rate	O
at	O
24	O
hours	O
was	O
significantly	O
higher	O
in	O
the	O
vaginal	O
group	O
(	O
85	O
%	O
)	O
compared	O
with	O
the	O
sublingual	O
group	O
(	O
64	O
%	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
median	O
induction-to-abortion	O
interval	O
(	O
sublingual	O
:	O
13.8	O
hours	O
;	O
vaginal	O
:	O
12.0	O
hours	O
)	O
.	O

Significantly	O
more	O
women	O
in	O
the	O
sublingual	O
group	O
preferred	O
the	O
route	O
to	O
which	O
they	O
were	O
assigned	O
when	O
compared	O
with	O
the	O
vaginal	O
group	O
.	O

The	O
incidence	O
of	O
fever	O
was	O
also	O
less	O
in	O
the	O
sublingual	O
group	O
.	O

CONCLUSION	O
The	O
use	O
of	O
vaginal	Pharmacological
misoprostol	Pharmacological
for	O
second	O
trimester	O
medical	O
abortion	O
resulted	O
in	O
a	O
higher	O
success	O
rate	O
than	O
sublingual	O
misoprostol	Pharmacological
at	O
24	O
hours	O
but	O
the	O
abortion	O
rate	O
was	O
similar	O
at	O
48	O
hours	O
.	O

Vaginal	Pharmacological
misoprostol	Pharmacological
should	O
be	O
the	O
regimen	O
of	O
choice	O
but	O
sublingual	Pharmacological
misoprostol	Pharmacological
is	O
also	O
an	O
effective	O
alternative	O
.	O

Timing	O
for	O
delivering	O
individualized	Educational
patient	Educational
education	Educational
intervention	Educational
to	O
Coronary	O
Artery	O
Bypass	O
Graft	O
patients	O
:	O
An	O
RCT	O
.	O

BACKGROUND	O
The	O
primary	O
focus	O
of	O
this	O
study	O
is	O
on	O
the	O
timing	O
of	O
the	O
delivery	O
of	O
education	O
to	O
patients	O
who	O
had	O
CABG	Surgical
surgery	Surgical
.	Surgical

AIM	O
To	O
determine	O
the	O
efficacy	O
of	O
an	O
individualized	Educational
telephone	Educational
patient	Educational
education	Educational
intervention	Educational
,	O
delivered	O
at	O
two	O
different	O
points	O
in	O
time	O
(	O
1-2	O
days	O
pre-discharge	O
versus	O
1-2	O
days	O
post-discharge	O
)	O
in	O
enhancing	O
the	O
CABG	O
patient	O
's	O
knowledge	O
of	O
self-care	O
behaviours	O
,	O
performance	O
of	O
self-care	O
behaviours	O
,	O
and	O
symptom	O
frequency	O
.	O

METHOD	O
A	O
randomized	O
clinical	O
trial	O
that	O
included	O
a	O
convenience	O
sample	O
of	O
first	O
time	O
CABG	O
patients	O
.	O

Individuals	O
who	O
received	O
education	Educational
pre-discharge	Educational
were	O
compared	O
to	O
individuals	O
who	O
received	O
education	O
post-discharge	O
on	O
the	O
outcomes	O
.	O

RESULTS	O
Results	O
indicated	O
no	O
statistically	O
significant	O
difference	O
in	O
outcomes	O
between	O
the	O
two	O
time	O
points	O
.	O

As	O
well	O
,	O
anxiety	O
levels	O
were	O
found	O
to	O
be	O
significantly	O
higher	O
in	O
the	O
pre-discharge	O
group	O
than	O
the	O
post-discharge	O
group	O
.	O

CONCLUSIONS	O
The	O
individualized	O
nature	O
of	O
the	O
educational	Educational
intervention	Educational
may	O
have	O
accounted	O
for	O
non-significant	O
findings	O
reported	O
in	O
outcomes	O
between	O
the	O
two	O
time	O
points	O
.	O

PRACTICE	O
IMPLICATIONS	O
Nurses	O
may	O
consider	O
assessing	O
anxiety	O
levels	O
prior	O
to	O
delivery	O
of	O
educational	O
interventions	O
,	O
implement	O
interventions	O
aimed	O
at	O
reducing	O
anxiety	O
levels	O
,	O
and	O
provide	O
individualized	O
teaching	O
.	O

Moderate	Pharmacological
sodium	Pharmacological
restriction	Pharmacological
,	O
angiotensin	Pharmacological
converting	Pharmacological
enzyme	Pharmacological
inhibition	Pharmacological
,	O
and	O
thiazide	Pharmacological
diuretic	Pharmacological
in	O
the	O
management	O
of	O
essential	O
hypertension	O
.	O

Dietary	Physical
sodium	Physical
restriction	Physical
alone	O
is	O
effective	O
in	O
lowering	O
blood	O
pressure	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
patients	O
with	O
essential	O
hypertension	O
.	O

Homeostatic	O
mechanisms	O
,	O
including	O
activation	O
of	O
the	O
renin-aldosterone	O
system	O
,	O
may	O
counteract	O
the	O
effects	O
of	O
sodium	Physical
restriction	O
.	O

Angiotensin	Pharmacological
converting	Pharmacological
enzyme	Pharmacological
(	Pharmacological
ACE	Pharmacological
)	Pharmacological
inhibitors	Pharmacological
are	O
also	O
effective	O
as	O
sole	O
therapy	O
in	O
many	O
patients	O
with	O
essential	O
hypertension	O
,	O
but	O
may	O
be	O
less	O
effective	O
in	O
those	O
with	O
low-renin	O
hypertension	O
.	O

The	O
combination	O
of	O
dietary	Pharmacological
sodium	Pharmacological
restriction	Pharmacological
with	O
blockade	O
of	O
the	O
renin	O
system	O
by	O
an	O
ACE	Pharmacological
inhibitor	Pharmacological
is	O
a	O
particularly	O
effective	O
way	O
to	O
improve	O
blood	O
pressure	O
control	O
.	O

Addition	O
of	O
a	O
thiazide	Pharmacological
diuretic	Pharmacological
will	O
reduce	O
pressure	O
further	O
.	O

Pegfilgrastim	Pharmacological
for	O
peripheral	O
CD34+	O
mobilization	O
in	O
patients	O
with	O
solid	O
tumours	O
.	O

The	O
efficacy	O
of	O
pegfilgrastim+/-chemotherapy	Pharmacological
for	O
mobilizing	O
stem	O
cells	O
in	O
patients	O
with	O
solid	O
tumours	O
was	O
assessed	O
.	O

In	O
cycle	O
0	O
,	O
a	O
14-day	O
prechemotherapy	O
cycle	O
,	O
patients	O
(	O
N=61	O
)	O
were	O
randomized	O
open-label	O
to	O
single	O
doses	O
of	O
pegfilgrastim	Pharmacological
(	O
6	O
,	O
12	O
or	O
18	O
mg	O
)	O
on	O
day	O
1	O
,	O
or	O
daily	O
filgrastim	Pharmacological
(	O
10	O
microg/kg	O
)	O
for	O
<	O
or	O
=7	O
days	O
.	O

Mean	O
peak	O
peripheral	O
CD34+	O
cell	O
counts	O
increased	O
with	O
pegfilgrastim	Pharmacological
dose	O
,	O
but	O
were	O
significantly	O
higher	O
than	O
filgrastim	Pharmacological
only	O
at	O
the	O
18	O
mg	O
dose	O
(	O
10.17	O
vs	O
4.96	O
x	O
10	O
(	O
4	O
)	O
/ml	O
;	O
P=0.014	O
)	O
.	O

In	O
the	O
clinically	O
relevant	O
period	O
of	O
days	O
3-7	O
,	O
both	O
12	O
and	O
18	O
mg	O
pegfilgrastim	Pharmacological
doses	O
produced	O
significantly	O
higher	O
peak	O
CD34+	O
counts	O
(	O
8.18	O
and	O
9.96	O
vs	O
4.51	O
x	O
10	O
(	O
4	O
)	O
/ml	O
for	O
filgrastim	Pharmacological
;	Pharmacological
P=0.034	O
and	O
0.006	O
)	O
.	O

In	O
cycle	O
1	O
,	O
patients	O
received	O
carboplatin/paclitaxel	Pharmacological
on	O
day	O
1	O
,	O
followed	O
from	O
day	O
2	O
by	O
pegfilgrastim	Pharmacological
6-18	O
mg	O
or	O
daily	O
filgrastim	Pharmacological
(	O
5	O
microg/kg/day	O
for	O
<	O
or	O
=14	O
days	O
)	O
as	O
per	O
randomization	O
in	O
cycle	O
0	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
mean	O
peak	O
CD34+	O
count	O
between	O
pegfilgrastim	Pharmacological
and	O
filgrastim	Pharmacological
,	O
but	O
there	O
was	O
an	O
advantage	O
for	O
pegfilgrastim	Pharmacological
18	O
mg	O
in	O
the	O
relevant	O
period	O
of	O
days	O
7-12	O
(	O
3.14	O
vs	O
1.19	O
x	O
10	O
(	O
4	O
)	O
/ml	O
;	O
P=0.043	O
)	O
.	O

A	O
single	O
pegfilgrastim	Pharmacological
dose	O
(	O
>	O
or	O
=6	O
mg	O
)	O
could	O
be	O
substituted	O
for	O
daily	O
filgrastim	Pharmacological
in	O
cytokine-only	O
peripheral	O
CD34+	O
cell	O
mobilization	O
.	O

Double-blind	O
comparison	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
trandolapril	Pharmacological
2	O
mg	O
and	O
hydrochlorothiazide	Pharmacological
25	O
mg	O
in	O
patients	O
with	O
mild-to-moderate	O
essential	O
hypertension	O
.	O

Investigator	O
Study	O
Group	O
.	O

This	O
multicenter	O
international	O
trial	O
recruited	O
205	O
patients	O
from	O
16	O
investigators	O
.	O

After	O
a	O
4-week	O
,	O
single-blind	O
placebo	Control
run-in	O
,	O
patients	O
were	O
randomized	O
to	O
receive	O
16	O
weeks	O
of	O
trandolapril	Pharmacological
2	O
mg/day	O
(	O
68	O
patients	O
)	O
,	O
hydrochlorothiazide	Pharmacological
(	Pharmacological
HCTZ	Pharmacological
)	Pharmacological
25	O
mg/day	O
(	O
68	O
patients	O
)	O
,	O
or	O
the	O
combination	O
(	O
69	O
patients	O
)	O
.	O

Morning	O
predosing	O
supine	O
diastolic	O
blood	O
pressure	O
(	O
DBP	O
)	O
was	O
the	O
primary	O
efficacy	O
measurement	O
.	O

Intention-to-treat	O
analysis	O
showed	O
significant	O
decreases	O
in	O
all	O
three	O
groups	O
in	O
mean	O
(	O
+/-	O
SEM	O
)	O
supine	O
DBP	O
throughout	O
the	O
study	O
,	O
with	O
no	O
significant	O
differences	O
at	O
week	O
16	O
between	O
trandolapril	O
(	O
-10.6	O
+/-	O
1.3	O
mm	O
Hg	O
)	O
and	O
HCTZ	O
(	O
-10.9	O
+/-	O
1.3	O
mm	O
Hg	O
)	O
.	O

The	O
combination	O
gave	O
a	O
significantly	O
greater	O
reduction	O
than	O
either	O
drug	O
alone	O
(	O
-15.1	O
+/-	O
1.13	O
mm	O
Hg	O
)	O
.	O

Blood	O
pressure	O
was	O
normalized	O
in	O
the	O
combination	O
group	O
in	O
67	O
%	O
of	O
patients	O
,	O
a	O
significantly	O
higher	O
proportion	O
than	O
either	O
trandolapril	O
(	O
63	O
%	O
)	O
or	O
HCTZ	O
(	O
60	O
%	O
;	O
p	O
=	O
0.04	O
)	O
.	O

Each	O
treatment	O
was	O
well	O
tolerated	O
.	O

The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
in	O
all	O
three	O
groups	O
.	O

Trandolapril	O
2	O
mg	O
once	O
daily	O
is	O
an	O
effective	O
antihypertensive	O
agent	O
,	O
comparable	O
to	O
HCTZ	O
.	O

Furthermore	O
,	O
the	O
combination	O
of	O
the	O
two	O
drugs	O
was	O
shown	O
to	O
enhance	O
the	O
antihypertensive	O
effect	O
of	O
the	O
two	O
compounds	O
alone	O
.	O

Pilot	O
comparison	O
between	O
potassium	Surgical
titanyl	Surgical
phosphate	Surgical
laser	Surgical
and	O
bipolar	Surgical
radiofrequency	Surgical
in	O
paediatric	O
tonsillectomy	O
.	O

OBJECTIVES	O
To	O
compare	O
the	O
advantages	O
and	O
disadvantages	O
of	O
potassium	Surgical
titanyl	Surgical
phosphate	Surgical
laser	Surgical
with	O
those	O
of	O
bipolar	Surgical
radiofrequency	Surgical
techniques	Surgical
,	O
in	O
paediatric	O
tonsillectomy	O
.	O

STUDY	O
DESIGN	O
Prospective	O
,	O
randomised	O
,	O
clinical	O
study	O
.	O

PATIENTS	O
AND	O
METHODS	O
From	O
July	O
2004	O
to	O
April	O
2006	O
,	O
80	O
patients	O
aged	O
between	O
10	O
and	O
15	O
years	O
,	O
with	O
tonsillectomy	Surgical
planned	O
for	O
chronic	O
tonsillitis	O
,	O
were	O
included	O
in	O
the	O
study	O
.	O

Children	O
were	O
prospectively	O
randomised	O
into	O
two	O
equal	O
groups	O
:	O
potassium	Surgical
titanyl	Surgical
phosphate	Surgical
laser	Surgical
tonsillectomy	Surgical
and	O
bipolar	Surgical
radiofrequency	Surgical
tonsillectomy	Surgical
.	O

Operative	O
time	O
and	O
intra-operative	O
blood	O
loss	O
were	O
recorded	O
.	O

Patients	O
were	O
scheduled	O
for	O
follow	O
up	O
during	O
the	O
first	O
,	O
second	O
and	O
fourth	O
post-operative	O
weeks	O
.	O

They	O
were	O
asked	O
to	O
record	O
their	O
pain	O
and	O
discomfort	O
on	O
a	O
standardised	O
visual	O
analogue	O
scale	O
,	O
from	O
zero	O
(	O
no	O
pain	O
)	O
to	O
10	O
(	O
severe	O
pain	O
)	O
.	O

Post-operative	O
complications	O
were	O
also	O
recorded	O
and	O
managed	O
.	O

RESULTS	O
The	O
potassium	Surgical
titanyl	Surgical
phosphate	Surgical
laser	Surgical
group	Surgical
showed	O
a	O
slightly	O
longer	O
operative	O
time	O
(	O
mean	O
12	O
minutes	O
)	O
than	O
the	O
bipolar	O
radiofrequency	O
group	O
(	O
mean	O
10	O
minutes	O
)	O
.	O

Intra-operative	O
blood	O
loss	O
was	O
significantly	O
less	O
in	O
the	O
potassium	Surgical
titanyl	Surgical
phosphate	Surgical
laser	Surgical
group	O
(	O
mean	O
21	O
cm3	O
)	O
than	O
in	O
the	O
bipolar	Surgical
radiofrequency	Surgical
group	Surgical
(	O
mean	O
30	O
cm3	O
)	O
.	O

In	O
the	O
first	O
week	O
,	O
post-operative	O
pain	O
scores	O
were	O
less	O
in	O
the	O
potassium	Surgical
titanyl	Surgical
phosphate	Surgical
laser	Surgical
group	O
than	O
in	O
the	O
bipolar	O
radiofrequency	O
group	O
(	O
means	O
7.5	O
and	O
8.5	O
,	O
respectively	O
)	O
.	O

However	O
,	O
in	O
the	O
second	O
week	O
pain	O
scores	O
increased	O
more	O
in	O
the	O
potassium	O
titanyl	O
phosphate	O
laser	O
group	O
than	O
in	O
the	O
bipolar	O
radiofrequency	O
group	O
(	O
means	O
8.5	O
and	O
6	O
,	O
respectively	O
)	O
.	O

In	O
the	O
fourth	O
week	O
,	O
both	O
groups	O
showed	O
equal	O
and	O
nearly	O
normal	O
pain	O
scores	O
.	O

No	O
case	O
of	O
reactionary	O
post-tonsillectomy	O
haemorrhage	O
was	O
recorded	O
in	O
either	O
group	O
.	O

Only	O
one	O
case	O
of	O
secondary	O
post-tonsillectomy	O
haemorrhage	O
was	O
recorded	O
,	O
in	O
the	O
potassium	O
titanyl	O
phosphate	O
laser	O
group	O
(	O
2.5	O
per	O
cent	O
)	O
,	O
managed	O
conservatively	O
.	O

CONCLUSION	O
Both	O
the	O
potassium	Surgical
titanyl	Surgical
phosphate	Surgical
and	O
the	O
bipolar	Surgical
radiofrequency	Surgical
techniques	Surgical
were	O
safe	O
and	O
easy	O
to	O
use	O
for	O
tonsillectomy	O
,	O
with	O
reduced	O
operative	O
time	O
,	O
blood	O
loss	O
and	O
complication	O
rates	O
and	O
better	O
post-operative	O
general	O
patient	O
condition	O
.	O

Potassium	Surgical
titanyl	Surgical
phosphate	Surgical
laser	Surgical
resulted	O
in	O
reduced	O
operative	O
bleeding	O
and	O
immediate	O
post-operative	O
pain	O
,	O
compared	O
with	O
the	O
bipolar	O
radiofrequency	O
technique	O
.	O

However	O
,	O
potassium	Surgical
titanyl	Surgical
phosphate	Surgical
laser	Surgical
required	O
slightly	O
more	O
operative	O
time	O
and	O
caused	O
more	O
late	O
post-operative	O
pain	O
than	O
the	O
bipolar	O
radiofrequency	O
technique	O
.	O

The	O
low	O
rate	O
of	O
recorded	O
complications	O
showed	O
that	O
both	O
techniques	O
cause	O
little	O
damage	O
to	O
the	O
tonsillar	O
bed	O
during	O
dissection	O
,	O
thus	O
minimising	O
complications	O
.	O

Comparison	O
of	O
the	O
time	O
required	O
to	O
administer	O
three	O
different	O
fluke	Pharmacological
and	Pharmacological
worm	Pharmacological
combination	Pharmacological
products	Pharmacological
to	O
commercial	O
beef	O
cattle	O
at	O
housing	O
.	O

Larger	O
livestock	O
units	O
,	O
a	O
decline	O
in	O
the	O
farm	O
labor	O
force	O
,	O
animal	O
welfare	O
concerns	O
,	O
and	O
a	O
trend	O
toward	O
more	O
selective	O
use	O
of	O
drugs	O
have	O
increased	O
the	O
focus	O
on	O
animal	O
handling	O
,	O
time	O
management	O
,	O
convenience	O
,	O
and	O
compliance	O
in	O
administering	O
veterinary	O
therapeutics	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
quantify	O
and	O
compare	O
the	O
time	O
needed	O
to	O
treat	O
commercial	O
beef	O
cattle	O
with	O
three	Pharmacological
fluke	Pharmacological
and	Pharmacological
worm	Pharmacological
combination	Pharmacological
products	Pharmacological
with	O
different	O
administration	O
profiles	O
.	O

Young	O
beef	O
cattle	O
(	O
n	O
=	O
270	O
)	O
weighing	O
approximately	O
400	O
kg	O
were	O
allocated	O
to	O
batches	O
of	O
five	O
,	O
which	O
were	O
randomly	O
assigned	O
to	O
receive	O
ivermectin	Pharmacological
+	O
clorsulon	Pharmacological
injection	Pharmacological
,	O
ivermectin	Pharmacological
+	O
closantel	Pharmacological
injection	Pharmacological
,	O
or	O
levamisole	Pharmacological
+	O
triclabendazole	Pharmacological
oral	O
drench	O
.	O

The	O
mean	O
time	O
needed	O
to	O
administer	O
ivermectin	Pharmacological
+	O
clorsulon	Pharmacological
(	O
single	O
injection	O
)	O
to	O
five	O
cattle	O
was	O
31	O
seconds	O
,	O
which	O
was	O
significantly	O
less	O
than	O
the	O
100	O
seconds	O
needed	O
for	O
ivermectin	Pharmacological
+	O
closantel	Pharmacological
(	O
two	O
injections	O
)	O
and	O
the	O
126	O
seconds	O
needed	O
for	O
levamisole	Pharmacological
+	O
triclabendazole	Pharmacological
(	O
P	O
<	O
.001	O
)	O
.	O

Such	O
quantitative	O
data	O
can	O
allow	O
for	O
better	O
planning	O
and	O
selection	O
of	O
parasiticide	O
treatment	O
approaches	O
at	O
the	O
farm	O
level	O
.	O

18F-FDG	O
PET/CT	O
for	O
early	O
prediction	O
of	O
response	O
to	O
neoadjuvant	Pharmacological
lapatinib	Pharmacological
,	O
trastuzumab	Pharmacological
,	O
and	O
their	Pharmacological
combination	Pharmacological
in	O
HER2-positive	O
breast	O
cancer	O
:	O
results	O
from	O
Neo-ALTTO	O
.	O

UNLABELLED	O
Molecular	O
imaging	O
receives	O
increased	O
attention	O
for	O
selecting	O
patients	O
who	O
will	O
benefit	O
from	O
targeted	O
anticancer	O
therapies	O
.	O

Neo-ALTTO	O
(	O
Neoadjuvant	Pharmacological
Lapatinib	Pharmacological
and/or	O
Trastuzumab	Pharmacological
Treatment	O
Optimisation	O
)	O
enrolled	O
455	O
women	O
with	O
invasive	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
(	O
HER2	O
)	O
-positive	O
breast	O
cancer	O
and	O
compared	O
rates	O
of	O
pathologic	O
complete	O
response	O
(	O
pCR	O
)	O
to	O
neoadjuvant	Pharmacological
lapatinib	Pharmacological
,	O
trastuzumab	Pharmacological
,	O
and	O
their	O
combination	Pharmacological
.	O

Each	O
anti-HER2	Pharmacological
therapy	Pharmacological
was	O
given	O
alone	O
for	O
6	O
wk	O
,	O
followed	O
by	O
12	O
wk	O
of	O
the	O
same	O
therapy	O
plus	O
weekly	O
paclitaxel	Pharmacological
.	Pharmacological

The	O
early	O
metabolic	O
effects	O
of	O
the	O
anti-HER2	Pharmacological
therapies	Pharmacological
on	O
the	O
primary	O
tumors	O
and	O
their	O
predictive	O
values	O
for	O
pCR	O
were	O
assessed	O
in	O
a	O
subset	O
of	O
patients	O
.	O

METHODS	O
Eighty-six	O
patients	O
underwent	O
(	O
18	O
)	O
F-FDG	O
PET/CT	O
at	O
baseline	O
and	O
weeks	O
2	O
and	O
6	O
of	O
anti-HER2	Pharmacological
treatment	Pharmacological
.	Pharmacological

An	O
imaging	O
core	O
laboratory	O
provided	O
central	O
validation	O
,	O
and	O
2	O
independent	O
reviewers	O
,	O
masked	O
to	O
assigned	O
treatment	O
arm	O
and	O
clinical	O
outcomes	O
,	O
performed	O
consensus	O
(	O
18	O
)	O
F-FDG	O
PET/CT	O
readings	O
.	O

Maximum	O
standardized	O
uptake	O
value	O
(	O
SUVmax	O
)	O
reductions	O
from	O
baseline	O
were	O
used	O
to	O
measure	O
metabolic	O
response	O
.	O

RESULTS	O
Seventy-seven	O
of	O
the	O
86	O
enrolled	O
patients	O
presented	O
an	O
evaluable	O
baseline	O
(	O
18	O
)	O
F-FDG	O
PET/CT	O
scan	O
;	O
of	O
these	O
,	O
68	O
and	O
66	O
were	O
evaluable	O
at	O
weeks	O
2	O
and	O
6	O
,	O
respectively	O
.	O

Metabolic	O
responses	O
in	O
the	O
primary	O
tumors	O
were	O
evident	O
after	O
2	O
wk	O
of	O
targeted	O
therapy	O
and	O
correlated	O
highly	O
with	O
metabolic	O
responses	O
at	O
week	O
6	O
(	O
R	O
(	O
2	O
)	O
=	O
0.81	O
)	O
.	O

pCRs	O
were	O
associated	O
with	O
greater	O
SUVmax	O
reductions	O
at	O
both	O
time	O
points	O
.	O

Mean	O
SUVmax	O
reductions	O
for	O
pCR	O
and	O
non-pCR	O
,	O
respectively	O
,	O
were	O
54.3	O
%	O
versus	O
32.8	O
%	O
at	O
week	O
2	O
(	O
P	O
=	O
0.02	O
)	O
and	O
61.5	O
%	O
versus	O
34.1	O
%	O
at	O
week	O
6	O
(	O
P	O
=	O
0.02	O
)	O
.	O

(	O
18	O
)	O
F-FDG	O
PET/CT	O
metabolic	O
response	O
rates	O
at	O
weeks	O
2	O
and	O
6	O
were	O
71.6	O
%	O
and	O
60	O
%	O
,	O
respectively	O
using	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
criteria	O
;	O
pCR	O
rates	O
were	O
twice	O
as	O
high	O
for	O
(	O
18	O
)	O
F-FDG	O
PET/CT	O
responders	O
than	O
nonresponders	O
(	O
week	O
2	O
:	O
42	O
%	O
vs.	O
21	O
%	O
,	O
P	O
=	O
0.12	O
;	O
week	O
6	O
:	O
44	O
%	O
vs.	O
19	O
%	O
,	O
P	O
=	O
0.05	O
)	O
.	O

CONCLUSION	O
Early	O
metabolic	O
assessment	O
using	O
(	O
18	O
)	O
F-FDG	O
PET/CT	O
can	O
identify	O
patients	O
with	O
an	O
increased	O
likelihood	O
of	O
pCR	O
after	O
neoadjuvant	Pharmacological
trastuzumab	Pharmacological
,	O
lapatinib	Pharmacological
,	O
or	O
their	O
combination	Pharmacological
when	O
given	O
with	O
chemotherapy	Pharmacological
.	Pharmacological

Double-blind	O
comparison	O
of	O
doxepin	Pharmacological
versus	O
bupropion	Pharmacological
in	O
outpatients	O
with	O
a	O
major	O
depressive	O
disorder	O
.	O

A	O
double-blind	O
controlled	O
study	O
comparing	O
the	O
effects	O
of	O
bupropion	Pharmacological
to	O
doxepin	Pharmacological
in	O
outpatients	O
with	O
primary	O
depression	O
was	O
conducted	O
to	O
evaluate	O
efficacy	O
and	O
safety	O
differences	O
between	O
the	O
two	O
drugs	O
.	O

Following	O
a	O
7-day	O
placebo	Control
washout	O
period	O
,	O
patients	O
could	O
be	O
treated	O
for	O
up	O
to	O
13	O
weeks	O
on	O
either	O
treatment	O
.	O

Antidepressant	O
response	O
was	O
assessed	O
by	O
the	O
Hamilton	O
Depression	O
and	O
Anxiety	O
Scales	O
,	O
Clinical	O
Global	O
Severity	O
and	O
Improvement	O
Ratings	O
,	O
and	O
the	O
Zung	O
Self-Rating	O
Depression	O
Scale	O
.	O

Comparable	O
efficacy	O
between	O
the	O
compounds	O
was	O
found	O
across	O
the	O
13-week	O
study	O
.	O

Doxepin	Pharmacological
differed	O
from	O
bupropion	Pharmacological
mainly	O
on	O
the	O
sleep	O
factor	O
of	O
the	O
Hamilton	O
Depression	O
Scale	O
,	O
with	O
doxepin	Pharmacological
improving	O
sleep	O
to	O
a	O
greater	O
extent	O
than	O
bupropion	Pharmacological
.	Pharmacological

Doxepin	Pharmacological
produced	O
a	O
greater	O
incidence	O
of	O
anticholinergic	O
side	O
effects	O
,	O
including	O
dry	O
mouth	O
,	O
constipation	O
,	O
sleepiness	O
,	O
and	O
tiredness	O
,	O
in	O
comparison	O
to	O
bupropion	Pharmacological
.	Pharmacological

Also	O
,	O
increased	O
appetite	O
and	O
weight	O
gain	O
were	O
consistent	O
side	O
effects	O
of	O
doxepin	Pharmacological
relative	O
to	O
bupropion	Pharmacological
.	Pharmacological

Controlled	O
clinical	O
trial	O
of	O
IV	O
cyclophosphamide	Pharmacological
versus	O
IV	O
methylprednisolone	Pharmacological
in	O
severe	O
neurological	O
manifestations	O
in	O
systemic	O
lupus	O
erythematosus	O
.	O

BACKGROUND	O
Severe	O
neurological	O
involvement	O
in	O
systemic	O
lupus	O
erythematosus	O
(	O
NPSLE	O
)	O
is	O
one	O
of	O
the	O
most	O
dreadful	O
complications	O
of	O
the	O
disease	O
.	O

OBJECTIVE	O
To	O
identify	O
the	O
best	O
drug	O
,	O
dose	O
,	O
and	O
treatment	O
.	O

PATIENTS	O
AND	O
METHODS	O
The	O
study	O
was	O
a	O
controlled	O
clinical	O
trial	O
at	O
two	O
tertiary	O
care	O
centres	O
of	O
patients	O
with	O
SLE	O
according	O
to	O
the	O
ACR	O
criteria	O
,	O
with	O
incident	O
(	O
no	O
more	O
than	O
15	O
days	O
)	O
onset	O
of	O
severe	O
NP	O
manifestations	O
such	O
as	O
seizures	O
,	O
optic	O
neuritis	O
,	O
peripheral	O
or	O
cranial	O
neuropathy	O
,	O
coma	O
,	O
brainstem	O
disease	O
,	O
or	O
transverse	O
myelitis	O
.	O

Induction	O
treatment	O
with	O
3	O
g	O
of	O
IV	O
methylprednisolone	Pharmacological
(	O
MP	O
)	O
followed	O
by	O
either	O
IV	O
monthly	O
cyclophosphamide	Pharmacological
(	O
Cy	O
)	O
versus	O
IV	Pharmacological
MP	Pharmacological
bimonthly	Pharmacological
every	O
4	O
months	O
for	O
1	O
year	O
and	O
then	O
IV	O
Cy	O
or	O
IV	O
MP	O
every	O
3	O
months	O
for	O
another	O
year	O
.	O

The	O
primary	O
end	O
point	O
was	O
response	O
to	O
treatment	O
:	O
at	O
least	O
20	O
%	O
improvement	O
from	O
basal	O
conditions	O
on	O
clinical	O
,	O
laboratory	O
,	O
or	O
specific	O
neurological	O
testing	O
variables	O
.	O

RESULTS	O
Overall	O
,	O
a	O
response	O
rate	O
of	O
75	O
%	O
was	O
observed	O
.	O

Of	O
the	O
32	O
patients	O
studied	O
,	O
18/19	O
receiving	O
Cy	O
and	O
7/13	O
receiving	O
MP	O
responded	O
to	O
treatment	O
(	O
p	O
<	O
0.03	O
)	O
.	O

CONCLUSIONS	O
Cy	O
seems	O
to	O
be	O
more	O
effective	O
than	O
MP	O
in	O
the	O
treatment	O
of	O
acute	O
,	O
severe	O
NPSLE	O
.	O

[	O
Effect	O
of	O
liu	Pharmacological
wei	Pharmacological
di	Pharmacological
huang	Pharmacological
or	O
jin	Pharmacological
gui	Pharmacological
shen	Pharmacological
qi	Pharmacological
decoction	Pharmacological
as	O
on	O
adjuvant	O
treatment	O
in	O
small	O
cell	O
lung	O
cancer	O
]	O
.	O

Eighty-three	O
patients	O
with	O
small	O
cell	O
lung	O
cancer	O
were	O
randomized	O
with	O
or	O
without	O
using	O
a	O
traditional	Pharmacological
Chinese	Pharmacological
Kidney-tonifying	Pharmacological
decoction	Pharmacological
(	O
Liu	Pharmacological
Wei	Pharmacological
Di	Pharmacological
Huang	Pharmacological
or	O
Jin	Pharmacological
Gui	Pharmacological
Shen	Pharmacological
Qi	Pharmacological
medicinal	Pharmacological
decoction	Pharmacological
)	O
in	O
chemotherapy	O
or	O
radiotherapy	O
courses	O
.	O

74	O
patients	O
were	O
availble	O
to	O
be	O
analysis	O
.	O

The	O
two	O
treatment	O
groups	O
were	O
well-matched	O
in	O
age	O
,	O
sex	O
,	O
stage	O
and	O
performance	O
status	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
difference	O
in	O
response	O
rate	O
and	O
the	O
median	O
survival	O
between	O
two	O
groups	O
.	O

The	O
overall	O
response	O
rate	O
(	O
CR+PR	O
)	O
was	O
91.5	O
%	O
for	O
Chinese	Pharmacological
herb	Pharmacological
group	O
and	O
46.9	O
%	O
for	O
control	O
group	O
(	O
P	O
less	O
than	O
0.001	O
)	O
.	O

The	O
median	O
survival	O
was	O
16	O
months	O
for	O
the	O
traditional	O
Chinese	Pharmacological
Kidney-tonifying	Pharmacological
decoction	Pharmacological
group	O
,	O
and	O
10	O
months	O
for	O
the	O
control	O
group	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

Survival	O
curve	O
(	O
Kaplan-meire	O
's	O
)	O
of	O
the	O
Chinese	O
herb	O
group	O
was	O
better	O
than	O
that	O
of	O
the	O
control	O
group	O
.	O

10	O
patients	O
of	O
Chinese	Pharmacological
herb	Pharmacological
group	O
was	O
alive	O
beyond	O
more	O
than	O
2	O
years	O
.	O

Until	O
now	O
,	O
4	O
patients	O
in	O
the	O
Chinese	Pharmacological
herb	Pharmacological
group	O
,	O
one	O
in	O
the	O
control	O
group	O
are	O
still	O
enjoying	O
their	O
disease-free	O
life	O
for	O
more	O
than	O
7	O
years	O
.	O

Hematologic	O
toxicities	O
were	O
observed	O
much	O
frequently	O
in	O
the	O
patients	O
of	O
the	O
control	O
group	O
(	O
P	O
less	O
than	O
0.005	O
and	O
0.01/WBC	O
and	O
BPC	O
)	O
.	O

Results	O
of	O
animal	O
experiments	O
with	O
the	O
same	O
traditional	O
medicinal	O
decoctions	O
as	O
used	O
in	O
clinic	O
have	O
showed	O
immuno-enhancement	O
activities	O
.	O

These	O
results	O
have	O
showed	O
that	O
the	O
traditional	Pharmacological
Chinese	Pharmacological
Kidney-tonifying	Pharmacological
decoction	Pharmacological
may	O
enhance	O
non-specific	O
immunology	O
activities	O
and	O
may	O
be	O
much	O
useful	O
for	O
solid	O
cancer	O
patients	O
as	O
an	O
adjuvant	O
treatment	O
.	O

Comparative	O
efficacy	O
and	O
safety	O
of	O
twice	O
daily	O
fluticasone	Pharmacological
propionate	Pharmacological
powder	Pharmacological
versus	O
placebo	Control
in	O
the	O
treatment	O
of	O
moderate	O
asthma	O
.	O

BACKGROUND	O
Fluticasone	Pharmacological
propionate	Pharmacological
,	O
an	O
inhaled	O
corticosteroid	O
with	O
negligible	O
systemic	O
bioavailability	O
via	O
the	O
oral	O
route	O
,	O
is	O
efficacious	O
in	O
the	O
treatment	O
of	O
asthma	O
when	O
administered	O
via	O
metered-dose	O
inhaler	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
inhaled	Pharmacological
fluticasone	Pharmacological
propionate	Pharmacological
powder	Pharmacological
in	O
patients	O
with	O
moderate	O
asthma	O
previously	O
treated	O
with	O
an	O
inhaled	O
corticosteroid	O
.	O

METHODS	O
This	O
was	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
parallel-group	O
,	O
multicenter	O
study	O
of	O
342	O
adolescent	O
and	O
adult	O
patients	O
with	O
moderate	O
asthma	O
[	O
forced	O
expiratory	O
volume	O
in	O
1	O
second	O
(	O
FEV1	O
)	O
between	O
50	O
%	O
and	O
80	O
%	O
of	O
predicted	O
]	O
treated	O
previously	O
by	O
beclomethasone	Pharmacological
dipropionate	Pharmacological
or	O
triamcinolone	Pharmacological
acetonide	Pharmacological
.	Pharmacological

Patients	O
received	O
fluticasone	Pharmacological
propionate	Pharmacological
powder	Pharmacological
50	O
micrograms	O
,	O
100	O
micrograms	O
,	O
250	O
micrograms	O
,	O
or	O
placebo	Control
via	O
a	O
breath-actuated	O
inhalation	O
device	O
,	O
the	O
Diskhaler	O
,	O
twice	O
daily	O
for	O
12	O
weeks	O
.	O

RESULTS	O
Patients	O
in	O
the	O
fluticasone	O
propionate	O
groups	O
experienced	O
a	O
mean	O
increase	O
from	O
baseline	O
to	O
endpoint	O
in	O
FEV1	O
ranging	O
from	O
0.43	O
L	O
to	O
0.47	O
L.	O
Patients	O
in	O
the	O
placebo	O
group	O
experienced	O
a	O
mean	O
decrease	O
from	O
baseline	O
of	O
0.22	O
L	O
(	O
P	O
<	O
.001	O
)	O
.	O

The	O
probability	O
of	O
patients	O
remaining	O
in	O
the	O
study	O
over	O
time	O
without	O
developing	O
signs	O
of	O
exacerbating	O
asthma	O
was	O
significantly	O
greater	O
in	O
the	O
fluticasone	O
propionate	O
groups	O
than	O
in	O
the	O
placebo	O
group	O
(	O
P	O
=	O
.001	O
)	O
.	O

Asthma	O
symptom	O
scores	O
,	O
supplemental	O
rescue	O
albuterol	O
use	O
,	O
and	O
number	O
of	O
nighttime	O
awakenings	O
due	O
to	O
asthma	O
requiring	O
treatment	O
also	O
improved	O
significantly	O
with	O
all	O
fluticasone	O
propionate	O
treatment	O
regimens	O
compared	O
with	O
placebo	O
(	O
P	O
<	O
.001	O
)	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
at	O
endpoint	O
among	O
the	O
three	O
fluticasone	O
propionate	O
groups	O
.	O

No	O
serious	O
drug-related	O
adverse	O
events	O
occurred	O
.	O

CONCLUSIONS	O
Fluticasone	O
propionate	O
powder	O
(	O
50	O
,	O
100	O
,	O
and	O
250	O
micrograms	O
)	O
was	O
well-tolerated	O
and	O
significantly	O
improved	O
lung	O
function	O
in	O
patients	O
with	O
moderate	O
asthma	O
.	O

Factors	O
predictive	O
of	O
severe	O
hypoglycemia	O
in	O
type	O
1	O
diabetes	O
:	O
analysis	O
from	O
the	O
Juvenile	O
Diabetes	O
Research	O
Foundation	O
continuous	O
glucose	O
monitoring	O
randomized	O
control	O
trial	O
dataset	O
.	O

OBJECTIVE	O
Identify	O
factors	O
predictive	O
of	O
severe	O
hypoglycemia	O
(	O
SH	O
)	O
and	O
assess	O
the	O
clinical	O
utility	O
of	O
continuous	Other
glucose	Other
monitoring	Other
(	Other
CGM	Other
)	Other
to	O
warn	O
of	O
impending	O
SH	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
In	O
a	O
multicenter	O
randomized	O
clinical	O
trial	O
,	O
436	O
children	O
and	O
adults	O
with	O
type	O
1	O
diabetes	O
were	O
randomized	O
to	O
a	O
treatment	O
group	O
that	O
used	O
CGM	Other
(	O
N	O
=	O
224	O
)	O
,	O
or	O
a	O
control	Control
group	O
that	O
used	O
standard	Control
home	Control
blood	Control
glucose	Control
monitoring	Control
(	O
N	O
=	O
212	O
)	O
and	O
completed	O
12	O
months	O
of	O
follow-up	O
.	O

After	O
6	O
months	O
,	O
the	O
original	O
control	O
group	O
initiated	O
CGM	Other
while	O
the	O
treatment	O
group	O
continued	O
use	O
of	O
CGM	O
for	O
6	O
months	O
.	O

Baseline	O
risk	O
factors	O
for	O
SH	O
were	O
evaluated	O
over	O
12	O
months	O
of	O
follow-up	O
using	O
proportional	O
hazards	O
regression	O
.	O

CGM-derived	O
indices	O
of	O
hypoglycemia	O
were	O
used	O
to	O
predict	O
episodes	O
of	O
SH	O
over	O
a	O
24-h	O
time	O
horizon	O
.	O

RESULTS	O
The	O
SH	O
rate	O
was	O
17.9	O
per	O
100	O
person-years	O
,	O
and	O
a	O
higher	O
rate	O
was	O
associated	O
with	O
the	O
occurrence	O
of	O
SH	O
in	O
the	O
prior	O
6	O
months	O
and	O
female	O
sex	O
.	O

SH	O
frequency	O
increased	O
eightfold	O
when	O
30	O
%	O
of	O
CGM	Other
values	O
were	O
?	O
70	O
mg/dL	O
on	O
the	O
prior	O
day	O
(	O
4.5	O
vs.	O
0.5	O
%	O
;	O
P	O
<	O
0.001	O
)	O
,	O
but	O
the	O
positive	O
predictive	O
value	O
(	O
PPV	O
)	O
was	O
low	O
(	O
<	O
5	O
%	O
)	O
.	O

Results	O
were	O
similar	O
for	O
hypoglycemic	O
area	O
under	O
the	O
curve	O
and	O
the	O
low	O
blood	O
glucose	O
index	O
calculated	O
by	O
CGM	Other
.	O

CONCLUSIONS	O
SH	O
in	O
the	O
6	O
months	O
prior	O
to	O
the	O
study	O
was	O
the	O
strongest	O
predictor	O
of	O
SH	O
during	O
the	O
study	O
.	O

CGM-measured	O
hypoglycemia	O
over	O
a	O
24-h	O
span	O
is	O
highly	O
associated	O
with	O
SH	O
the	O
following	O
day	O
(	O
P	O
<	O
0.001	O
)	O
,	O
but	O
the	O
PPV	O
is	O
low	O
.	O

Clofarabine	Pharmacological
?	Pharmacological
fludarabine	Pharmacological
with	O
once	O
daily	O
i.v	O
.	O

busulfan	O
as	O
pretransplant	O
conditioning	O
therapy	O
for	O
advanced	O
myeloid	O
leukemia	O
and	O
MDS	O
.	O

Although	O
a	O
combination	O
of	O
i.v	O
.	O

busulfan	O
(	O
Bu	O
)	O
and	O
fludarabine	Pharmacological
(	O
Flu	O
)	O
is	O
a	O
safe	O
,	O
reduced-toxicity	O
conditioning	O
program	O
for	O
acute	O
myelogenous	O
leukemia/myelodysplastic	O
syndromes	O
(	O
AML/MDS	O
)	O
,	O
recurrent	O
leukemia	O
posttransplantation	O
remains	O
a	O
problem	O
.	O

To	O
enhance	O
the	O
conditioning	O
regimen	O
's	O
antileukemic	O
effect	O
,	O
we	O
decided	O
to	O
supplant	O
Flu	O
with	O
clofarabine	Pharmacological
(	O
Clo	O
)	O
,	O
and	O
assayed	O
the	O
interactions	O
of	O
these	O
nucleoside	O
analogs	O
alone	O
and	O
in	O
combination	O
with	O
Bu	O
in	O
Bu-resistant	O
human	O
cell	O
lines	O
in	O
vitro	O
.	O

We	O
found	O
pronounced	O
synergy	O
between	O
each	O
nucleoside	O
and	O
the	O
alkylator	O
but	O
even	O
more	O
enhanced	O
cytotoxic	O
synergy	O
when	O
the	O
nucleoside	O
analogs	O
were	O
combined	O
prior	O
to	O
exposing	O
the	O
cells	O
to	O
Bu	O
.	O

We	O
then	O
designed	O
a	O
4-arm	O
clinical	O
trial	O
in	O
patients	O
with	O
myeloid	O
leukemia	O
undergoing	O
allogeneic	O
stem	O
cell	O
transplantation	O
(	O
allo-SCT	O
)	O
.	O

Patients	O
were	O
adaptively	O
randomized	O
as	O
follows	O
:	O
Arm	O
I-Clo	O
:	O
Flu	O
10:30	O
mg/m	O
(	O
2	O
)	O
,	O
Arm	O
II-20:20	O
mg/m	O
(	O
2	O
)	O
,	O
Arm	O
III-30:10	O
mg/m	O
(	O
2	O
)	O
,	O
and	O
Arm	O
IV-single-agent	O
Clo	O
at	O
40	O
mg/m	O
(	O
2	O
)	O
.	O

The	O
nucleoside	O
analog	O
(	O
s	O
)	O
were/was	O
infused	O
over	O
1	O
hour	O
once	O
daily	O
for	O
4	O
days	O
,	O
followed	O
on	O
each	O
day	O
by	O
Bu	O
,	O
infused	O
over	O
3	O
hours	O
to	O
a	O
pharmacokinetically	O
targeted	O
daily	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
of	O
6000	O
?Mol-min	O
?	O
10	O
%	O
.	O

Fifty-one	O
patients	O
have	O
been	O
enrolled	O
with	O
a	O
minimum	O
follow-up	O
exceeding	O
100	O
days	O
.	O

There	O
were	O
32	O
males	O
and	O
19	O
females	O
,	O
with	O
a	O
median	O
age	O
of	O
45	O
years	O
(	O
range	O
:	O
6-59	O
)	O
.	O

Nine	O
patients	O
had	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
(	O
BC	O
:	O
2	O
,	O
second	O
AP	O
:	O
3	O
,	O
and	O
tyrosine-kinase	O
inhibitor	O
refractory	O
first	O
chronic	O
phase	O
[	O
CP	O
]	O
:	O
4	O
)	O
.	O

Forty-two	O
patients	O
had	O
AML	O
:	O
14	O
were	O
induction	O
failures	O
,	O
8	O
in	O
first	O
chemotherapy-refractory	O
relapse	O
,	O
7	O
in	O
untreated	O
relapse	O
,	O
3	O
in	O
second	O
or	O
subsequent	O
relapse	O
,	O
4	O
were	O
in	O
second	O
complete	O
remission	O
(	O
CR	O
)	O
,	O
and	O
3	O
in	O
second	O
CR	O
without	O
platelet	O
recovery	O
(	O
CRp	O
)	O
,	O
2	O
were	O
in	O
high-risk	O
CR1	O
.	O

Finally	O
,	O
1	O
patient	O
was	O
in	O
first	O
CRp	O
.	O

Graft-versus-host	O
disease	O
(	O
GVHD	O
)	O
prophylaxis	O
was	O
tacrolimus	O
and	O
mini-methorexate	O
(	O
MTX	O
)	O
,	O
and	O
those	O
who	O
had	O
an	O
unrelated	O
or	O
1	O
antigen-mismatched	O
donor	O
received	O
low-dose	O
rabbit-ATG	O
(	O
Thymoglobulin?	O
)	O
.	O

All	O
patients	O
engrafted	O
.	O

Forty-one	O
patients	O
had	O
active	O
leukemia	O
at	O
the	O
time	O
of	O
transplant	O
,	O
and	O
35	O
achieved	O
CR	O
(	O
85	O
%	O
)	O
.	O

Twenty	O
of	O
the	O
42	O
AML	O
patients	O
and	O
5	O
of	O
9	O
CML	O
patients	O
are	O
alive	O
with	O
a	O
projected	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
of	O
23	O
months	O
.	O

Marrow	O
and	O
blood	O
(	O
T	O
cell	O
)	O
chimerism	O
studies	O
at	O
day	O
+100	O
revealed	O
that	O
both	O
in	O
the	O
lower-dose	O
Clo	O
groups	O
(	O
groups	O
1+2	O
)	O
and	O
the	O
higher-dose	O
Clo	O
groups	O
(	O
groups	O
3+4	O
)	O
,	O
the	O
patients	O
had	O
a	O
median	O
of	O
100	O
%	O
donor	O
(	O
T	O
cell	O
)	O
-derived	O
DNA	O
.	O

There	O
has	O
been	O
no	O
secondary	O
graft	O
failure	O
.	O

In	O
the	O
first	O
100	O
days	O
,	O
1	O
patient	O
died	O
of	O
pneumonia	O
,	O
and	O
1	O
of	O
liver	O
GVHD	O
.	O

We	O
conclude	O
that	O
(	O
1	O
)	O
Clo	O
?	O
Flu	O
with	O
i.v	O
.	O

Bu	O
as	O
pretransplant	O
conditioning	O
is	O
safe	O
in	O
high-risk	O
myeloid	O
leukemia	O
patients	O
;	O
(	O
2	O
)	O
clofarabine	O
is	O
sufficiently	O
immunosuppressive	O
to	O
support	O
allo-SCT	O
in	O
myeloid	O
leukemia	O
;	O
and	O
(	O
3	O
)	O
the	O
median	O
OS	O
of	O
23	O
months	O
in	O
this	O
high-risk	O
patient	O
population	O
is	O
encouraging	O
.	O

Additional	O
studies	O
to	O
evaluate	O
the	O
antileukemic	O
efficacy	O
of	O
Clo	O
?	O
Flu	O
with	O
i.v	O
.	O

Bu	O
as	O
pretransplant	O
conditioning	O
therapy	O
are	O
warranted	O
.	O

Genotyping	Other
of	Other
CYP21	Other
,	O
linked	O
chromosome	O
6p	O
markers	O
,	O
and	O
a	O
sex-specific	O
gene	O
in	O
neonatal	O
screening	O
for	O
congenital	O
adrenal	O
hyperplasia	O
.	O

We	O
investigated	O
the	O
feasibility	O
and	O
diagnostic	O
utility	O
of	O
genotyping	Other
9	Other
CYP21	Other
mutations	O
,	O
linked	O
chromosome	O
6p	O
markers	O
,	O
and	O
a	O
dimorphic	O
X-Y	O
marker	O
from	O
neonatal	O
screening	O
samples	O
.	O

Blood-impregnated	Other
filter	Other
papers	Other
(	O
Guthrie	O
cards	O
)	O
from	O
603	O
randomly	O
chosen	O
New	O
Zealand	O
neonates	O
were	O
genotyped	O
blind	O
to	O
17-hydroxyprogesterone	Other
(	O
17-OHP	O
)	O
levels	O
.	O

Another	O
50	O
samples	O
from	O
Swiss	O
and	O
North	O
American	O
infants	O
with	O
correlative	O
hormonal	O
data	O
were	O
also	O
genotyped	O
.	O

DNA	O
was	O
extracted	O
,	O
and	O
gene-specific	O
PCR	O
was	O
performed	O
.	O

CYP21	Other
PCR	Other
products	O
were	O
subjected	O
to	O
ligase	O
detection	O
reaction	O
,	O
simultaneously	O
analyzing	O
9	O
CYP21	O
mutations	O
;	O
PCR	O
products	O
of	O
other	O
genes	O
were	O
subjected	O
to	O
direct	O
gel	O
analysis	O
.	O

CYP21	Other
genotyping	O
indicated	O
a	O
heterozygote	O
rate	O
of	O
2.8	O
%	O
for	O
classic	O
mutations	O
(	O
excluding	O
CYP21	O
deletions	O
)	O
,	O
and	O
2.0	O
%	O
for	O
nonclassic	O
mutations	O
in	O
New	O
Zealanders	O
.	O

Ten	O
full-term	O
affected	O
neonates	O
showed	O
a	O
wide	O
range	O
of	O
17-OHP	O
levels	O
(	O
15-1400	O
nmol/L	O
)	O
.	O

Sick	O
or	O
preterm	O
infants	O
or	O
infants	O
screened	O
on	O
the	O
first	O
day	O
of	O
life	O
with	O
high	O
17-OHP	O
proved	O
genetically	O
unaffected	O
.	O

Genetic	O
linkage	O
disequilibrium	O
was	O
found	O
between	O
two	O
CYP21	O
mutations	O
and	O
chromosome	O
6p	O
markers	O
.	O

Guthrie	O
cards	O
can	O
be	O
used	O
to	O
accurately	O
genotype	O
CYP21	O
and	O
other	O
relevant	O
markers	O
,	O
potentially	O
enhancing	O
the	O
specificity	O
and	O
sensitivity	O
of	O
congenital	O
adrenal	O
hyperplasia	O
screening	O
.	O

CYP21	Other
heterozygote	O
frequency	O
for	O
classic	O
mutations	O
is	O
higher	O
than	O
expected	O
based	O
on	O
genotype	O
compared	O
with	O
that	O
predicted	O
by	O
hormonal	O
newborn	O
screening	O
.	O

A	O
description	O
of	O
the	O
clinical	O
characteristics	O
at	O
baseline	O
of	O
patients	O
recruited	O
into	O
the	O
Carvedilol	Pharmacological
or	O
Metoprolol	Pharmacological
European	O
Trial	O
(	O
COMET	O
)	O
.	O

BACKGROUND	O
&	O
AIMS	O
The	O
COMET	O
trial	O
was	O
a	O
prospective	O
,	O
double-blind	O
,	O
randomised	O
trial	O
comparing	O
carvedilol	Pharmacological
,	O
a	O
comprehensive	O
adrenergic	O
receptor	O
antagonist	Pharmacological
,	O
with	O
metoprolol	Pharmacological
,	O
a	O
beta-1-selective	Pharmacological
agent	Pharmacological
in	O
patients	O
with	O
heart	O
failure	O
and	O
left	O
ventricular	O
systolic	O
dysfunction	O
.	O

The	O
trial	O
showed	O
a	O
reduction	O
in	O
mortality	O
with	O
carvedilol	Pharmacological
that	O
was	O
consistent	O
across	O
subgroups	O
.	O

The	O
purpose	O
of	O
this	O
report	O
is	O
to	O
describe	O
in	O
greater	O
detail	O
the	O
heterogeneity	O
of	O
this	O
population	O
at	O
baseline	O
with	O
particular	O
reference	O
to	O
the	O
impact	O
of	O
symptomatic	O
severity	O
,	O
age	O
and	O
gender	O
on	O
patient	O
characteristics	O
.	O

METHODS	O
A	O
descriptive	O
report	O
using	O
data	O
entered	O
in	O
the	O
COMET	O
study	O
data-base	O
.	O

RESULTS	O
The	O
characteristics	O
of	O
the	O
population	O
studied	O
were	O
similar	O
to	O
those	O
reported	O
in	O
previous	O
trials	O
of	O
beta-blockers	O
.	O

Almost	O
all	O
patients	O
were	O
receiving	O
diuretics	Pharmacological
and	O
ACE	Pharmacological
inhibitors	Pharmacological
with	O
few	O
patients	O
taking	O
angiotensin	Pharmacological
receptor	Pharmacological
blockers	Pharmacological
.	Pharmacological

As	O
expected	O
,	O
older	O
patients	O
had	O
more	O
co-morbidity	O
.	O

Older	O
patients	O
and	O
women	O
reported	O
worse	O
symptoms	O
and	O
poorer	O
well-being	O
despite	O
similar	O
ventricular	O
dimensions	O
and	O
systolic	O
dysfunction	O
.	O

NT-proBNP	O
was	O
higher	O
in	O
patients	O
with	O
more	O
severe	O
symptoms	O
and	O
older	O
patients	O
but	O
not	O
in	O
women	O
,	O
although	O
differences	O
in	O
NT-proBNP	O
may	O
have	O
been	O
confounded	O
by	O
differences	O
in	O
renal	O
function	O
.	O

CONCLUSION	O
Age	O
and	O
gender	O
,	O
as	O
well	O
as	O
the	O
severity	O
of	O
cardiac	O
dysfunction	O
,	O
appear	O
to	O
have	O
an	O
important	O
effect	O
on	O
the	O
severity	O
of	O
heart	O
failure	O
symptoms	O
and	O
patient	O
'well-being	O
'	O
.	O

This	O
could	O
have	O
important	O
implications	O
for	O
the	O
relationship	O
between	O
symptoms	O
and	O
prognosis	O
and	O
therefore	O
the	O
way	O
in	O
which	O
patients	O
are	O
selected	O
for	O
clinical	O
trials	O
and	O
the	O
goals	O
of	O
treatment	O
.	O

This	O
will	O
be	O
the	O
subject	O
of	O
further	O
analyses	O
.	O

Is	O
a	O
calculated	O
total	O
hip	O
BMD	O
of	O
clinical	O
use	O
?	O
The	O
diagnosis	O
of	O
osteoporosis	O
is	O
based	O
on	O
bone	O
mass	O
measurement	O
.	O

To	O
avoid	O
the	O
errors	O
associated	O
with	O
the	O
measurement	O
of	O
spinal	O
bone	O
density	O
the	O
total	O
hip	O
has	O
been	O
accepted	O
as	O
the	O
standard	O
measurement	O
site	O
.	O

This	O
information	O
is	O
not	O
available	O
for	O
many	O
early	O
measurements	O
.	O

We	O
have	O
assessed	O
whether	O
it	O
is	O
possible	O
to	O
derive	O
clinically	O
useful	O
information	O
about	O
total	Other
hip	Other
bone	Other
mineral	Other
density	Other
(	O
BMD	O
)	O
from	O
measurements	O
at	O
other	O
hip	O
sites	O
.	O

The	O
bone	O
mass	O
measurements	O
of	O
46	O
patients	O
participating	O
in	O
a	O
current	O
trial	O
of	O
therapy	O
for	O
osteoporosis	O
were	O
reviewed	O
.	O

The	O
total	O
hip	O
BMD	O
as	O
directly	O
measured	O
was	O
compared	O
with	O
that	O
obtained	O
from	O
the	O
formula	O
:	O
Total	O
hip	O
BMD	O
=	O
0.48	O
x	O
Neck	O
BMD	O
+	O
0.62	O
x	O
Trochanteric	O
BMD	O
+	O
0.03	O
.	O

In	O
30	O
patients	O
with	O
follow-up	O
data	O
the	O
rate	O
of	O
change	O
in	O
hip	O
BMD	O
over	O
a	O
year	O
was	O
also	O
determined	O
by	O
both	O
methods	O
.	O

In	O
the	O
pretreatment	O
state	O
there	O
was	O
good	O
agreement	O
between	O
the	O
two	O
measures	O
(	O
r2	O
=	O
0.96	O
,	O
SEE	O
0.012	O
g/cm2	O
)	O
.	O

If	O
the	O
formula	O
was	O
used	O
to	O
compute	O
a	O
change	O
in	O
total	O
hip	O
BMD	O
,	O
the	O
agreement	O
between	O
both	O
methods	O
remained	O
good	O
.	O

However	O
,	O
the	O
standard	O
error	O
of	O
the	O
estimate	O
of	O
the	O
change	O
represented	O
59	O
%	O
of	O
the	O
observed	O
change	O
.	O

This	O
indicates	O
that	O
the	O
error	O
associated	O
with	O
this	O
estimate	O
is	O
too	O
great	O
to	O
allow	O
clinically	O
meaningful	O
conclusions	O
to	O
be	O
drawn	O
from	O
calculated	O
total	O
hip	O
BMD	O
.	O

We	O
conclude	O
that	O
,	O
whilst	O
it	O
may	O
be	O
possible	O
to	O
obtain	O
reasonable	O
point	O
estimates	O
of	O
total	O
hip	O
BMD	O
from	O
other	O
measures	O
in	O
the	O
hip	O
,	O
these	O
estimates	O
are	O
too	O
imprecise	O
to	O
allow	O
conclusions	O
about	O
change	O
in	O
BMD	O
to	O
be	O
made	O
.	O

Changes	O
in	O
H	O
reflex	O
and	O
V	O
wave	O
following	O
short-term	Physical
endurance	Physical
and	O
strength	Physical
training	Physical
.	O

This	O
study	O
examined	O
the	O
effects	O
of	O
3	O
wk	O
of	O
either	O
endurance	Physical
or	O
strength	Physical
training	Physical
on	O
plasticity	O
of	O
the	O
neural	O
mechanisms	O
involved	O
in	O
the	O
soleus	O
H	O
reflex	O
and	O
V	O
wave	O
.	O

Twenty-five	O
sedentary	O
healthy	O
subjects	O
were	O
randomized	O
into	O
an	O
endurance	Physical
group	Physical
(	O
n	O
=	O
13	O
)	O
or	O
strength	Physical
group	Physical
(	O
n	O
=	O
12	O
)	O
.	O

Evoked	O
V-wave	O
,	O
H-reflex	O
,	O
and	O
M-wave	O
recruitment	O
curves	O
,	O
maximal	O
voluntary	O
contraction	O
(	O
MVC	O
)	O
,	O
and	O
time-to-task-failure	O
(	O
isometric	O
contraction	O
at	O
40	O
%	O
MVC	O
)	O
of	O
the	O
plantar	O
flexors	O
were	O
recorded	O
before	O
and	O
after	O
training	O
.	O

Following	O
strength	Physical
training	Physical
,	O
MVC	O
of	O
the	O
plantar	O
flexors	O
increased	O
by	O
14.4	O
?	O
5.2	O
%	O
in	O
the	O
strength	O
group	O
(	O
P	O
<	O
0.001	O
)	O
,	O
whereas	O
time-to-task-failure	O
was	O
prolonged	O
in	O
the	O
endurance	O
group	O
(	O
22.7	O
?	O
17.1	O
%	O
;	O
P	O
<	O
0.05	O
)	O
.	O

The	O
V	O
wave-to-maximal	O
M	O
wave	O
(	O
V/M	O
(	O
max	O
)	O
)	O
ratio	O
increased	O
significantly	O
(	O
55.1	O
?	O
28.3	O
%	O
;	O
P	O
<	O
0.001	O
)	O
following	O
strength	O
training	O
,	O
but	O
the	O
maximal	O
H	O
wave-to-maximal	O
M	O
wave	O
(	O
H	O
(	O
max	O
)	O
/M	O
(	O
max	O
)	O
)	O
ratio	O
remained	O
unchanged	O
.	O

Conversely	O
,	O
in	O
the	O
endurance	O
group	O
the	O
V/M	O
(	O
max	O
)	O
ratio	O
was	O
not	O
altered	O
,	O
whereas	O
the	O
H	O
(	O
max	O
)	O
/M	O
(	O
max	O
)	O
ratio	O
increased	O
by	O
30.8	O
?	O
21.7	O
%	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
endurance	Physical
training	Physical
group	O
also	O
displayed	O
a	O
reduction	O
in	O
the	O
H-reflex	O
excitability	O
threshold	O
while	O
the	O
H-reflex	O
amplitude	O
on	O
the	O
ascending	O
limb	O
of	O
the	O
recruitment	O
curve	O
increased	O
.	O

Strength	O
training	O
only	O
elicited	O
a	O
significant	O
decrease	O
in	O
H-reflex	O
excitability	O
threshold	O
,	O
while	O
H-reflex	O
amplitudes	O
over	O
the	O
ascending	O
limb	O
remained	O
unchanged	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
H-reflex	O
pathway	O
is	O
strongly	O
involved	O
in	O
the	O
enhanced	O
endurance	O
resistance	O
that	O
occurs	O
following	O
endurance	Physical
training	Physical
.	O

On	O
the	O
contrary	O
,	O
the	O
improvements	O
in	O
MVC	O
following	O
strength	O
training	O
are	O
likely	O
attributed	O
to	O
increased	O
descending	O
drive	O
and/or	O
modulation	O
in	O
afferents	O
other	O
than	O
Ia	O
afferents	O
.	O

Comparison	O
of	O
patient-controlled	Pharmacological
and	O
nurse-administered	Pharmacological
analgesia	Pharmacological
using	O
intravenous	O
fentanyl	O
during	O
labor	O
.	O

Preliminary	O
observations	O
have	O
shown	O
that	O
fentanyl	Pharmacological
citrate	Pharmacological
,	O
a	O
potent	O
narcotic	O
,	O
is	O
helpful	O
during	O
labor	O
without	O
undue	O
side	O
effects	O
.	O

This	O
randomized	O
prospective	O
investigation	O
compared	O
the	O
patient-controlled	Pharmacological
administration	Pharmacological
of	Pharmacological
fentanyl	Pharmacological
with	O
that	O
of	O
administration	Pharmacological
by	Pharmacological
nurses	Pharmacological
on	Pharmacological
request	Pharmacological
.	Pharmacological

Eighty	O
healthy	O
women	O
beginning	O
active	O
labor	O
(	O
cervical	O
dilation	O
4	O
cm	O
)	O
at	O
term	O
were	O
assigned	O
to	O
receive	O
fentanyl	Pharmacological
intravenously	O
by	O
either	O
patient-controlled	Pharmacological
administration	O
(	O
n=37	O
)	O
or	O
nurse	Pharmacological
administration	Pharmacological
on	O
demand	O
(	O
n=43	O
)	O
.	O

Pain	O
intensity	O
measurements	O
during	O
early	O
and	O
late	O
labor	O
revealed	O
the	O
degree	O
of	O
analgesia	O
to	O
be	O
the	O
same	O
in	O
both	O
groups	O
.	O

The	O
delay	O
in	O
setting	O
up	O
the	O
infusion	O
system	O
and	O
the	O
short	O
time	O
between	O
requesting	O
analgesia	O
and	O
vaginal	O
delivery	O
were	O
limitations	O
with	O
self-administration	O
.	O

Maternal	O
oversedation	O
and	O
vomiting	O
did	O
not	O
occur	O
.	O

Neonatal	O
naloxone	O
therapy	O
was	O
used	O
infrequently	O
,	O
umbilical	O
serum	O
levels	O
of	O
fentanyl	O
were	O
the	O
same	O
in	O
both	O
groups	O
,	O
and	O
postnatal	O
neuroadaptive	O
testing	O
revealed	O
comparable	O
results	O
in	O
both	O
groups	O
.	O

Despite	O
the	O
usefulness	O
of	O
fentanyl	O
during	O
labor	O
,	O
administration	Pharmacological
by	Pharmacological
the	Pharmacological
patient	Pharmacological
had	O
no	O
advantages	O
over	O
administration	Pharmacological
by	Pharmacological
the	Pharmacological
nurses	Pharmacological
in	O
significantly	O
reducing	O
drug	O
use	O
,	O
improving	O
pain	O
relief	O
,	O
or	O
avoiding	O
drowsiness	O
.	O

Nutritional	O
orientation	O
,	O
knowledge	O
and	O
quality	O
of	O
diet	O
in	O
heart	O
failure	O
:	O
randomized	O
clinical	O
trial	O
.	O

BACKGROUND	O
Non-pharmacological	O
measures	O
are	O
recommended	O
for	O
heart	O
failure	O
patients	O
.	O

However	O
,	O
most	O
studies	O
evaluate	O
low	O
sodium	O
diet	O
,	O
while	O
little	O
is	O
known	O
about	O
the	O
effects	O
of	O
interventions	O
to	O
improve	O
adherence	O
and	O
knowledge	O
of	O
patients	O
about	O
diet	O
content	O
.	O

OBJECTIVE	O
To	O
evaluate	O
if	O
a	O
global	O
nutritional	Educational
orientation	Educational
could	O
affect	O
nutritional	O
knowledge	O
,	O
adherence	O
to	O
food	O
guidelines	O
,	O
anthropometrics	O
and	O
quality	O
of	O
life	O
in	O
heart	O
failure	O
patients	O
.	O

METHODS	O
Forty	O
six	O
patients	O
were	O
randomized	O
to	O
intervention	O
or	O
control	O
group	O
.	O

Both	O
groups	O
received	O
usual	Educational
care	Educational
with	Educational
medical	Educational
and	Educational
nursing	Educational
staff	Educational
;	Educational
the	Educational
intervention	Educational
group	Educational
received	Educational
additional	Educational
nutritional	Educational
guidance	Educational
about	Educational
diet	Educational
and	Educational
its	Educational
relationship	Educational
with	Educational
disease	Educational
,	Educational
sources	Educational
of	Educational
nutrients	Educational
,	Educational
and	Educational
reduction	Educational
of	Educational
dietary	Educational
sodium	Educational
and	Educational
fats	Educational
.	Educational

Enforcement	Physical
of	Physical
the	Physical
nutritional	Physical
guidance	Physical
was	O
performed	O
after	O
4	O
weeks	O
.	O

Both	O
groups	O
were	O
evaluated	O
at	O
baseline	O
,	O
and	O
after	O
6	O
weeks	O
and	O
6	O
months	O
.	O

Evaluations	O
included	O
anthropometric	O
parameters	O
,	O
sodium	O
excretion	O
in	O
24-hour	O
urine	O
,	O
dietary	O
recall	O
,	O
nutrition	O
knowledge	O
and	O
quality	O
of	O
life	O
questionnaires	O
.	O

RESULTS	O
Mean	O
age	O
of	O
included	O
patients	O
was	O
58	O
?	O
10	O
years	O
and	O
70	O
%	O
were	O
male	O
.	O

After	O
6	O
months	O
of	O
follow-up	O
,	O
the	O
nutritional	O
knowledge	O
of	O
intervention	O
group	O
increased	O
compared	O
to	O
control	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Caloric	O
,	O
fat	O
and	O
sodium	O
intake	O
decreased	O
in	O
the	O
intervention	O
group	O
compared	O
to	O
control	O
(	O
p	O
<	O
0.05	O
)	O
.	O

No	O
significant	O
differences	O
were	O
seen	O
in	O
quality	O
of	O
life	O
or	O
anthropometric	O
parameters	O
.	O

CONCLUSIONS	O
Nutritional	Physical
orientation	Physical
was	O
effective	O
to	O
modify	O
1	O
)	O
knowledge	O
about	O
food	O
and	O
nutrition	O
,	O
and	O
2	O
)	O
quality	O
of	O
diet	O
in	O
outpatients	O
with	O
heart	O
failure	O
.	O

Further	O
studies	O
are	O
necessary	O
to	O
evaluate	O
the	O
benefits	O
on	O
quality	O
of	O
life	O
and	O
prognosis	O
.	O

[	O
Long	O
term	O
observation	O
in	O
effects	O
of	O
potassium	Pharmacological
and	O
calcium	Pharmacological
supplementation	Pharmacological
on	O
arterial	O
blood	O
pressure	O
and	O
sodium	O
metabolism	O
in	O
adolescents	O
with	O
higher	O
blood	O
pressure	O
]	O
.	O

OBJECTIVE	O
To	O
investigate	O
the	O
effects	O
of	O
potassium	Pharmacological
and	O
calcium	Pharmacological
supplementation	Pharmacological
in	O
table	O
salt	O
on	O
reduction	O
of	O
arterial	O
blood	O
pressure	O
and	O
sodium	O
metabolism	O
in	O
adolescents	O
with	O
higher	O
blood	O
pressure	O
.	O

METHODS	O
A	O
single	O
blind	O
placebo-controlled	Control
trial	O
was	O
carried	O
out	O
for	O
two	O
years	O
in	O
220	O
adolescents	O
with	O
higher	O
blood	O
pressure	O
,	O
aged	O
18	O
-	O
22	O
years	O
,	O
who	O
were	O
randomly	O
divided	O
into	O
supplementary	O
group	O
(	O
n	O
=	O
110	O
)	O
and	O
control	O
group	O
(	O
n	O
=	O
110	O
)	O
.	O

Each	O
of	O
the	O
subjects	O
in	O
the	O
supplementary	O
group	O
and	O
their	O
family	O
members	O
was	O
given	O
10	O
mmol	O
of	O
potassium	Pharmacological
and	O
10	O
mmol	O
of	O
calcium	Pharmacological
mixed	O
in	O
their	O
table	O
salt	O
daily	O
for	O
24	O
months	O
.	O

RESULTS	O
Night	O
urinary	O
sodium	O
and	O
potassium	O
excretion	O
increased	O
(	O
urinary	O
Na	O
(	O
+	O
)	O
,	O
P	O
<	O
0.05	O
;	O
urinary	O
K	O
(	O
+	O
)	O
,	O
P	O
<	O
0.01	O
)	O
and	O
blood	O
pressure	O
lowered	O
by	O
5.3	O
mm	O
Hg/1.8	O
mm	O
Hg	O
in	O
average	O
from	O
the	O
baseline	O
in	O
the	O
supplementary	O
group	O
two	O
years	O
after	O
potassium	Pharmacological
and	O
calcium	Pharmacological
supplementation	Pharmacological
,	O
as	O
compared	O
with	O
that	O
in	O
the	O
control	O
group	O
increased	O
by	O
(	O
1.3/1.7	O
)	O
mm	O
Hg	O
.	O

CONCLUSIONS	O
Adequate	O
supplement	Pharmacological
of	Pharmacological
potassium	Pharmacological
and	O
calcium	Pharmacological
in	O
daily	O
table	O
salt	O
intake	O
was	O
an	O
effective	O
way	O
to	O
prevent	O
form	O
hypertension	O
and	O
could	O
promote	O
their	O
urinary	O
sodium	O
excretion	O
and	O
reduction	O
of	O
arterial	O
blood	O
pressure	O
in	O
adolescents	O
with	O
higher	O
blood	O
pressure	O
.	O

Monitoring	O
tumour	O
cells	O
in	O
the	O
peripheral	O
blood	O
of	O
small	O
cell	O
lung	O
cancer	O
patients	O
.	O

BACKGROUND	O
Flow	Other
cytometry	Other
was	O
used	O
to	O
enumerate	O
tumour	O
cells	O
in	O
longitudinal	O
studies	O
of	O
peripheral	O
blood	O
from	O
small	O
cell	O
lung	O
cancer	O
(	O
SCLC	O
)	O
patients	O
,	O
together	O
with	O
magnetic	O
bead	O
selection	O
to	O
isolate	O
and	O
identify	O
these	O
cells	O
.	O

As	O
part	O
of	O
a	O
trial	O
,	O
11	O
patients	O
received	O
either	O
standard	O
(	O
four	O
weekly	O
)	O
chemotherapy	Pharmacological
with	O
ifosfamide	Pharmacological
,	O
carboplatin	Pharmacological
,	O
and	O
etoposide	Pharmacological
(	Pharmacological
ICE	Pharmacological
)	Pharmacological
or	O
accelerated	O
(	O
two	O
weekly	O
)	O
ICE	Pharmacological
with	Pharmacological
filgrastim	Pharmacological
(	Pharmacological
granulocyte	Pharmacological
colony-stimulating	Pharmacological
factor	Pharmacological
[	Pharmacological
G-CSF	Pharmacological
]	Pharmacological
)	Pharmacological
and	O
autologous	Pharmacological
stem	Pharmacological
cell	Pharmacological
support	Pharmacological
.	O

METHODS	O
Fresh	O
venous	O
blood	O
was	O
taken	O
throughout	O
treatment	O
and	O
follow-up	O
.	O

Aliquots	O
were	O
stained	O
with	O
a	O
tumour-specific	O
antibody	O
against	O
epithelial	O
tissue	O
(	O
Ber	O
EP4	O
)	O
,	O
verified	O
as	O
a	O
good	O
marker	O
of	O
SCLC	O
cells	O
by	O
immunohistochemistry	O
.	O

Matched	O
samples	O
labelled	O
with	O
Ber	O
EP4	O
were	O
separated	O
magnetically	O
by	O
adding	O
a	O
secondary	O
bead-antibody	O
conjugate	O
for	O
confirmation	O
of	O
tumour	O
cell	O
identity	O
.	O

RESULTS	O
Circulating	O
tumour	O
cells	O
were	O
detected	O
and	O
monitored	O
throughout	O
treatment	O
periods	O
.	O

An	O
initial	O
rise	O
in	O
circulating	O
cells	O
after	O
the	O
first	O
cycle	O
was	O
followed	O
by	O
a	O
fall	O
in	O
both	O
treatment	O
arms	O
to	O
baseline	O
levels	O
set	O
by	O
normal	O
controls	O
.	O

This	O
was	O
achieved	O
by	O
week	O
12	O
in	O
the	O
accelerated	O
treatment	O
arm	O
and	O
by	O
week	O
24	O
in	O
the	O
standard	O
arm	O
.	O

CONCLUSIONS	O
Flow	O
cytometry	O
and	O
magnetic	O
bead	O
isolation	O
can	O
be	O
used	O
to	O
identify	O
changes	O
in	O
numbers	O
of	O
circulating	O
tumour	O
cells	O
in	O
patients	O
undergoing	O
chemotherapy	Pharmacological
for	O
SCLC	O
and	O
thereafter	O
during	O
follow-up	O
periods	O
.	O

Absence	O
of	O
tumour	O
cells	O
may	O
indicate	O
a	O
more	O
favourable	O
patient	O
group	O
who	O
would	O
benefit	O
from	O
a	O
more	O
intense	O
course	O
of	O
treatment	O
.	O

Long-term	O
exposure	O
to	O
belatacept	O
in	O
recipients	O
of	O
extended	O
criteria	O
donor	O
kidneys	O
.	O

Patients	O
in	O
the	O
BENEFIT-EXT	O
study	O
received	O
extended	O
criteria	O
donor	O
kidneys	O
and	O
a	O
more	O
intensive	Pharmacological
(	Pharmacological
MI	Pharmacological
)	Pharmacological
or	Pharmacological
less	Pharmacological
intensive	Pharmacological
(	Pharmacological
LI	Pharmacological
)	Pharmacological
belatacept	Pharmacological
immunosuppression	Pharmacological
regimen	Pharmacological
,	O
or	O
cyclosporine	Pharmacological
A	Pharmacological
(	Pharmacological
CsA	Pharmacological
)	Pharmacological
.	O

Patients	O
who	O
remained	O
on	O
assigned	O
therapy	O
through	O
year	O
3	O
were	O
eligible	O
to	O
enter	O
a	O
long-term	O
extension	O
(	O
LTE	O
)	O
study	O
.	O

Three	O
hundred	O
four	O
patients	O
entered	O
the	O
LTE	O
(	O
n	O
=	O
104	O
MI	O
;	O
n	O
=	O
113	O
LI	O
;	O
n	O
=	O
87	O
CsA	O
)	O
,	O
and	O
260	O
continued	O
treatment	O
through	O
year	O
5	O
(	O
n	O
=	O
91	O
MI	O
;	O
n	O
=	O
100	O
LI	O
;	O
n	O
=	O
69	O
CsA	O
)	O
.	O

Twenty	O
patients	O
died	O
during	O
the	O
LTE	O
(	O
n	O
=	O
5	O
MI	O
;	O
n	O
=	O
9	O
LI	O
;	O
n	O
=	O
6	O
CsA	O
)	O
,	O
and	O
eight	O
experienced	O
graft	O
loss	O
(	O
n	O
=	O
2	O
MI	O
;	O
n	O
=	O
1	O
LI	O
;	O
n	O
=	O
5	O
CsA	O
)	O
.	O

Three	O
patients	O
experienced	O
an	O
acute	O
rejection	O
episode	O
(	O
n	O
=	O
2	O
MI	O
;	O
n	O
=	O
1	O
LI	O
)	O
.	O

The	O
incidence	O
rate	O
of	O
serious	O
adverse	O
events	O
,	O
viral	O
infections	O
and	O
fungal	O
infections	O
was	O
similar	O
across	O
groups	O
during	O
the	O
LTE	O
.	O

There	O
were	O
four	O
cases	O
of	O
posttransplant	O
lymphoproliferative	O
disorder	O
(	O
PTLD	O
)	O
from	O
the	O
beginning	O
of	O
the	O
LTE	O
to	O
year	O
5	O
(	O
n	O
=	O
3	O
LI	O
;	O
n	O
=	O
1	O
CsA	O
)	O
;	O
two	O
of	O
three	O
PTLD	O
cases	O
in	O
the	O
LI	O
group	O
were	O
in	O
patients	O
who	O
were	O
seronegative	O
for	O
Epstein-Barr	O
virus	O
(	O
EBV	O
(	O
-	O
)	O
)	O
at	O
transplantation	O
.	O

Mean	O
?	O
SD	O
calculated	O
GFR	O
at	O
year	O
5	O
was	O
55.9	O
?	O
17.5	O
(	O
MI	O
)	O
,	O
59.0	O
?	O
29.1	O
(	O
LI	O
)	O
and	O
44.6	O
?	O
16.4	O
(	O
CsA	O
)	O
mL/min/1.73	O
m	O
(	O
2	O
)	O
.	O

Continued	O
treatment	O
with	O
belatacept	O
was	O
associated	O
with	O
a	O
consistent	O
safety	O
profile	O
and	O
sustained	O
improvement	O
in	O
renal	O
function	O
versus	O
CsA	O
over	O
time	O
.	O

The	O
costs	O
and	O
effects	O
of	O
a	O
nutritional	Educational
education	Educational
program	Educational
following	O
work-site	O
cholesterol	O
screening	O
.	O

OBJECTIVES	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
costs	O
and	O
impact	O
of	O
a	O
nutrition	Educational
education	Educational
program	Educational
following	O
a	O
cholesterol	O
screening	O
.	O

METHODS	O
Forty	O
work-sites	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
educational	Educational
interventions	Educational
:	Educational
a	O
usual	Educational
intervention	Educational
of	Educational
5	Educational
minutes	Educational
of	Educational
counseling	Educational
,	Educational
or	Educational
a	Educational
special	Educational
intervention	Educational
of	Educational
2	Educational
hours	Educational
of	Educational
behaviorally	Educational
based	Educational
education	Educational
on	Educational
dietary	Educational
changes	Educational
to	Educational
lower	Educational
serum	Educational
cholesterol	Educational
.	Educational

Costs	O
were	O
monitored	O
,	O
and	O
cholesterol	O
levels	O
were	O
retested	O
6	O
and	O
12	O
months	O
later	O
.	O

RESULTS	O
The	O
total	O
per-person	O
cost	O
for	O
screening	O
and	O
the	O
educational	O
intervention	O
was	O
about	O
$	O
50	O
.	O

Cholesterol	O
levels	O
differed	O
little	O
between	O
the	O
two	O
intervention	O
groups	O
6	O
months	O
after	O
screening	O
,	O
but	O
after	O
12	O
months	O
those	O
in	O
the	O
special	O
intervention	O
worksites	O
showed	O
a	O
6.5	O
%	O
drop	O
in	O
cholesterol	O
,	O
whereas	O
those	O
at	O
the	O
usual	O
intervention	O
worksites	O
showed	O
a	O
drop	O
of	O
only	O
3.0	O
%	O
.	O

Hence	O
a	O
3.5	O
%	O
cholesterol	O
reduction	O
was	O
attributable	O
to	O
the	O
special	O
intervention	O
.	O

CONCLUSIONS	O
A	O
behaviorally	Educational
based	Educational
nutrition	Educational
education	Educational
program	Educational
following	O
cholesterol	O
screening	O
can	O
have	O
a	O
meaningful	O
impact	O
on	O
long-term	O
cholesterol	O
levels	O
at	O
a	O
low	O
cost	O
.	O

Nutrition	Educational
education	Educational
in	O
work-sites	O
may	O
therefore	O
be	O
a	O
useful	O
way	O
to	O
lower	O
the	O
risk	O
of	O
heart	O
disease	O
in	O
communities	O
.	O

A	O
comparative	O
study	O
of	O
methyldopa	Pharmacological
and	O
labetalol	Pharmacological
in	O
the	O
treatment	O
of	O
hypertension	O
.	O

1	O
Twenty	O
patients	O
with	O
essential	O
hypertension	O
completed	O
a	O
double-blind	O
,	O
dose-tritrated	O
,	O
cross-over	O
comparison	O
of	O
methyldopa	Pharmacological
and	O
labetalol	Pharmacological
.	O

2	O
Average	O
lying	O
BPs	O
(	O
systolic/diastolic	O
)	O
were	O
reduced	O
by	O
28/15	O
mmHg	O
with	O
methyldopa	Pharmacological
and	O
by	O
23/15	O
mmHg	O
with	O
labetalol	Pharmacological
.	Pharmacological

3	O
Average	O
standing	O
BPs	O
(	O
systolic/diastolic	O
)	O
were	O
reduced	O
by	O
29/14	O
mmHg	O
with	O
methyldopa	Pharmacological
and	O
by	O
29/15	O
mmHg	O
with	O
labetalol	Pharmacological
.	Pharmacological

4	O
Both	O
lying	O
and	O
standing	O
heart	O
rates	O
were	O
reduced	O
with	O
labetalol	Pharmacological
.	Pharmacological

5	O
It	O
is	O
concluded	O
that	O
the	O
antihypertensive	O
properties	O
of	O
labetalol	Pharmacological
and	O
methyldopa	Pharmacological
are	O
similar	O
but	O
that	O
larger	O
patient	O
populations	O
are	O
needed	O
to	O
study	O
the	O
relative	O
incidence	O
of	O
subjective	O
adverse	O
effects	O
.	O

Mechanisms	O
underlying	O
the	O
lack	O
of	O
effect	O
of	O
implantable	Surgical
cardioverter-defibrillator	Surgical
therapy	Surgical
on	O
mortality	O
in	O
high-risk	O
patients	O
with	O
recent	O
myocardial	O
infarction	O
:	O
insights	O
from	O
the	O
Defibrillation	O
in	O
Acute	O
Myocardial	O
Infarction	O
Trial	O
(	O
DINAMIT	O
)	O
.	O

BACKGROUND	O
although	O
implantable	Surgical
cardioverter-defibrillators	Surgical
(	O
ICDs	O
)	O
lower	O
mortality	O
in	O
stable	O
patients	O
with	O
low	O
ejection	O
fraction	O
late	O
after	O
myocardial	O
infarction	O
,	O
randomized	O
trials	O
of	O
ICD	Surgical
versus	O
control	O
subjects	O
implanted	O
early	O
after	O
myocardial	O
infarction	O
do	O
not	O
show	O
mortality	O
benefit	O
.	O

Our	O
objective	O
was	O
to	O
investigate	O
possible	O
mechanisms	O
underlying	O
the	O
lack	O
of	O
mortality	O
benefit	O
in	O
the	O
Defibrillation	O
in	O
Acute	O
Myocardial	O
Infarction	O
Trial	O
(	O
DINAMIT	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
this	O
is	O
a	O
secondary	O
analysis	O
of	O
the	O
prospective	O
randomized	O
clinical	O
trial	O
.	O

Outpatients	O
with	O
recent	O
(	O
6	O
to	O
40	O
days	O
)	O
acute	O
myocardial	O
infarction	O
,	O
left	O
ventricular	O
dysfunction	O
(	O
ejection	O
fraction	O
<	O
35	O
%	O
)	O
,	O
and	O
low	O
heart	O
rate	O
variability	O
were	O
randomized	O
to	O
ICD	Surgical
(	O
n=311	O
)	O
or	O
to	O
standard	Control
medical	Control
therapy	Control
(	O
n=342	O
)	O
.	O

In	O
a	O
competing-risks	O
analysis	O
,	O
those	O
factors	O
that	O
increased	O
the	O
risk	O
of	O
arrhythmic	O
death	O
also	O
increased	O
the	O
risk	O
of	O
nonarrhythmic	O
deaths	O
.	O

After	O
adjustment	O
for	O
these	O
factors	O
,	O
receiving	O
an	O
ICD	O
was	O
associated	O
with	O
a	O
decreased	O
risk	O
of	O
arrhythmic	O
death	O
(	O
hazard	O
ratio	O
,	O
0.33	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.15	O
to	O
0.71	O
)	O
but	O
an	O
increase	O
in	O
nonarrhythmic	O
death	O
(	O
hazard	O
ratio	O
,	O
1.70	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.00	O
to	O
2.80	O
)	O
.	O

In	O
an	O
adjusted	O
time-dependent	O
analysis	O
,	O
patients	O
receiving	O
an	O
ICD	O
and	O
having	O
appropriate	O
ICD	O
therapy	O
had	O
a	O
15.1	O
%	O
yearly	O
hazard	O
of	O
mortality	O
compared	O
with	O
5.2	O
%	O
in	O
ICD	O
patients	O
with	O
no	O
appropriate	O
therapy	O
(	O
P	O
<	O
0.001	O
)	O
.	O

The	O
reduction	O
in	O
sudden	O
death	O
in	O
ICD	O
patients	O
was	O
completely	O
offset	O
by	O
increased	O
nonarrhythmic	O
deaths	O
,	O
which	O
were	O
greatest	O
in	O
patients	O
receiving	O
ICD	O
shock	O
therapy	O
(	O
hazard	O
ratio	O
,	O
6.0	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
2.8	O
to	O
12.7	O
)	O
.	O

CONCLUSIONS	O
in	O
patients	O
receiving	O
ICDs	O
early	O
after	O
myocardial	O
infarction	O
,	O
those	O
factors	O
that	O
are	O
associated	O
with	O
arrhythmia	O
requiring	O
ICD	O
therapy	O
are	O
also	O
associated	O
with	O
a	O
high	O
risk	O
of	O
nonsudden	O
death	O
,	O
negating	O
the	O
benefit	O
of	O
ICDs	O
in	O
this	O
setting	O
.	O

Predictors	O
of	O
postdischarge	O
outcomes	O
from	O
information	O
acquired	O
shortly	O
after	O
admission	O
for	O
acute	O
heart	O
failure	O
:	O
a	O
report	O
from	O
the	O
Placebo-Controlled	Control
Randomized	O
Study	O
of	O
the	O
Selective	O
A1	O
Adenosine	O
Receptor	O
Antagonist	O
Rolofylline	Pharmacological
for	O
Patients	O
Hospitalized	O
With	O
Acute	O
Decompensated	O
Heart	O
Failure	O
and	O
Volume	O
Overload	O
to	O
Assess	O
Treatment	O
Effect	O
on	O
Congestion	O
and	O
Renal	O
Function	O
(	O
PROTECT	O
)	O
Study	O
.	O

BACKGROUND	O
Acute	O
heart	O
failure	O
is	O
a	O
common	O
reason	O
for	O
admission	O
,	O
and	O
outcome	O
is	O
often	O
poor	O
.	O

Improved	O
prognostic	O
risk	O
stratification	O
may	O
assist	O
in	O
the	O
design	O
of	O
future	O
trials	O
and	O
in	O
patient	O
management	O
.	O

Using	O
data	O
from	O
a	O
large	O
randomized	O
trial	O
,	O
we	O
explored	O
the	O
prognostic	O
value	O
of	O
clinical	O
variables	O
,	O
measured	O
at	O
hospital	O
admission	O
for	O
acute	O
heart	O
failure	O
,	O
to	O
determine	O
whether	O
a	O
few	O
selected	O
variables	O
were	O
inferior	O
to	O
an	O
extended	O
data	O
set	O
.	O

METHODS	O
AND	O
RESULTS	O
The	O
prognostic	O
model	O
included	O
37	O
clinical	O
characteristics	O
collected	O
at	O
baseline	O
in	O
PROTECT	O
,	O
a	O
study	O
comparing	O
rolofylline	Pharmacological
and	O
placebo	Control
in	O
2033	O
patients	O
admitted	O
with	O
acute	O
heart	O
failure	O
.	O

Prespecified	O
outcomes	O
at	O
30	O
days	O
were	O
death	O
or	O
rehospitalization	O
for	O
any	O
reason	O
;	O
death	O
or	O
rehospitalization	O
for	O
cardiovascular	O
or	O
renal	O
reasons	O
;	O
and	O
,	O
at	O
both	O
30	O
and	O
180	O
days	O
,	O
all-cause	O
mortality	O
.	O

No	O
variable	O
had	O
a	O
c-index	O
>	O
0.70	O
,	O
and	O
few	O
had	O
values	O
>	O
0.60	O
;	O
c-indices	O
were	O
lower	O
for	O
composite	O
outcomes	O
than	O
for	O
mortality	O
.	O

Blood	O
urea	O
was	O
generally	O
the	O
strongest	O
single	O
predictor	O
.	O

Eighteen	O
variables	O
contributed	O
independent	O
prognostic	O
information	O
,	O
but	O
a	O
reduced	O
model	O
using	O
only	O
8	O
items	O
(	O
age	O
,	O
previous	O
heart	O
failure	O
hospitalization	O
,	O
peripheral	O
edema	O
,	O
systolic	O
blood	O
pressure	O
,	O
serum	O
sodium	O
,	O
urea	O
,	O
creatinine	O
,	O
and	O
albumin	O
)	O
performed	O
similarly	O
.	O

For	O
prediction	O
of	O
all-cause	O
mortality	O
at	O
180	O
days	O
,	O
the	O
model	O
c-index	O
using	O
all	O
variables	O
was	O
0.72	O
and	O
for	O
the	O
simplified	O
model	O
,	O
also	O
0.72	O
.	O

CONCLUSIONS	O
A	O
few	O
simple	O
clinical	O
variables	O
measured	O
on	O
admission	O
in	O
patients	O
with	O
acute	O
heart	O
failure	O
predict	O
a	O
variety	O
of	O
adverse	O
outcomes	O
with	O
accuracy	O
similar	O
to	O
more	O
complex	O
models	O
.	O

However	O
,	O
predictive	O
models	O
were	O
of	O
only	O
moderate	O
accuracy	O
,	O
especially	O
for	O
outcomes	O
that	O
included	O
nonfatal	O
events	O
.	O

Better	O
methods	O
of	O
risk	O
stratification	O
are	O
required	O
.	O

CLINICAL	O
TRIAL	O
REGISTRATION	O
URL	O
:	O
http	O
:	O
//www.clinicaltrials.gov	O
.	O

Unique	O
identifiers	O
:	O
NCT00328692	O
and	O
NCT00354458	O
.	O

Online	Other
conductivity	Other
monitoring	Other
:	O
validation	O
and	O
usefulness	O
in	O
a	O
clinical	O
trial	O
of	O
reduced	Other
dialysate	Other
conductivity	Other
.	O

Relatively	Other
low	Other
dialysate	Other
conductivity	Other
(	Other
Cndi	Other
)	Other
may	O
improve	O
outcomes	O
by	O
reducing	O
the	O
overall	O
sodium	O
burden	O
in	O
dialysis	O
patients	O
.	O

Excess	O
sodium	O
removal	O
,	O
however	O
,	O
could	O
lead	O
to	O
hemodynamic	O
instability	O
.	O

We	O
performed	O
a	O
randomized	O
controlled	O
trial	O
of	O
reduction	Other
of	Other
Cndi	Other
.	Other

For	O
the	O
study	O
,	O
28	O
patients	O
were	O
randomized	O
to	O
maintenance	O
of	O
Cndi	Other
at	O
13.6	O
mS/cm	O
(	O
equivalent	O
to	O
135	O
mmol/L	O
of	O
Na+	O
)	O
or	O
serial	O
reduction	O
of	O
Cndi	Other
in	O
steps	O
of	O
0.2	O
mS/cm	O
,	O
guided	O
by	O
symptoms	O
and	O
blood	O
pressure	O
.	O

Sodium	O
removal	O
estimated	O
from	O
pre-	O
and	O
postplasma	O
concentrations	O
correlated	O
well	O
with	O
removal	O
measured	O
by	O
conductivity	O
monitoring	O
as	O
ionic	O
mass	O
balance	O
(	O
R2	O
0.66	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

Of	O
the	O
16	O
patients	O
randomized	O
to	O
reduction	Other
of	Other
Cndi	Other
,	O
6	O
achieved	O
Cndi	O
13.4	O
mS/cm	O
,	O
6	O
achieved	O
13.2	O
mS/cm	O
,	O
and	O
4	O
achieved	O
13.0	O
mS/cm	O
.	O

No	O
episodes	O
of	O
disequilibrium	O
occurred	O
.	O

Interdialytic	O
weight	O
gain	O
was	O
reduced	O
from	O
2.34	O
+/-	O
0.10	O
kg	O
to	O
1.57	O
+/-	O
0.11	O
kg	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

Predialysis	O
systolic	O
blood	O
pressure	O
fell	O
from	O
144	O
+/-	O
3	O
mm	O
Hg	O
to	O
137	O
+/-	O
4	O
mm	O
Hg	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
reduction	O
in	O
convective	Physical
sodium	Physical
removal	Physical
was	O
balanced	O
by	O
an	O
increase	O
in	O
diffusive	O
sodium	O
removal	O
(	O
95	O
+/-	O
9	O
mmol	O
cf	O
.	O

175	O
+/-	O
14	O
mmol	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

Reduction	Other
in	Other
Cndi	Other
monitored	O
by	O
IMB	O
is	O
safe	O
and	O
practical	O
and	O
leads	O
to	O
improved	O
interdialytic	O
weight	O
gains	O
and	O
blood	O
pressure	O
control	O
,	O
while	O
avoiding	O
excessive	O
sodium	O
removal	O
.	O

[	O
Effects	O
of	O
small	Physical
needle-knife	Physical
comprehensive	Physical
therapy	Physical
on	O
pain	O
and	O
lumbar	O
flexion	O
range	O
in	O
the	O
chronic	O
nonspecific	O
low	O
back	O
pain	O
patient	O
]	O
.	O

OBJECTIVE	O
To	O
observe	O
therapeutic	O
effect	O
of	O
small	Physical
needle-knife	Physical
comprehensive	Physical
therapy	Physical
on	O
pain	O
and	O
lumbar	O
flexion	O
range	O
in	O
the	O
chronic	O
nonspecific	O
low	O
back	O
pain	O
patient	O
.	O

METHODS	O
Three	O
hundred	O
and	O
five	O
cases	O
were	O
randomly	O
divided	O
into	O
a	O
needle-knife	Physical
group	Physical
of	O
153	O
cases	O
and	O
a	O
physiotherapy	Physical
group	Physical
of	O
152	O
cases	O
.	O

The	O
needle-knife	Physical
group	O
were	O
treated	O
with	O
small	Physical
needle-knife	Physical
releasing	Physical
therapy	Physical
,	Physical
blocking	Physical
and	Physical
functional	Physical
training	Physical
.	Physical

The	O
physiotherapy	Physical
group	O
were	O
treated	O
with	O
ultra-short	Physical
wave	Physical
,	Physical
modulated	Physical
medium	Physical
frequency	Physical
current	Physical
,	Physical
massage	Physical
and	Physical
functional	Physical
training	Physical
.	Physical

Pain	O
was	O
assessed	O
by	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
and	O
the	O
lumbar	O
flexion	O
range	O
was	O
determined	O
before	O
and	O
after	O
treatment	O
.	O

RESULTS	O
After	O
treatment	O
,	O
the	O
pain	O
and	O
the	O
lumbar	O
flexion	O
range	O
were	O
significantly	O
improved	O
in	O
the	O
two	O
groups	O
;	O
and	O
after	O
treatment	O
,	O
the	O
VAS	O
score	O
and	O
the	O
lumbar	O
flexion	O
range	O
were	O
(	O
1.60	O
+/-	O
0.38	O
)	O
points	O
and	O
(	O
65.76	O
+/-	O
15.11	O
)	O
cm	O
in	O
the	O
needle-knife	Physical
group	O
and	O
(	O
4.59	O
+/-	O
1.09	O
)	O
points	O
and	O
(	O
53.74	O
+/-	O
15.13	O
)	O
cm	O
in	O
the	O
physiotherapy	O
group	O
,	O
respectively	O
,	O
the	O
needle-knife	Physical
group	O
being	O
significantly	O
better	O
than	O
the	O
physiotherapy	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Follow-up	O
survey	O
of	O
6-36	O
months	O
showed	O
that	O
the	O
VAS	O
score	O
and	O
the	O
lumbar	O
flexion	O
range	O
in	O
the	O
needle-knife	Physical
group	O
were	O
superior	O
to	O
those	O
in	O
the	O
physiotherapy	Physical
group	O
.	O

CONCLUSION	O
Small	Physical
needle-knife	Physical
comprehensive	Physical
therapy	Physical
can	O
significantly	O
improve	O
pain	O
and	O
lumbar	O
flexion	O
range	O
in	O
the	O
chronic	O
nonspecific	O
low	O
back	O
pain	O
patient	O
,	O
with	O
a	O
stable	O
long-term	O
therapeutic	O
effect	O
.	O

Reactive	O
balance	O
adjustments	O
to	O
unexpected	Physical
perturbations	Physical
during	O
human	O
walking	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
determine	O
the	O
effect	O
of	O
unexpected	Physical
forward	Physical
perturbations	Physical
(	Physical
FP	Physical
)	Physical
during	O
gait	O
on	O
lower	O
extremity	O
joint	O
mechanics	O
and	O
muscle	O
Electromyographic	O
(	O
EMG	O
)	O
patterns	O
in	O
healthy	O
adults	O
.	O

The	O
muscles	O
surrounding	O
the	O
hip	O
were	O
found	O
to	O
be	O
most	O
important	O
in	O
maintaining	O
control	O
of	O
the	O
trunk	O
and	O
preventing	O
collapse	O
in	O
response	O
to	O
the	O
FP	O
.	O

Distinct	O
lower	O
extremity	O
joint	O
moment	O
and	O
power	O
patterns	O
were	O
observed	O
in	O
response	O
to	O
the	O
FP	Physical
but	O
an	O
overall	O
positive	O
moment	O
of	O
support	O
(	O
M	O
(	O
s	O
)	O
)	O
was	O
maintained	O
.	O

Therefore	O
,	O
reactive	O
balance	O
control	O
was	O
a	O
synchronized	O
effort	O
of	O
the	O
lower	O
extremity	O
joints	O
to	O
prevent	O
collapse	O
during	O
the	O
FP	Physical
.	Physical

The	O
prophylactic	O
effect	O
of	O
valproate	Pharmacological
on	O
glyceryltrinitrate	O
induced	O
migraine	O
.	O

In	O
this	O
study	O
the	O
human	O
glyceryltrinitrate	O
(	O
GTN	O
)	O
model	O
of	O
migraine	O
was	O
for	O
the	O
first	O
time	O
used	O
to	O
test	O
the	O
effect	O
of	O
a	O
prophylactic	O
drug	O
.	O

We	O
chose	O
to	O
test	O
valproate	Pharmacological
due	O
to	O
its	O
well	O
documented	O
effect	O
as	O
a	O
migraine	Pharmacological
prophylactic	Pharmacological
drug	Pharmacological
.	Pharmacological

Efficacy	O
of	O
this	O
compound	O
would	O
support	O
the	O
usefulness	O
of	O
the	O
model	O
in	O
prophylactic	O
antimigraine	O
drug	O
development	O
.	O

Twelve	O
patients	O
with	O
migraine	O
without	O
aura	O
were	O
included	O
in	O
a	O
randomized	O
double	O
blind	O
crossover	O
study	O
.	O

Valproate	Pharmacological
1000	O
mg	O
or	O
placebo	Control
was	O
given	O
daily	O
,	O
each	O
for	O
a	O
minimum	O
of	O
13	O
days	O
.	O

On	O
the	O
last	O
treatment	O
day	O
of	O
each	O
arm	O
a	O
20	O
min	O
intravenous	O
infusion	O
of	O
GTN	Pharmacological
(	O
0.25	O
microg/kg/min	O
)	O
was	O
given	O
.	O

Headache	O
was	O
registered	O
for	O
12	O
h	O
after	O
the	O
infusion	O
and	O
headache	O
intensity	O
was	O
scored	O
on	O
a	O
scale	O
from	O
0	O
to	O
10	O
.	O

Fulfillment	O
of	O
IHS	O
criteria	O
was	O
recorded	O
for	O
24	O
h.	O
The	O
middle	O
cerebral	O
arteries	O
were	O
evaluated	O
by	O
transcranial	O
Doppler	O
and	O
the	O
diameter	O
of	O
the	O
superficial	O
temporal	O
and	O
radial	O
arteries	O
were	O
measured	O
with	O
high	O
frequency	O
ultrasound	O
.	O

GTN	Pharmacological
evoked	O
migraine	O
fulfilling	O
IHS	O
criteria	O
1.1	O
in	O
6	O
patients	O
after	O
placebo	Control
and	O
in	O
2	O
patients	O
after	O
valproate	Pharmacological
(	O
P	O
=	O
0.125	O
)	O
.	O

Including	O
additionally	O
3	O
patients	O
on	O
placebo	Control
and	O
1	O
patient	O
on	O
valproate	Pharmacological
who	O
felt	O
they	O
had	O
suffered	O
a	O
migraine	O
attack	O
,	O
but	O
who	O
had	O
as	O
associated	O
symptoms	O
only	O
photophobia	O
or	O
phonophobia	O
,	O
a	O
significant	O
reduction	O
in	O
the	O
number	O
of	O
patients	O
with	O
induced	O
migraine	O
after	O
valproate	Pharmacological
was	O
seen	O
(	O
P	O
=	O
0.031	O
)	O
.	O

Median	O
peak	O
headache	O
intensity	O
was	O
1	O
(	O
range	O
0-9	O
)	O
after	O
valproate	Pharmacological
compared	O
to	O
4.5	O
(	O
range	O
0-8	O
)	O
after	O
placebo	Control
(	O
P	O
=	O
0.120	O
)	O
.	O

Pretreatment	O
with	O
valproate	Pharmacological
as	O
compared	O
to	O
placebo	Control
reduced	O
the	O
velocity	O
in	O
both	O
middle	O
cerebral	O
arteries	O
after	O
GTN	O
(	O
left	O
P	O
=	O
0.021	O
,	O
right	O
P	O
=	O
0.031	O
)	O
.	O

No	O
effect	O
of	O
valproate	Pharmacological
was	O
seen	O
in	O
the	O
diameter	O
of	O
the	O
superficial	O
temporal	O
artery	O
(	O
P	O
=	O
0.781	O
)	O
or	O
the	O
radial	O
artery	O
(	O
P	O
=	O
0.367	O
)	O
before	O
or	O
after	O
GTN	O
.	O

The	O
study	O
indicates	O
that	O
a	O
prophylactic	O
effect	O
of	O
valproate	Pharmacological
may	O
be	O
demonstrated	O
using	O
the	O
GTN	Pharmacological
human	Pharmacological
migraine	Pharmacological
model	Pharmacological
.	Pharmacological

Although	O
,	O
all	O
headache	O
parameters	O
were	O
reduced	O
after	O
valproate	Pharmacological
compared	O
to	O
placebo	Control
,	O
only	O
one	O
parameter	O
was	O
statistically	O
significantly	O
reduced	O
probably	O
because	O
of	O
the	O
small	O
number	O
of	O
patients	O
.	O

The	O
size	O
of	O
the	O
effect	O
was	O
similar	O
to	O
that	O
of	O
valproate	O
in	O
clinical	O
trials	O
.	O

The	O
GTN	Pharmacological
model	Pharmacological
may	O
therefore	O
be	O
a	O
valid	O
tool	O
for	O
testing	O
new	O
prophylactic	O
antimigraine	O
drugs	O
.	O

Intravenous	Pharmacological
or	Pharmacological
intramuscular	Pharmacological
teicoplanin	Pharmacological
once	O
daily	O
for	O
skin	O
and	O
soft-tissue	O
infections	O
.	O

Teicoplanin	Pharmacological
is	O
a	O
new	O
glycopeptide	O
antibiotic	O
with	O
potent	O
activity	O
against	O
gram-positive	O
bacteria	O
and	O
pharmacokinetics	O
that	O
allow	O
once	O
daily	O
administration	O
.	O

To	O
study	O
the	O
efficacy	O
and	O
safety	O
of	O
teicoplanin	Pharmacological
for	O
skin	O
and	O
soft-tissue	O
infections	O
,	O
75	O
patients	O
received	O
teicoplanin	Pharmacological
intravenously	Pharmacological
(	Pharmacological
38	Pharmacological
)	Pharmacological
or	Pharmacological
intramuscularly	Pharmacological
(	O
37	O
,	O
of	O
which	O
16	O
were	O
outpatients	O
)	O
.	O

Of	O
62	O
clinically	O
evaluable	O
patients	O
,	O
97	O
percent	O
of	O
teicoplanin	Pharmacological
iv	O
and	O
93	O
percent	O
of	O
teicoplanin	Pharmacological
im	O
patients	O
were	O
cured	O
or	O
improved	O
.	O

All	O
teicoplanin	Pharmacological
iv	O
patients	O
and	O
64	O
percent	O
of	O
teicoplanin	Pharmacological
im	O
patients	O
were	O
cured	O
microbiologically	O
at	O
24-48	O
hours	O
posttherapy	O
.	O

Persistence	O
of	O
organisms	O
frequently	O
was	O
associated	O
with	O
skin	O
ulcers	O
or	O
abscess	O
cavities	O
and	O
usually	O
had	O
no	O
bearing	O
on	O
clinical	O
outcome	O
.	O

Possible	O
adverse	O
clinical	O
and	O
laboratory	O
reactions	O
caused	O
by	O
teicoplanin	Pharmacological
occurred	O
in	O
4	O
of	O
38	O
teicoplanin	O
iv	O
patients	O
(	O
11	O
percent	O
)	O
and	O
in	O
8	O
of	O
37	O
teicoplanin	Pharmacological
im	O
patients	O
(	O
22	O
percent	O
)	O
.	O

Reactions	O
were	O
mild	O
and	O
resolved	O
with	O
discontinuation	O
of	O
teicoplanin	Pharmacological
in	O
most	O
cases	O
.	O

In	O
this	O
study	O
,	O
teicoplanin	O
appeared	O
to	O
be	O
safe	O
,	O
efficacious	O
,	O
and	O
convenient	O
for	O
both	O
hospital	O
staff	O
and	O
patients	O
,	O
and	O
potentially	O
cost-effective	O
for	O
the	O
treatment	O
of	O
skin	O
and	O
soft-tissue	O
infections	O
.	O

In	O
particular	O
,	O
teicoplanin	Pharmacological
appears	O
to	O
be	O
appropriate	O
for	O
outpatient	O
parenteral	O
therapy	O
.	O

Cyclosporin	Pharmacological
versus	O
cyclophosphamide	Pharmacological
for	O
patients	O
with	O
steroid-dependent	O
and	O
frequently	O
relapsing	O
idiopathic	O
nephrotic	O
syndrome	O
:	O
a	O
multicentre	O
randomized	O
controlled	O
trial	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
efficacy	O
(	O
maintenance	O
of	O
remission	O
)	O
,	O
safety	O
and	O
tolerability	O
of	O
cyclosporin	Pharmacological
(	Pharmacological
CsA	Pharmacological
)	Pharmacological
with	O
those	O
of	O
cyclophosphamide	Pharmacological
in	O
patients	O
with	O
steroid-dependent	O
or	O
frequently	O
relapsing	O
nephrotic	O
syndrome	O
(	O
NS	O
)	O
.	O

DESIGN	O
Open	O
,	O
prospective	O
,	O
randomized	O
,	O
multicentre	O
,	O
controlled	O
study	O
for	O
parallel	O
groups	O
,	O
stratified	O
for	O
adults	O
and	O
children	O
.	O

The	O
setting	O
was	O
in	O
nephrological	O
departments	O
in	O
Italy	O
.	O

SUBJECTS	O
AND	O
INTERVENTIONS	O
Seventy-three	O
patients	O
with	O
steroid-sensitive	O
idiopathic	O
NS	O
admitted	O
to	O
the	O
study	O
were	O
randomly	O
assigned	O
to	O
cyclophosphamide	Pharmacological
(	O
2.5	O
mg/kg/day	O
)	O
for	O
8	O
weeks	O
or	O
CsA	Pharmacological
(	O
5	O
mg/kg/day	O
in	O
adults	O
,	O
6	O
mg/kg/day	O
in	O
children	O
)	O
for	O
9	O
months	O
,	O
tapered	O
off	O
by	O
25	O
%	O
every	O
month	O
until	O
complete	O
discontinuation	O
at	O
month	O
12	O
.	O

Seven	O
patients	O
lost	O
to	O
follow	O
up	O
were	O
not	O
considered	O
in	O
the	O
analysis	O
.	O

The	O
remaining	O
66	O
patients	O
were	O
followed	O
up	O
for	O
3-24	O
months	O
after	O
randomization	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Relapse-free	O
survival	O
;	O
number	O
of	O
N.S	O
.	O

relapses/patient/year	O
;	O
cumulative	O
dose	O
of	O
prednisone/patient	O
;	O
laboratory	O
investigations	O
(	O
kidney	O
and	O
liver	O
functions	O
,	O
haematological	O
parameters	O
)	O
;	O
incidence	O
of	O
adverse	O
events	O
.	O

RESULTS	O
At	O
month	O
9	O
,	O
26	O
of	O
35	O
CsA-treated	O
patients	O
were	O
still	O
in	O
complete	O
remission	O
and	O
a	O
further	O
five	O
patients	O
were	O
in	O
partial	O
remission	O
;	O
18	O
of	O
28	O
cyclophosphamide-treated	Pharmacological
patients	O
were	O
in	O
complete	O
remission	O
,	O
and	O
one	O
in	O
partial	O
remission	O
(	O
P	O
=	O
NS	O
)	O
.	O

No	O
difference	O
between	O
adults	O
and	O
children	O
was	O
seen	O
with	O
either	O
treatment	O
.	O

The	O
risk	O
of	O
relapse	O
was	O
similar	O
between	O
frequent	O
relapsers	O
(	O
19	O
of	O
22	O
)	O
and	O
steroid-dependent	O
patients	O
(	O
8	O
of	O
14	O
)	O
given	O
CsA	O
,	O
and	O
those	O
given	O
cyclophosphamide	Pharmacological
(	O
5	O
of	O
15	O
and	O
6	O
of	O
15	O
)	O
.	O

The	O
mean	O
number	O
of	O
relapses	O
per	O
year	O
and	O
the	O
mean	O
dose	O
of	O
prednisone	O
per	O
year	O
were	O
significantly	O
less	O
(	O
P	O
<	O
0.001	O
)	O
in	O
both	O
groups	O
for	O
the	O
experimental	O
year	O
than	O
for	O
the	O
year	O
before	O
randomization	O
.	O

At	O
2	O
years	O
,	O
25	O
%	O
of	O
the	O
patients	O
given	O
CsA	Pharmacological
(	O
50	O
%	O
adults	O
and	O
20	O
%	O
children	O
)	O
and	O
63	O
%	O
of	O
those	O
given	O
cyclophosphamide	Pharmacological
(	O
40	O
%	O
adults	O
and	O
68	O
%	O
children	O
)	O
had	O
not	O
had	O
any	O
relapse	O
of	O
NS	O
.	O

Tolerance	O
to	O
the	O
two	O
drugs	O
was	O
generally	O
good	O
.	O

The	O
CsA-related	Pharmacological
side-effects	O
were	O
mild	O
and	O
disappeared	O
after	O
drug	O
discontinuation	O
.	O

CONCLUSIONS	O
This	O
study	O
shows	O
that	O
both	O
treatments	O
are	O
effective	O
and	O
well	O
tolerated	O
;	O
more	O
patients	O
given	O
cyclophosphamide	Pharmacological
had	O
stable	O
remissions	O
.	O

Pedantic	Psychological
speaking	Psychological
style	O
differentiates	O
Asperger	O
syndrome	O
from	O
high-functioning	O
autism	O
.	O

Asperger	O
syndrome	O
(	O
AS	O
)	O
is	O
a	O
pervasive	O
developmental	O
disorder	O
recently	O
introduced	O
as	O
a	O
new	O
diagnostic	O
category	O
in	O
the	O
ICD-10	O
and	O
the	O
DSM-IV	O
.	O

Along	O
with	O
motor	O
clumsiness	O
,	O
pedantic	Psychological
speech	Psychological
has	O
been	O
proposed	O
as	O
a	O
clinical	O
feature	O
of	O
AS	O
.	O

However	O
,	O
few	O
attempts	O
have	O
been	O
made	O
to	O
define	O
and	O
measure	O
this	O
symptom	O
.	O

We	O
studied	O
17	O
patients	O
with	O
AS	O
(	O
ICD-10	O
;	O
14	O
male	O
,	O
3	O
female	O
;	O
mean	O
age	O
16.4	O
years	O
,	O
mean	O
full-scale	O
IQ	O
97	O
)	O
and	O
compared	O
them	O
with	O
a	O
control	O
group	O
of	O
13	O
patients	O
with	O
normal-intelligence	O
autism	O
or	O
high-functioning	O
autism	O
(	O
HFA	O
)	O
(	O
ICD-10/DSM-III-R	O
;	O
12	O
male	O
,	O
1	O
female	O
;	O
mean	O
age	O
15.5	O
years	O
,	O
mean	O
full-scale	O
IQ	O
81.2	O
)	O
.	O

An	O
operational	O
definition	O
of	O
pedantic	O
speech	O
was	O
formulated	O
and	O
a	O
rating	O
scale	O
devised	O
.	O

13	O
(	O
76	O
%	O
)	O
of	O
the	O
AS	O
patients	O
were	O
rated	O
as	O
pedantic	Psychological
compared	O
to	O
4	O
(	O
31	O
%	O
)	O
of	O
the	O
HFA	O
group	O
(	O
chi	O
2	O
=	O
6.3	O
;	O
p	O
=	O
.01	O
)	O
.	O

Results	O
suggest	O
that	O
pedantic	Psychological
speech	Psychological
is	O
common	O
in	O
AS	O
and	O
may	O
help	O
differentiate	O
AS	O
from	O
high-functioning	O
autism	O
.	O

Lack	O
of	O
effect	O
of	O
food	Physical
on	O
the	O
steady	O
state	O
pharmacokinetics	O
of	O
BMS-181101	O
,	O
an	O
antidepressant	O
,	O
in	O
healthy	O
subjects	O
.	O

The	O
effect	O
of	O
food	O
on	O
the	O
pharmacokinetics	O
of	O
BMS-181101	Pharmacological
,	O
a	O
new	O
anti-depressant	O
under	O
development	O
,	O
was	O
investigated	O
in	O
12	O
healthy	O
male	O
volunteers	O
at	O
steady	O
state	O
.	O

Each	O
subject	O
received	O
a	O
15	O
mg	O
oral	O
dose	O
of	O
BMS-181101	Pharmacological
twice	O
a	O
day	O
(	O
q	O
12	O
h	O
)	O
for	O
11	O
days	O
and	O
a	O
morning	O
dose	O
of	O
BMS-181101	Pharmacological
on	O
day	O
12	O
.	O

Six	O
subjects	O
were	O
randomly	O
assigned	O
to	O
receive	O
BMS-181101	Pharmacological
under	O
fasted	O
conditions	O
from	O
days	O
1	O
to	O
6	O
and	O
then	O
crossed	O
over	O
to	O
fed	O
conditions	O
from	O
days	O
7	O
to	O
12	O
.	O

The	O
other	O
six	O
subjects	O
received	O
the	O
reverse	O
conditions	O
,	O
fed	O
for	O
days	O
1-6	O
and	O
fasted	O
for	O
days	O
7-12	O
.	O

Serial	O
blood	O
samples	O
were	O
collected	O
up	O
to	O
12	O
h	O
on	O
days	O
6	O
and	O
12	O
following	O
the	O
administration	O
of	O
the	O
morning	O
dose	O
.	O

In	O
addition	O
,	O
trough	O
blood	O
samples	O
were	O
collected	O
on	O
days	O
4	O
,	O
5	O
,	O
10	O
,	O
and	O
11	O
prior	O
to	O
the	O
morning	O
dose	O
.	O

Plasma	O
samples	O
were	O
analyzed	O
for	O
intact	O
BMS-181101	Pharmacological
using	O
a	O
validated	O
high-performance	O
liquid	O
chromatography	O
method	O
with	O
an	O
electrochemical	O
detector	O
.	O

BMS-181101	O
was	O
well	O
tolerated	O
both	O
with	O
and	O
without	O
ingestion	O
of	O
food	O
.	O

The	O
statistical	O
evaluation	O
of	O
the	O
Cmin	O
values	O
indicated	O
that	O
steady	O
state	O
of	O
BMS-181101	Pharmacological
was	O
achieved	O
by	O
the	O
fourth	O
day	O
of	O
dosing	O
regardless	O
of	O
whether	O
the	O
subject	O
was	O
fasted	O
or	O
fed	O
.	O

When	O
BMS-181101	O
was	O
administered	O
with	O
food	O
,	O
Cmax	O
was	O
reduced	O
by	O
about	O
25	O
%	O
and	O
tmax	O
was	O
prolonged	O
by	O
1	O
h.	O
However	O
,	O
AUCtau	O
,	O
t1/2	O
,	O
and	O
time	O
to	O
attain	O
steady	O
state	O
of	O
BMS-181101	O
were	O
not	O
altered	O
by	O
ingestion	O
of	O
food	O
.	O

In	O
summary	O
,	O
BMS-181101	Pharmacological
can	O
be	O
given	O
with	O
food	O
without	O
adversely	O
impacting	O
the	O
safety	O
or	O
pharmacokinetic	O
profiles	O
of	O
the	O
drug	O
.	O

Salbutamol	Pharmacological
or	O
mist	Pharmacological
in	O
acute	O
bronchiolitis	O
.	O

BACKGROUND	O
The	O
role	O
of	O
bronchodilators	O
in	O
the	O
treatment	O
of	O
bronchiolitis	O
remains	O
controversial	O
.	O

METHODS	O
A	O
double-blind	O
,	O
placebo	O
controlled	O
trial	O
was	O
performed	O
to	O
evaluate	O
the	O
clinical	O
response	O
to	O
nebulized	O
salbutamol	Pharmacological
.	Pharmacological

One	O
hundred	O
and	O
fifty-six	O
infants	O
aged	O
between	O
7	O
weeks	O
and	O
24	O
months	O
who	O
had	O
had	O
an	O
episode	O
of	O
wheezing	O
and	O
other	O
signs	O
and	O
symptoms	O
of	O
bronchiolitis	O
were	O
randomized	O
to	O
three	O
groups	O
as	O
follows	O
:	O
(	O
i	O
)	O
nebulized	Pharmacological
salbutamol	Pharmacological
was	O
administered	O
to	O
52	O
patients	O
in	O
group	O
I	O
at	O
a	O
dose	O
of	O
0.15	O
mg/kg	O
in	O
2	O
mL	O
saline	Control
;	Control
(	O
ii	O
)	O
saline	Control
was	O
nebulized	O
to	O
52	O
patients	O
in	O
group	O
II	O
and	O
(	O
iii	O
)	O
in	O
group	O
III	O
52	O
patients	O
received	O
mist	Pharmacological
in	O
a	O
tent	O
.	O

All	O
three	O
groups	O
were	O
administered	O
oxygen	Pharmacological
during	O
the	O
procedures	O
.	O

Treatment	O
was	O
repeated	O
with	O
the	O
same	O
agent	O
after	O
30	O
min	O
if	O
the	O
respiratory	O
score	O
was	O
5	O
or	O
more	O
.	O

Respiratory	O
rate	O
,	O
heart	O
rate	O
,	O
oxygen	O
saturation	O
and	O
presence	O
of	O
cyanosis	O
,	O
wheezing	O
,	O
retractions	O
were	O
recorded	O
before	O
and	O
after	O
each	O
treatment	O
.	O

RESULTS	O
The	O
decrease	O
in	O
the	O
respiratory	O
score	O
was	O
5.2	O
+/-	O
1.8	O
,	O
0.82	O
+/-	O
2.4	O
and	O
1.7	O
+/-	O
1.3	O
in	O
group	O
I	O
,	O
II	O
and	O
III	O
,	O
respectively	O
.	O

The	O
decrease	O
in	O
group	O
I	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
other	O
groups	O
.	O

Heart	O
rate	O
was	O
similar	O
between	O
groups	O
.	O

Oxygen	O
saturation	O
decreased	O
in	O
group	O
I	O
without	O
reaching	O
statistical	O
significance	O
.	O

CONCLUSIONS	O
Salbutamol	Pharmacological
was	O
shown	O
to	O
be	O
effective	O
and	O
safe	O
in	O
the	O
treatment	O
of	O
acute	O
bronchiolitis	O
.	O

The	O
effect	O
of	O
use	O
of	O
pyridostigmine	Pharmacological
and	O
requirement	O
of	O
vecuronium	Pharmacological
in	O
patients	O
with	O
myasthenia	O
gravis	O
.	O

CONTEXT	O
Patients	O
with	O
myasthenia	O
gravis	O
receive	O
pyridostigmine	Pharmacological
,	O
an	O
anticholinesterase	Pharmacological
agent	Pharmacological
,	O
as	O
a	O
part	O
of	O
therapy	O
.	O

These	O
patients	O
demonstrate	O
a	O
heightened	O
sensitivity	O
towards	O
non-depolarising	O
muscle	O
relaxants	O
.	O

Continuing	O
pyridostigmine	Pharmacological
till	O
the	O
day	O
of	O
the	O
surgery	O
or	O
omitting	O
it	O
on	O
the	O
night	O
before	O
surgery	O
could	O
provide	O
variable	O
results	O
with	O
regards	O
to	O
the	O
effect	O
of	O
vecuronium	Pharmacological
.	Pharmacological

AIMS	O
Myographic	O
evaluation	O
of	O
a	O
dose	O
of	O
vecuronium	O
in	O
patients	O
with	O
myasthenia	O
gravis	O
on	O
pyridostigmine	O
therapy	O
.	O

SETTING	O
AND	O
DESIGN	O
A	O
randomised	O
,	O
double-blind	O
,	O
clinical	O
study	O
conducted	O
in	O
a	O
teaching	O
hospital	O
.	O

SUBJECTS	O
AND	O
METHODS	O
Medically	O
(	Pharmacological
oral	Pharmacological
pyridostigmine	Pharmacological
)	Pharmacological
well-controlled	O
adult	O
patients	O
with	O
myasthenia	O
gravis	O
who	O
were	O
posted	O
for	O
thymectomy	Surgical
,	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
.	O

Patients	O
in	O
Group	O
1	O
received	O
their	O
last	O
dose	O
of	O
pyridostigmine	Pharmacological
on	O
the	O
night	O
before	O
surgery	O
while	O
those	O
in	O
Group	O
2	O
received	O
even	O
the	O
morning	O
dose	O
of	O
the	O
drug	O
on	O
the	O
day	O
of	O
surgery	O
.	O

Neostigmine	Pharmacological
(	O
1-2	O
mg	O
)	O
intravenously	O
was	O
used	O
as	O
rescue	O
medication	O
.	O

Vecuronium	Pharmacological
(	O
0.01	O
mg/kg	O
)	O
was	O
used	O
for	O
intubation	O
and	O
muscle	O
relaxation	O
during	O
trans-sternal	Surgical
thymectomy	Surgical
and	O
its	O
effect	O
was	O
reversed	O
using	O
neostigmine	O
and	O
atropine	O
.	O

RESULTS	O
Fourteen	O
patients	O
(	O
7	O
in	O
each	O
group	O
)	O
belonging	O
to	O
both	O
sexes	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

The	O
intubating	O
dose	O
of	O
vecuronium	O
showed	O
quicker	O
onset	O
time	O
(	O
155	O
sec	O
or	O
2.7	O
min	O
approx	O
.	O

)	O
and	O
peak	O
effect	O
(	O
99	O
%	O
T1	O
suppression	O
)	O
in	O
patients	O
belonging	O
to	O
Group	O
1	O
,	O
and	O
3/7	O
(	O
43	O
%	O
)	O
complained	O
of	O
respiratory	O
discomfort	O
while	O
waiting	O
for	O
surgery	O
.	O

By	O
giving	O
the	O
morning	O
dose	O
of	O
pyridostigmine	Pharmacological
(	O
Group	O
2	O
)	O
,	O
an	O
identical	O
intubating	O
dose	O
of	O
vecuronium	Pharmacological
showed	O
relative	O
resistance	O
(	O
peak	O
effect-97	O
%	O
T1	O
suppression	O
)	O
and	O
delayed	O
onset	O
time	O
(	O
198	O
sec	O
approx.	O
)	O
.	O

However	O
,	O
the	O
reversal	O
was	O
complete	O
at	O
the	O
end	O
of	O
surgery	O
in	O
both	O
the	O
regimens	O
.	O

CONCLUSIONS	O
Omission	O
of	O
the	O
pyridostigmine	Pharmacological
dose	O
on	O
the	O
day	O
of	O
surgery	O
predisposed	O
patients	O
with	O
myasthenia	O
gravis	O
to	O
the	O
possibility	O
of	O
respiratory	O
discomfort	O
and	O
sensitivity	O
to	O
vecuronium	Pharmacological
.	Pharmacological

Continued	O
administration	O
significantly	O
prolonged	O
the	O
onset	O
time	O
of	O
vecuronium	Pharmacological
and	O
the	O
patients	O
required	O
a	O
higher	O
dose	O
of	O
vecuronium	Pharmacological
.	Pharmacological

Pilot	O
study	O
of	O
Panax	Pharmacological
quinquefolius	Pharmacological
(	Pharmacological
American	Pharmacological
ginseng	Pharmacological
)	Pharmacological
to	O
improve	O
cancer-related	O
fatigue	O
:	O
a	O
randomized	O
,	O
double-blind	O
,	O
dose-finding	O
evaluation	O
:	O
NCCTG	O
trial	O
N03CA	O
.	O

PURPOSE	O
This	O
pilot	O
trial	O
sought	O
to	O
investigate	O
whether	O
any	O
of	O
three	O
doses	O
of	O
American	Pharmacological
ginseng	Pharmacological
(	Pharmacological
Panax	Pharmacological
quinquefolius	Pharmacological
)	Pharmacological
might	O
help	O
cancer-related	O
fatigue	O
.	O

A	O
secondary	O
aim	O
was	O
to	O
evaluate	O
toxicity	O
.	O

METHODS	O
Eligible	O
adults	O
with	O
cancer	O
were	O
randomized	O
in	O
a	O
double-blind	O
manner	O
,	O
to	O
receive	O
American	Pharmacological
ginseng	Pharmacological
in	O
doses	O
of	O
750	O
,	O
1,000	O
,	O
or	O
2,000	O
mg/day	O
or	O
placebo	Control
given	O
in	O
twice	O
daily	O
dosing	O
over	O
8	O
weeks	O
.	O

Outcome	O
measures	O
included	O
the	O
Brief	O
Fatigue	O
Inventory	O
,	O
vitality	O
subscale	O
of	O
the	O
Medical	O
Outcome	O
Scale	O
Short	O
Form-36	O
(	O
SF-36	O
)	O
,	O
and	O
the	O
Global	O
Impression	O
of	O
Benefit	O
Scale	O
at	O
4	O
and	O
8	O
weeks	O
.	O

RESULTS	O
Two	O
hundred	O
ninety	O
patients	O
were	O
accrued	O
to	O
this	O
trial	O
.	O

Nonsignificant	O
trends	O
for	O
all	O
outcomes	O
were	O
seen	O
in	O
favor	O
of	O
the	O
1,000-	O
and	O
2,000-mg/day	O
doses	O
of	O
American	Pharmacological
ginseng	Pharmacological
.	Pharmacological

Area	O
under	O
the	O
curve	O
analysis	O
of	O
activity	O
interference	O
from	O
the	O
Brief	O
Fatigue	O
Inventory	O
was	O
460-467	O
in	O
the	O
placebo	Control
group	O
and	O
750	O
mg/day	O
group	O
versus	O
480-551	O
in	O
the	O
1,000-	O
and	O
2,000-mg/day	O
arms	O
,	O
respectively	O
.	O

Change	O
from	O
baseline	O
in	O
the	O
vitality	O
subscale	O
of	O
the	O
SF-36	O
was	O
7.3-7.8	O
in	O
the	O
placebo	Control
and	O
the	O
750-mg/day	O
arm	O
,	O
versus	O
10.5-14.6	O
in	O
the	O
1,000-	O
and	O
2,000-mg/day	O
arms	O
.	O

Over	O
twice	O
as	O
many	O
patients	O
on	O
ginseng	Pharmacological
perceived	O
a	O
benefit	O
and	O
were	O
satisfied	O
with	O
treatment	O
over	O
those	O
on	O
placebo	Control
.	Control

There	O
were	O
no	O
significant	O
differences	O
in	O
any	O
measured	O
toxicities	O
between	O
any	O
of	O
the	O
arms	O
.	O

CONCLUSION	O
There	O
appears	O
to	O
be	O
some	O
activity	O
and	O
tolerable	O
toxicity	O
at	O
1,000-2,000	O
mg/day	O
doses	O
of	O
American	Pharmacological
ginseng	Pharmacological
with	O
regard	O
to	O
cancer-related	O
fatigue	O
.	O

Thus	O
,	O
further	O
study	O
of	O
American	Pharmacological
ginseng	Pharmacological
is	O
warranted	O
.	O

Extracorporeal	Physical
shock	Physical
wave	Physical
therapy	Physical
(	Physical
ESWT	Physical
)	Physical
in	O
patients	O
with	O
chronic	O
proximal	O
plantar	O
fasciitis	O
:	O
a	O
2-year	O
follow-up	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effect	O
of	O
extracorporeal	Physical
shock	Physical
wave	Physical
therapy	Physical
(	O
ESWT	O
)	O
in	O
patients	O
with	O
chronically	O
painful	O
proximal	O
plantar	O
fasciitis	O
with	O
a	O
further	O
conventional	O
conservative	O
treatment	O
.	O

Forty-seven	O
patients	O
(	O
49	O
feet	O
)	O
with	O
a	O
previously	O
unsuccessful	O
nonsurgical	O
treatment	O
of	O
at	O
least	O
6	O
months	O
were	O
randomized	O
to	O
two	O
groups	O
.	O

Heel	Physical
cups	Physical
had	O
to	O
be	O
worn	O
throughout	O
the	O
study	O
.	O

Group	O
1	O
(	O
25	O
heels	O
)	O
was	O
treated	O
immediately	O
with	O
three	O
sessions	O
of	O
ESWT	Physical
(	O
3000	O
shock	O
waves/session	O
of	O
0.2	O
mJ/mm2	O
)	O
at	O
weekly	O
intervals	O
.	O

The	O
patients	O
of	O
group	O
2	O
(	O
24	O
heels	O
)	O
continued	O
nonsurgical	O
treatment	O
(	O
iontophoresis	Pharmacological
with	Pharmacological
diclofenac	Pharmacological
and	O
an	O
oral	O
nonsteroidal	Pharmacological
anti-inflammatory	Pharmacological
drug	Pharmacological
)	O
for	O
12	O
weeks	O
.	O

After	O
this	O
period	O
they	O
were	O
treated	O
using	O
the	O
protocol	O
of	O
group	O
1	O
.	O

No	O
significant	O
difference	O
of	O
pain	O
and	O
walking	O
time	O
after	O
further	O
nonsurgical	O
treatment	O
(	O
3	O
months	O
)	O
was	O
seen	O
in	O
group	O
2	O
.	O

At	O
12	O
weeks	O
after	O
ESWT	O
,	O
the	O
pain	O
estimation	O
on	O
the	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
for	O
activities	O
of	O
daily	O
living	O
diminished	O
significantly	O
by	O
62.9	O
%	O
in	O
group	O
1	O
and	O
by	O
63.0	O
%	O
in	O
group	O
2	O
.	O

The	O
comfortable	O
walking	O
time	O
had	O
increased	O
significantly	O
in	O
both	O
groups	O
.	O

Two	O
years	O
after	O
ESWT	O
,	O
pain	O
during	O
activities	O
of	O
daily	O
living	O
decreased	O
by	O
94	O
%	O
in	O
group	O
1	O
and	O
by	O
90	O
%	O
in	O
group	O
2	O
on	O
the	O
VAS	O
and	O
the	O
comfortable	O
walking	O
time	O
had	O
increased	O
significantly	O
in	O
both	O
groups	O
.	O

Sunbathing	O
and	O
sunbed	O
use	O
related	O
to	O
self-image	O
in	O
a	O
randomized	O
sample	O
of	O
Swedish	O
adolescents	O
.	O

In	O
1996	O
a	O
randomized	O
sample	O
of	O
4,020	O
Swedish	O
adolescents	O
from	O
three	O
birth	O
cohorts	O
were	O
sent	O
a	O
questionnaire	O
consisting	O
of	O
50	O
items	O
concerning	O
habitual	O
sun-related	O
behaviours	O
and	O
attitudes	O
,	O
knowledge	O
about	O
melanoma	O
,	O
risk	O
perception	O
and	O
self-image	O
.	O

A	O
total	O
of	O
2,615	O
questionnaires	O
were	O
returned	O
.	O

Girls	O
sunbathed	O
and	O
used	O
sunbeds	O
more	O
than	O
boys	O
at	O
all	O
ages	O
.	O

Sunbathing	O
and	O
sunbed	O
use	O
increased	O
with	O
age	O
.	O

Boys	O
who	O
were	O
most	O
satisfied	O
and	O
girls	O
least	O
satisfied	O
with	O
themselves	O
sunbathed	O
most	O
.	O

Those	O
who	O
were	O
least	O
satisfied	O
with	O
themselves	O
used	O
sunbeds	O
most	O
frequently	O
.	O

Girls	O
reported	O
a	O
higher	O
perceived	O
susceptibility	O
to	O
melanoma	O
than	O
did	O
boys	O
.	O

The	O
perception	O
of	O
susceptibility	O
increased	O
with	O
age	O
.	O

Those	O
who	O
were	O
least	O
satisfied	O
with	O
themselves	O
reported	O
feeling	O
most	O
susceptible	O
.	O

The	O
overall	O
main	O
reason	O
for	O
sunbathing	O
was	O
appearance	O
,	O
both	O
for	O
own	O
sunbathing	O
,	O
and	O
to	O
an	O
even	O
higher	O
degree	O
,	O
as	O
a	O
supposed	O
reason	O
for	O
other	O
adolescents	O
'	O
behaviour	O
,	O
and	O
was	O
reported	O
most	O
frequently	O
by	O
girls	O
and	O
the	O
older	O
age	O
groups	O
.	O

The	O
second	O
most	O
'important	O
'	O
reason	O
for	O
sunbathing	O
was	O
'feeling	O
warm	O
and	O
comfortable	O
'	O
.	O

Preventive	O
programmes	O
aimed	O
at	O
a	O
change	O
of	O
sun	O
related	O
behaviours	O
among	O
Swedish	O
adolescents	O
have	O
to	O
be	O
tailored	O
to	O
the	O
climate	O
and	O
cultural	O
conditions	O
and	O
must	O
take	O
into	O
account	O
that	O
having	O
a	O
tan	O
,	O
and	O
the	O
warmth	O
of	O
the	O
sun	O
,	O
are	O
highly	O
valued	O
by	O
most	O
adolescents	O
.	O

Laser	Surgical
conization	Surgical
versus	O
cold	Surgical
knife	Surgical
conization	Surgical
.	Surgical

This	O
prospective	O
,	O
randomized	O
study	O
compares	O
,	O
for	O
the	O
first	O
time	O
,	O
measured	O
blood	O
loss	O
at	O
conization	O
and	O
within	O
24	O
hours	O
after	O
using	O
either	O
the	O
cold	Surgical
knife	Surgical
technique	Surgical
or	O
the	O
carbon	Surgical
dioxide	Surgical
laser	Surgical
scalpel	Surgical
.	O

One	O
hundred	O
and	O
ten	O
consecutive	O
patients	O
were	O
evaluated	O
.	O

The	O
median	O
blood	O
loss	O
in	O
the	O
laser	O
group	O
of	O
55	O
patients	O
was	O
4.6	O
milliliters	O
at	O
,	O
and	O
within	O
,	O
24	O
hours	O
after	O
operation	O
compared	O
with	O
30.1	O
milliliters	O
in	O
the	O
cold	Surgical
knife	Surgical
group	O
of	O
55	O
patients	O
.	O

More	O
important	O
,	O
however	O
,	O
is	O
that	O
the	O
corresponding	O
figures	O
for	O
the	O
range	O
of	O
bleeding	O
were	O
0.4	O
to	O
155.4	O
milliliters	O
and	O
5.6	O
to	O
1,570.9	O
milliliters	O
,	O
respectively	O
.	O

The	O
incidence	O
rate	O
for	O
bleeding	O
complications	O
requiring	O
surgical	O
intervention	O
was	O
1.8	O
per	O
cet	O
for	O
the	O
laser	O
group	O
and	O
14.6	O
per	O
cent	O
for	O
the	O
cold	Surgical
knife	Surgical
group	O
.	O

This	O
difference	O
was	O
statistically	O
significant	O
,	O
p	O
less	O
than	O
0.015	O
--	O
Fischer	O
's	O
exact	O
test	O
.	O

Conization	O
for	O
treatment	O
of	O
premalignant	O
changes	O
of	O
the	O
cervix	O
uteri	O
will	O
probably	O
remain	O
the	O
treatment	O
of	O
choice	O
for	O
some	O
time	O
to	O
come	O
.	O

It	O
is	O
our	O
opinion	O
that	O
,	O
in	O
the	O
future	O
,	O
laser	Surgical
conization	O
will	O
replace	O
cold	Surgical
knife	Surgical
conization	O
.	O

No	O
effect	O
of	O
acetylsalicylic	Pharmacological
acid	Pharmacological
on	O
B-thromboglobulin	O
and	O
platelet	O
factor	O
4	O
plasma	O
levels	O
in	O
patients	O
with	O
transient	O
ischaemic	O
attacks	O
.	O

We	O
studied	O
the	O
effect	O
of	O
acetylsalicylic	Pharmacological
acid	Pharmacological
(	Pharmacological
ASA	Pharmacological
)	Pharmacological
versus	O
placebo	Control
on	O
B-thromboglobulin	O
(	O
B-TG	O
)	O
and	O
platelet	O
factor	O
4	O
(	O
PF4	O
)	O
plasma	O
levels	O
and	O
ADP-induced	O
platelet	O
aggregation	O
in	O
25	O
male	O
patients	O
with	O
transient	O
ischaemic	O
attacks	O
(	O
TIA	O
)	O
.	O

The	O
patients	O
were	O
allocated	O
randomly	O
to	O
two	O
groups	O
:	O
14	O
patients	O
received	O
oral	O
treatment	O
with	O
ASA	Pharmacological
500	O
mg	O
b.i.d	O
.	O

for	O
14	O
days	O
,	O
11	O
patients	O
placebo	Control
b.i.d	O
.	O

for	O
the	O
same	O
period	O
.	O

B-TG	O
and	O
PF4	O
plasma	O
levels	O
and	O
ADP-induced	O
platelet	O
aggregation	O
were	O
determined	O
in	O
basal	O
conditions	O
,	O
and	O
two	O
hours	O
,	O
and	O
seven	O
and	O
fourteen	O
days	O
after	O
starting	O
with	O
ASA	O
or	O
placebo	O
.	O

In	O
addition	O
,	O
the	O
same	O
parameters	O
were	O
studied	O
in	O
a	O
group	O
of	O
20	O
healthy	O
males	O
of	O
matched	O
age	O
.	O

Basal	O
levels	O
of	O
plasma	O
B-TG	O
and	O
PF4	O
and	O
the	O
maximal	O
amplitude	O
of	O
ADP-induced	O
platelet	O
aggregation	O
were	O
abnormally	O
high	O
in	O
TIA	O
patients	O
.	O

ASA	O
caused	O
a	O
significant	O
reduction	O
of	O
B-TG	O
plasma	O
levels	O
in	O
TIA	O
patients	O
2	O
hours	O
after	O
the	O
first	O
administration	O
,	O
but	O
no	O
effect	O
was	O
observed	O
at	O
the	O
7th	O
and	O
14th	O
day	O
of	O
treatment	O
.	O

PF4	O
plasma	O
levels	O
were	O
unaffected	O
by	O
ASA	O
treatment	O
.	O

It	O
is	O
concluded	O
that	O
ASA	O
,	O
at	O
the	O
dose	O
conventionally	O
used	O
in	O
clinical	O
trials	O
,	O
does	O
not	O
affect	O
the	O
release	O
of	O
two	O
alpha-granule	O
proteins	O
.	O

Computer-navigated	Surgical
versus	O
conventional	Surgical
total	Surgical
knee	Surgical
arthroplasty	Surgical
a	O
prospective	O
randomized	O
trial	O
.	O

BACKGROUND	O
The	O
literature	O
lacks	O
studies	O
that	O
confirm	O
whether	O
the	O
improved	O
radiographic	O
alignment	O
that	O
can	O
be	O
achieved	O
with	O
computer-navigated	Surgical
total	Surgical
knee	Surgical
arthroplasty	Surgical
improves	O
patients?	O
activities	O
of	O
daily	O
living	O
or	O
the	O
durability	O
of	O
total	O
knee	O
prostheses	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
computer-navigated	Surgical
total	Surgical
knee	Surgical
arthroplasty	Surgical
improves	O
the	O
clinical	O
function	O
,	O
alignment	O
,	O
and	O
survivorship	O
of	O
the	O
components	O
.	O

METHODS	O
We	O
prospectively	O
compared	O
the	O
results	O
of	O
520	O
patients	O
with	O
osteoarthritis	O
who	O
underwent	O
computer-navigated	Surgical
total	Surgical
knee	Surgical
arthroplasty	Surgical
for	O
one	O
knee	O
and	O
conventional	Surgical
total	Surgical
knee	Surgical
arthroplasty	Surgical
for	O
the	O
other	O
.	O

The	O
assignment	O
of	O
the	O
knee	O
to	O
navigation	O
or	O
not	O
was	O
done	O
randomly	O
.	O

There	O
were	O
452	O
women	O
(	O
904	O
knees	O
)	O
and	O
sixty-eight	O
men	O
(	O
136	O
knees	O
)	O
with	O
a	O
mean	O
age	O
of	O
sixty-eight	O
years	O
(	O
range	O
,	O
forty-nine	O
to	O
eighty-eight	O
years	O
)	O
at	O
the	O
time	O
of	O
the	O
index	O
arthroplasty	O
.	O

The	O
mean	O
follow-up	O
period	O
was	O
10.8	O
years	O
(	O
range	O
,	O
ten	O
to	O
twelve	O
years	O
)	O
.	O

The	O
patients	O
were	O
assessed	O
clinically	O
and	O
radiographically	O
with	O
the	O
rating	O
system	O
of	O
the	O
Knee	O
Society	O
and	O
with	O
the	O
Western	O
Ontario	O
and	O
McMaster	O
Universities	O
Osteoarthritis	O
Index	O
(	O
WOMAC	O
)	O
score	O
at	O
three	O
months	O
,	O
one	O
year	O
,	O
and	O
annually	O
thereafter	O
.	O

RESULTS	O
Total	O
knee	O
scores	O
,	O
knee	O
function	O
scores	O
,	O
pain	O
scores	O
,	O
WOMAC	O
scores	O
,	O
knee	O
motion	O
,	O
and	O
activity	O
scores	O
did	O
not	O
show	O
statistically	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
preoperatively	O
or	O
at	O
the	O
time	O
of	O
the	O
final	O
follow-up	O
.	O

Alignment	O
and	O
the	O
survivorship	O
of	O
the	O
components	O
were	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O

The	O
Kaplan-Meier	O
survivorship	O
with	O
revision	O
as	O
the	O
end	O
point	O
at	O
10.8	O
years	O
was	O
98.8	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.96	O
to	O
1.00	O
)	O
in	O
the	O
computernavigated	Surgical
total	Surgical
knee	Surgical
arthroplasty	Surgical
group	O
and	O
99.2	O
%	O
(	O
95	O
%	O
CI	O
,	O
0.96	O
to	O
1.00	O
)	O
in	O
the	O
conventional	Surgical
total	Surgical
knee	Surgical
arthroplasty	Surgical
group	O
.	O

CONCLUSIONS	O
Our	O
data	O
demonstrated	O
no	O
difference	O
in	O
clinical	O
function	O
or	O
alignment	O
and	O
survivorship	O
of	O
the	O
components	O
between	O
the	O
knees	O
that	O
underwent	O
computer-navigated	Surgical
total	Surgical
knee	Surgical
arthroplasty	Surgical
and	O
those	O
that	O
underwent	O
conventional	Surgical
total	Surgical
knee	Surgical
arthroplasty	Surgical
.	O

Creon	Pharmacological
10,000	Pharmacological
Minimicrospheres	Pharmacological
vs.	O
Creon	Pharmacological
8,000	Pharmacological
microspheres	Pharmacological
--	O
an	O
open	O
randomised	O
crossover	O
preference	O
study	O
.	O

Creon	Pharmacological
10,000	Pharmacological
Minimicrospherestrade	Pharmacological
mark	Pharmacological
(	Pharmacological
Creon	Pharmacological
)	Pharmacological
10,000	Pharmacological
MMS	Pharmacological
)	Pharmacological
is	O
a	O
pancreatic	O
enzyme	O
formulation	O
that	O
contains	O
smaller	O
spheres	O
of	O
pancreatin	O
in	O
a	O
50	O
%	O
smaller	O
capsule	O
than	O
conventional	O
microspheres	Pharmacological
(	Pharmacological
Creon	Pharmacological
)	Pharmacological
8,000	Pharmacological
)	Pharmacological
.	Pharmacological

This	O
three-centre	O
study	O
investigated	O
the	O
preference	O
of	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
patients	O
for	O
these	O
products	O
.	O

In	O
one	O
centre	O
,	O
72	O
h	O
stool	O
fat	O
excretion	O
and	O
coefficient	O
of	O
fat	O
absorption	O
(	O
CFA	O
)	O
were	O
also	O
compared	O
.	O

Fifty-nine	O
patients	O
with	O
a	O
mean	O
age	O
10	O
years	O
(	O
range	O
3-17	O
)	O
took	O
Creon	O
8,000	O
ms	O
for	O
14	O
days	O
and	O
were	O
then	O
randomised	O
to	O
28	O
days	O
of	O
Creon	Pharmacological
8,000	Pharmacological
ms	Pharmacological
followed	O
by	O
28	O
days	O
of	O
Creon	Pharmacological
10,000	Pharmacological
MMS	Pharmacological
,	O
or	O
vice	O
versa	O
.	O

Dosing	O
was	O
lipase	O
for	O
lipase	O
according	O
to	O
the	O
labelled	O
declaration	O
.	O

At	O
the	O
end	O
of	O
the	O
second	O
treatment	O
period	O
,	O
51	O
of	O
54	O
patients	O
who	O
completed	O
the	O
study	O
expressed	O
a	O
preference	O
,	O
with	O
a	O
statistically	O
significant	O
preference	O
in	O
favour	O
of	O
Creon	O
10,000	O
MMS	O
(	O
47/51	O
;	O
87	O
%	O
)	O
vs.	O
Creon	O
8,000	O
ms	O
(	O
4/51	O
;	O
7.4	O
%	O
;	O
P	O
<	O
0.0001	O
)	O
.	O

Stool	O
fat	O
(	O
g/day	O
)	O
and	O
CFA	O
(	O
%	O
)	O
were	O
measured	O
in	O
24	O
patients	O
at	O
the	O
end	O
of	O
each	O
treatment	O
period	O
:	O
the	O
products	O
were	O
therapeutically	O
equivalent	O
(	O
Creon	Pharmacological
10,000	O
:	O
8.4	O
g/day	O
,	O
91.3	O
%	O
CFA	O
;	O
Creon	O
8,000	O
:	O
6.7	O
g/day	O
,	O
93.5	O
%	O
CFA	O
)	O
.	O

Both	O
products	O
were	O
well	O
tolerated	O
.	O

In	O
conclusion	O
,	O
in	O
CF	O
children	O
we	O
found	O
a	O
clear	O
preference	O
for	O
Creon	O
10,000	O
MMS	O
compared	O
with	O
Creon	O
8,000	O
ms	O
with	O
no	O
difference	O
in	O
fat	O
absorption	O
between	O
the	O
two	O
products	O
.	O

Creon	Pharmacological
10,000s	O
smaller	O
capsules	O
are	O
easier	O
to	O
take	O
and	O
should	O
aid	O
patient	O
compliance	O
.	O

A	O
comparison	O
of	O
intermittent	O
vaginal	O
administration	O
of	O
misoprostol	Pharmacological
with	O
continuous	O
dinoprostone	Pharmacological
for	O
cervical	O
ripening	O
and	O
labor	O
induction	O
.	O

OBJECTIVE	O
Our	O
purpose	O
was	O
to	O
compare	O
the	O
effect	O
of	O
vaginal	O
administration	O
of	O
misoprostol	Pharmacological
(	Pharmacological
Cytotec	Pharmacological
)	Pharmacological
with	O
that	O
of	O
dinoprostone	Pharmacological
(	Pharmacological
Cervidil	Pharmacological
)	Pharmacological
on	O
cervical	O
ripening	O
and	O
labor	O
induction	O
.	O

STUDY	O
DESIGN	O
Two	O
hundred	O
patients	O
with	O
indications	O
for	O
induction	O
of	O
labor	O
and	O
unfavorable	O
cervical	O
examinations	O
were	O
randomly	O
assigned	O
to	O
receive	O
vaginally	O
administered	O
misoprostol	Pharmacological
(	Pharmacological
prostaglandin	Pharmacological
E1	Pharmacological
)	Pharmacological
or	O
the	O
dinoprostone	Pharmacological
(	Pharmacological
prostaglandin	Pharmacological
E2	Pharmacological
)	Pharmacological
vaginal	O
insert	O
.	O

Twenty-five	O
microgram	O
tablets	O
of	O
misoprostol	Pharmacological
were	O
placed	O
in	O
the	O
posterior	O
vaginal	O
fornix	O
every	O
4	O
hours	O
for	O
a	O
maximum	O
of	O
six	O
doses	O
.	O

Additional	O
misoprostol	Pharmacological
was	O
not	O
given	O
after	O
either	O
spontaneous	O
rupture	O
of	O
membranes	O
,	O
adequate	O
cervical	O
ripening	O
(	O
Bishop	O
score	O
of	O
>	O
or	O
=	O
8	O
or	O
cervical	O
dilatation	O
of	O
>	O
or	O
=	O
3	O
cm	O
)	O
,	O
or	O
beginning	O
of	O
active	O
labor	O
.	O

The	O
vaginal	O
insert	O
,	O
Cervidil	Pharmacological
,	O
containing	O
10	O
mg	O
of	O
dinoprostone	Pharmacological
in	O
a	O
timed-release	O
preparation	O
was	O
placed	O
in	O
the	O
posterior	O
vaginal	O
formix	O
for	O
a	O
maximum	O
period	O
of	O
24	O
hours	O
.	O

The	O
vaginal	O
insert	O
was	O
removed	O
for	O
spontaneous	O
rupture	O
of	O
membranes	O
,	O
entry	O
into	O
active	O
labor	O
,	O
adequate	O
cervical	O
ripening	O
,	O
or	O
abnormality	O
of	O
uterine	O
contractile	O
pattern	O
or	O
fetal	O
cardiac	O
activity	O
.	O

RESULTS	O
Of	O
the	O
200	O
patients	O
enrolled	O
,	O
99	O
were	O
randomized	O
to	O
misoprostol	Pharmacological
and	O
101	O
to	O
dinoprostone	Pharmacological
.	Pharmacological

The	O
average	O
interval	O
from	O
start	O
of	O
induction	O
to	O
vaginal	O
delivery	O
was	O
1	O
hour	O
shorter	O
in	O
the	O
misoprostol	Pharmacological
group	O
(	O
1296.7	O
+/-	O
722.1	O
minutes	O
)	O
than	O
in	O
the	O
dinoprostone	Pharmacological
group	O
(	O
1360.0	O
+/-	O
792.0	O
minutes	O
)	O
,	O
but	O
this	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0.97	O
)	O
.	O

Oxytocin	Pharmacological
augmentation	O
of	O
labor	O
was	O
used	O
in	O
50	O
(	O
50.5	O
%	O
)	O
misoprostol-treated	Pharmacological
patients	O
and	O
43	O
(	O
43.5	O
%	O
)	O
dinoprostone-treated	Pharmacological
patients	O
(	O
relative	O
risk	O
1.14	O
,	O
95	O
%	O
confidence	O
interval	O
0.86	O
to	O
1.51	O
,	O
p	O
=	O
0.35	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
routes	O
of	O
delivery	O
with	O
misoprostol	Pharmacological
or	O
dinoprostone	Pharmacological
.	Pharmacological

Overall	O
,	O
38	O
patients	O
(	O
19.3	O
%	O
)	O
had	O
cesarean	O
deliveries	O
.	O

There	O
was	O
a	O
significantly	O
lower	O
prevalence	O
of	O
tachysystole	O
(	O
six	O
or	O
more	O
uterine	O
contractions	O
in	O
a	O
10-minute	O
window	O
for	O
two	O
consecutive	O
10-minute	O
periods	O
)	O
in	O
the	O
misoprostol	Pharmacological
group	O
(	O
7.1	O
%	O
)	O
than	O
in	O
the	O
dinoprostone	Pharmacological
group	O
(	O
18.4	O
%	O
)	O
(	O
relative	O
risk	O
0.52	O
,	O
95	O
%	O
confidence	O
interval	O
0.31	O
to	O
0.89	O
,	O
p	O
=	O
0.02	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
frequency	O
of	O
uterine	O
hyperstimulation	O
or	O
hypertonus	O
.	O

Abnormal	O
fetal	O
heart	O
rate	O
tracings	O
were	O
found	O
in	O
23	O
(	O
23.2	O
%	O
)	O
of	O
misoprostol-treated	Pharmacological
patients	O
and	O
35	O
(	O
35.7	O
%	O
)	O
of	O
dinoprostone-treated	Pharmacological
patients	O
(	O
relative	O
risk	O
0.73	O
,	O
95	O
%	O
confidence	O
interval	O
0.52	O
to	O
1.01	O
,	O
p	O
=	O
0.0546	O
)	O
.	O

No	O
significant	O
differences	O
were	O
found	O
in	O
meconium	O
passage	O
,	O
1-	O
or	O
5-minute	O
Apgar	O
scores	O
<	O
7	O
,	O
neonatal	O
resuscitations	O
,	O
or	O
admissions	O
to	O
the	O
neonatal	O
intensive	O
care	O
unit	O
between	O
the	O
two	O
groups	O
.	O

CONCLUSIONS	O
Vaginally	O
administered	O
misoprostol	Pharmacological
is	O
as	O
effective	O
as	O
dinoprostone	O
for	O
cervical	O
ripening	O
and	O
the	O
induction	O
of	O
labor	O
.	O

Mean	O
time	O
intervals	O
to	O
delivery	O
,	O
need	O
for	O
oxytocin	Pharmacological
augmentation	O
,	O
and	O
routes	O
of	O
delivery	O
were	O
similar	O
between	O
the	O
two	O
groups	O
.	O

Incidence	O
of	O
uterine	O
tachysystole	O
with	O
misoprostol	Pharmacological
every	O
4	O
hours	O
was	O
significantly	O
less	O
than	O
with	O
dinoprostone	Pharmacological
.	O

Acute	O
exposure	O
to	O
acid	O
fog	O
:	O
influence	O
of	O
breathing	O
pattern	O
on	O
effective	O
dose	O
.	O

Concern	O
about	O
the	O
possible	O
adverse	O
health	O
effects	O
of	O
acid	O
fog	O
has	O
been	O
fed	O
by	O
two	O
observations	O
:	O
air	O
pollution	O
disasters	O
earlier	O
in	O
this	O
century	O
were	O
typically	O
associated	O
with	O
fog	O
,	O
and	O
current	O
samples	O
of	O
fog	O
water	O
can	O
be	O
strongly	O
acid	O
.	O

To	O
study	O
the	O
acute	O
effects	O
of	O
acid	O
fog	O
on	O
the	O
lung	O
,	O
the	O
authors	O
generated	O
a	O
monodisperse	Pharmacological
10	Pharmacological
microM	Pharmacological
MMAD	Pharmacological
aerosol	Pharmacological
of	Pharmacological
H2SO4	Pharmacological
with	O
a	O
pH	O
of	O
2.0	O
and	O
a	O
nominal	O
concentration	O
of	O
500	O
micrograms/m3	O
.	O

They	O
exposed	O
seven	O
healthy	O
young	O
men	O
on	O
alternate	O
days	O
to	O
acid	Control
or	Control
control	Control
equiosmolar	Control
NaCl	Control
aerosol	Control
during	O
40	O
min	O
of	O
resting	O
ventilation	O
and	O
20	O
min	O
of	O
exercise	O
;	O
the	O
latter	O
was	O
sufficiently	O
intense	O
to	O
induce	O
oronasal	O
breathing	O
.	O

Exposure	O
was	O
by	O
means	O
of	O
a	O
head	O
dome	O
,	O
a	O
head-only	O
exposure	O
device	O
that	O
permitted	O
continuous	O
measurement	O
(	O
unfettered	O
breathing	O
)	O
of	O
Vr	O
,	O
f	O
,	O
VE	O
,	O
and	O
the	O
onset	O
and	O
persistence	O
of	O
oronasal	O
breathing	O
.	O

In	O
this	O
article	O
the	O
authors	O
compare	O
the	O
relative	O
importance	O
of	O
parameters	O
contributing	O
to	O
the	O
between-subject	O
variability	O
in	O
estimated	O
hydrogen	O
ion	O
dose	O
to	O
the	O
lower	O
airways	O
(	O
H+LAW	O
)	O
,	O
based	O
on	O
analysis	O
of	O
variance	O
.	O

Physiologic	O
parameters	O
accounted	O
for	O
70	O
%	O
of	O
the	O
variability	O
,	O
of	O
which	O
34	O
%	O
was	O
due	O
to	O
differences	O
in	O
duration	O
of	O
oronasal	O
breathing	O
(	O
tON	O
)	O
and	O
36	O
%	O
to	O
differences	O
in	O
ventilation	O
rate	O
during	O
oronasal	O
breathing	O
(	O
VE	O
(	O
ON	O
)	O
)	O
;	O
inhaled	O
hydrogen	O
ion	O
concentration	O
[	O
H+	O
]	O
,	O
the	O
environmental	O
parameter	O
,	O
contributed	O
only	O
30	O
%	O
.	O

Minute	O
ventilation	O
at	O
the	O
time	O
of	O
transition	O
from	O
nasal	O
to	O
oronasal	O
breathing	O
varied	O
significantly	O
among	O
subjects	O
even	O
if	O
normalized	O
to	O
FVC	O
,	O
an	O
index	O
of	O
lung	O
size	O
.	O

A	O
randomized	O
controlled	O
study	O
of	O
parent-assisted	Educational
Children	Educational
's	Educational
Friendship	Educational
Training	Educational
with	O
children	O
having	O
autism	O
spectrum	O
disorders	O
.	O

This	O
study	O
evaluated	O
Children	Educational
's	Educational
Friendship	Educational
Training	Educational
(	Educational
CFT	Educational
)	Educational
,	Educational
a	Educational
manualized	Educational
parent-assisted	Educational
intervention	Educational
to	O
improve	O
social	O
skills	O
among	O
second	O
to	O
fifth	O
grade	O
children	O
with	O
autism	O
spectrum	O
disorders	O
.	O

Comparison	O
was	O
made	O
with	O
a	O
delayed	Educational
treatment	Educational
control	Educational
group	Educational
(	Educational
DTC	Educational
)	Educational
.	O

Targeted	O
skills	O
included	O
conversational	O
skills	O
,	O
peer	O
entry	O
skills	O
,	O
developing	O
friendship	O
networks	O
,	O
good	O
sportsmanship	O
,	O
good	O
host	O
behavior	O
during	O
play	O
dates	O
,	O
and	O
handling	O
teasing	O
.	O

At	O
post-testing	O
,	O
the	O
CFT	O
group	O
was	O
superior	O
to	O
the	O
DTC	O
group	O
on	O
parent	O
measures	O
of	O
social	O
skill	O
and	O
play	O
date	O
behavior	O
,	O
and	O
child	O
measures	O
of	O
popularity	O
and	O
loneliness	O
,	O
At	O
3-month	O
follow-up	O
,	O
parent	O
measures	O
showed	O
significant	O
improvement	O
from	O
baseline	O
.	O

Post-hoc	O
analysis	O
indicated	O
more	O
than	O
87	O
%	O
of	O
children	O
receiving	O
CFT	Educational
showed	O
reliable	O
change	O
on	O
at	O
least	O
one	O
measure	O
at	O
post-test	O
and	O
66.7	O
%	O
after	O
3	O
months	O
follow-up	O
.	O

Physostigmine	Pharmacological
reverses	O
propofol-induced	O
unconsciousness	O
and	O
attenuation	O
of	O
the	O
auditory	O
steady	O
state	O
response	O
and	O
bispectral	O
index	O
in	O
human	O
volunteers	O
.	O

BACKGROUND	O
It	O
is	O
postulated	O
that	O
alteration	O
of	O
central	O
cholinergic	O
transmission	O
plays	O
an	O
important	O
role	O
in	O
the	O
mechanism	O
by	O
which	O
anesthetics	O
produce	O
unconsciousness	O
.	O

The	O
authors	O
investigated	O
the	O
effect	O
of	O
altering	O
central	O
cholinergic	O
transmission	O
,	O
by	O
physostigmine	Pharmacological
and	O
scopolamine	Pharmacological
,	O
on	O
unconsciousness	O
produced	O
by	O
propofol	O
.	O

METHODS	O
Propofol	Pharmacological
was	O
administered	O
to	O
American	O
Society	O
of	O
Anesthesiologists	O
physical	O
status	O
1	O
(	O
n	O
=	O
17	O
)	O
volunteers	O
with	O
use	O
of	O
a	O
computer-controlled	O
infusion	O
pump	O
at	O
increasing	O
concentrations	O
until	O
unconsciousness	O
resulted	O
(	O
inability	O
to	O
respond	O
to	O
verbal	O
commands	O
,	O
abolition	O
of	O
spontaneous	O
movement	O
)	O
.	O

Central	O
nervous	O
system	O
function	O
was	O
assessed	O
by	O
use	O
of	O
the	O
Auditory	O
Steady	O
State	O
Response	O
(	O
ASSR	O
)	O
and	O
Bispectral	O
Index	O
(	O
BIS	O
)	O
analysis	O
of	O
electrooculogram	O
.	O

During	O
continuous	O
administration	O
of	O
propofol	O
,	O
reversal	O
of	O
unconsciousness	O
produced	O
by	O
physostigmine	Pharmacological
(	O
28	O
microgram/kg	O
)	O
and	O
block	O
of	O
this	O
reversal	O
by	O
scopolamine	Pharmacological
(	O
8.6	O
microgram/kg	O
)	O
were	O
evaluated	O
.	O

RESULTS	O
Propofol	O
produced	O
unconsciousness	O
at	O
a	O
plasma	O
concentration	O
of	O
3.2	O
+/-	O
0.8	O
(	O
+/-	O
SD	O
)	O
microgram/ml	O
(	O
n	O
=	O
17	O
)	O
.	O

Unconsciousness	O
was	O
associated	O
with	O
reductions	O
in	O
ASSR	O
(	O
0.10	O
+/-	O
0.08	O
microV	O
[	O
awake	O
baseline	O
0.32	O
+/-	O
0.18	O
microV	O
]	O
,	O
P	O
<	O
0.001	O
)	O
and	O
BIS	O
(	O
55.7	O
+/-	O
8.8	O
[	O
awake	O
baseline	O
92.4	O
+/-	O
3.9	O
]	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Physostigmine	O
restored	O
consciousness	O
in	O
9	O
of	O
11	O
subjects	O
,	O
with	O
concomitant	O
increases	O
in	O
ASSR	O
(	O
0.38	O
+/-	O
0.17	O
microV	O
,	O
P	O
<	O
0.01	O
)	O
and	O
BIS	O
(	O
75.3	O
+/-	O
8.3	O
,	O
P	O
<	O
0.001	O
)	O
.	O

In	O
all	O
subjects	O
(	O
n	O
=	O
6	O
)	O
scopolamine	O
blocked	O
the	O
physostigmine-induced	O
reversal	O
of	O
unconsciousness	O
and	O
the	O
increase	O
of	O
the	O
ASSR	O
and	O
BIS	O
(	O
ASSR	O
and	O
BIS	O
during	O
propofol-induced	O
unconsciousness	O
:	O
0.09	O
+/-	O
0.09	O
microV	O
and	O
58.2	O
+/-	O
7.5	O
,	O
respectively	O
;	O
ASSR	O
and	O
BIS	O
after	O
physostigmine	O
administration	O
:	O
0.08	O
+/-	O
0.06	O
microV	O
and	O
56.8	O
+/-	O
6.7	O
,	O
respectively	O
,	O
NS	O
)	O
.	O

CONCLUSIONS	O
These	O
findings	O
suggest	O
that	O
the	O
unconsciousness	O
produced	O
by	O
propofol	O
is	O
mediated	O
at	O
least	O
in	O
part	O
via	O
interruption	O
of	O
central	O
cholinergic	O
muscarinic	O
transmission	O
.	O

Information	Educational
source	Educational
affects	O
peers	O
'	O
initial	O
attitudes	O
toward	O
autism	O
.	O

Authors	O
examined	O
the	O
effects	O
of	O
information	O
source	O
on	O
peers	O
'	O
cognitive	O
and	O
behavioral	O
attitudes	O
toward	O
an	O
unfamiliar	O
child	O
with	O
autism	O
.	O

Children	O
(	O
N=296	O
;	O
M	O
age=10.21	O
years	O
)	O
received	O
information	O
about	O
an	O
unfamiliar	O
child	O
with	O
autism	O
from	O
one	O
of	O
the	O
following	O
sources	O
:	O
(	O
a	O
)	O
videotape	Educational
,	O
(	O
b	O
)	O
teacher	Educational
,	O
(	O
c	O
)	O
hypothetical	Educational
mother	Educational
,	O
(	O
d	O
)	O
hypothetical	Educational
father	Educational
,	O
or	O
(	O
e	O
)	O
hypothetical	Educational
doctor	Educational
.	Educational

Interactive	O
effects	O
between	O
source	O
,	O
and	O
sex	O
and	O
grade	O
were	O
found	O
for	O
cognitive	O
and	O
behavioral	O
attitudes	O
.	O

Fifth-graders	O
reported	O
more	O
favorable	O
cognitive	O
and	O
behavioral	O
attitudes	O
when	O
information	O
was	O
provided	O
by	O
extra-familial	O
sources	O
(	O
i.e.	O
,	O
doctor	O
)	O
versus	O
parent	O
sources	O
.	O

Mother	O
yielded	O
more	O
persuasive	O
effects	O
on	O
behavioral	O
attitudes	O
for	O
third-graders	O
versus	O
fifth-graders	O
.	O

Attitudes	O
toward	O
autism	O
differ	O
depending	O
on	O
who	O
provides	O
information	O
about	O
the	O
disability	O
.	O

Persuasion	O
theory	O
appears	O
useful	O
to	O
guide	O
evaluation	O
of	O
educational	O
interventions	O
to	O
improve	O
attitudes	O
towards	O
autism	O
.	O

Implications	O
of	O
the	O
findings	O
,	O
study	O
limitations	O
,	O
and	O
recommendations	O
for	O
future	O
research	O
are	O
discussed	O
.	O

Brief	O
report	O
:	O
imitation	Psychological
effects	O
on	O
children	O
with	O
autism	O
.	O

Twenty	O
children	O
with	O
autism	O
(	O
mean	O
age	O
,	O
5	O
years	O
)	O
were	O
recruited	O
for	O
the	O
study	O
from	O
a	O
school	O
for	O
children	O
with	O
autism	O
.	O

The	O
children	O
were	O
randomly	O
assigned	O
to	O
an	O
imitation	Psychological
(	O
n	O
=	O
10	O
)	O
or	O
contingently	Psychological
responsive	Psychological
(	O
n	O
=	O
10	O
)	O
interaction	O
group	O
based	O
on	O
a	O
stratification	O
table	O
for	O
gender	O
and	O
developmental	O
and	O
chronological	O
age	O
.	O

The	O
sessions	O
consisted	O
of	O
four	O
phases	O
,	O
with	O
each	O
phase	O
lasting	O
3	O
minutes	O
.	O

In	O
the	O
first	O
phase	O
,	O
the	O
child	O
walked	O
into	O
a	O
room	O
that	O
was	O
furnished	O
with	O
a	O
sofa	O
,	O
a	O
table	O
,	O
chairs	O
,	O
and	O
two	O
sets	O
of	O
identical	O
toys	O
.	O

An	O
adult	O
was	O
in	O
the	O
room	O
sitting	O
very	O
still	O
like	O
a	O
statue	O
(	O
first	O
still-face	O
condition	O
)	O
.	O

In	O
the	O
second	O
phase	O
,	O
the	O
adult	O
either	O
imitated	O
the	O
child	O
or	O
was	O
contingently	Psychological
responsive	Psychological
to	O
the	O
child	O
.	O

In	O
the	O
third	O
phase	O
,	O
the	O
adult	O
sat	O
still	O
again	O
(	O
second	O
still-face	O
condition	O
)	O
,	O
and	O
in	O
the	O
fourth	O
phase	O
,	O
the	O
adult	O
engaged	O
in	O
a	O
spontaneous	O
interaction	O
.	O

During	O
the	O
third	O
phase	O
(	O
the	O
second	O
still-face	O
condition	O
)	O
,	O
the	O
children	O
in	O
the	O
imitation	Psychological
group	O
spent	O
less	O
time	O
in	O
gross	O
motor	O
activity	O
and	O
more	O
time	O
touching	O
the	O
adult	O
,	O
as	O
if	O
attempting	O
to	O
initiate	O
an	O
interaction	O
.	O

The	O
contingency	Educational
condition	O
appeared	O
to	O
be	O
a	O
more	O
effective	O
way	O
to	O
facilitate	O
a	O
distal	O
social	O
behavior	O
(	O
attention	O
)	O
,	O
whereas	O
the	O
imitative	Psychological
condition	O
was	O
a	O
more	O
effective	O
way	O
to	O
facilitate	O
a	O
proximal	O
social	O
behavior	O
(	O
touching	O
)	O
.	O

[	O
Clinical	O
observation	O
on	O
different	O
acupuncture	Physical
and	O
moxibustion	Pharmacological
therapies	O
for	O
treatment	O
of	O
postsurgical	O
gastroparesis	O
syndrome	O
]	O
.	O

OBJECTIVE	O
To	O
optimize	O
therapy	O
of	O
acupuncture	Physical
and	O
moxibustion	Pharmacological
for	O
postsurgical	O
gastroparesis	O
syndrome	O
(	O
PGS	O
)	O
.	O

METHODS	O
Forty-one	O
cases	O
of	O
PGS	O
were	O
randomly	O
divided	O
into	O
3	O
groups	O
in	O
order	O
of	O
visiting	O
.	O

Group	O
A	O
(	O
n	O
=	O
17	O
)	O
were	O
treated	O
by	O
warming	O
needle	O
moxibustion	Pharmacological
,	O
group	O
B	O
(	O
n	O
=	O
12	O
)	O
by	O
acupuncture	Physical
plus	O
auricular	Physical
point	Physical
sticking	Physical
,	O
and	O
group	O
C	O
(	O
n	O
=	O
12	O
)	O
by	O
routine	Physical
acupuncture	Physical
.	Physical

Changes	O
of	O
gastric	O
drainage	O
volume	O
,	O
therapeutic	O
times	O
and	O
cured	O
rate	O
were	O
investigated	O
in	O
the	O
3	O
groups	O
.	O

RESULTS	O
All	O
the	O
3	O
therapeutic	O
methods	O
could	O
significantly	O
decrease	O
gastric	O
drainage	O
volume	O
.	O

The	O
cured	O
rate	O
was	O
100.0	O
%	O
and	O
the	O
therapeutic	O
times	O
was	O
(	O
7.24	O
+/-	O
3.87	O
)	O
in	O
the	O
group	O
A	O
,	O
66.7	O
%	O
,	O
(	O
9.83	O
+/-	O
4.60	O
)	O
times	O
in	O
the	O
group	O
B	O
and	O
75.0	O
%	O
,	O
(	O
15.25	O
+/-	O
3.81	O
)	O
times	O
in	O
the	O
group	O
C	O
,	O
with	O
significant	O
differences	O
in	O
the	O
cured	O
rate	O
and	O
the	O
therapeutic	O
times	O
among	O
the	O
3	O
groups	O
(	O
P	O
<	O
0.05	O
,	O
P	O
<	O
0.01	O
)	O
.	O

CONCLUSION	O
The	O
warming	O
needle	O
moxibustion	Pharmacological
is	O
the	O
best	O
method	O
for	O
PGS	O
,	O
with	O
less	O
therapeutic	O
times	O
,	O
high	O
cured	O
rate	O
and	O
rapid	O
effect	O
.	O

Direct	Physical
trocar	Physical
insertion	Physical
vs.	O
Verres	Physical
needle	Physical
use	Physical
for	O
laparoscopic	O
sterilization	O
.	O

A	O
randomized	O
,	O
prospective	O
trial	O
was	O
designed	O
to	O
compare	O
direct	Physical
trocar	Physical
insertion	Physical
with	O
prior	O
peritoneal	O
insufflation	O
with	O
a	O
Verres	Physical
needle	Physical
for	O
laparoscopic	O
tubal	O
sterilization	O
.	O

Direct	Physical
trocar	Physical
insertion	Physical
resulted	O
in	O
fewer	O
instrument	O
insertions	O
(	O
21.8	O
%	O
vs.	O
7.8	O
%	O
)	O
and	O
use	O
of	O
smaller	O
volumes	O
of	O
CO2	O
(	O
2.67	O
vs.	O
2.32	O
L	O
)	O
.	O

Direct	Physical
trocar	Physical
use	O
resulted	O
in	O
a	O
decrease	O
in	O
operating	O
time	O
from	O
9	O
minutes	O
,	O
40	O
seconds	O
in	O
the	O
needle	O
group	O
to	O
7	O
minutes	O
,	O
30	O
seconds	O
in	O
the	O
trocar	O
group	O
.	O

Minor	O
omental	O
injuries	O
occurred	O
in	O
a	O
small	O
percentage	O
of	O
each	O
group	O
,	O
while	O
serious	O
complications	O
occurred	O
once	O
in	O
each	O
group	O
.	O

Endometrial	O
cytodiagnosis	O
using	O
a	O
new	Other
softcyte	Other
versus	O
a	O
conventional	Other
endocyte	Other
.	O

A	O
new	O
endometrial	O
cytologic	O
sampling	O
device	O
,	O
softcyte	O
,	O
was	O
used	O
in	O
cytological	O
screening	O
for	O
endometrial	O
cancer	O
,	O
and	O
was	O
compared	O
with	O
the	O
endocyte	Other
with	O
regard	O
to	O
manipulability	O
,	O
adverse	O
effects	O
(	O
including	O
pain	O
and	O
hemorrhage	O
)	O
,	O
and	O
cellular	O
findings	O
(	O
including	O
the	O
quantity	O
of	O
cells	O
collected	O
,	O
the	O
success	O
rate	O
,	O
cell	O
freshness	O
,	O
and	O
cellular	O
clumping	O
)	O
.	O

A	O
total	O
of	O
315	O
women	O
(	O
premenopause	O
251	O
,	O
postmenopause	O
64	O
)	O
were	O
randomly	O
assigned	O
to	O
two	O
groups	O
who	O
underwent	O
the	O
endometrial	Other
cytological	Other
screening	Other
with	Other
either	Other
the	Other
softcyte	Other
or	O
the	O
endocyte	Other
.	O

To	O
assess	O
the	O
value	O
of	O
the	O
softcyte	Other
we	O
compared	O
it	O
with	O
the	O
endocyte	Other
.	Other

Endometrial	O
cytology	O
using	O
a	O
softcyte	Other
or	O
an	O
endocyte	Other
achieved	O
high	O
correct	O
diagnosis	O
rate	O
for	O
cancer	O
,	O
and	O
both	O
instruments	O
are	O
valuable	O
as	O
endometrial	O
cytologic	O
sample	O
devices	O
.	O

The	O
softcyte	O
causes	O
only	O
mild	O
pain	O
on	O
introduction	O
and	O
during	O
collection	O
,	O
and	O
a	O
large	O
quantity	O
of	O
cells	O
could	O
be	O
harvested	O
.	O

These	O
results	O
suggest	O
that	O
the	O
softcyte	O
is	O
a	O
useful	O
cytologic	O
sampling	O
device	O
in	O
screening	O
for	O
endometrial	O
cancer	O
.	O

Effects	O
of	O
three	O
oral	O
analgesics	Pharmacological
on	O
postoperative	O
pain	O
following	O
root	O
canal	O
preparation	O
:	O
a	O
controlled	O
clinical	O
trial	O
.	O

AIM	O
To	O
compare	O
the	O
effects	O
of	O
single	O
doses	O
of	O
three	O
oral	O
medications	O
on	O
postoperative	O
pain	O
following	O
instrumentation	O
of	O
root	O
canals	O
in	O
teeth	O
with	O
irreversible	O
pulpitis	O
.	O

METHODOLOGY	O
In	O
this	O
double-blind	O
clinical	O
trial	O
,	O
100	O
patients	O
who	O
had	O
anterior	O
or	O
premolar	O
teeth	O
with	O
irreversible	O
pulpitis	O
without	O
any	O
signs	O
and	O
symptoms	O
of	O
acute	O
or	O
chronic	O
apical	O
periodontitis	O
and	O
moderate	O
to	O
severe	O
pain	O
were	O
divided	O
by	O
balanced	O
block	O
random	O
allocation	O
into	O
four	O
groups	O
of	O
25	O
each	O
,	O
a	O
control	Control
group	Control
receiving	O
a	O
placebo	Control
medication	O
,	O
and	O
three	O
experimental	O
groups	O
receiving	O
a	O
single	O
dose	O
of	O
either	O
Tramadol	Pharmacological
(	O
100	O
mg	O
)	O
,	O
Novafen	Pharmacological
(	O
325	O
mg	O
of	O
paracetamol	Pharmacological
,	O
200	O
mg	O
ibuprofen	Pharmacological
and	O
40	O
mg	O
caffeine	Pharmacological
anhydrous	Pharmacological
)	O
or	O
Naproxen	Pharmacological
(	O
500	O
mg	O
)	O
immediately	O
after	O
the	O
first	O
appointment	O
where	O
the	O
pulp	O
was	O
removed	O
,	O
and	O
the	O
canals	O
were	O
fully	O
prepared	O
.	O

The	O
intensity	O
of	O
pain	O
was	O
scored	O
based	O
on	O
10-point	O
VAS	O
before	O
and	O
after	O
treatment	O
for	O
up	O
to	O
24	O
h	O
postoperatively	O
.	O

Data	O
were	O
submitted	O
to	O
repeated	O
analysis	O
of	O
variance	O
.	O

RESULTS	O
At	O
the	O
6	O
,	O
12	O
and	O
24	O
h	O
postoperative	O
intervals	O
after	O
drug	O
administration	O
,	O
the	O
intensity	O
of	O
pain	O
was	O
significantly	O
lower	O
in	O
the	O
experimental	O
groups	O
than	O
in	O
the	O
placebo	Pharmacological
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Tramadol	Pharmacological
was	O
significantly	O
less	O
effective	O
(	O
P	O
<	O
0.05	O
)	O
than	O
Naproxen	Pharmacological
,	O
and	O
Novafen	Pharmacological
that	O
were	O
similar	O
to	O
each	O
other	O
(	O
P	O
>	O
0.05	O
)	O
.	O

CONCLUSION	O
A	O
single	O
oral	O
dose	O
of	O
Naproxen	Pharmacological
,	O
Novafen	Pharmacological
and	O
Tramadol	Pharmacological
taken	O
immediately	O
after	O
treatment	O
reduced	O
postoperative	O
pain	O
following	O
pulpectomy	O
and	O
root	O
canal	O
preparation	O
of	O
teeth	O
with	O
irreversible	O
pulpitis	O
.	O

Social	Educational
support	Educational
and	O
abstinence	Educational
from	O
opiates	O
and	O
cocaine	O
during	O
opioid	Pharmacological
maintenance	Pharmacological
treatment	Pharmacological
.	O

Social	Educational
support	Educational
may	O
play	O
an	O
important	O
role	O
in	O
helping	O
drug	O
users	O
achieve	O
abstinence	O
;	O
however	O
these	O
benefits	O
may	O
depend	O
on	O
the	O
type	O
of	O
support	O
experienced	O
.	O

In	O
this	O
prospective	O
observational	O
study	O
,	O
we	O
examined	O
the	O
extent	O
to	O
which	O
general	Educational
and	Educational
abstinence-specific	Educational
support	Educational
,	Educational
both	Educational
structural	Educational
and	Educational
functional	Educational
,	O
predicted	O
opiate	O
and	O
cocaine	O
abstinence	O
in	O
128	O
opioid	O
maintenance	O
patients	O
receiving	O
either	O
methadone	Pharmacological
or	O
LAAM	Pharmacological
.	O

A	O
new	O
multidimensional	O
self-report	O
instrument	O
assessing	O
abstinence-specific	Educational
functional	O
support	O
was	O
developed	O
for	O
the	O
study	O
.	O

Previously	O
validated	O
measures	O
were	O
used	O
to	O
assess	O
the	O
remaining	O
types	O
of	O
support	O
.	O

With	O
baseline	O
abstinence	O
and	O
other	O
statistically	O
important	O
covariates	O
adjusted	O
,	O
hierarchical	O
logistic	O
regression	O
analyses	O
demonstrated	O
that	O
the	O
associations	O
between	O
social	O
support	O
at	O
study	O
baseline	O
and	O
biochemically	O
confirmed	O
abstinence	O
3	O
months	O
later	O
varied	O
by	O
type	O
of	O
support	O
and	O
by	O
drug	O
.	O

Greater	O
abstinence-specific	Educational
structural	O
support	O
(	O
operationalized	O
as	O
fewer	O
drug	O
users	O
in	O
the	O
social	O
network	O
)	O
and	O
decreases	O
in	O
three	O
types	O
of	O
negative	O
abstinence-specific	Educational
functional	O
support	O
(	O
Complaints	O
about	O
Drug	O
Use	O
,	O
Drug	O
Exposure	O
,	O
and	O
Demoralization	O
)	O
predicted	O
cocaine	O
,	O
but	O
not	O
opiate	O
abstinence	O
.	O

There	O
were	O
no	O
effects	O
for	O
general	O
support	O
,	O
whether	O
structural	O
or	O
functional	O
,	O
on	O
abstinence	O
from	O
either	O
drug	O
.	O

Interventions	O
that	O
focus	O
on	O
modifying	O
patients	O
'	O
abstinence-specific	Educational
support	O
may	O
be	O
helpful	O
in	O
reducing	O
the	O
high	O
rates	O
of	O
cocaine	O
use	O
disorders	O
in	O
this	O
population	O
.	O

Recombinant	Pharmacological
human	Pharmacological
erythropoietin	Pharmacological
therapy	Pharmacological
for	O
anemic	O
cancer	O
patients	O
on	O
combination	O
chemotherapy	O
.	O

BACKGROUND	O
Patients	O
with	O
advanced	O
cancer	O
frequently	O
experience	O
clinically	O
significant	O
anemia	O
,	O
which	O
is	O
often	O
exacerbated	O
by	O
myelosuppressive	O
chemotherapy	O
.	O

Consistent	O
with	O
the	O
anemia	O
of	O
chronic	O
disease	O
,	O
studies	O
have	O
documented	O
serum	O
erythropoietin	O
levels	O
that	O
are	O
inappropriately	O
low	O
for	O
the	O
degree	O
of	O
anemia	O
in	O
cancer	O
patients	O
.	O

Myelosuppressive	O
chemotherapy	O
impairs	O
erythropoiesis	O
,	O
which	O
may	O
not	O
fully	O
recover	O
between	O
treatment	O
cycles	O
.	O

Recombinant	Pharmacological
human	Pharmacological
erythropoietin	Pharmacological
(	Pharmacological
rHuEPO	Pharmacological
)	Pharmacological
has	O
been	O
used	O
safely	O
and	O
effectively	O
to	O
treat	O
anemia	O
in	O
AIDS	O
patients	O
receiving	O
zidovudine	O
(	O
AZT	O
)	O
and	O
in	O
patients	O
with	O
chronic	O
renal	O
failure	O
.	O

PURPOSE	O
This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
clinical	O
role	O
of	O
rHuEPO	O
in	O
reducing	O
symptomatic	O
anemia	O
in	O
patients	O
with	O
advanced	O
cancer	O
who	O
were	O
receiving	O
myelosuppressive	O
chemotherapy	O
(	O
excluding	O
cisplatin	O
)	O
.	O

METHODS	O
We	O
studied	O
153	O
anemic	O
cancer	O
patients	O
receiving	O
cyclic	Pharmacological
combination	Pharmacological
chemotherapy	Pharmacological
in	O
a	O
prospective	O
multicenter	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
.	O

The	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
rHuEPO	Pharmacological
(	O
150	O
U/kg	O
)	O
or	O
placebo	Control
subcutaneously	O
three	O
times	O
a	O
week	O
for	O
a	O
maximum	O
of	O
12	O
weeks	O
or	O
until	O
the	O
hematocrit	O
level	O
increased	O
to	O
38	O
%	O
-40	O
%	O
.	O

If	O
the	O
hematocrit	O
reached	O
this	O
target	O
level	O
before	O
12	O
weeks	O
,	O
the	O
rHuEPO	Pharmacological
dose	O
could	O
be	O
reduced	O
to	O
maintain	O
the	O
hematocrit	O
at	O
that	O
level	O
for	O
the	O
duration	O
of	O
the	O
study	O
.	O

Response	O
to	O
rHuEPO	Pharmacological
therapy	O
was	O
assessed	O
by	O
measuring	O
changes	O
in	O
hematocrit	O
level	O
,	O
transfusion	O
requirements	O
,	O
and	O
quality	O
of	O
life	O
.	O

Quality-of-life	O
assessment	O
was	O
based	O
on	O
patients	O
'	O
responses	O
to	O
questionnaires	O
before	O
and	O
after	O
the	O
courses	O
of	O
therapy	O
.	O

RESULTS	O
The	O
increase	O
in	O
hematocrit	O
in	O
the	O
rHuEPO-treated	Pharmacological
group	O
compared	O
with	O
hematocrit	O
in	O
the	O
placebo-treated	Control
group	O
was	O
statistically	O
significant	O
(	O
P	O
=	O
.0001	O
)	O
as	O
measured	O
by	O
percentage	O
point	O
of	O
change	O
from	O
baseline	O
to	O
final	O
evaluation	O
,	O
by	O
an	O
increase	O
in	O
hematocrit	O
level	O
of	O
six	O
percentage	O
points	O
or	O
more	O
unrelated	O
to	O
transfusion	O
,	O
and	O
by	O
a	O
rise	O
in	O
hematocrit	O
level	O
to	O
38	O
%	O
or	O
more	O
unrelated	O
to	O
transfusion	O
.	O

There	O
was	O
a	O
trend	O
toward	O
the	O
reduction	O
in	O
mean	O
units	O
of	O
blood	O
transfused	O
per	O
patient	O
during	O
months	O
2	O
and	O
3	O
of	O
therapy	O
combined	O
in	O
rHuEPO-treated	Pharmacological
patients	O
compared	O
with	O
placebo-treated	O
patients	O
(	O
0.91	O
U	O
versus	O
1.65	O
U	O
;	O
P	O
=	O
.056	O
)	O
.	O

In	O
addition	O
,	O
rHuEPO-treated	Pharmacological
patients	O
experienced	O
a	O
statistically	O
significant	O
improvement	O
in	O
energy	O
level	O
and	O
ability	O
to	O
perform	O
daily	O
activities	O
(	O
P	O
<	O
or	O
=	O
.05	O
)	O
.	O

The	O
two	O
treatment	O
groups	O
showed	O
no	O
statistically	O
significant	O
differences	O
in	O
toxic	O
effects	O
except	O
for	O
increased	O
incidence	O
of	O
diaphoresis	O
(	O
P	O
<	O
.05	O
)	O
and	O
diarrhea	O
(	O
P	O
=	O
.05	O
)	O
in	O
the	O
rHuEPO-treated	O
group	O
.	O

CONCLUSIONS	O
We	O
conclude	O
that	O
rHuEPO	Pharmacological
is	O
safe	O
and	O
effective	O
for	O
reversing	O
anemia	O
related	O
to	O
advanced	O
cancer	O
or	O
to	O
chemotherapy	O
for	O
cancer	O
.	O

Warfarin	Pharmacological
for	O
atrial	O
fibrillation	O
.	O

The	O
patient	O
's	O
perspective	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
minimal	O
clinically	O
important	O
difference	O
(	O
MCID	O
)	O
of	O
warfarin	Pharmacological
therapy	O
for	O
the	O
treatment	O
of	O
nonvalvular	O
atrial	O
fibrillation	O
from	O
the	O
perspective	O
of	O
patients	O
using	O
2	O
different	O
elicitation	O
methods	O
.	O

DESIGN	O
All	O
patients	O
completed	O
2	O
face-to-face	O
interviews	O
,	O
which	O
were	O
2	O
weeks	O
apart	O
.	O

For	O
each	O
interview	O
,	O
they	O
were	O
randomized	O
to	O
receive	O
1	O
of	O
2	O
elicitation	O
methods	O
:	O
ping-ponging	O
or	O
starting	O
at	O
the	O
known	O
efficacy	O
.	O

SETTING	O
The	O
practices	O
of	O
2	O
university-affiliated	O
family	O
medicine	O
centers	O
(	O
8	O
physicians	O
each	O
)	O
,	O
14	O
community-based	O
family	O
physicians	O
,	O
and	O
2	O
cardiologists	O
.	O

PATIENTS	O
Sixty-four	O
patients	O
with	O
nonvalvular	O
atrial	O
fibrillation	O
who	O
were	O
initiated	O
with	O
warfarin	O
therapy	O
at	O
least	O
3	O
months	O
before	O
the	O
study	O
.	O

INTERVENTION	O
During	O
each	O
interview	O
,	O
the	O
patients	O
'	O
MCIDs	O
were	O
determined	O
by	O
using	O
(	O
1	O
)	O
a	O
pictorial	O
flip	O
chart	O
to	O
describe	O
atrial	O
fibrillation	O
;	O
the	O
consequences	O
of	O
a	O
minor	O
stroke	O
,	O
a	O
major	O
stroke	O
,	O
and	O
a	O
major	O
bleeding	O
episode	O
;	O
the	O
chance	O
of	O
stroke	O
if	O
not	O
taking	O
warfarin	O
;	O
the	O
chance	O
of	O
a	O
major	O
bleeding	O
episode	O
if	O
taking	O
warfarin	O
;	O
examples	O
of	O
the	O
inconvenience	O
,	O
minor	O
side	O
effects	O
,	O
and	O
costs	O
of	O
warfarin	O
therapy	O
;	O
and	O
then	O
(	O
2	O
)	O
1	O
of	O
the	O
2	O
elicitation	O
methods	O
to	O
determine	O
their	O
MCIDs	O
(	O
the	O
smallest	O
reduction	O
in	O
stroke	O
risk	O
at	O
which	O
the	O
patients	O
were	O
willing	O
to	O
take	O
warfarin	O
)	O
.	O

Patients	O
'	O
knowledge	O
of	O
their	O
stroke	O
risk	O
,	O
acceptability	O
of	O
the	O
interview	O
process	O
,	O
and	O
factors	O
determining	O
their	O
preferences	O
were	O
also	O
assessed	O
.	O

MAIN	O
RESULTS	O
Given	O
a	O
baseline	O
risk	O
of	O
having	O
a	O
stroke	O
in	O
the	O
next	O
2	O
years	O
,	O
if	O
not	O
taking	O
warfarin	Pharmacological
,	O
of	O
10	O
of	O
100	O
,	O
the	O
mean	O
MCID	O
was	O
2.01	O
of	O
100	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
1.60-2.42	O
)	O
.	O

Fifty-two	O
percent	O
of	O
the	O
patients	O
would	O
take	O
warfarin	Pharmacological
for	O
an	O
absolute	O
decrease	O
in	O
stroke	O
risk	O
of	O
1	O
%	O
over	O
2	O
years	O
.	O

Before	O
eliciting	O
their	O
MCIDs	O
,	O
patients	O
showed	O
poor	O
knowledge	O
of	O
their	O
stroke	O
risk	O
,	O
which	O
improved	O
afterward	O
.	O

The	O
interview	O
process	O
was	O
well	O
accepted	O
by	O
the	O
patients	O
.	O

The	O
MCID	O
using	O
the	O
ping-ponging	O
elicitation	O
method	O
was	O
1.015	O
of	O
100	O
smaller	O
compared	O
with	O
use	O
of	O
the	O
starting	O
at	O
the	O
known	O
efficacy	O
method	O
(	O
P	O
=	O
.01	O
)	O
.	O

CONCLUSIONS	O
We	O
were	O
able	O
to	O
determine	O
the	O
MCID	O
of	O
warfarin	Pharmacological
therapy	Pharmacological
for	O
the	O
prevention	O
of	O
stroke	O
from	O
the	O
perspective	O
of	O
patients	O
with	O
nonvalvular	O
atrial	O
fibrillation	O
.	O

Their	O
MCIDs	O
were	O
much	O
smaller	O
than	O
those	O
that	O
have	O
been	O
implied	O
by	O
some	O
experts	O
and	O
clinicians	O
.	O

The	O
interview	O
process	O
,	O
using	O
the	O
flip	O
chart	O
approach	O
,	O
appeared	O
to	O
improve	O
the	O
patients	O
'	O
knowledge	O
of	O
their	O
disease	O
and	O
its	O
consequences	O
and	O
treatment	O
.	O

The	O
method	O
used	O
to	O
elicit	O
the	O
patients	O
'	O
MCIDs	O
can	O
have	O
a	O
clinically	O
important	O
effect	O
on	O
patient	O
responses	O
.	O

The	O
method	O
used	O
in	O
our	O
study	O
can	O
be	O
generalized	O
to	O
other	O
conditions	O
and	O
,	O
thus	O
,	O
could	O
be	O
helpful	O
in	O
3	O
ways	O
:	O
(	O
1	O
)	O
from	O
a	O
clinical	O
decision-making	O
perspective	O
,	O
it	O
could	O
facilitate	O
patient-physician	O
communication	O
;	O
(	O
2	O
)	O
it	O
could	O
clarify	O
the	O
patient	O
perspective	O
when	O
interpreting	O
the	O
results	O
of	O
previously	O
completed	O
trials	O
;	O
and	O
(	O
3	O
)	O
it	O
could	O
be	O
used	O
to	O
derive	O
more	O
clinically	O
relevant	O
sample	O
sizes	O
for	O
randomized	O
treatment	O
trials	O
.	O

Echocardiographic	O
evaluation	O
of	O
children	O
with	O
systemic	O
ventricular	O
dysfunction	O
treated	O
with	O
carvedilol	Pharmacological
.	Pharmacological

Echocardiography	Physical
is	O
used	O
to	O
measure	O
the	O
therapeutic	O
effectiveness	O
of	O
heart	O
failure	O
therapy	O
in	O
adults	O
and	O
children	O
.	O

The	O
purposes	O
of	O
this	O
study	O
were	O
(	O
1	O
)	O
to	O
assess	O
baseline	O
echocardiographic	O
predictors	O
of	O
clinical	O
outcome	O
,	O
(	O
2	O
)	O
to	O
investigate	O
changes	O
in	O
echocardiographic	O
parameters	O
,	O
and	O
(	O
3	O
)	O
to	O
compare	O
these	O
echocardiographic	O
changes	O
with	O
changes	O
in	O
plasma	O
levels	O
of	O
b-type	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
in	O
a	O
population	O
of	O
children	O
with	O
systemic	O
ventricular	O
dysfunction	O
and	O
symptomatic	O
heart	O
failure	O
treated	O
with	O
carvedilol	Pharmacological
or	O
placebo	Control
.	O

All	O
available	O
baseline	O
and	O
6-month	O
echocardiograms	O
from	O
Pediatric	O
Carvedilol	O
Trial	O
(	O
PCT	O
)	O
participants	O
(	O
carvedilol	Pharmacological
n	O
=	O
161	O
;	O
placebo	Control
n	O
=	O
55	O
)	O
were	O
reviewed	O
.	O

Systolic	O
and	O
diastolic	O
sphericity	O
index	O
(	O
SI	O
;	O
n	O
=	O
110	O
)	O
,	O
TEI	O
index	O
(	O
n	O
=	O
145	O
)	O
,	O
and	O
systemic	O
ventricular	O
dP/dt	O
(	O
n	O
=	O
70	O
)	O
were	O
measured	O
.	O

The	O
PCT	O
composite	O
definition	O
of	O
clinical	O
outcome	O
(	O
i.e.	O
,	O
worsened	O
,	O
improved	O
,	O
or	O
unchanged	O
)	O
was	O
used	O
.	O

For	O
all	O
patients	O
,	O
baseline	O
TEI	O
index	O
was	O
a	O
predictor	O
of	O
worsened	O
outcome	O
.	O

Only	O
children	O
treated	O
with	O
carvedilol	Pharmacological
showed	O
a	O
significant	O
decrease	O
in	O
systolic	O
SI	O
(	O
P	O
B	O
0.0001	O
)	O
,	O
diastolic	O
SI	O
(	O
P	O
B	O
0.0001	O
)	O
,	O
and	O
TEI	O
index	O
(	O
P	O
=	O
0.02	O
)	O
.	O

An	O
inverse	O
correlation	O
between	O
changes	O
in	O
BNP	O
and	O
changes	O
in	O
dP/dt	O
(	O
r	O
=	O
-0.45	O
,	O
P	O
=	O
0.04	O
)	O
was	O
found	O
only	O
in	O
the	O
carvedilol	Pharmacological
group	O
.	O

In	O
conclusion	O
,	O
TEI	O
index	O
predicted	O
outcome	O
in	O
children	O
with	O
systemic	O
ventricular	O
dysfunction	O
and	O
heart	O
failure	O
.	O

Carvedilol	Pharmacological
may	O
have	O
a	O
beneficial	O
effect	O
on	O
reversal	O
of	O
left	O
ventricular	O
remodeling	O
and	O
global	O
ventricular	O
function	O
in	O
pediatric	O
heart	O
failure	O
.	O

[	O
Radiotherapy	Surgical
of	O
malignant	O
brain	O
gliomas	O
using	O
teniposide	Pharmacological
]	O
.	O

Efficacy	O
of	O
radiochemotherapy	Pharmacological
of	O
malignantly-converted	O
brain	O
gliomas	O
using	O
teniposide	Pharmacological
was	O
evaluated	O
in	O
a	O
randomized	O
prospective	O
study	O
.	O

Combined	O
use	O
of	O
cytostatics	Pharmacological
and	O
irradiation	Surgical
appeared	O
safe	O
,	O
tolerable	O
and	O
significantly	O
more	O
effective	O
than	O
radiotherapy	Surgical
alone	O
as	O
assessed	O
by	O
local	O
control	O
of	O
tumor	O
and	O
survival	O
.	O

Dose	O
response	O
effect	O
of	O
cyclical	Pharmacological
medroxyprogesterone	Pharmacological
on	O
blood	O
pressure	O
in	O
postmenopausal	O
women	O
.	O

OBJECTIVE	O
This	O
study	O
was	O
designed	O
to	O
compare	O
with	O
placebo	Control
the	O
dose-response	O
effect	O
of	O
cyclical	O
doses	O
of	O
the	O
C21	Pharmacological
progestogen	Pharmacological
,	O
medroxyprogesterone	Pharmacological
acetate	Pharmacological
(	O
MPA	O
)	O
on	O
blood	O
pressure	O
(	O
BP	O
)	O
when	O
administered	O
to	O
normotensive	O
postmenopausal	O
women	O
receiving	O
a	O
fixed	O
mid-range	O
daily	O
dose	O
of	O
conjugated	Pharmacological
equine	Pharmacological
oestrogen	Pharmacological
(	Pharmacological
CEE	Pharmacological
)	Pharmacological
.	Pharmacological

MATERIALS	O
AND	O
METHODS	O
Twenty	O
normotensive	O
postmenopausal	O
women	O
(	O
median	O
age	O
53	O
years	O
)	O
participated	O
in	O
the	O
study	O
which	O
used	O
a	O
double-blind	O
crossover	O
design	O
.	O

There	O
were	O
four	O
randomised	O
treatment	O
phases	O
,	O
each	O
of	O
4	O
weeks	O
duration	O
.	O

The	O
four	O
blinded	O
treatments	O
were	O
MPA	Pharmacological
2.5	O
mg	O
,	O
MPA	Pharmacological
5	O
mg	O
,	O
MPA	Pharmacological
10	O
mg	O
and	O
matching	O
placebo	Control
,	O
taken	O
for	O
the	O
last	O
14	O
days	O
of	O
each	O
28	O
day	O
treatment	O
cycle	O
.	O

CEE	O
0.625	O
mg	O
was	O
also	O
administered	O
once	O
daily	O
as	O
open	O
labelled	O
tablets	O
to	O
all	O
subjects	O
throughout	O
the	O
study	O
.	O

Clinic	O
BP	O
was	O
measured	O
weekly	O
with	O
the	O
mean	O
values	O
of	O
weeks	O
3	O
and	O
4	O
of	O
each	O
phase	O
used	O
for	O
analysis	O
.	O

Ambulatory	O
BP	O
was	O
performed	O
in	O
the	O
final	O
week	O
of	O
each	O
phase	O
.	O

RESULTS	O
Compared	O
with	O
the	O
placebo	O
phase	O
,	O
end	O
of	O
phase	O
clinic	O
BP	O
was	O
unchanged	O
by	O
any	O
of	O
the	O
progestogen	O
treatments	O
.	O

There	O
was	O
a	O
dose-dependent	O
decrease	O
in	O
ambulatory	O
daytime	O
diastolic	O
and	O
mean	O
arterial	O
BP	O
with	O
the	O
progestogen	O
treatments	O
compared	O
with	O
placebo	O
(	O
P	O
<	O
0.05	O
)	O
.	O

CONCLUSION	O
In	O
a	O
regimen	O
of	O
postmenopausal	O
hormone	O
replacement	O
therapy	O
with	O
a	O
fixed	O
mid-range	O
daily	O
dose	O
of	O
CEE	O
combined	O
with	O
a	O
cyclical	O
regimen	O
of	O
a	O
C21	O
progestogen	O
spanning	O
the	O
current	O
clinical	O
dose	O
range	O
,	O
the	O
progestogen	Pharmacological
has	O
either	O
no	O
effect	O
or	O
a	O
small	O
dose-dependent	O
reduction	O
in	O
clinic	O
and	O
ambulatory	O
BPs	O
over	O
one	O
treatment	O
cycle	O
.	O

Double-blind	O
randomized	O
evaluation	O
of	O
intercostal	Pharmacological
nerve	Pharmacological
blocks	Pharmacological
as	O
an	O
adjuvant	O
to	O
subarachnoid	O
administered	O
morphine	Pharmacological
for	O
post-thoracotomy	O
analgesia	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
Thoracotomy	O
is	O
associated	O
with	O
pain	O
and	O
compromised	O
pulmonary	O
function	O
.	O

Intercostal	Pharmacological
nerve	Pharmacological
blocks	Pharmacological
(	Pharmacological
INB	Pharmacological
)	Pharmacological
and	O
subarachnoid	Pharmacological
morphine	Pharmacological
(	Pharmacological
SM	Pharmacological
)	Pharmacological
act	O
on	O
different	O
portions	O
of	O
the	O
pain	O
pathway	O
.	O

Each	O
is	O
effective	O
for	O
post-thoracotomy	O
pain	O
relief	O
.	O

The	O
combination	O
of	O
these	O
two	O
modalities	O
in	O
relieving	O
post-thoracotomy	O
pain	O
and	O
improving	O
postoperative	O
pulmonary	O
function	O
has	O
not	O
been	O
investigated	O
.	O

METHODS	O
In	O
a	O
double-blind	O
study	O
,	O
20	O
patients	O
undergoing	O
lateral	O
thoracotomy	Surgical
for	O
lung	O
resection	O
were	O
randomized	O
to	O
receive	O
0.5	O
mg	O
SM	Pharmacological
preoperatively	O
and	O
INB	Pharmacological
with	O
bupivacaine	Pharmacological
(	Pharmacological
INB+	Pharmacological
)	Pharmacological
prior	O
to	O
wound	O
closure	O
or	O
0.5	O
mg	O
SM	Pharmacological
with	O
INB	Pharmacological
using	O
saline	Control
(	O
INB-	O
)	O
.	O

Visual	O
analog	O
scale	O
pain	O
scores	O
at	O
rest	O
,	O
with	O
cough	O
,	O
and	O
with	O
movement	O
of	O
the	O
ipsilateral	O
arm	O
,	O
forced	O
expiratory	O
volume	O
in	O
1	O
second	O
(	O
FEV1	O
)	O
,	O
and	O
forced	O
vital	O
capacity	O
(	O
FVC	O
)	O
were	O
measured	O
at	O
4	O
,	O
24	O
,	O
48	O
,	O
and	O
72	O
hours	O
after	O
the	O
operation	O
.	O

Opioid	O
use	O
was	O
measured	O
during	O
the	O
initial	O
24	O
hours	O
after	O
the	O
operation	O
.	O

RESULTS	O
At	O
4	O
hours	O
,	O
the	O
INB+	Pharmacological
group	O
demonstrated	O
better	O
FEV1	O
(	O
56.6	O
%	O
vs.	O
40.4	O
%	O
of	O
baseline	O
,	O
P	O
<	O
.05	O
)	O
and	O
FVC	O
values	O
(	O
54.6	O
%	O
vs.	O
39.6	O
%	O
of	O
baseline	O
,	O
P	O
<	O
.05	O
)	O
and	O
less	O
resting	O
and	O
cough	O
pain	O
(	O
P	O
<	O
.05	O
)	O
.	O

However	O
,	O
FEV1	O
continued	O
to	O
decline	O
in	O
the	O
INB+	Pharmacological
group	O
at	O
24	O
hours	O
to	O
lower	O
than	O
the	O
INB-	Pharmacological
group	O
although	O
pain	O
scores	O
were	O
similar	O
beyond	O
4	O
hours	O
.	O

Opioid	O
usage	O
during	O
the	O
first	O
24	O
hours	O
was	O
similar	O
(	Pharmacological
INB-	Pharmacological
,	O
16.7	O
mg	O
vs.	O
INB+	Pharmacological
,	O
13.2	O
mg	O
,	O
P	O
=	O
.7	O
)	O
.	O

CONCLUSIONS	O
Although	O
postoperative	O
INB	Pharmacological
provided	O
modest	O
improvements	O
in	O
pain	O
and	O
pulmonary	O
function	O
when	O
used	O
as	O
an	O
adjuvant	O
to	O
0.5	O
mg	O
SM	Pharmacological
for	O
post-thoracotomy	O
analgesia	O
,	O
the	O
benefits	O
were	O
transient	O
.	O

The	O
authors	O
do	O
not	O
recommend	O
adding	O
INB	Pharmacological
for	O
patients	O
undergoing	O
lateral	O
thoracotomy	O
who	O
receive	O
0.5	O
mg	O
SM	Pharmacological
.	Pharmacological

Clonidine	Pharmacological
increases	O
the	O
sweating	O
threshold	O
,	O
but	O
does	O
not	O
reduce	O
the	O
gain	O
of	O
sweating	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
clonidine	Pharmacological
produces	O
a	O
dose-dependent	O
increase	O
in	O
the	O
sweating	O
threshold	O
but	O
does	O
not	O
reduce	O
the	O
gain	O
of	O
sweating	O
.	O

Six	O
healthy	O
male	O
volunteers	O
were	O
evaluated	O
,	O
each	O
on	O
three	O
separate	O
days	O
in	O
random	O
order	O
.	O

In	O
one	O
,	O
saline	Control
was	O
administered	O
;	O
in	O
another	O
,	O
a	O
2-micrograms/kg	O
bolus	O
of	O
clonidine	Pharmacological
was	O
followed	O
by	O
an	O
infusion	O
at	O
2	O
micrograms.kg-1.h-1	O
,	O
and	O
on	O
a	O
third	O
day	O
,	O
a	O
4-micrograms/kg	O
bolus	O
was	O
followed	O
by	O
an	O
infusion	O
at	O
4	O
micrograms.kg-1.h-1	O
.	O

Core	O
temperature	O
was	O
measured	O
at	O
the	O
tympanic	O
membrane	O
and	O
mean	O
skin	O
temperature	O
was	O
determined	O
from	O
four	O
sites	O
.	O

A	O
chest	O
sweating	O
rate	O
of	O
40	O
g.m-2.h-1	O
was	O
considered	O
significant	O
.	O

The	O
core	O
temperature	O
triggering	O
sweating	O
,	O
adjusted	O
to	O
a	O
designated	O
mean	O
skin	O
temperature	O
of	O
34	O
degrees	O
C	O
,	O
identified	O
the	O
threshold	O
for	O
this	O
response	O
.	O

Gain	O
was	O
defined	O
by	O
the	O
adjusted	O
core	O
temperature	O
increase	O
required	O
to	O
augment	O
sweating	O
from	O
100	O
to	O
300	O
g.m-2.h-1	O
.	O

degree	O
C-1	O
.	O

Plasma	O
clonidine	O
concentrations	O
were	O
0.8	O
+/-	O
0.1	O
and	O
1.6	O
+/-	O
0.2	O
ng/mL	O
on	O
the	O
small-	O
and	O
large-dose	O
days	O
,	O
respectively	O
.	O

Clonidine	O
administration	O
increased	O
the	O
sweating	O
threshold	O
approximately	O
0.4	O
degree	O
C	O
(	O
P	O
<	O
0.05	O
)	O
,	O
but	O
the	O
increase	O
was	O
comparable	O
at	O
each	O
dose	O
.	O

The	O
gain	O
of	O
sweating	O
was	O
approximately	O
0.2	O
degree	O
C	O
and	O
was	O
not	O
influenced	O
by	O
clonidine	O
administration	O
.	O

The	O
thermoregulatory	O
effects	O
of	O
clonidine	O
thus	O
resemble	O
those	O
of	O
volatile	O
anesthetics	O
,	O
opioids	O
,	O
and	O
propofol	O
.	O

These	O
data	O
suggest	O
that	O
the	O
antishivering	O
effect	O
of	O
clonidine	O
results	O
from	O
central	O
thermoregulatory	O
inhibition	O
rather	O
than	O
a	O
specific	O
peripheral	O
action	O
on	O
thermogenic	O
muscular	O
activity	O
.	O

Unlike	O
other	O
sedatives	O
and	O
anesthetics	O
,	O
the	O
concentration-dependence	O
of	O
clonidine	O
demonstrates	O
a	O
ceiling	O
beyond	O
which	O
the	O
administration	O
of	O
an	O
additional	O
drug	O
fails	O
to	O
enhance	O
the	O
effect	O
,	O
suggesting	O
that	O
the	O
thermoregulatory	O
effect	O
of	O
clonidine	O
may	O
be	O
limited	O
,	O
even	O
at	O
high	O
plasma	O
concentrations	O
.	O

The	O
gain	O
of	O
sweating	O
was	O
well	O
preserved	O
indicating	O
that	O
this	O
response	O
remains	O
effective	O
in	O
the	O
presence	O
of	O
sedatives	O
and	O
anesthetics	O
.	O

Acute	O
effects	O
of	O
decaffeinated	Pharmacological
coffee	Pharmacological
and	O
the	O
major	O
coffee	O
components	O
chlorogenic	Pharmacological
acid	O
and	O
trigonelline	Pharmacological
on	O
glucose	O
tolerance	O
.	O

OBJECTIVE	O
Coffee	Pharmacological
consumption	O
has	O
been	O
associated	O
with	O
lower	O
risk	O
of	O
type	O
2	O
diabetes	O
.	O

We	O
evaluated	O
the	O
acute	O
effects	O
of	O
decaffeinated	Pharmacological
coffee	Pharmacological
and	O
the	O
major	O
coffee	O
components	O
chlorogenic	O
acid	O
and	O
trigonelline	O
on	O
glucose	O
tolerance	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
We	O
conducted	O
a	O
randomized	O
crossover	O
trial	O
of	O
the	O
effects	O
of	O
12	O
g	O
decaffeinated	Pharmacological
coffee	Pharmacological
,	O
1	O
g	O
chlorogenic	Pharmacological
acid	Pharmacological
,	O
500	O
mg	O
trigonelline	Pharmacological
,	O
and	O
placebo	Control
(	O
1	O
g	O
mannitol	Pharmacological
)	Pharmacological
on	O
glucose	O
and	O
insulin	O
concentrations	O
during	O
a	O
2-h	O
oral	O
glucose	O
tolerance	O
test	O
(	O
OGTT	O
)	O
in	O
15	O
overweight	O
men	O
.	O

RESULTS	O
Chlorogenic	O
acid	O
and	O
trigonelline	O
ingestion	O
significantly	O
reduced	O
glucose	O
(	O
-0.7	O
mmol/l	O
,	O
P	O
=	O
0.007	O
,	O
and	O
-0.5	O
mmol/l	O
,	O
P	O
=	O
0.024	O
,	O
respectively	O
)	O
and	O
insulin	O
(	O
-73	O
pmol/l	O
,	O
P	O
=	O
0.038	O
,	O
and	O
-117	O
pmol/l	O
,	O
P	O
=	O
0.007	O
)	O
concentrations	O
15	O
min	O
following	O
an	O
OGTT	O
compared	O
with	O
placebo	O
.	O

None	O
of	O
the	O
treatments	O
affected	O
insulin	O
or	O
glucose	O
area	O
under	O
the	O
curve	O
values	O
during	O
the	O
OGTT	O
compared	O
with	O
placebo	Control
.	Control

CONCLUSIONS	O
Chlorogenic	O
acid	O
and	O
trigonelline	O
reduced	O
early	O
glucose	O
and	O
insulin	O
responses	O
during	O
an	O
OGTT	O
.	O

[	O
Effects	O
of	O
transcutaneous	Physical
electrical	Physical
stimulation	Physical
of	Physical
auricular	Physical
Shenmen	Physical
point	Physical
on	O
postoperative	O
nausea	O
and	O
vomiting	O
and	O
patient-controlled	O
epidural	O
analgesia	O
in	O
cesarean	O
section	O
]	O
.	O

OBJECTIVE	O
To	O
investigate	O
the	O
effects	O
of	O
transcutaneous	O
electrical	O
stimulation	O
of	O
auricular	O
Shenmen	O
point	O
on	O
postoperative	O
nausea	O
and	O
vomiting	O
and	O
patient-controlled	O
epidural	O
analgesia	O
in	O
cesarean	O
section	O
.	O

METHODS	O
After	O
IRB	O
approval	O
and	O
informed	O
consent	O
,	O
one	O
hundred	O
and	O
eighty	O
singleton	O
primiparas	O
undergoing	O
elective	O
cesarean	O
section	O
,	O
in	O
Qingdao	O
Municipal	O
Hospital	O
,	O
and	O
Qingdao	O
Hiser	O
Medical	O
Center	O
,	O
from	O
November	O
2011	O
to	O
March	O
2012	O
,	O
were	O
randomly	O
assigned	O
to	O
three	O
groups	O
:	O
transcutaneous	Physical
electrical	Physical
stimulation	Physical
of	Physical
auricular	Physical
Shenmen	Physical
point	Physical
group	Physical
(	O
group	O
A	O
,	O
n	O
=	O
60	O
)	O
,	O
transcutaneous	Physical
electrical	Physical
stimulation	Physical
of	Physical
auricular	Physical
Eye	Physical
point	Physical
group	Physical
(	O
group	O
B	O
,	O
n	O
=	O
60	O
)	O
and	O
control	Control
group	Control
(	O
group	O
C	O
,	O
n	O
=	O
60	O
)	O
.	O

Women	O
of	O
group	O
A	O
received	O
transcutaneous	Physical
electrical	Physical
stimulation	Physical
of	O
auricular	O
Shenmen	O
point	O
(	O
frequency	O
1.5	O
HZ	O
)	O
at	O
the	O
time	O
of	O
preoperation	O
,	O
4	O
,	O
10	O
and	O
22	O
hours	O
of	O
postoperation	O
for	O
30	O
minutes	O
.	O

The	O
strength	O
was	O
controlled	O
by	O
themselves	O
.	O

Women	O
of	O
group	O
B	O
received	O
stimulation	O
of	O
auricular	O
Eye	O
point	O
as	O
group	O
A	O
.	O

Women	O
of	O
group	O
C	O
received	O
pressurization	O
and	O
connected	O
line	O
were	O
the	O
same	O
with	O
group	O
A	O
,	O
but	O
without	O
electrical	Control
stimulation	Control
.	O

The	O
following	O
indexes	O
was	O
observed	O
:	O
the	O
incidence	O
of	O
postoperative	O
nausea	O
and	O
vomiting	O
(	O
PONV	O
)	O
for	O
48	O
hours	O
;	O
the	O
rate	O
of	O
metoclopramide	O
;	O
the	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
score	O
of	O
rest	O
pain	O
,	O
uterine	O
contration	O
pain	O
and	O
dynamic	O
pain	O
at	O
the	O
time	O
of	O
postoperation	O
for	O
6	O
,	O
12	O
,	O
24	O
and	O
48	O
hours	O
(	O
T	O
(	O
1	O
)	O
-T	O
(	O
4	O
)	O
)	O
;	O
the	O
total	O
number	O
and	O
effective	O
compressions	O
number	O
of	O
patient-controlled	O
epidural	O
analgesia	O
(	O
PCEA	O
)	O
;	O
the	O
dose	O
of	O
analgesia	O
mixture	O
;	O
the	O
anal	O
exhaust	O
time	O
;	O
the	O
volume	O
of	O
postoperative	O
bleeding	O
for	O
6	O
hours	O
of	O
postoperation	O
and	O
the	O
other	O
side	O
effects	O
.	O

RESULTS	O
Compared	O
with	O
group	O
B	O
and	O
group	O
C	O
,	O
the	O
incidence	O
of	O
PONV	O
,	O
the	O
rate	O
of	O
metoclopramide	O
,	O
the	O
VAS	O
score	O
at	O
the	O
time	O
T	O
(	O
1	O
)	O
-T	O
(	O
4	O
)	O
,	O
the	O
total	O
number	O
and	O
effective	O
compressions	O
number	O
of	O
PCEA	O
,	O
the	O
ratio	O
of	O
the	O
total	O
number	O
with	O
effective	O
compressions	O
number	O
and	O
the	O
dose	O
of	O
analgesia	O
mixture	O
were	O
decreased	O
in	O
group	O
A	O
(	O
P	O
<	O
0.05	O
)	O
,	O
but	O
no	O
difference	O
compared	O
group	O
B	O
with	O
group	O
C	O
(	O
P	O
>	O
0.05	O
)	O
.	O

The	O
anal	O
exhaust	O
time	O
and	O
the	O
volume	O
of	O
postoperative	O
bleeding	O
for	O
6	O
hours	O
of	O
postoperation	O
were	O
no	O
difference	O
in	O
the	O
three	O
groups	O
(	O
P	O
>	O
0.05	O
)	O
.	O

No	O
other	O
side	O
effects	O
were	O
observed	O
.	O

CONCLUSION	O
Transcutaneous	O
electrical	O
stimulation	O
of	O
auricular	O
Shenmen	O
point	O
can	O
reduce	O
the	O
incidence	O
of	O
PONV	O
and	O
improves	O
analgesia	O
effect	O
of	O
PCEA	O
in	O
postoperation	O
of	O
cesarean	O
section	O
.	O

Memantine	Pharmacological
add-on	O
to	O
risperidone	Pharmacological
for	O
treatment	O
of	O
negative	O
symptoms	O
in	O
patients	O
with	O
stable	O
schizophrenia	O
:	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O

We	O
aimed	O
to	O
evaluate	O
the	O
efficacy	O
of	O
memantine	Pharmacological
add-on	O
in	O
the	O
treatment	O
of	O
primary	O
negative	O
symptoms	O
of	O
patients	O
with	O
stable	O
schizophrenia	O
.	O

In	O
a	O
double-blind	O
placebo-controlled	O
clinical	O
trial	O
,	O
40	O
patients	O
with	O
schizophrenia	O
(	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders	O
,	O
Fourth	O
Edition	O
)	O
who	O
were	O
stabilized	O
on	O
risperidone	Pharmacological
for	O
a	O
minimum	O
of	O
8	O
weeks	O
were	O
randomized	O
to	O
either	O
memantine	Pharmacological
(	O
20	O
mg	O
)	O
or	O
placebo	Control
in	O
addition	O
to	O
risperidone	Pharmacological
,	O
6	O
mg/d	O
,	O
for	O
eight	O
weeks	O
.	O

Assessment	O
was	O
done	O
using	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
at	O
baseline	O
,	O
week	O
4	O
,	O
and	O
week	O
8	O
.	O

The	O
Hamilton	O
Depression	O
Rating	O
Scale	O
and	O
the	O
Extrapyramidal	O
Symptom	O
Rating	O
Scale	O
at	O
baseline	O
and	O
week	O
8	O
were	O
used	O
to	O
assess	O
depression	O
and	O
extrapyramidal	O
symptoms	O
,	O
respectively	O
.	O

All	O
40	O
patients	O
had	O
at	O
least	O
one	O
postbaseline	O
measurement	O
,	O
and	O
38	O
patients	O
completed	O
the	O
trial	O
.	O

Patients	O
in	O
the	O
memantine	O
group	O
showed	O
a	O
significantly	O
greater	O
improvement	O
on	O
negative	O
subscale	O
than	O
the	O
placebo	Control
group	O
at	O
end	O
point	O
(	O
P	O
<	O
0.001	O
)	O
.	O

The	O
same	O
effect	O
was	O
observed	O
for	O
the	O
total	O
score	O
(	O
P	O
<	O
0.001	O
)	O
and	O
the	O
general	O
psychopathology	O
subscale	O
score	O
(	O
P	O
=	O
0.002	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
reduction	O
of	O
positive	O
symptoms	O
score	O
between	O
the	O
2	O
groups	O
(	O
P	O
=	O
0.757	O
)	O
.	O

Changes	O
in	O
the	O
Hamilton	O
Depression	O
Rating	O
Scale	O
and	O
the	O
Extrapyramidal	O
Symptom	O
Rating	O
Scale	O
scores	O
and	O
frequency	O
of	O
adverse	O
effects	O
did	O
not	O
differ	O
between	O
the	O
2	O
groups	O
.	O

Our	O
study	O
showed	O
that	O
memantine	O
is	O
a	O
tolerable	O
and	O
efficacious	O
add-on	O
treatment	O
for	O
primary	O
negative	O
symptoms	O
of	O
schizophrenia	O
.	O

VLDL	O
,	O
apolipoproteins	O
B	O
,	O
CIII	O
,	O
and	O
E	O
,	O
and	O
risk	O
of	O
recurrent	O
coronary	O
events	O
in	O
the	O
Cholesterol	O
and	O
Recurrent	O
Events	O
(	O
CARE	O
)	O
trial	O
.	O

BACKGROUND	O
Plasma	O
triglyceride	O
concentration	O
has	O
been	O
an	O
inconsistent	O
independent	O
risk	O
factor	O
for	O
coronary	O
heart	O
disease	O
,	O
perhaps	O
because	O
of	O
the	O
metabolic	O
heterogeneity	O
among	O
VLDL	O
particles	O
,	O
the	O
main	O
carriers	O
of	O
triglycerides	O
in	O
plasma	O
.	O

METHODS	O
AND	O
RESULTS	O
We	O
conducted	O
a	O
prospective	O
,	O
nested	O
case-control	O
study	O
in	O
the	O
Cholesterol	O
and	O
Recurrent	O
Events	O
(	O
CARE	O
)	O
trial	O
,	O
a	O
randomized	O
placebo-controlled	Control
trial	O
of	O
pravastatin	Pharmacological
in	O
4159	O
patients	O
with	O
myocardial	O
infarction	O
and	O
average	O
LDL	O
concentrations	O
at	O
baseline	O
(	O
115	O
to	O
174	O
mg/dL	O
,	O
mean	O
139	O
mg/dL	O
)	O
.	O

Baseline	O
concentrations	O
of	O
VLDL-apolipoprotein	O
(	O
apo	O
)	O
B	O
(	O
the	O
VLDL	O
particle	O
concentration	O
)	O
,	O
VLDL	O
lipids	O
,	O
and	O
apoCIII	O
and	O
apoE	O
in	O
VLDL+LDL	O
and	O
in	O
HDL	O
were	O
compared	O
in	O
patients	O
who	O
had	O
either	O
a	O
myocardial	O
infarction	O
or	O
coronary	O
death	O
(	O
cases	O
,	O
n=418	O
)	O
with	O
those	O
in	O
patients	O
who	O
did	O
not	O
have	O
a	O
cardiovascular	O
event	O
(	O
control	O
subjects	O
,	O
n=370	O
)	O
in	O
5	O
years	O
of	O
follow-up	O
.	O

VLDL-cholesterol	O
,	O
VLDL-triglyceride	O
,	O
VLDL-apoB	O
,	O
apoCIII	O
and	O
apoE	O
in	O
VLDL+LDL	O
and	O
apoE	O
in	O
HDL	O
were	O
all	O
interrelated	O
,	O
and	O
each	O
was	O
a	O
univariate	O
predictor	O
of	O
subsequent	O
coronary	O
events	O
.	O

The	O
significant	O
independent	O
predictors	O
were	O
VLDL-apoB	O
(	O
relative	O
risk	O
[	O
RR	O
]	O
3.2	O
for	O
highest	O
to	O
lowest	O
quintiles	O
,	O
P	O
:	O
=0.04	O
)	O
,	O
apoCIII	O
in	O
VLDL+LDL	O
(	O
RR	O
2.3	O
,	O
P	O
:	O
=0.04	O
)	O
,	O
and	O
apoE	O
in	O
HDL	O
(	O
RR	O
1.8	O
,	O
P	O
:	O
=0.02	O
)	O
.	O

Plasma	O
triglycerides	O
,	O
a	O
univariate	O
predictor	O
of	O
coronary	O
events	O
(	O
RR	O
1.6	O
,	O
P	O
:	O
=0.03	O
)	O
,	O
was	O
not	O
related	O
to	O
coronary	O
events	O
(	O
RR	O
1.3	O
,	O
P	O
:	O
=0.6	O
)	O
when	O
apoCIII	O
in	O
VLDL+LDL	O
was	O
included	O
in	O
the	O
model	O
,	O
whereas	O
apoCIII	O
remained	O
significant	O
.	O

Adjustment	O
for	O
LDL-	O
and	O
HDL-cholesterol	O
did	O
not	O
affect	O
these	O
results	O
.	O

CONCLUSIONS	O
The	O
plasma	O
concentrations	O
of	O
VLDL	O
particles	O
and	O
apoCIII	O
in	O
VLDL	O
and	O
LDL	O
are	O
more	O
specific	O
measures	O
of	O
coronary	O
heart	O
disease	O
risk	O
than	O
plasma	O
triglycerides	O
perhaps	O
because	O
their	O
known	O
metabolic	O
properties	O
link	O
them	O
more	O
closely	O
to	O
atherosclerosis	O
.	O

Gastric	O
ulcer	O
treatment	O
with	O
intravenous	O
human	Pharmacological
epidermal	Pharmacological
growth	Pharmacological
factor	Pharmacological
:	Pharmacological
a	O
double-blind	O
controlled	O
clinical	O
study	O
.	O

We	O
introduced	O
a	O
double-blind	O
controlled	O
clinical	O
study	O
to	O
compare	O
intravenous	Pharmacological
human	Pharmacological
epidermal	Pharmacological
growth	Pharmacological
factor	Pharmacological
(	Pharmacological
hEGF	Pharmacological
)	Pharmacological
to	O
cetraxate	Pharmacological
hydrochloride	Pharmacological
(	Pharmacological
CH	Pharmacological
)	Pharmacological
,	O
an	O
antiulcer	O
drug	O
,	O
for	O
their	O
healing	O
effect	O
on	O
gastric	O
ulcers	O
.	O

We	O
also	O
prospected	O
an	O
oral	O
use	O
of	O
EGF	Pharmacological
on	O
the	O
basis	O
of	O
our	O
experimental	O
evidence	O
.	O

In	O
the	O
clinical	O
trial	O
,	O
the	O
rate	O
of	O
ulcer	O
healing	O
within	O
8	O
weeks	O
was	O
77.9	O
%	O
(	O
67/86	O
)	O
in	O
patients	O
receiving	O
6	O
micrograms	O
EGF	Pharmacological
intravenously	O
twice	O
a	O
week	O
,	O
being	O
significantly	O
greater	O
than	O
51.7	O
%	O
(	O
45/87	O
)	O
in	O
those	O
given	O
CH	Pharmacological
.	Pharmacological

Taking	O
together	O
all	O
aspects	O
assessed	O
including	O
the	O
healing	O
rate	O
,	O
pain	O
relief	O
,	O
blood	O
examination	O
and	O
adverse	O
reactions	O
,	O
we	O
judged	O
the	O
hEGF	Pharmacological
to	O
be	O
a	O
useful	O
and	O
safe	O
anticuler	O
drug	O
.	O

In	O
rats	O
,	O
50	O
micrograms/kg	O
mouse	O
EGF	O
(	O
mEGF	O
)	O
and	O
2	O
%	O
hydroxypropyl	Pharmacological
cellulose	Pharmacological
(	O
HPC	O
)	O
or	O
1.0	O
g/kg	O
sucralfate	O
given	O
by	O
gastric	O
intubation	O
significantly	O
raised	O
the	O
residual	O
mEGF	O
levels	O
in	O
both	O
gastric	O
luminal	O
content	O
(	O
HPC	O
:	O
x	O
30	O
;	O
sucralfate	O
:	O
x	O
300	O
as	O
high	O
as	O
those	O
in	O
EGF	O
alone	O
)	O
and	O
tissue	O
(	O
HPC	O
:	O
x	O
60	O
;	O
sucralfate	O
:	O
x	O
100	O
)	O
.	O

In	O
addition	O
,	O
the	O
combined	O
treatments	O
significantly	O
promoted	O
healing	O
of	O
rat	O
gastric	O
ulcers	O
whereas	O
each	O
agent	O
alone	O
had	O
no	O
significant	O
effect	O
as	O
compared	O
with	O
control	O
(	O
saline	O
)	O
.	O

This	O
indicated	O
the	O
beneficial	O
effect	O
on	O
ulcers	O
of	O
oral	O
administration	O
of	O
EGF	Pharmacological
with	O
agents	O
allowing	O
it	O
to	O
remain	O
at	O
high	O
levels	O
in	O
the	O
stomach	O
,	O
whereas	O
most	O
reports	O
suggested	O
less	O
effect	O
of	O
oral	O
EGF	O
on	O
healing	O
of	O
gastroduodenal	O
ulcers	O
.	O

Subsequent	O
to	O
the	O
clinical	O
study	O
,	O
evaluation	O
of	O
oral	O
use	O
of	O
EGF	Pharmacological
may	O
be	O
expected	O
as	O
the	O
next	O
step	O
in	O
the	O
treatment	O
of	O
ulcers	O
.	O

The	O
experimental	O
evidence	O
above	O
would	O
possibly	O
be	O
a	O
guide	O
for	O
such	O
trial	O
.	O

Sodium	Pharmacological
bicarbonate	Pharmacological
,	O
N-acetylcysteine	Pharmacological
,	O
and	O
saline	Control
for	O
prevention	O
of	O
radiocontrast-induced	O
nephropathy	O
.	O

A	O
comparison	O
of	O
3	O
regimens	O
for	O
protecting	O
contrast-induced	O
nephropathy	O
in	O
patients	O
undergoing	O
coronary	Surgical
procedures	Surgical
.	Surgical

A	O
single-center	O
prospective	O
controlled	O
trial	O
.	O

BACKGROUND	O
Several	O
protective	O
therapies	O
have	O
been	O
developed	O
to	O
prevent	O
contrast-induced	O
nephropathy	O
(	O
CIN	O
)	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
efficacy	O
of	O
sodium	Pharmacological
bicarbonate	Pharmacological
by	O
comparing	O
2	O
other	O
regimens	O
,	O
including	O
combination	O
of	O
N-acetylcysteine	Surgical
(	Surgical
NAC	Surgical
)	Surgical
plus	O
sodium	Pharmacological
chloride	Pharmacological
and	O
sodium	Pharmacological
chloride	Pharmacological
alone	O
,	O
to	O
prevent	O
CIN	O
in	O
patients	O
undergoing	O
cardiovascular	O
procedures	O
.	O

METHODS	O
We	O
prospectively	O
enrolled	O
264	O
patients	O
who	O
were	O
scheduled	O
for	O
cardiovascular	O
procedures	O
and	O
had	O
a	O
baseline	O
creatinine	O
level	O
>	O
1.2	O
mg/dL	O
.	O

The	O
patients	O
were	O
assigned	O
1	O
of	O
3	O
prophylactic	O
regimens	O
:	O
infusion	O
of	O
sodium	Pharmacological
bicarbonate	Pharmacological
,	O
sodium	Pharmacological
chloride	Pharmacological
,	O
sodium	Pharmacological
chloride	Pharmacological
plus	O
oral	O
NAC	Pharmacological
(	O
600	O
mg	O
bid	O
)	O
.	O

Contrast-induced	O
nephropathy	O
was	O
defined	O
as	O
an	O
increase	O
in	O
serum	O
creatinine	O
level	O
>	O
25	O
%	O
or	O
0.5	O
mg/dL	O
after	O
48	O
hours	O
.	O

RESULTS	O
There	O
were	O
no	O
significant	O
differences	O
among	O
groups	O
regarding	O
baseline	O
demographic	O
properties	O
and	O
nephropathy	O
risk	O
factors	O
.	O

The	O
change	O
in	O
creatinine	O
clearance	O
was	O
significantly	O
better	O
in	O
the	O
sodium	Pharmacological
bicarbonate	Pharmacological
group	O
than	O
other	O
2	O
groups	O
(	O
P	O
=	O
.007	O
)	O
.	O

The	O
incidence	O
of	O
CIN	O
was	O
significantly	O
lower	O
in	O
the	O
sodium	Pharmacological
bicarbonate	Pharmacological
group	O
(	O
4.5	O
%	O
)	O
compared	O
with	O
sodium	Pharmacological
chloride	Pharmacological
alone	O
(	O
13.6	O
%	O
,	O
P	O
=	O
.036	O
)	O
and	O
tended	O
to	O
be	O
lower	O
than	O
in	O
the	O
combination	O
group	O
(	O
12.5	O
%	O
,	O
P	O
=	O
.059	O
)	O
.	O

After	O
adjusting	O
the	O
Mehran	O
nephropathy	O
risk	O
score	O
,	O
the	O
risk	O
of	O
CIN	O
significantly	O
reduced	O
with	O
sodium	Pharmacological
bicarbonate	Pharmacological
compared	O
with	O
sodium	Pharmacological
chloride	Pharmacological
alone	O
(	O
adjusted	O
risk	O
ratio	O
0.29	O
,	O
P	O
=	O
.043	O
)	O
.	O

CONCLUSIONS	O
Hydration	O
with	O
sodium	Pharmacological
bicarbonate	Pharmacological
provides	O
better	O
protection	O
against	O
CIN	O
than	O
the	O
sodium	Pharmacological
chloride	Pharmacological
infusion	Pharmacological
does	O
alone	O
.	O

Combination	O
therapy	O
of	O
NAC	Pharmacological
plus	Pharmacological
sodium	Pharmacological
chloride	Pharmacological
did	O
not	O
offer	O
additional	O
benefit	O
over	O
hydration	O
with	O
sodium	Pharmacological
chloride	Pharmacological
alone	O
.	O

Treatment	O
of	O
stable	O
angina	O
of	O
effort	O
with	O
verapamil	Pharmacological
:	Pharmacological
a	O
double-blind	O
,	O
placebo-controlled	Control
randomized	O
crossover	O
study	O
.	O

The	O
effects	O
of	O
verapamil	Pharmacological
were	O
assessed	O
in	O
26	O
patients	O
with	O
stable	O
exertional	O
angina	O
pectoris	O
in	O
a	O
double-blind	O
,	O
placebo-controlled	O
,	O
randomized	O
crossover	O
protocol	O
using	O
serial	O
treadmill	O
tests	O
.	O

Verapamil	Pharmacological
,	O
480	O
mg/day	O
,	O
reduced	O
anginal	O
frequency	O
from	O
5.6	O
+/-	O
7.3	O
to	O
2.2	O
+/-	O
3.9	O
attacks	O
per	O
week	O
(	O
p	O
less	O
than	O
0.001	O
)	O
and	O
nitroglycerin	Pharmacological
consumption	O
from	O
3.4	O
+/-	O
4.9	O
to	O
1.2	O
+/-	O
2.5	O
tablets	O
per	O
week	O
(	O
p	O
less	O
than	O
0.05	O
)	O
compared	O
with	O
placebo	Control
.	Control

Treadmill	O
time	O
increased	O
from	O
6.4	O
+/-	O
2.1	O
minutes	O
during	O
the	O
placebo	Control
phase	O
to	O
7.5	O
+/-	O
1.8	O
minutes	O
during	O
the	O
verapamil	Pharmacological
phase	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

Verapamil	Pharmacological
's	Pharmacological
beneficial	O
effect	O
appeared	O
to	O
be	O
related	O
,	O
in	O
part	O
,	O
to	O
a	O
10	O
%	O
reduction	O
of	O
the	O
rate-pressure	O
product	O
at	O
rest	O
(	O
p	O
less	O
than	O
0.05	O
)	O
and	O
a	O
12	O
%	O
reduction	O
during	O
submaximal	O
exercise	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

Verapamil	Pharmacological
also	O
caused	O
less	O
marked	O
ST-segment	O
depressions	O
at	O
peak	O
exercise	O
(	O
p	O
less	O
than	O
0.05	O
)	O
at	O
a	O
similar	O
rate-pressure	O
product	O
,	O
suggesting	O
a	O
favorable	O
redistribution	O
of	O
coronary	O
blood	O
flow	O
to	O
the	O
ischemic	O
zone	O
.	O

Side	O
effects	O
from	O
verapamil	Pharmacological
were	O
minimal	O
,	O
consisting	O
mainly	O
of	O
constipation	O
(	O
six	O
patients	O
)	O
.	O

Verapamil	Pharmacological
appears	O
to	O
be	O
a	O
safe	O
and	O
effective	O
drug	O
for	O
treating	O
angina	O
of	O
effort	O
.	O

Transdermal	O
scopolamine	Pharmacological
patch	O
in	O
addition	O
to	O
ondansetron	Pharmacological
for	O
postoperative	O
nausea	O
and	O
vomiting	O
prophylaxis	O
in	O
patients	O
undergoing	O
ambulatory	O
cosmetic	O
surgery	O
.	O

STUDY	O
OBJECTIVE	O
To	O
determine	O
the	O
efficacy	O
of	O
transdermal	O
scopolamine	Pharmacological
in	O
addition	O
to	O
ondansetron	Pharmacological
in	O
decreasing	O
the	O
incidence	O
of	O
postoperative	O
nausea	O
and	O
vomiting	O
(	O
PONV	O
)	O
.	O

DESIGN	O
Randomized	O
controlled	O
trial	O
.	O

SETTING	O
Academic	O
hospital	O
.	O

PATIENTS	O
126	O
ASA	O
physical	O
status	O
I	O
and	O
II	O
patients	O
undergoing	O
outpatient	O
plastic	O
surgery	O
with	O
three	O
or	O
more	O
risk	O
factors	O
for	O
PONV	O
.	O

INTERVENTIONS	O
Patients	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
groups	O
to	O
receive	O
(	O
Group	O
1	O
)	O
a	O
transdermal	O
scopolamine	Pharmacological
(	O
TDS	O
)	O
patch	O
or	O
(	O
Group	O
2	O
)	O
,	O
a	O
placebo	Control
patch	O
two	O
hours	O
before	O
surgery	O
.	O

MEASUREMENTS	O
Occurrence	O
of	O
vomiting	O
,	O
severity	O
of	O
nausea	O
using	O
a	O
visual	O
analog	O
scale	O
(	O
VAS	O
)	O
,	O
rescue	O
medication	O
,	O
pain	O
intensity	O
and	O
pain	O
medications	O
,	O
and	O
side	O
effects	O
were	O
recorded	O
every	O
hour	O
until	O
discharge	O
from	O
hospital	O
,	O
then	O
every	O
4	O
hours	O
thereafter	O
for	O
a	O
total	O
of	O
24	O
hours	O
.	O

MAIN	O
RESULTS	O
A	O
statistically	O
significant	O
reduction	O
in	O
postoperative	O
nausea	O
between	O
8	O
and	O
24	O
hours	O
in	O
patients	O
receiving	O
TDS	O
was	O
noted	O
.	O

CONCLUSIONS	O
Transdermal	O
scopolamine	Pharmacological
in	O
addition	O
to	O
ondansetron	O
benefits	O
patients	O
at	O
high	O
risk	O
for	O
PONV	O
undergoing	O
outpatient	O
plastic	O
surgery	O
for	O
up	O
to	O
20	O
hours	O
after	O
surgery	O
.	O

Effect	O
of	O
four	Physical
intermediate	Physical
layer	Physical
treatments	Physical
on	O
microleakage	O
of	O
Class	O
II	O
composite	O
restorations	O
.	O

This	O
in	O
vitro	O
study	O
examines	O
the	O
marginal	O
sealing	O
ability	O
of	O
four	Other
different	Other
intermediate	Other
materials	Other
applied	O
before	O
placement	O
of	O
a	O
condensable	Other
composite	Other
.	Other

Class	O
II	O
preparations	O
were	O
made	O
with	O
gingival	O
margins	O
placed	O
1.0	O
mm	O
apical	O
to	O
the	O
cementoenamel	O
junction	O
of	O
60	O
extracted	O
teeth	O
,	O
randomly	O
assigned	O
to	O
five	O
groups	O
of	O
12	O
.	O

Following	O
restoration	O
,	O
teeth	O
were	O
thermocycled	O
,	O
soaked	O
in	O
0.5	O
%	O
basic	O
fuchsin	O
,	O
and	O
sectioned	O
longitudinally	O
.	O

The	O
resin-modified	Other
glass	Other
ionomer	Other
cement	Other
demonstrated	O
significantly	O
less	O
microleakage	O
than	O
the	O
use	O
of	O
a	O
dentin	Other
bonding	Other
agent	Other
alone	Other
or	O
in	O
combination	Other
with	Other
flowable	Other
composite	Other
,	O
flowable	O
compomer	O
,	O
or	O
autoploymerizing	O
composite	O
(	O
p	O
<	O
0.05	O
,	O
Dunn	O
's	O
test	O
)	O
.	O

This	O
study	O
supports	O
the	O
use	O
of	O
the	O
glass	Physical
ionomer	Physical
open	Physical
sandwich	Physical
technique	Physical
in	O
deep	O
Class	O
II	O
direct	O
composite	O
restorations	O
.	O

Use	O
and	O
limitations	O
of	O
Holter	Physical
electrocardiography	Physical
in	O
assessing	O
drug	O
therapy	O
of	O
myocardial	O
ischemia	O
during	O
the	O
peri-PTCA	O
period	O
.	O

Incidence	O
and	O
pattern	O
of	O
myocardial	O
ischemia	O
during	O
the	O
peri-PTCA	O
(	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
)	O
period	O
and	O
the	O
possible	O
role	O
of	O
continuous	Pharmacological
intravenous	Pharmacological
isosorbide	Pharmacological
dinitrate	Pharmacological
in	O
its	O
prevention	O
were	O
examined	O
prospectively	O
in	O
30	O
patients	O
.	O

Holter	Physical
electrocardiographic	Physical
monitoring	Physical
was	O
performed	O
for	O
21	O
+/-	O
3	O
h	O
before	O
PTCA	O
and	O
continued	O
during	O
and	O
for	O
41	O
+/-	O
8	O
h	O
after	O
the	O
procedure	O
.	O

Before	O
PTCA	O
,	O
19	O
ischemic	O
episodes	O
were	O
present	O
in	O
10	O
(	O
33	O
%	O
)	O
of	O
30	O
patients	O
.	O

PTCA	O
produced	O
an	O
abrupt	O
decrease	O
in	O
number	O
(	O
p	O
=	O
0.015	O
)	O
and	O
duration	O
(	O
p	O
=	O
0.03	O
)	O
of	O
spontaneous	O
ischemic	O
episodes	O
.	O

The	O
rarity	O
of	O
recurrent	O
myocardial	O
ischemic	O
events	O
by	O
Holter	Physical
monitoring	Physical
after	O
PTCA	O
negated	O
any	O
attempt	O
at	O
assessing	O
the	O
efficacy	O
of	O
intravenous	O
isosorbide	Pharmacological
dinitrate	Pharmacological
in	O
their	O
prevention	O
.	O

Holter	Physical
monitoring	Physical
could	O
not	O
be	O
used	O
as	O
an	O
early	O
predictor	O
of	O
late	O
coronary	O
restenosis	O
.	O

Tetracaine	Pharmacological
(	Pharmacological
ametop	Pharmacological
)	Pharmacological
compared	O
to	O
placebo	O
for	O
reducing	O
pain	O
associated	O
with	O
intramuscular	O
injection	O
of	O
palivizumab	O
(	O
synagis	O
)	O
.	O

Infants	O
receive	O
many	O
painful	O
immunizations	O
before	O
they	O
are	O
2	O
years	O
old	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
if	O
topical	Pharmacological
tetracaine	Pharmacological
reduces	O
the	O
pain	O
of	O
intramuscular	O
palivizumab	Pharmacological
compared	O
to	O
placebo	Control
.	Control

There	O
were	O
two	O
study	O
injections	O
,	O
one	O
with	O
tetracaine	Pharmacological
and	O
one	O
with	O
placebo	Control
.	Control

Pain	O
was	O
scored	O
by	O
their	O
parents	O
and	O
a	O
pediatric	O
nurse	O
.	O

Topical	O
tetracaine	Pharmacological
was	O
not	O
associated	O
with	O
a	O
significant	O
reduction	O
in	O
pain	O
score	O
,	O
although	O
it	O
did	O
lead	O
to	O
faster	O
recovery	O
times	O
.	O

Additional	O
pain-reduction	O
strategies	O
are	O
required	O
.	O

Low-dose	Pharmacological
aspirin	Pharmacological
and	O
incidence	O
of	O
colorectal	O
tumors	O
in	O
a	O
randomized	O
trial	O
.	O

BACKGROUND	O
Laboratory	O
,	O
clinical	O
,	O
and	O
epidemiologic	O
studies	O
have	O
recently	O
suggested	O
that	O
regular	O
use	O
of	O
aspirin	Pharmacological
can	O
reduce	O
colorectal	O
cancer	O
incidence	O
or	O
mortality	O
.	O

However	O
,	O
observational	O
epidemiologic	O
analyses	O
have	O
had	O
limited	O
opportunity	O
to	O
control	O
for	O
confounding	O
bias	O
or	O
to	O
specify	O
aspirin	Pharmacological
doses	O
used	O
.	O

PURPOSE	O
Our	O
purpose	O
was	O
to	O
examine	O
the	O
relationship	O
between	O
regular	O
use	O
of	O
low-dose	Pharmacological
aspirin	Pharmacological
and	O
incidence	O
of	O
invasive	O
and	O
noninvasive	O
colorectal	O
tumors	O
by	O
utilizing	O
data	O
from	O
the	O
Physicians	O
'	O
Health	O
Study	O
,	O
a	O
randomized	O
,	O
double-blinded	O
,	O
placebo-controlled	Control
trial	O
of	O
aspirin	Pharmacological
and	O
beta	Pharmacological
carotene	Pharmacological
.	O

We	O
also	O
attempted	O
to	O
determine	O
whether	O
invasive	O
cancers	O
among	O
aspirin	Pharmacological
users	O
were	O
associated	O
with	O
rectal	O
bleeding	O
and	O
early	O
stage	O
at	O
diagnosis	O
.	O

METHODS	O
The	O
Physicians	O
'	O
Health	O
Study	O
includes	O
22071	O
U.S.	O
male	O
physicians	O
.	O

The	O
aspirin	O
arm	O
was	O
terminated	O
in	O
1988	O
after	O
a	O
mean	O
follow-up	O
of	O
5	O
years	O
.	O

Stage	O
at	O
diagnosis	O
and	O
signs	O
and/or	O
symptoms	O
during	O
presentation	O
were	O
abstracted	O
from	O
medical	O
records	O
.	O

Cox	O
proportional	O
hazards	O
models	O
were	O
used	O
to	O
estimate	O
relative	O
risk	O
(	O
RR	O
)	O
,	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
,	O
and	O
the	O
association	O
between	O
aspirin	O
and	O
bleeding	O
.	O

Differences	O
between	O
aspirin	Pharmacological
and	O
placebo	Control
groups	O
in	O
tumor	O
risk	O
over	O
time	O
were	O
visualized	O
with	O
Kaplan-Meier	O
curves	O
.	O

We	O
assessed	O
the	O
association	O
between	O
aspirin	O
and	O
stage	O
at	O
diagnosis	O
with	O
a	O
Mann-Whitney	O
rank	O
sum	O
statistic	O
for	O
non-parametric	O
comparison	O
of	O
two	O
ordinal	O
distributions	O
.	O

RESULTS	O
The	O
RR	O
of	O
developing	O
colorectal	O
cancer	O
for	O
aspirin	O
compared	O
with	O
placebo	O
was	O
1.15	O
(	O
95	O
%	O
CI	O
=	O
0.80-1.65	O
)	O
.	O

For	O
in	O
situ	O
cancers	O
and	O
polyps	O
,	O
the	O
RR	O
was	O
0.86	O
(	O
95	O
%	O
CI	O
=	O
0.68-1.10	O
)	O
.	O

There	O
was	O
no	O
significant	O
trend	O
for	O
decreasing	O
RR	O
by	O
year	O
of	O
follow-up	O
for	O
invasive	O
cancers	O
(	O
P	O
=	O
.09	O
)	O
or	O
noninvasive	O
tumors	O
(	O
P	O
=	O
.96	O
)	O
.	O

Aspirin	O
and	O
placebo	O
groups	O
did	O
not	O
differ	O
in	O
stage	O
or	O
prevalence	O
of	O
rectal	O
bleeding	O
at	O
diagnosis	O
.	O

CONCLUSIONS	O
Regular	O
aspirin	Pharmacological
use	O
,	O
at	O
a	O
dose	O
adequate	O
for	O
preventing	O
myocardial	O
infarction	O
,	O
was	O
not	O
associated	O
with	O
a	O
substantial	O
reduction	O
in	O
the	O
incidence	O
of	O
colorectal	O
cancer	O
during	O
5	O
years	O
of	O
randomized	O
treatment	O
and	O
follow-up	O
.	O

A	O
small	O
decrease	O
in	O
polyps	O
in	O
the	O
aspirin	O
group	O
could	O
not	O
be	O
reliably	O
distinguished	O
from	O
a	O
chance	O
association	O
.	O

Our	O
results	O
suggest	O
that	O
among	O
low-dose	O
aspirin	Pharmacological
users	O
,	O
(	O
a	O
)	O
colorectal	O
cancer	O
mortality	O
is	O
not	O
likely	O
to	O
be	O
reduced	O
by	O
earlier	O
detection	O
and	O
(	O
b	O
)	O
incidence	O
is	O
not	O
likely	O
to	O
be	O
increased	O
due	O
to	O
aspirin-induced	O
gastrointestinal	O
bleeding	O
.	O

IMPLICATIONS	O
The	O
potential	O
for	O
a	O
benefit	O
from	O
higher	O
doses	O
of	O
aspirin	O
or	O
longer	O
duration	O
of	O
use	O
should	O
be	O
addressed	O
by	O
more	O
detailed	O
observational	O
epidemiologic	O
studies	O
and	O
prevention	O
trials	O
with	O
longer	O
follow-up	O
of	O
randomized	O
participants	O
.	O

Study	O
of	O
the	O
vaginal	O
tolerance	O
to	O
Acidform	Pharmacological
,	Pharmacological
an	Pharmacological
acid-buffering	Pharmacological
,	Pharmacological
bioadhesive	Pharmacological
gel	Pharmacological
.	Pharmacological

Vaginal	O
tolerance	O
tests	O
were	O
performed	O
with	O
a	O
new	O
potential	O
microbicidal	O
and	O
spermicidal	O
product	O
,	O
an	O
acid-buffering	Pharmacological
vaginal	Pharmacological
gel	Pharmacological
(	Pharmacological
Acidform	Pharmacological
)	Pharmacological
without	Pharmacological
or	Pharmacological
with	Pharmacological
nonoxynol-9	Pharmacological
(	Pharmacological
N-9	Pharmacological
)	Pharmacological
.	Pharmacological

The	O
potential	O
advantages	O
over	O
other	O
vaginal	O
products	O
include	O
keeping	O
a	O
low	O
pH	O
,	O
decrease	O
of	O
the	O
irritating	O
effect	O
of	O
N-9	Pharmacological
on	O
the	O
cervix	O
or	O
vaginal	O
mucosa	O
associated	O
with	O
greater	O
retention	O
of	O
the	O
product	O
after	O
application	O
,	O
and	O
decreasing	O
messiness	O
as	O
compared	O
to	O
other	O
vaginal	O
products	O
.	O

Three	O
groups	O
of	O
six	O
women	O
were	O
admitted	O
and	O
randomly	O
assigned	O
to	O
use	O
Acidform	Pharmacological
with	O
0	O
%	O
,	O
2.5	O
%	O
,	O
and	O
5	O
%	O
N-9	Pharmacological
.	Pharmacological

Colposcopic	O
evaluation	O
for	O
vulvar	O
,	O
vaginal	O
,	O
and	O
cervical	O
signs	O
of	O
irritation	O
was	O
performed	O
and	O
photographs	O
were	O
taken	O
,	O
following	O
a	O
specific	O
World	O
Health	O
Organization	O
protocol	O
,	O
at	O
time	O
0	O
,	O
and	O
after	O
24	O
h	O
and	O
6	O
days	O
of	O
application	O
of	O
the	O
gel	O
.	O

No	O
irritation	O
or	O
symptom	O
was	O
reported	O
by	O
users	O
of	O
Acidform	Pharmacological
without	Pharmacological
N-9	Pharmacological
.	Pharmacological

A	O
generalized	O
and	O
intense	O
erythema	O
in	O
cervix	O
was	O
observed	O
in	O
10	O
of	O
12	O
Acidform/N-9	Pharmacological
users	O
and	O
abrasion	O
occurred	O
in	O
nine	O
of	O
them	O
.	O

Vulvar	O
irritation	O
was	O
seen	O
in	O
seven	O
of	O
these	O
10	O
volunteers	O
.	O

N-9	O
concentration	O
in	O
the	O
gel	O
(	O
2.5	O
%	O
or	O
5.0	O
%	O
)	O
was	O
not	O
related	O
to	O
the	O
findings	O
.	O

No	O
ulcer	O
,	O
exulceration	O
,	O
or	O
de-epithelialization	O
was	O
observed	O
.	O

Acidform	Pharmacological
without	Pharmacological
N-9	Pharmacological
was	O
well	O
tolerated	O
by	O
volunteers	O
,	O
but	O
it	O
was	O
unable	O
to	O
protect	O
the	O
cervix	O
,	O
vagina	O
,	O
and	O
vulva	O
from	O
the	O
N-9	O
effects	O
.	O

Dissociation	O
between	O
cortical	O
activation	O
and	O
cognitive	O
performance	O
under	O
pharmacological	O
blood	O
pressure	O
elevation	O
in	O
chronic	O
hypotension	O
.	O

The	O
present	O
study	O
explored	O
the	O
impact	O
of	O
pharmacological	Pharmacological
blood	Pharmacological
pressure	Pharmacological
elevation	Pharmacological
on	O
cortical	O
activation	O
and	O
reaction	O
time	O
in	O
chronic	O
hypotension	O
.	O

Effects	O
of	O
the	O
sympathomimetic	O
etilefrine	O
were	O
investigated	O
in	O
50	O
hypotensive	O
persons	O
based	O
on	O
a	O
randomized	O
,	O
placebo-controlled	Control
double	O
blind	O
design	O
.	O

As	O
an	O
indicator	O
of	O
cortical	O
excitability	O
,	O
the	O
contingent	O
negative	O
variation	O
(	O
CNV	O
)	O
,	O
induced	O
by	O
a	O
constant	O
foreperiod	O
reaction	O
time	O
task	O
,	O
was	O
assessed	O
at	O
frontal	O
(	O
F3	O
,	O
Fz	O
,	O
F4	O
)	O
and	O
central	O
(	O
C3	O
,	O
Cz	O
,	O
C4	O
)	O
scalp	O
sites	O
.	O

Etilefrine	Pharmacological
provoked	O
a	O
decrease	O
in	O
the	O
frontal	O
and	O
central	O
CNV	O
.	O

In	O
contrast	O
,	O
shorter	O
reaction	O
times	O
were	O
observed	O
following	O
drug	O
administration	O
.	O

The	O
degree	O
of	O
pharmacologically	O
induced	O
blood	O
pressure	O
elevation	O
was	O
correlated	O
to	O
CNV	O
attrition	O
as	O
well	O
as	O
to	O
performance	O
enhancement	O
.	O

Inhibitory	O
effects	O
of	O
baroreceptor	O
activation	O
on	O
cortical	O
excitability	O
and	O
enhanced	O
cerebral	O
blood	O
flow	O
are	O
considered	O
to	O
be	O
involved	O
in	O
mediating	O
the	O
effects	O
of	O
blood	O
pressure	O
elevation	O
on	O
cerebral	O
functioning	O
.	O

Implications	O
for	O
the	O
treatment	O
of	O
chronic	O
hypotension	O
are	O
discussed	O
.	O

Secretin	Pharmacological
and	O
sleep	O
in	O
children	O
with	O
autism	O
.	O

The	O
objectives	O
of	O
this	O
pilot	O
study	O
were	O
1	O
)	O
to	O
examine	O
possible	O
effects	O
of	O
secretin	Pharmacological
infusions	O
on	O
sleep-wake	O
state	O
organization	O
in	O
children	O
with	O
autism	O
,	O
and	O
2	O
)	O
to	O
assess	O
the	O
feasibility	O
of	O
home	O
recordings	O
using	O
time-lapse	O
videosomnography	O
in	O
children	O
with	O
autism	O
.	O

Participants	O
were	O
a	O
subset	O
of	O
subjects	O
from	O
two	O
double	O
blind	O
,	O
placebo-control	O
,	O
multi-center	O
clinical	O
trials	O
.	O

One	O
trial	O
,	O
the	O
UC	O
Irvine	O
study	O
,	O
assessed	O
the	O
effects	O
of	O
porcine	Pharmacological
secretin	Pharmacological
vs.	Pharmacological
saline	Control
infusions	Control
on	O
children	O
's	O
behavior	O
,	O
language	O
and	O
IQ	O
.	O

The	O
UC	O
Davis	O
trial	O
assessed	O
the	O
effects	O
of	O
synthetic	Pharmacological
human	Pharmacological
secretin	Pharmacological
vs.	O
saline	Control
infusions	Control
on	O
behavior	O
,	O
language	O
and	O
gastrointestinal	O
function	O
.	O

The	O
sleep	O
study	O
enrolled	O
some	O
of	O
the	O
children	O
from	O
each	O
of	O
the	O
two	O
trials	O
to	O
observe	O
possible	O
secretin	O
effects	O
on	O
sleep	O
.	O

To	O
examine	O
sleep	O
,	O
the	O
UC	O
Irvine	O
trial	O
used	O
the	O
Children	O
's	O
Sleep	O
Habits	O
Questionnaire	O
and	O
daily	O
sleep	O
diaries	O
,	O
whereas	O
the	O
UC	O
Davis	O
study	O
used	O
home-recorded	O
time-lapse	O
videosomnography	O
.	O

Because	O
of	O
the	O
small	O
sample	O
size	O
,	O
the	O
results	O
from	O
both	O
trials	O
are	O
preliminary	O
.	O

They	O
suggest	O
that	O
secretin	Pharmacological
,	Pharmacological
porcine	Pharmacological
or	Pharmacological
synthetic	Pharmacological
,	O
does	O
not	O
improve	O
sleep-wake	O
state	O
organization	O
dramatically	O
.	O

Effect	O
of	O
a	O
multi-faceted	Physical
intervention	Physical
on	O
gingival	O
health	O
among	O
adults	O
with	O
systemic	O
sclerosis	O
.	O

OBJECTIVES	O
To	O
evaluate	O
the	O
effect	O
of	O
adaptive	Surgical
oral	Surgical
hygiene	Surgical
devices	Surgical
and	O
orofacial	Physical
exercise	Physical
to	O
improve	O
gingival	O
health	O
among	O
adults	O
with	O
systemic	O
sclerosis	O
(	O
SSc	O
)	O
.	O

METHODS	O
Forty-eight	O
patients	O
with	O
SSc	O
were	O
assigned	O
randomly	O
to	O
the	O
multifaceted	Physical
oral	Physical
health	Physical
intervention	Physical
or	O
usual	Control
dental	Control
care	Control
control	O
group	O
.	O

Participants	O
in	O
the	O
intervention	O
group	O
received	O
a	O
rechargeable	O
,	O
powered	O
Oral-B?	Physical
oscillating-rotating-pulsating	Physical
toothbrush	Physical
and	O
a	O
Reach?	Physical
Access?	Physical
Flosser	Physical
that	O
has	O
a	O
toothbrush-like	O
handle	O
.	O

For	O
those	O
with	O
an	O
oral	O
aperture	O
of	O
less	O
than	O
40	O
mm	O
,	O
orofacial	O
exercises	O
were	O
taught	O
.	O

Participants	O
in	O
the	O
control	O
group	O
were	O
each	O
given	O
a	O
manual	O
toothbrush	O
and	O
dental	O
floss	O
.	O

Participants	O
in	O
both	O
groups	O
received	O
instructions	O
and	O
demonstration	O
on	O
the	O
use	O
of	O
the	O
devices	O
,	O
and	O
were	O
requested	O
to	O
perform	O
the	O
respective	O
intervention	O
twice	O
a	O
day	O
for	O
6	O
months	O
.	O

Evaluations	O
were	O
at	O
baseline	O
,	O
3-	O
,	O
and	O
6-months	O
.	O

The	O
main	O
outcome	O
was	O
gingival	O
index	O
(	O
GI	O
)	O
,	O
an	O
indicator	O
of	O
gingival	O
inflammation	O
.	O

RESULTS	O
Both	O
groups	O
showed	O
significant	O
reduction	O
in	O
GI	O
scores	O
at	O
6	O
months	O
(	O
ps	O
<	O
0.005	O
)	O
.	O

Reduction	O
in	O
GI	O
scores	O
of	O
the	O
intervention	O
group	O
at	O
6	O
months	O
was	O
20.8	O
%	O
which	O
is	O
considered	O
to	O
be	O
clinically	O
significant	O
.	O

Compared	O
to	O
the	O
control	O
group	O
,	O
the	O
intervention	O
group	O
showed	O
a	O
significant	O
and	O
larger	O
reduction	O
in	O
GI	O
score	O
by	O
8	O
%	O
at	O
6	O
months	O
(	O
p=0.0007	O
)	O
.	O

CONCLUSIONS	O
Results	O
support	O
the	O
use	O
of	O
adaptive	Surgical
devices	Surgical
and	O
orofacial	Physical
exercise	Physical
to	O
improve	O
gingival	O
health	O
in	O
adults	O
with	O
SSc	O
when	O
compared	O
to	O
use	O
of	O
manual	Control
toothbrushing	Control
and	O
finger-held	Control
flossing	Control
.	O

Recommending	O
and	O
educating	O
patients	O
with	O
SSc	O
to	O
use	O
adaptive	O
devices	O
to	O
clean	O
the	O
tooth	O
surfaces	O
looks	O
promising	O
for	O
long-term	O
oral	O
health	O
improvement	O
.	O

Effects	O
of	O
long-term	Pharmacological
vitamin	Pharmacological
E	Pharmacological
supplementation	Pharmacological
on	O
cardiovascular	O
events	O
and	O
cancer	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

CONTEXT	O
Experimental	O
and	O
epidemiological	O
data	O
suggest	O
that	O
vitamin	Pharmacological
E	Pharmacological
supplementation	Pharmacological
may	O
prevent	O
cancer	O
and	O
cardiovascular	O
events	O
.	O

Clinical	O
trials	O
have	O
generally	O
failed	O
to	O
confirm	O
benefits	O
,	O
possibly	O
due	O
to	O
their	O
relatively	O
short	O
duration	O
.	O

OBJECTIVE	O
To	O
evaluate	O
whether	O
long-term	Pharmacological
supplementation	Pharmacological
with	Pharmacological
vitamin	Pharmacological
E	Pharmacological
decreases	O
the	O
risk	O
of	O
cancer	O
,	O
cancer	O
death	O
,	O
and	O
major	O
cardiovascular	O
events	O
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PATIENTS	O
A	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
international	O
trial	O
(	O
the	O
initial	O
Heart	O
Outcomes	O
Prevention	O
Evaluation	O
[	O
HOPE	O
]	O
trial	O
conducted	O
between	O
December	O
21	O
,	O
1993	O
,	O
and	O
April	O
15	O
,	O
1999	O
)	O
of	O
patients	O
at	O
least	O
55	O
years	O
old	O
with	O
vascular	O
disease	O
or	O
diabetes	O
mellitus	O
was	O
extended	O
(	O
HOPE-The	O
Ongoing	O
Outcomes	O
[	O
HOPE-TOO	O
]	O
)	O
between	O
April	O
16	O
,	O
1999	O
,	O
and	O
May	O
26	O
,	O
2003	O
.	O

Of	O
the	O
initial	O
267	O
HOPE	O
centers	O
that	O
had	O
enrolled	O
9541	O
patients	O
,	O
174	O
centers	O
participated	O
in	O
the	O
HOPE-TOO	O
trial	O
.	O

Of	O
7030	O
patients	O
enrolled	O
at	O
these	O
centers	O
,	O
916	O
were	O
deceased	O
at	O
the	O
beginning	O
of	O
the	O
extension	O
,	O
1382	O
refused	O
participation	O
,	O
3994	O
continued	O
to	O
take	O
the	O
study	O
intervention	O
,	O
and	O
738	O
agreed	O
to	O
passive	O
follow-up	O
.	O

Median	O
duration	O
of	O
follow-up	O
was	O
7.0	O
years	O
.	O

INTERVENTION	O
Daily	O
dose	O
of	O
natural	Pharmacological
source	Pharmacological
vitamin	Pharmacological
E	Pharmacological
(	O
400	O
IU	O
)	O
or	O
matching	O
placebo	Control
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Primary	O
outcomes	O
included	O
cancer	O
incidence	O
,	O
cancer	O
deaths	O
,	O
and	O
major	O
cardiovascular	O
events	O
(	O
myocardial	O
infarction	O
,	O
stroke	O
,	O
and	O
cardiovascular	O
death	O
)	O
.	O

Secondary	O
outcomes	O
included	O
heart	O
failure	O
,	O
unstable	O
angina	O
,	O
and	O
revascularizations	O
.	O

RESULTS	O
Among	O
all	O
HOPE	O
patients	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
primary	O
analysis	O
:	O
for	O
cancer	O
incidence	O
,	O
there	O
were	O
552	O
patients	O
(	O
11.6	O
%	O
)	O
in	O
the	O
vitamin	Pharmacological
E	Pharmacological
group	O
vs	O
586	O
(	O
12.3	O
%	O
)	O
in	O
the	O
placebo	Control
group	O
(	O
relative	O
risk	O
[	O
RR	O
]	O
,	O
0.94	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.84-1.06	O
;	O
P	O
=	O
.30	O
)	O
;	O
for	O
cancer	O
deaths	O
,	O
156	O
(	O
3.3	O
%	O
)	O
vs	O
178	O
(	O
3.7	O
%	O
)	O
,	O
respectively	O
(	O
RR	O
,	O
0.88	O
;	O
95	O
%	O
CI	O
,	O
0.71-1.09	O
;	O
P	O
=	O
.24	O
)	O
;	O
and	O
for	O
major	O
cardiovascular	O
events	O
,	O
1022	O
(	O
21.5	O
%	O
)	O
vs	O
985	O
(	O
20.6	O
%	O
)	O
,	O
respectively	O
(	O
RR	O
,	O
1.04	O
;	O
95	O
%	O
CI	O
,	O
0.96-1.14	O
;	O
P	O
=	O
.34	O
)	O
.	O

Patients	O
in	O
the	O
vitamin	Pharmacological
E	Pharmacological
group	O
had	O
a	O
higher	O
risk	O
of	O
heart	O
failure	O
(	O
RR	O
,	O
1.13	O
;	O
95	O
%	O
CI	O
,	O
1.01-1.26	O
;	O
P	O
=	O
.03	O
)	O
and	O
hospitalization	O
for	O
heart	O
failure	O
(	O
RR	O
,	O
1.21	O
;	O
95	O
%	O
CI	O
,	O
1.00-1.47	O
;	O
P	O
=	O
.045	O
)	O
.	O

Similarly	O
,	O
among	O
patients	O
enrolled	O
at	O
the	O
centers	O
participating	O
in	O
the	O
HOPE-TOO	O
trial	O
,	O
there	O
were	O
no	O
differences	O
in	O
cancer	O
incidence	O
,	O
cancer	O
deaths	O
,	O
and	O
major	O
cardiovascular	O
events	O
,	O
but	O
higher	O
rates	O
of	O
heart	O
failure	O
and	O
hospitalizations	O
for	O
heart	O
failure	O
.	O

CONCLUSION	O
In	O
patients	O
with	O
vascular	O
disease	O
or	O
diabetes	O
mellitus	O
,	O
long-term	Pharmacological
vitamin	Pharmacological
E	Pharmacological
supplementation	Pharmacological
does	O
not	O
prevent	O
cancer	O
or	O
major	O
cardiovascular	O
events	O
and	O
may	O
increase	O
the	O
risk	O
for	O
heart	O
failure	O
.	O

Effect	O
of	O
acute	Physical
exercise	Physical
on	O
executive	O
function	O
in	O
children	O
with	O
attention	O
deficit	O
hyperactivity	O
disorder	O
.	O

This	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
effect	O
of	O
acute	Physical
aerobic	Physical
exercise	Physical
on	O
executive	O
function	O
in	O
children	O
with	O
attention	O
deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
.	O

Forty	O
children	O
with	O
ADHD	O
were	O
randomly	O
assigned	O
into	O
exercise	O
or	O
control	O
groups	O
.	O

Participants	O
in	O
the	O
exercise	O
group	O
performed	O
a	O
moderate	Physical
intensity	Physical
aerobic	Physical
exercise	Physical
for	Physical
30	Physical
min	Physical
,	O
whereas	O
the	O
control	O
group	O
watched	O
a	O
running/exercise-related	Other
video	Other
.	Other

Neuropsychological	O
tasks	O
,	O
the	O
Stroop	O
Test	O
and	O
the	O
Wisconsin	O
Card	O
Sorting	O
Test	O
(	O
WCST	O
)	O
,	O
were	O
assessed	O
before	O
and	O
after	O
each	O
treatment	O
.	O

The	O
results	O
indicated	O
that	O
acute	O
exercise	O
facilitated	O
performance	O
in	O
the	O
Stroop	O
Test	O
,	O
particularly	O
in	O
the	O
Stroop	O
Color-Word	O
condition	O
.	O

Additionally	O
,	O
children	O
in	O
the	O
exercise	O
group	O
demonstrated	O
improvement	O
in	O
specific	O
WCST	O
performances	O
in	O
Non-perseverative	O
Errors	O
and	O
Categories	O
Completed	O
,	O
whereas	O
no	O
influences	O
were	O
found	O
in	O
those	O
performances	O
in	O
the	O
control	O
group	O
.	O

Tentative	O
explanations	O
for	O
the	O
exercise	O
effect	O
postulate	O
that	O
exercise	O
allocates	O
attention	O
resources	O
,	O
influences	O
the	O
dorsolateral	O
prefrontal	O
cortex	O
,	O
and	O
is	O
implicated	O
in	O
exercise-induced	O
dopamine	O
release	O
.	O

These	O
findings	O
are	O
promising	O
and	O
additional	O
investigations	O
to	O
explore	O
the	O
efficacy	O
of	O
exercise	Physical
on	O
executive	O
function	O
in	O
children	O
with	O
ADHD	O
are	O
encouraged	O
.	O

PROCLAIM	O
:	O
pilot	O
study	O
to	O
examine	O
the	O
effects	O
of	O
clopidogrel	Pharmacological
on	O
inflammatory	O
markers	O
in	O
patients	O
with	O
metabolic	O
syndrome	O
receiving	O
low-dose	O
aspirin	Pharmacological
.	Pharmacological

Metabolic	O
syndrome	O
is	O
associated	O
with	O
intravascular	O
inflammation	O
,	O
as	O
determined	O
by	O
increased	O
levels	O
of	O
inflammatory	O
biomarkers	O
and	O
an	O
increased	O
risk	O
of	O
ischemic	O
atherothrombotic	O
events	O
.	O

Evidence	O
suggests	O
that	O
atherothrombosis	O
and	O
intravascular	O
inflammation	O
share	O
predictive	O
biomarkers	O
,	O
including	O
high-sensitivity	O
C-reactive	O
protein	O
,	O
CD40	O
ligand	O
,	O
P-selectin	O
,	O
and	O
N-terminal	O
pro-brain	O
natriuretic	O
peptide	O
.	O

Patients	O
who	O
had	O
metabolic	O
syndrome	O
were	O
randomized	O
to	O
receive	O
clopidogrel	Pharmacological
75	O
mg/day	O
plus	O
aspirin	Pharmacological
81	O
mg/day	O
(	O
n	O
=	O
89	O
)	O
or	O
placebo	Control
plus	O
aspirin	Pharmacological
81	O
mg/day	O
(	O
n	O
=	O
92	O
)	O
for	O
9	O
weeks	O
to	O
assess	O
the	O
efficacy	O
of	O
each	O
treatment	O
in	O
suppression	O
of	O
inflammatory	O
markers	O
.	O

Change	O
from	O
baseline	O
in	O
the	O
levels	O
of	O
high-sensitivity	O
C-reactive	O
protein	O
,	O
CD40	O
ligand	O
,	O
P-selectin	O
,	O
and	O
N-terminal	O
pro-brain	O
natriuretic	O
peptide	O
at	O
6	O
weeks	O
was	O
assessed	O
to	O
evaluate	O
each	O
treatment	O
.	O

There	O
was	O
a	O
significant	O
difference	O
at	O
Week	O
6	O
in	O
model-adjusted	O
CD40-ligand	O
levels	O
in	O
favor	O
of	O
clopidogrel	Pharmacological
plus	O
aspirin	Pharmacological
compared	O
with	O
placebo	Control
plus	O
aspirin	Pharmacological
in	O
both	O
the	O
intent-to-treat	O
population	O
(	O
difference	O
between	O
least-squares	O
means	O
=	O
-186.5	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
-342.3	O
to	O
-30.8	O
;	O
P	O
=	O
0.02	O
)	O
and	O
the	O
per-protocol	O
population	O
(	O
P	O
=	O
0.05	O
)	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
between	O
the	O
treatment	O
arms	O
for	O
high-sensitivity	O
C-reactive	O
protein	O
,	O
P-selectin	O
,	O
and	O
N-terminal	O
pro-brain	O
natriuretic	O
peptide	O
.	O

There	O
were	O
no	O
deaths	O
or	O
serious	O
adverse	O
events	O
in	O
either	O
treatment	O
arm	O
.	O

Data	O
from	O
this	O
study	O
suggest	O
that	O
clopidogrel	Pharmacological
can	O
decrease	O
the	O
expression	O
of	O
the	O
CD40-ligand	O
biomarker	O
.	O

Morphological	O
onset	O
and	O
early	O
diagnosis	O
in	O
apical	O
hypertrophic	O
cardiomyopathy	O
:	O
a	O
long	O
term	O
analysis	O
with	O
nuclear	Other
magnetic	Other
resonance	Other
imaging	Other
.	Other

OBJECTIVES	O
A	O
long-term	O
follow-up	O
study	O
with	O
nuclear	Other
magnetic	Other
resonance	Other
(	Other
NMR	Other
)	Other
imaging	Other
was	O
undertaken	O
to	O
detect	O
the	O
morphological	O
onset	O
and	O
to	O
establish	O
the	O
early	O
diagnosis	O
in	O
apical	O
hypertrophic	O
cardiomyopathy	O
(	O
HCM	O
)	O
.	O

BACKGROUND	O
A	O
spadelike	O
configuration	O
on	O
left	O
ventriculogram	O
(	O
LVG	O
)	O
is	O
regarded	O
as	O
a	O
diagnostic	O
criterion	O
for	O
the	O
classical	O
apical	O
HCM	O
.	O

There	O
also	O
exists	O
a	O
segmented	O
hypertrophy	O
at	O
the	O
apical	O
level	O
without	O
indicating	O
the	O
spadelike	O
features	O
(	O
a	O
nonspade	O
configuration	O
)	O
.	O

To	O
detect	O
the	O
hypertrophied	O
myocardium	O
of	O
the	O
nonspade	O
configuration	O
,	O
circumferential	O
scrutiny	O
of	O
the	O
apex	O
is	O
required	O
.	O

Although	O
both	O
configurations	O
can	O
be	O
underlying	O
causes	O
of	O
giant	O
negative	O
T	O
waves	O
,	O
etiological	O
relationship	O
between	O
the	O
two	O
is	O
not	O
clarified	O
.	O

METHODS	O
The	O
criteria	O
for	O
the	O
spadelike	O
configuration	O
defined	O
on	O
left	O
ventricular	O
short-axis	O
NMR	Other
images	Other
were	O
as	O
follows	O
:	O
(	O
apical	O
maximal	O
thickness	O
>	O
or	O
=	O
15	O
mm	O
)	O
,	O
(	O
apical	O
anterior	O
thickness	O
over	O
basal	O
anterior	O
thickness	O
>	O
or	O
=	O
1.3	O
)	O
and	O
(	O
apical	O
posterior	O
thickness	O
over	O
basal	O
posterior	O
thickness	O
>	O
or	O
=1.3	O
)	O
.	O

Thirteen	O
patients	O
who	O
had	O
predominant	O
hypertrophy	O
(	O
>	O
or	O
=	O
15	O
mm	O
)	O
at	O
the	O
apical	O
level	O
without	O
the	O
spadelike	O
configuration	O
underwent	O
NMR	Other
imaging	Other
twice	O
before	O
and	O
after	O
54+/-10	O
months	O
'	O
follow-up	O
.	O

RESULTS	O
Apical	O
hypertrophy	O
that	O
had	O
been	O
confined	O
to	O
the	O
lateral	O
wall	O
in	O
four	O
,	O
the	O
anterior-lateral	O
wall	O
in	O
two	O
,	O
and	O
the	O
septal-anterior	O
wall	O
in	O
one	O
developed	O
to	O
become	O
circumferential	O
hypertrophy	O
that	O
fulfilled	O
the	O
criteria	O
for	O
the	O
spadelike	O
configuration	O
after	O
the	O
follow-up	O
period	O
.	O

CONCLUSIONS	O
The	O
spadelike	O
configuration	O
can	O
begin	O
with	O
the	O
nonspade	O
configuration	O
and	O
therefore	O
,	O
both	O
can	O
constitute	O
a	O
single	O
disease	O
entity	O
of	O
apical	O
HCM	O
.	O

The	O
early	O
diagnosis	O
of	O
apical	O
HCM	O
can	O
be	O
achieved	O
by	O
identifying	O
the	O
hypertrophy	O
frequently	O
confined	O
to	O
the	O
lateral	O
wall	O
at	O
the	O
apical	O
level	O
.	O

The	O
dipeptidyl	Pharmacological
peptidase-4	Pharmacological
inhibitor	Pharmacological
PHX1149	Pharmacological
improves	O
blood	O
glucose	O
control	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
.	O

AIM	O
To	O
determine	O
the	O
efficacy	O
and	O
tolerability	O
of	O
PHX1149	Pharmacological
,	O
a	O
novel	O
dipeptidyl	O
peptidase-4	O
(	O
DPP4	O
)	O
inhibitor	O
,	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

METHODS	O
This	O
is	O
a	O
multicentre	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
4-week	O
study	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
with	O
suboptimal	O
metabolic	O
control	O
.	O

Patients	O
with	O
a	O
baseline	O
haemoglobin	O
A	O
(	O
1c	O
)	O
(	O
HbA	O
(	O
1c	O
)	O
)	O
of	O
7.3	O
to	O
11.0	O
%	O
were	O
randomized	O
1	O
:	O
1	O
:	O
1	O
:	O
1	O
to	O
receive	O
once-daily	O
oral	O
therapy	O
with	O
either	O
PHX1149	Pharmacological
(	O
100	O
,	O
200	O
or	O
400	O
mg	O
)	O
or	O
placebo	Control
;	O
patients	O
were	O
on	O
a	O
constant	O
background	O
therapy	O
of	O
either	O
metformin	O
alone	O
or	O
metformin	O
plus	O
a	O
glitazone	O
.	O

RESULTS	O
Treatment	O
with	O
100	O
,	O
200	O
or	O
400	O
mg	O
of	O
PHX1149	O
significantly	O
decreased	O
postprandial	O
glucose	O
area	O
under	O
the	O
curve	O
AUC	O
(	O
0-2	O
h	O
)	O
by	O
approximately	O
20	O
%	O
(	O
+0.11	O
+/-	O
0.50	O
,	O
-2.08	O
+/-	O
0.51	O
,	O
-1.73	O
+/-	O
0.49	O
and	O
-1.88	O
+/-	O
0.48	O
mmol/l	O
x	O
h	O
,	O
respectively	O
,	O
for	O
placebo	O
and	O
100	O
,	O
200	O
and	O
400	O
mg	O
(	O
p	O
=	O
0.002	O
,	O
0.008	O
and	O
0.004	O
vs.	O
placebo	O
)	O
.	O

Postprandial	O
AUC	O
(	O
0-2	O
h	O
)	O
of	O
intact	O
glucagon-like	O
peptide-1	O
,	O
the	O
principal	O
mediator	O
of	O
the	O
biological	O
effects	O
of	O
DPP4	O
inhibitors	O
,	O
was	O
increased	O
by	O
3.90	O
+/-	O
2.83	O
,	O
11.63	O
+/-	O
2.86	O
,	O
16.42	O
+/-	O
2.72	O
and	O
15.75	O
+/-	O
2.71	O
pmol/l	O
x	O
h	O
,	O
respectively	O
,	O
for	O
placebo	O
and	O
100	O
,	O
200	O
and	O
400	O
mg	O
(	O
p	O
=	O
0.053	O
,	O
0.001	O
and	O
0.002	O
vs.	O
placebo	O
)	O
.	O

Mean	O
HbA	O
(	O
1c	O
)	O
was	O
lower	O
in	O
all	O
dose	O
groups	O
;	O
the	O
placebo-corrected	O
change	O
in	O
the	O
groups	O
receiving	O
400	O
mg	O
PHX1149	O
was	O
-0.28	O
%	O
(	O
p	O
=	O
0.02	O
)	O
.	O

DPP4	O
inhibition	O
on	O
day	O
28	O
was	O
53	O
,	O
73	O
and	O
78	O
%	O
at	O
24	O
h	O
postdose	O
in	O
the	O
groups	O
receiving	O
100	O
,	O
200	O
and	O
400	O
mg	O
PHX1149	O
,	O
respectively	O
.	O

There	O
were	O
no	O
differences	O
in	O
adverse	O
events	O
between	O
PHX1149-treated	O
and	O
placebo	O
subjects	O
.	O

CONCLUSIONS	O
Addition	O
of	O
the	O
DPP4	O
inhibitor	O
PHX1149	O
to	O
a	O
stable	O
regimen	O
of	O
metformin	O
or	O
metformin	O
plus	O
a	O
glitazone	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
was	O
well	O
tolerated	O
and	O
improved	O
blood	O
glucose	O
control	O
.	O

Glibenclamide	Pharmacological
vs	O
gliclazide	Pharmacological
in	O
reducing	O
oxidative	O
stress	O
in	O
patients	O
of	O
noninsulin	O
dependent	O
diabetes	O
mellitus	O
--	O
a	O
double	O
blind	O
randomized	O
study	O
.	O

OBJECTIVE	O
Parameters	O
of	O
oxidative	O
stress	O
were	O
quantitated	O
in	O
50	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
in	O
uncontrolled	O
state	O
and	O
after	O
control	O
using	O
oral	O
glibenclamide	Pharmacological
or	O
gliclazide	Pharmacological
.	O

The	O
estimates	O
were	O
further	O
compared	O
between	O
the	O
two	O
groups	O
irrespective	O
of	O
drug	O
used	O
to	O
evaluate	O
the	O
difference	O
,	O
if	O
any	O
.	O

METHODS	O
The	O
study	O
was	O
a	O
double	O
blind	O
,	O
uncontrolled	O
,	O
noncrossover	O
and	O
randomized	O
trial	O
.	O

Fifty	O
patients	O
of	O
uncontrolled	O
type	O
2	O
diabetes	O
were	O
divided	O
in	O
to	O
two	O
groups	O
.	O

Group	O
I	O
(	O
25	O
patients	O
)	O
received	O
capsule	O
A	O
(	O
glibenclamide	Pharmacological
)	O
while	O
Group	O
II	O
(	O
25	O
patients	O
)	O
received	O
capsule	O
B	O
(	O
gliclazide	Pharmacological
)	O
.	O

The	O
parameters	O
studied	O
were	O
Superoxide	O
dismutase	O
(	O
SOD	O
)	O
,	O
malonyl-dialdehyde	O
(	O
MDA	O
)	O
and	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
.	O

They	O
were	O
done	O
at	O
(	O
a	O
)	O
uncontrolled	O
stage	O
(	O
FBS	O
--	O
165	O
+/-	O
16.7	O
mg/dl	O
,	O
PP	O
--	O
240	O
+/-	O
30.1	O
mg/dl	O
and	O
HbA1	O
--	O
10.5	O
+/-	O
0.9	O
%	O
in	O
group	O
I	O
and	O
FBS	O
--	O
150	O
+/-	O
15.8	O
mg/dl	O
,	O
PP	O
--	O
246	O
+/-	O
29.1	O
mg/dl	O
HbA1	O
10.6	O
+/-	O
0.8	O
%	O
in	O
group	O
II	O
)	O
and	O
during	O
controlled	O
stage	O
at	O
12	O
weeks	O
(	O
FBS	O
--	O
120	O
+/-	O
18.5	O
mg/dl	O
,	O
PP	O
--	O
180	O
+/-	O
19.1	O
mg/dl	O
and	O
HbA1	O
--	O
8.4	O
+/-	O
0.29	O
%	O
in	O
group	O
I	O
and	O
FBS	O
--	O
118	O
+/-	O
17.6	O
mg/dl	O
,	O
PP	O
--	O
176	O
+/-	O
20.1	O
mg/dl	O
and	O
HbA1	O
--	O
8.5	O
+/-	O
0.39	O
%	O
in	O
group	O
II	O
patients	O
)	O
.	O

RESULTS	O
The	O
significantly	O
raised	O
levels	O
of	O
MDA	O
and	O
SOD	O
,	O
and	O
decreased	O
levels	O
of	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
during	O
uncontrolled	O
stage	O
of	O
diabetes	O
indicated	O
free	O
radical	O
stress	O
induced	O
lipid	O
peroxidation	O
.	O

The	O
significant	O
fall	O
of	O
MDA	O
and	O
SOD	O
and	O
increased	O
levels	O
of	O
GSH	O
in	O
blood	O
in	O
both	O
groups	O
after	O
control	O
revealed	O
beneficial	O
effects	O
of	O
glycemic	O
control	O
on	O
oxidative	O
stress	O
.	O

The	O
levels	O
were	O
not	O
normalized	O
and	O
stayed	O
higher	O
than	O
those	O
in	O
controls	O
.	O

On	O
intergroup	O
comparison	O
;	O
the	O
control	O
of	O
diabetes	O
with	O
gliclazide	Pharmacological
(	O
group	O
II	O
)	O
showed	O
improvement	O
in	O
oxidative	O
stress	O
(	O
MDA	O
,	O
GSH	O
)	O
better	O
(	O
p	O
<	O
0.001	O
)	O
than	O
glibenclamide	Pharmacological
(	O
group	O
I	O
)	O
.	O

CONCLUSION	O
Oxidative	O
stress	O
in	O
uncontrolled	O
diabetes	O
is	O
decreased	O
with	O
glycemic	O
control	O
.	O

The	O
control	O
of	O
diabetes	O
with	O
gliclazide	Pharmacological
reduced	O
oxidative	O
stress	O
more	O
than	O
glibenclamide	Pharmacological
,	O
indicating	O
higher	O
antioxidant	O
properties	O
of	O
gliclazide	O
.	O

Normalization	O
of	O
oxidative	O
stress	O
was	O
not	O
achieved	O
.	O

Further	O
studies	O
are	O
required	O
to	O
see	O
long-term	O
effect	O
of	O
drug	O
therapy	O
in	O
combating	O
oxidative	O
stress	O
after	O
achieving	O
acceptable	O
control	O
of	O
diabetes	O
.	O

Effects	O
of	O
sibutramine	Pharmacological
on	O
thermogenesis	O
in	O
obese	O
patients	O
assessed	O
via	O
immersion	O
calorimetry	O
.	O

Glucose	O
utilization	O
studies	O
show	O
that	O
sibutramine-induced	Pharmacological
thermogenesis	O
is	O
mediated	O
via	O
selective	O
sympathetic	O
activation	O
of	O
brown	O
adipose	O
tissue	O
.	O

The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
use	O
a	O
new	O
calorimetry	O
method	O
in	O
which	O
resting	O
metabolic	O
rate	O
is	O
enhanced	O
to	O
evaluate	O
the	O
effects	O
of	O
sibutramine	Pharmacological
treatment	O
on	O
thermogenesis	O
.	O

Sixty	O
obese	O
women	O
were	O
included	O
in	O
the	O
study	O
.	O

Subjects	O
were	O
divided	O
into	O
2	O
equal	O
groups-the	O
placebo	Control
and	O
sibutramine	Pharmacological
treatment	O
groups	O
.	O

The	O
sibutramine	Pharmacological
group	O
was	O
given	O
sibutramine	Pharmacological
10	O
mg	O
daily	O
for	O
12	O
wk	O
.	O

At	O
baseline	O
and	O
at	O
the	O
end	O
of	O
the	O
12-wk	O
treatment	O
period	O
,	O
thermogenic	O
measurements	O
were	O
taken	O
with	O
the	O
use	O
of	O
water	O
immersion	O
calorimetry	O
.	O

Subjects	O
were	O
examined	O
at	O
weeks	O
4	O
,	O
8	O
,	O
and	O
12	O
of	O
treatment	O
to	O
identify	O
adverse	O
effects	O
.	O

Body	O
mass	O
index	O
,	O
measured	O
at	O
31.5+/-2.05	O
kg/m2	O
in	O
the	O
placebo	O
group	O
,	O
decreased	O
to	O
30.4+/-2.94	O
kg/m	O
(	O
2	O
)	O
after	O
12	O
wk	O
(	O
P=.07	O
)	O
.	O

In	O
the	O
sibutramine	Pharmacological
group	O
,	O
it	O
decreased	O
from	O
33.5+/-4.1	O
kg/m	O
(	O
2	O
)	O
to	O
30.9+/-4.8	O
kg/m	O
(	O
2	O
)	O
(	O
P	O
<	O
.05	O
)	O
.	O

In	O
the	O
sibutramine	Pharmacological
group	O
,	O
mean	O
thermogenic	O
response	O
changed	O
from	O
a	O
baseline	O
value	O
of	O
1.27+/-0.29	O
kcal/kg/h	O
to	O
1.44+/-0.13	O
kcal/kg/h	O
after	O
12	O
wk	O
of	O
treatment	O
.	O

In	O
the	O
placebo	O
group	O
,	O
the	O
baseline	O
value	O
was	O
1.56+/-0.27	O
kcal/kg/h	O
;	O
it	O
changed	O
to	O
1.33+/-0.36	O
kcal/kg/h	O
at	O
the	O
end	O
of	O
12	O
wk	O
.	O

The	O
findings	O
of	O
this	O
study	O
suggest	O
that	O
sibutramine	O
treatment	O
promotes	O
thermogenesis	O
,	O
thus	O
facilitating	O
weight	O
loss	O
.	O

Calorimetry	O
enhances	O
resting	O
metabolism	O
through	O
more	O
efficient	O
heat	O
transfer	O
from	O
the	O
body	O
.	O

1999	O
WHO/ISH	O
Guidelines	O
applied	O
to	O
a	O
1999	O
MONICA	O
sample	O
from	O
northern	O
Sweden	O
.	O

BACKGROUND	O
Treating	O
hypertension	O
with	O
drugs	O
is	O
so	O
far	O
the	O
most	O
cost-effective	O
way	O
to	O
reduce	O
this	O
important	O
risk	O
factor	O
for	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
.	O

It	O
is	O
,	O
however	O
,	O
important	O
to	O
determine	O
absolute	O
risk	O
,	O
and	O
thereby	O
estimate	O
indication	O
for	O
drug	O
treatment	O
,	O
in	O
order	O
to	O
maintain	O
a	O
cost-effective	O
drug	O
treatment	O
.	O

WHO/ISH	O
Hypertension	O
Guidelines	O
from	O
1999	O
propose	O
a	O
risk	O
stratification	O
for	O
estimating	O
absolute	O
risk	O
for	O
CVD	O
based	O
on	O
blood	O
pressure	O
and	O
additional	O
risk	O
factors	O
,	O
target	O
organ	O
damage	O
(	O
TOD	O
)	O
and	O
CVD	O
.	O

OBJECTIVES	O
We	O
studied	O
the	O
consequences	O
of	O
applying	O
the	O
recent	O
WHO/ISH	Pharmacological
risk	Pharmacological
stratification	Pharmacological
scheme	Pharmacological
to	O
a	O
MONICA	O
sample	O
of	O
6000	O
subjects	O
from	O
a	O
geographically	O
defined	O
population	O
in	O
northern	O
Sweden	O
,	O
regarding	O
indications	O
for	O
treatment	O
,	O
target	O
blood	O
pressure	O
and	O
risk	O
distribution	O
.	O

METHODS	O
We	O
have	O
risk-classified	O
each	O
of	O
these	O
patients	O
using	O
a	O
computer	Other
program	Other
,	O
according	O
to	O
the	O
WHO/ISH	O
scheme	O
.	O

Data	O
on	O
TOD	O
were	O
not	O
available	O
.	O

RESULTS	O
In	O
all	O
,	O
917	O
(	O
15	O
%	O
)	O
had	O
drug-treated	O
hypertension	O
.	O

Three-quarters	O
(	O
n	O
=	O
737	O
)	O
were	O
inadequately	O
treated	O
,	O
with	O
blood	O
pressure	O
levels	O
at	O
or	O
above	O
140	O
or	O
90	O
mmHg	O
.	O

1773	O
(	O
30	O
%	O
of	O
5997	O
)	O
untreated	O
subjects	O
had	O
a	O
blood	O
pressure	O
of	O
140/90	O
or	O
above	O
;	O
16	O
%	O
in	O
the	O
low-	O
,	O
62	O
%	O
in	O
the	O
medium-	O
,	O
8	O
%	O
in	O
the	O
high-	O
,	O
and	O
14	O
%	O
in	O
the	O
very-high-risk	O
group	O
.	O

The	O
corresponding	O
risk-group	O
pattern	O
for	O
the	O
inadequately	O
treated	O
hypertensives	O
(	O
n	O
=	O
737	O
)	O
was	O
5.5	O
,	O
48.3	O
,	O
11.1	O
and	O
35.2	O
%	O
,	O
respectively	O
.	O

If	O
we	O
shifted	O
the	O
target	O
blood	O
pressure	O
from	O
below	O
140/90	O
to	O
below	O
130/85	O
for	O
drug-treated	O
subjects	O
under	O
60	O
(	O
n	O
=	O
278	O
)	O
the	O
number	O
of	O
inadequately	O
treated	O
subjects	O
increased	O
by	O
34	O
(	O
12.2	O
%	O
of	O
278	O
)	O
;	O
14	O
in	O
the	O
low-risk	O
group	O
,	O
15	O
in	O
the	O
medium-risk	O
group	O
,	O
and	O
only	O
five	O
in	O
the	O
high-	O
or	O
very-high-risk	O
groups	O
.	O

CONCLUSIONS	O
Only	O
one-fifth	O
of	O
the	O
drug-treated	O
hypertensives	O
were	O
well	O
controlled	O
.	O

Moreover	O
,	O
the	O
incidence	O
of	O
newly	O
detected	O
blood	O
pressure	O
elevation	O
was	O
high	O
.	O

The	O
majority	O
of	O
younger	O
subjects	O
with	O
high	O
blood	O
pressure	O
had	O
low	O
risk	O
,	O
but	O
in	O
those	O
aged	O
45-54	O
this	O
had	O
already	O
risen	O
to	O
a	O
medium	O
risk	O
.	O

Changing	O
the	O
target	O
blood	O
pressure	O
to	O
below	O
130/85	O
,	O
for	O
subjects	O
aged	O
below	O
60	O
,	O
as	O
recommended	O
by	O
WHO/ISH	O
,	O
affects	O
predominantly	O
low-	O
and	O
medium-risk	O
groups	O
.	O

Sex	O
risk	O
behavior	O
among	O
adolescent	O
and	O
young	O
adult	O
children	O
of	O
opiate	O
addicts	O
:	O
outcomes	O
from	O
the	O
focus	O
on	O
families	O
prevention	O
trial	O
and	O
an	O
examination	O
of	O
childhood	O
and	O
concurrent	O
predictors	O
of	O
sex	O
risk	O
behavior	O
.	O

This	O
study	O
reports	O
on	O
rates	O
and	O
predictors	O
of	O
sex	O
risk	O
behavior	O
among	O
a	O
sample	O
of	O
adolescent	O
and	O
young	O
adult	O
children	O
of	O
parents	O
enrolled	O
in	O
methadone	Pharmacological
treatment	O
for	O
opiate	O
addiction	O
.	O

Data	O
are	O
from	O
151	O
participants	O
(	O
80	O
males	O
,	O
71	O
females	O
)	O
in	O
the	O
Focus	O
on	O
Families	O
(	O
FOF	O
)	O
project	O
,	O
a	O
randomized	O
trial	O
of	O
a	O
family	Educational
intervention	Educational
and	O
a	O
study	O
of	O
the	O
development	O
of	O
at-risk	O
children	O
.	O

The	O
study	O
participants	O
are	O
children	O
of	O
parents	O
enrolled	O
in	O
methadone	Pharmacological
treatment	O
between	O
1990	O
and	O
1993	O
.	O

Participants	O
were	O
interviewed	O
in	O
2005	O
when	O
they	O
ranged	O
in	O
age	O
from	O
15	O
to	O
29	O
years	O
.	O

In	O
the	O
year	O
prior	O
to	O
the	O
follow-up	O
,	O
79	O
%	O
of	O
the	O
males	O
and	O
83	O
%	O
of	O
females	O
were	O
sexually	O
active	O
,	O
26	O
%	O
of	O
males	O
and	O
10	O
%	O
of	O
females	O
had	O
more	O
than	O
one	O
partner	O
in	O
the	O
prior	O
year	O
,	O
and	O
34	O
%	O
of	O
males	O
and	O
24	O
%	O
of	O
females	O
reported	O
having	O
sex	O
outside	O
of	O
a	O
committed	O
relationship	O
.	O

Twenty-four	O
percent	O
of	O
males	O
and	O
17	O
%	O
of	O
females	O
met	O
criteria	O
for	O
high-risk	O
sexual	O
behavior	O
,	O
reporting	O
casual	O
or	O
multiple	O
partners	O
in	O
the	O
prior	O
year	O
and	O
inconsistent	O
condom	O
use	O
.	O

Participants	O
in	O
the	O
intervention	Other
and	O
control	Control
conditions	O
did	O
not	O
differ	O
significantly	O
in	O
terms	O
of	O
any	O
measure	O
of	O
sex	O
risk	O
behavior	O
examined	O
.	O

None	O
of	O
the	O
measures	O
of	O
parent	O
behavior	O
and	O
family	O
processes	O
derived	O
from	O
data	O
at	O
baseline	O
of	O
the	O
FOF	O
study	O
predicted	O
whether	O
participants	O
engaged	O
in	O
high-risk	O
sex	O
.	O

Among	O
measures	O
derived	O
from	O
data	O
collected	O
at	O
long-term	O
follow-up	O
,	O
however	O
,	O
having	O
ever	O
met	O
criteria	O
for	O
substance	O
abuse	O
or	O
dependence	O
predicted	O
greater	O
likelihood	O
of	O
high-risk	O
sexual	O
behavior	O
,	O
and	O
being	O
married	O
or	O
being	O
in	O
a	O
romantic	O
relationship	O
was	O
associated	O
with	O
lower	O
likelihood	O
of	O
high-risk	O
sexual	O
behavior	O
.	O

The	O
findings	O
point	O
to	O
the	O
important	O
role	O
of	O
committed	O
relationships	O
in	O
regulating	O
sex	O
risk	O
behavior	O
among	O
this	O
population	O
,	O
as	O
well	O
as	O
heightened	O
levels	O
of	O
sex	O
risk	O
behavior	O
associated	O
with	O
substance	O
abuse	O
or	O
dependence	O
.	O

Effects	O
of	O
tonabersat	Pharmacological
on	O
migraine	O
with	O
aura	O
:	O
a	O
randomised	O
,	O
double-blind	O
,	O
placebo-controlled	O
crossover	O
study	O
.	O

BACKGROUND	O
Migraine	O
with	O
aura	O
is	O
thought	O
likely	O
to	O
be	O
caused	O
by	O
cortical	O
spreading	O
depression	O
(	O
CSD	O
)	O
.	O

Tonabersat	Pharmacological
inhibits	O
CSD	O
,	O
and	O
we	O
therefore	O
investigated	O
whether	O
tonabersat	O
has	O
a	O
preventive	O
effect	O
in	O
migraine	O
with	O
aura	O
.	O

METHODS	O
In	O
this	O
randomised	O
,	O
double-blind	O
,	O
placebo-controlled	O
crossover	O
trial	O
,	O
40	O
mg	O
tonabersat	Pharmacological
once	O
daily	O
was	O
compared	O
with	O
matched	O
placebo	Control
in	O
patients	O
who	O
had	O
at	O
least	O
one	O
aura	O
attack	O
per	O
month	O
during	O
the	O
past	O
3	O
months	O
.	O

Randomisation	O
was	O
by	O
computer-generated	O
list	O
.	O

Patients	O
kept	O
a	O
detailed	O
diary	O
to	O
enable	O
objective	O
diagnosis	O
of	O
each	O
attack	O
as	O
migraine	O
with	O
aura	O
,	O
migraine	O
without	O
aura	O
,	O
or	O
other	O
type	O
of	O
headache	O
.	O

Primary	O
endpoints	O
were	O
a	O
reduction	O
in	O
aura	O
attacks	O
with	O
or	O
without	O
headache	O
and	O
a	O
reduction	O
in	O
migraine	O
headache	O
days	O
with	O
or	O
without	O
an	O
aura	O
.	O

Analysis	O
was	O
per	O
protocol	O
.	O

This	O
trial	O
is	O
registered	O
,	O
number	O
NCT00332007	O
.	O

FINDINGS	O
39	O
patients	O
were	O
included	O
in	O
the	O
study	O
,	O
of	O
whom	O
31	O
were	O
included	O
in	O
the	O
statistical	O
analysis	O
of	O
efficacy	O
.	O

Median	O
(	O
IQR	O
)	O
attacks	O
of	O
aura	O
were	O
reduced	O
from	O
3.2	O
(	O
1.0-5.0	O
)	O
per	O
12	O
weeks	O
on	O
placebo	Control
to	O
1.0	O
(	O
0-3.0	O
)	O
on	O
tonabersat	O
(	O
p=0.01	O
)	O
,	O
whereas	O
the	O
other	O
primary	O
outcome	O
measure	O
,	O
median	O
migraine	O
headache	O
days	O
with	O
or	O
without	O
aura	O
,	O
was	O
not	O
significantly	O
different	O
between	O
placebo	Control
and	O
tonabersat	Pharmacological
groups	O
(	O
3.0	O
days	O
in	O
each	O
group	O
;	O
p=0.09	O
)	O
.	O

Tonabersat	O
was	O
well	O
tolerated	O
but	O
overall	O
had	O
more	O
side-effects	O
than	O
placebo	O
.	O

INTERPRETATION	O
Tonabersat	Pharmacological
showed	O
a	O
preventive	O
effect	O
on	O
attacks	O
of	O
migraine	O
aura	O
but	O
no	O
efficacy	O
on	O
non-aura	O
attacks	O
,	O
in	O
keeping	O
with	O
its	O
known	O
inhibitory	O
effect	O
on	O
CSD	O
.	O

The	O
results	O
support	O
the	O
theory	O
that	O
auras	O
are	O
caused	O
by	O
CSD	O
and	O
that	O
this	O
phenomenon	O
is	O
not	O
involved	O
in	O
attacks	O
without	O
aura	O
.	O

FUNDING	O
Minster	O
Pharmaceuticals	O
;	O
Lundbeck	O
Foundation	O
.	O

Whole-body	Other
CT	Other
screening	Other
:	O
scan	O
delay	O
and	O
contrast	Pharmacological
injection	Pharmacological
duration	O
for	O
optimal	O
enhancement	O
of	O
abdominal	O
organs	O
and	O
deep	O
vessels	O
.	O

PURPOSE	O
To	O
assess	O
the	O
optimal	O
scan	O
delays	O
and	O
contrast	O
injection	O
durations	O
for	O
contrast-enhanced	Other
whole-body	Other
computed	Other
tomography	Other
(	Other
CT	Other
)	Other
.	Other

MATERIALS	O
AND	O
METHODS	O
One	O
hundred	O
forty-two	O
patients	O
were	O
randomized	O
into	O
three	O
groups	O
:	O
protocol	O
A-scan	O
delay	O
of	O
65	O
s	O
after	O
starting	O
contrast	Pharmacological
injection	Pharmacological
over	O
30	O
s	O
;	O
protocol	O
B-105	O
and	O
70	O
s	O
;	O
and	O
protocol	O
C-145	O
and	O
110	O
s	O
,	O
respectively	O
.	O

Contrast	O
enhancement	O
and	O
diagnostic	O
acceptability	O
were	O
assessed	O
.	O

RESULTS	O
Qualitative	O
assessment	O
was	O
subtle	O
among	O
the	O
three	O
protocols	O
.	O

Homogenous	O
enhancement	O
of	O
deep	O
veins	O
was	O
more	O
assuredly	O
achieved	O
with	O
protocol	O
C.	O
CONCLUSION	O
With	O
protocol	O
C	O
,	O
qualitatively	O
acceptable	O
enhancement	O
can	O
be	O
obtained	O
in	O
whole-body	Other
CT	Other
.	Other

A	O
randomized	O
comparison	O
of	O
the	O
Endeavor	Physical
zotarolimus-eluting	Physical
stent	Physical
versus	O
the	O
TAXUS	Physical
paclitaxel-eluting	Physical
stent	Physical
in	O
de	O
novo	O
native	O
coronary	O
lesions	O
12-month	O
outcomes	O
from	O
the	O
ENDEAVOR	O
IV	O
trial	O
.	O

OBJECTIVES	O
The	O
ENDEAVOR	O
IV	O
(	O
Randomized	O
Comparison	O
of	O
Zotarolimus-Eluting	Physical
and	O
Paclitaxel-Eluting	Physical
Stents	Physical
in	O
Patients	O
with	O
Coronary	O
Artery	O
Disease	O
)	O
trial	O
evaluated	O
the	O
safety	O
and	O
efficacy	O
of	O
the	O
zotarolimus-eluting	Physical
stent	Physical
(	Physical
ZES	Physical
)	Physical
compared	O
with	O
the	O
paclitaxel-eluting	Physical
stent	Physical
(	Physical
PES	Physical
)	Physical
.	O

BACKGROUND	O
First-generation	O
drug-eluting	O
stents	O
have	O
reduced	O
angiographic	O
and	O
clinical	O
restenosis	O
,	O
but	O
long-term	O
safety	O
remains	O
controversial	O
.	O

A	O
second-generation	O
drug-eluting	O
stent	O
,	O
which	O
delivers	O
zotarolimus	Pharmacological
,	O
a	O
potent	O
antiproliferative	O
agent	O
,	O
via	O
a	O
biocompatible	O
phosphorylcholine	O
polymer	O
on	O
a	O
cobalt	O
alloy	O
thin-strut	O
stent	O
has	O
shown	O
promising	O
experimental	O
and	O
early	O
clinical	O
results	O
.	O

METHODS	O
This	O
is	O
a	O
prospective	O
,	O
randomized	O
(	O
1:1	O
)	O
,	O
single-blind	O
,	O
controlled	O
trial	O
comparing	O
outcomes	O
of	O
patients	O
with	O
single	O
de	O
novo	O
coronary	O
lesions	O
treated	O
with	O
ZES	O
or	O
PES	O
.	O

The	O
primary	O
end	O
point	O
was	O
noninferiority	O
of	O
9-month	O
target	O
vessel	O
failure	O
defined	O
as	O
cardiac	O
death	O
,	O
myocardial	O
infarction	O
,	O
or	O
target	O
vessel	O
revascularization	O
.	O

RESULTS	O
Among	O
a	O
total	O
of	O
1,548	O
patients	O
assigned	O
to	O
ZES	Physical
(	O
n	O
=	O
773	O
)	O
or	O
PES	O
(	O
n	O
=	O
775	O
)	O
,	O
at	O
9	O
months	O
,	O
ZES	O
was	O
noninferior	O
to	O
PES	O
with	O
rates	O
of	O
target	O
vessel	O
failure	O
6.6	O
%	O
versus	O
7.1	O
%	O
,	O
respectively	O
(	O
p	O
(	O
noninferiority	O
)	O
<	O
or	O
=	O
0.001	O
)	O
.	O

There	O
were	O
fewer	O
periprocedural	O
myocardial	O
infarctions	O
with	O
ZES	Physical
(	O
0.5	O
%	O
vs.	O
2.2	O
%	O
;	O
p	O
=	O
0.007	O
)	O
,	O
whereas	O
at	O
12	O
months	O
,	O
there	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
in	O
rates	O
of	O
cardiac	O
death	O
,	O
myocardial	O
infarction	O
,	O
target	O
vessel	O
revascularization	O
,	O
or	O
stent	O
thrombosis	O
.	O

Although	O
incidence	O
of	O
8-month	O
binary	O
angiographic	O
in-segment	O
restenosis	O
was	O
higher	O
in	O
patients	O
treated	O
with	O
ZES	Physical
versus	O
PES	O
(	O
15.3	O
%	O
vs.	O
10.4	O
%	O
;	O
p	O
=	O
0.284	O
)	O
,	O
rates	O
of	O
12-month	O
target	O
lesion	O
revascularization	O
were	O
similar	O
(	O
4.5	O
%	O
vs.	O
3.2	O
%	O
;	O
p	O
=	O
0.228	O
)	O
,	O
especially	O
in	O
patients	O
without	O
planned	O
angiographic	O
follow-up	O
(	O
3.6	O
%	O
vs.	O
3.2	O
%	O
;	O
p	O
=	O
0.756	O
)	O
.	O

CONCLUSIONS	O
These	O
findings	O
demonstrate	O
that	O
ZES	Physical
has	O
similar	O
clinical	O
safety	O
and	O
efficacy	O
compared	O
with	O
PES	Physical
in	O
simple	O
and	O
medium	O
complexity	O
single	O
de	O
novo	O
coronary	O
lesions	O
.	O

(	O
ENDEAVOR	O
IV	O
Clinical	O
Trial	O
;	O
NCT00217269	O
)	O
.	O

Effect	O
of	O
cigarette	O
smoking	O
on	O
gastric	O
emptying	O
of	O
solids	O
in	O
Japanese	O
smokers	O
:	O
a	O
crossover	O
study	O
using	O
the	O
13C-octanoic	O
acid	O
breath	O
test	O
.	O

BACKGROUND	O
Cigarette	O
smoking	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
peptic	O
ulcer	O
and	O
gastroesophageal	O
reflux	O
disease	O
.	O

Gastric	O
emptying	O
disorders	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
these	O
upper	O
gastrointestinal	O
diseases	O
.	O

Thus	O
,	O
studies	O
examining	O
a	O
link	O
between	O
smoking	O
and	O
gastric	O
emptying	O
disorders	O
have	O
clinical	O
relevance	O
.	O

This	O
study	O
was	O
conducted	O
to	O
investigate	O
the	O
effect	O
of	O
smoking	O
on	O
gastric	O
emptying	O
of	O
solids	O
in	O
Japanese	O
smokers	O
.	O

METHODS	O
The	O
(	Other
13	Other
)	Other
C-octanoic	Other
acid	Other
breath	Other
test	Other
was	O
performed	O
in	O
eight	O
male	O
habitual	O
smokers	O
on	O
two	O
randomized	O
occasions	O
(	O
either	O
sham	O
smoking	O
or	O
actively	O
smoking	O
)	O
.	O

The	O
time	O
vs	O
(	O
13	O
)	O
CO	O
(	O
2	O
)	O
excretion	O
rate	O
curve	O
was	O
mathematically	O
fitted	O
to	O
a	O
conventional	O
formula	O
of	O
y	O
(	O
t	O
)	O
=	O
m*k*beta*e	O
(	O
-k*t	O
)	O
*	O
(	O
1	O
-	O
e	O
(	O
-k*t	O
)	O
)	O
(	O
beta-1	O
)	O
,	O
and	O
the	O
parameters	O
of	O
k	O
and	O
beta	O
were	O
determined	O
:	O
under	O
the	O
crossover	O
protocol	O
,	O
a	O
larger	O
(	O
smaller	O
)	O
beta	O
indicates	O
slower	O
(	O
faster	O
)	O
emptying	O
in	O
the	O
early	O
phase	O
,	O
and	O
a	O
larger	O
(	O
smaller	O
)	O
k	O
indicates	O
faster	O
(	O
slower	O
)	O
emptying	O
in	O
the	O
later	O
phase	O
.	O

The	O
half	O
(	O
13	O
)	O
CO	O
(	O
2	O
)	O
excretion	O
time	O
(	O
t	O
(	O
1/2b	O
)	O
=	O
-	O
[	O
ln	O
(	O
1	O
-	O
2	O
(	O
-1/beta	O
)	O
)	O
]	O
/k	O
)	O
and	O
the	O
time	O
of	O
maximal	O
(	O
13	O
)	O
CO	O
(	O
2	O
)	O
excretion	O
rate	O
(	O
t	O
(	O
max	O
)	O
=	O
[	O
lnbeta	O
]	O
/k	O
)	O
were	O
also	O
calculated	O
.	O

Between	O
the	O
two	O
occasions	O
,	O
k	O
,	O
beta	O
,	O
t	O
(	O
1/2b	O
)	O
,	O
and	O
t	O
(	O
max	O
)	O
were	O
compared	O
by	O
the	O
Wilcoxon	O
signed-rank	O
test	O
.	O

RESULTS	O
After	O
smoking	O
,	O
k	O
was	O
significantly	O
increased	O
.	O

No	O
significant	O
differences	O
were	O
found	O
in	O
beta	O
,	O
t	O
(	O
1/2	O
)	O
,	O
and	O
t	O
(	O
max	O
)	O
between	O
the	O
two	O
occasions	O
.	O

CONCLUSIONS	O
The	O
increase	O
in	O
k	O
suggests	O
the	O
acceleration	O
of	O
gastric	O
emptying	O
in	O
the	O
later	O
phase	O
.	O

For	O
the	O
first	O
time	O
,	O
this	O
study	O
has	O
revealed	O
that	O
acute	O
smoking	O
speeds	O
the	O
gastric	O
emptying	O
of	O
solids	O
in	O
Japanese	O
habitual	O
smokers	O
.	O

Effects	O
of	O
bifidobacterium	Pharmacological
breve	Pharmacological
supplementation	O
on	O
intestinal	O
flora	O
of	O
low	O
birth	O
weight	O
infants	O
.	O

BACKGROUND	O
It	O
is	O
known	O
that	O
the	O
bifidobacteria	O
flora	O
play	O
important	O
roles	O
in	O
mucosal	O
host	O
defense	O
and	O
can	O
prevent	O
infectious	O
diseases	O
.	O

Because	O
bacterial	O
populations	O
develop	O
during	O
the	O
first	O
day	O
of	O
life	O
,	O
the	O
authors	O
examined	O
whether	O
the	O
early	O
administration	O
of	O
bifidobacteria	O
has	O
a	O
positive	O
effect	O
on	O
the	O
health	O
of	O
low	O
birth	O
weight	O
infants	O
.	O

METHODS	O
The	O
effects	O
of	O
oral	O
administration	O
of	O
Bifidobacterium	Pharmacological
breve	Pharmacological
(	Pharmacological
B.	Pharmacological
breve	Pharmacological
)	Pharmacological
supplements	Pharmacological
were	O
studied	O
in	O
a	O
controlled	O
trial	O
with	O
low	O
birth	O
weight	O
infants	O
(	O
average	O
birth	O
weight	O
1489	O
g	O
)	O
.	O

The	O
infants	O
were	O
divided	O
into	O
three	O
groups	O
:	O
Group	O
A	O
and	O
B	O
received	O
a	O
dose	O
of	O
1.6	O
x	O
10	O
(	O
8	O
)	O
cells	O
of	O
B.	O
breve	O
supplement	O
twice	O
a	O
day	O
,	O
commencing	O
either	O
from	O
several	O
hours	O
after	O
birth	O
(	O
group	O
A	O
)	O
or	O
24	O
h	O
after	O
birth	O
(	O
group	O
B	O
)	O
.	O

Group	O
C	O
,	O
the	O
control	Control
group	Control
,	O
received	O
no	O
supplement	O
.	O

RESULTS	O
There	O
were	O
no	O
significant	O
differences	O
in	O
birth	O
weight	O
,	O
treatment	O
with	O
antibiotics	O
,	O
and	O
the	O
starting	O
time	O
of	O
breast-feeding	O
among	O
the	O
three	O
groups	O
.	O

A	O
Bifidobacterium-predominant	O
flora	O
was	O
formed	O
at	O
an	O
average	O
of	O
2	O
weeks	O
after	O
birth	O
in	O
group	O
A	O
and	O
at	O
an	O
average	O
of	O
4	O
weeks	O
after	O
birth	O
in	O
group	O
B	O
,	O
while	O
no	O
Bifidobacterium	O
was	O
isolated	O
in	O
eight	O
out	O
of	O
10	O
infants	O
in	O
group	O
C	O
during	O
the	O
observation	O
period	O
of	O
7	O
weeks	O
.	O

In	O
comparison	O
between	O
group	O
A	O
and	O
B	O
,	O
Bifidobacterium	O
was	O
detected	O
significantly	O
earlier	O
in	O
group	O
A	O
,	O
and	O
the	O
number	O
of	O
Enterobacteriaceae	O
present	O
in	O
the	O
infants	O
at	O
2	O
weeks	O
after	O
birth	O
was	O
significantly	O
lower	O
in	O
group	O
A	O
.	O

CONCLUSION	O
The	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
very	O
early	O
administration	O
of	O
B.	O
breve	O
to	O
low	O
birth	O
weight	O
infants	O
is	O
useful	O
in	O
promoting	O
the	O
colonization	O
of	O
the	O
Bifidobacterium	O
and	O
the	O
formation	O
of	O
a	O
normal	O
intestinal	O
flora	O
.	O

Teacher	O
and	O
child	O
predictors	O
of	O
achieving	O
IEP	Educational
goals	O
of	O
children	O
with	O
autism	O
.	O

It	O
is	O
encouraging	O
that	O
children	O
with	O
autism	O
show	O
a	O
strong	O
response	O
to	O
early	O
intervention	O
,	O
yet	O
more	O
research	O
is	O
needed	O
for	O
understanding	O
the	O
variability	O
in	O
responsiveness	O
to	O
specialized	O
programs	O
.	O

Treatment	O
predictor	O
variables	O
from	O
47	O
teachers	O
and	O
children	O
who	O
were	O
randomized	O
to	O
receive	O
the	O
COMPASS	Educational
intervention	Educational
(	O
Ruble	O
et	O
al	O
.	O

in	O
The	O
collaborative	O
model	O
for	O
promoting	O
competence	O
and	O
success	O
for	O
students	O
with	O
ASD	O
.	O

Springer	O
,	O
New	O
York	O
,	O
2012a	O
)	O
were	O
analyzed	O
.	O

Predictors	O
evaluated	O
against	O
child	O
IEP	O
goal	O
attainment	O
included	O
child	O
,	O
teacher	O
,	O
intervention	O
practice	O
,	O
and	O
implementation	O
practice	O
variables	O
based	O
on	O
an	O
implementation	O
science	O
framework	O
(	O
Dunst	O
and	O
Trivette	O
in	O
J	O
Soc	O
Sci	O
8:143-148	O
,	O
2012	O
)	O
.	O

Findings	O
revealed	O
one	O
child	O
(	O
engagement	O
)	O
,	O
one	O
teacher	O
(	O
exhaustion	O
)	O
,	O
two	O
intervention	O
quality	O
(	O
IEP	O
quality	O
for	O
targeted	O
and	O
not	O
targeted	O
elements	O
)	O
,	O
and	O
no	O
implementation	O
quality	O
variables	O
accounted	O
for	O
variance	O
in	O
child	O
outcomes	O
when	O
analyzed	O
separately	O
.	O

When	O
the	O
four	O
significant	O
variables	O
were	O
compared	O
against	O
each	O
other	O
in	O
a	O
single	O
regression	O
analysis	O
,	O
IEP	Educational
quality	O
accounted	O
for	O
one	O
quarter	O
of	O
the	O
variance	O
in	O
child	O
outcomes	O
.	O

Comparison	O
of	O
the	O
effect	O
of	O
gonadotropin-releasing	Pharmacological
hormone	Pharmacological
analog	Pharmacological
(	Pharmacological
Diphereline	Pharmacological
)	Pharmacological
and	O
Cabergoline	Pharmacological
(	Pharmacological
Dostinex	Pharmacological
)	Pharmacological
treatment	O
on	O
uterine	O
myoma	O
regression	O
.	O

OBJECTIVE	O
To	O
investigate	O
the	O
effect	O
of	O
cabergoline	Pharmacological
(	Pharmacological
Dostinex	Pharmacological
,	Pharmacological
a	Pharmacological
dopamine	Pharmacological
agonist	Pharmacological
)	Pharmacological
on	O
the	O
myoma	O
growth	O
compared	O
to	O
Diphereline	Pharmacological
(	Pharmacological
a	Pharmacological
gonadotropin-releasing	Pharmacological
hormone	Pharmacological
agonist	Pharmacological
)	Pharmacological
.	Pharmacological

METHODS	O
This	O
study	O
took	O
place	O
in	O
the	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
of	O
Tabriz	O
University	O
of	O
Medical	O
Sciences	O
,	O
Tabriz	O
,	O
Iran	O
from	O
July	O
2004	O
to	O
December	O
2005	O
.	O

Fifty	O
women	O
with	O
uterine	O
myoma	O
,	O
who	O
met	O
the	O
criteria	O
of	O
the	O
study	O
thoroughly	O
,	O
were	O
randomly	O
allocated	O
into	O
2	O
equal	O
groups	O
to	O
take	O
either	O
Diphereline	Pharmacological
or	O
Cabergoline	Pharmacological
.	Pharmacological

The	O
first	O
Group	O
took	O
3.75	O
mg	O
of	O
Diphereline	Pharmacological
4	O
times	O
every	O
28	O
days	O
and	O
the	O
second	O
group	O
took	O
0.5	O
mg	O
of	O
Cabergoline	Pharmacological
once	O
a	O
week	O
for	O
6	O
weeks	O
.	O

RESULTS	O
The	O
Cabergoline	Pharmacological
was	O
well	O
tolerated	O
and	O
fewer	O
adverse	O
effects	O
were	O
noted	O
.	O

The	O
tumor	O
regressed	O
significantly	O
and	O
volume	O
reduction	O
rate	O
of	O
individual	O
tumor	O
nodule	O
varied	O
from	O
46-53	O
%	O
.	O

The	O
gonadotropin	Pharmacological
releasing	Pharmacological
hormone	Pharmacological
agonist	Pharmacological
group	O
all	O
responded	O
to	O
the	O
treatment	O
,	O
and	O
volume	O
reduction	O
rate	O
of	O
the	O
individual	O
tumor	O
nodule	O
varied	O
from	O
21-97	O
%	O
.	O

The	O
extent	O
of	O
tumor	O
shrinkage	O
was	O
positively	O
correlated	O
to	O
the	O
number	O
of	O
nodules	O
(	O
p=0.881	O
,	O
p	O
<	O
0.005	O
and	O
0.701	O
,	O
p	O
<	O
0.005	O
)	O
.	O

CONCLUSION	O
In	O
light	O
of	O
therapeutic	O
efficacy	O
and	O
few	O
adverse	O
effects	O
,	O
the	O
dopamine	Pharmacological
agonists	Pharmacological
may	O
hold	O
promise	O
as	O
novel	O
treatment	O
modalities	O
for	O
leiomyoma	O
.	O

Further	O
studies	O
are	O
warranted	O
to	O
determine	O
the	O
optimal	O
strategy	O
for	O
the	O
treatment	O
of	O
leiomyoma	O
through	O
these	O
agents	O
.	O

Perioperative	O
fever	O
and	O
outcome	O
in	O
surgical	O
patients	O
with	O
aneurysmal	O
subarachnoid	O
hemorrhage	O
.	O

OBJECTIVE	O
We	O
examined	O
the	O
incidence	O
of	O
perioperative	O
fever	O
and	O
its	O
relationship	O
to	O
outcome	O
among	O
patients	O
enrolled	O
in	O
the	O
Intraoperative	O
Hypothermia	O
for	O
Aneurysm	O
Surgery	O
Trial	O
.	O

METHODS	O
One	O
thousand	O
patients	O
with	O
initial	O
World	O
Federation	O
of	O
Neurological	O
Surgeons	O
grades	O
of	O
I	O
to	O
III	O
undergoing	O
clipping	O
of	O
intracranial	O
aneurysms	O
after	O
subarachnoid	O
hemorrhage	O
were	O
randomized	O
to	O
intraoperative	Other
normothermia	Other
(	O
36	O
degrees	O
C-37	O
degrees	O
C	O
)	O
or	O
hypothermia	Other
(	O
32.5	O
degrees	O
C-33.5	O
degrees	O
C	O
)	O
.	O

Fever	O
(	O
>	O
or	O
=38.5	O
degrees	O
C	O
)	O
and	O
other	O
complications	O
(	O
including	O
infections	O
)	O
occurring	O
between	O
admission	O
and	O
discharge	O
(	O
or	O
death	O
)	O
were	O
recorded	O
.	O

Functional	O
and	O
neuropsychologic	O
outcomes	O
were	O
assessed	O
3	O
months	O
postoperatively	O
.	O

The	O
primary	O
outcome	O
variable	O
for	O
the	O
trial	O
was	O
dichotomized	O
Glasgow	O
Outcome	O
Scale	O
(	O
good	O
outcome	O
versus	O
all	O
others	O
)	O
.	O

RESULTS	O
Fever	O
was	O
reported	O
in	O
41	O
%	O
of	O
patients	O
.	O

In	O
97	O
%	O
of	O
these	O
,	O
fever	O
occurred	O
in	O
the	O
postoperative	O
period	O
.	O

The	O
median	O
time	O
from	O
surgery	O
to	O
first	O
fever	O
was	O
3	O
days	O
.	O

All	O
measures	O
of	O
outcome	O
were	O
worse	O
in	O
patients	O
who	O
developed	O
fever	O
,	O
even	O
in	O
those	O
without	O
infections	O
or	O
who	O
were	O
World	O
Federation	O
of	O
Neurological	O
Surgeons	O
grade	O
I.	O
Logistic	O
regression	O
analyses	O
were	O
performed	O
to	O
adjust	O
for	O
differences	O
in	O
preoperative	O
factors	O
(	O
e.g.	O
,	O
age	O
,	O
Fisher	O
grade	O
,	O
initial	O
neurological	O
status	O
)	O
.	O

This	O
demonstrated	O
that	O
fever	O
continued	O
to	O
be	O
significantly	O
associated	O
with	O
most	O
outcome	O
measures	O
,	O
even	O
when	O
infection	O
was	O
added	O
to	O
the	O
model	O
.	O

An	O
alternative	O
stepwise	O
model	O
selection	O
process	O
including	O
all	O
fever-related	O
measures	O
from	O
the	O
preoperative	O
and	O
intraoperative	O
period	O
(	O
e.g.	O
,	O
hydrocephalus	O
,	O
duration	O
of	O
surgery	O
,	O
intraoperative	O
blood	O
loss	O
)	O
resulted	O
in	O
the	O
loss	O
of	O
significance	O
for	O
dichotomized	O
Glasgow	O
Outcome	O
Scale	O
,	O
but	O
significant	O
associations	O
between	O
fever	O
and	O
several	O
other	O
outcome	O
measures	O
remained	O
.	O

After	O
adding	O
postoperative	O
delayed	O
ischemic	O
neurological	O
deficits	O
to	O
the	O
model	O
,	O
only	O
worsened	O
National	O
Institutes	O
of	O
Health	O
Stroke	O
Scale	O
score	O
,	O
Barthel	O
Activities	O
of	O
Daily	O
Living	O
index	O
,	O
and	O
discharge	O
destination	O
(	O
home	O
versus	O
other	O
)	O
remained	O
independently	O
associated	O
with	O
fever	O
.	O

CONCLUSION	O
These	O
findings	O
suggest	O
that	O
fever	O
is	O
associated	O
with	O
worsened	O
outcome	O
in	O
surgical	O
subarachnoid	O
hemorrhage	O
patients	O
,	O
although	O
,	O
because	O
the	O
association	O
between	O
fever	O
and	O
the	O
primary	O
outcome	O
measure	O
for	O
the	O
trial	O
is	O
dependent	O
on	O
the	O
covariates	O
used	O
in	O
the	O
analysis	O
(	O
particularly	O
operative	O
events	O
and	O
delayed	O
ischemic	O
neurological	O
deficits	O
)	O
,	O
we	O
can	O
not	O
rule	O
out	O
the	O
possibility	O
that	O
fever	O
is	O
a	O
marker	O
for	O
other	O
events	O
.	O

Only	O
a	O
formal	O
trial	O
of	O
fever	O
treatment	O
or	O
prevention	O
can	O
address	O
this	O
issue	O
.	O

Effects	O
of	O
weight-bearing	Physical
versus	O
nonweight-bearing	Physical
exercise	Physical
on	O
function	O
,	O
walking	O
speed	O
,	O
and	O
position	O
sense	O
in	O
participants	O
with	O
knee	O
osteoarthritis	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

OBJECTIVE	O
To	O
investigate	O
whether	O
weight-bearing	Physical
(	Physical
WB	Physical
)	Physical
exercise	Physical
enhances	O
functional	O
capacity	O
to	O
a	O
greater	O
extent	O
than	O
nonweight-bearing	Physical
(	Physical
NWB	Physical
)	Physical
exercise	Physical
in	O
participants	O
with	O
knee	O
osteoarthritis	O
.	O

DESIGN	O
Randomized	O
controlled	O
trial	O
.	O

SETTING	O
Kinesiology	O
laboratory	O
.	O

PARTICIPANTS	O
Participants	O
(	O
N=106	O
)	O
were	O
randomly	O
assigned	O
to	O
WB	Physical
exercise	Physical
,	O
NWB	Physical
exercise	Physical
,	O
or	O
a	O
control	Control
group	Control
(	Control
no	Control
exercise	Control
)	Control
.	O

INTERVENTION	O
WB	Physical
exercise	Physical
and	O
NWB	Physical
exercise	Physical
groups	Physical
underwent	O
an	O
8-week	Physical
knee	Physical
extension-flexion	Physical
exercise	Physical
program	Physical
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Western	O
Ontario	O
and	O
McMaster	O
Universities	O
Osteoarthritis	O
Index	O
(	O
WOMAC	O
)	O
function	O
scale	O
,	O
walking	O
speed	O
,	O
muscle	O
torque	O
,	O
and	O
knee	O
reposition	O
error	O
were	O
assessed	O
before	O
and	O
after	O
intervention	O
.	O

RESULTS	O
Equally	O
significant	O
improvements	O
were	O
apparent	O
for	O
all	O
outcomes	O
after	O
WB	O
exercise	O
and	O
NWB	O
exercise	O
,	O
except	O
for	O
reposition	O
error	O
,	O
for	O
which	O
improvement	O
was	O
greater	O
in	O
the	O
WB	Physical
exercise	Physical
group	O
.	O

In	O
contrast	O
,	O
there	O
were	O
no	O
improvements	O
in	O
the	O
control	O
group	O
.	O

CONCLUSIONS	O
Simple	O
knee	O
flexion	O
and	O
extension	O
exercises	O
(	Physical
WB	Physical
and	O
NWB	Physical
)	O
performed	O
over	O
8	O
weeks	O
resulted	O
in	O
significant	O
improvement	O
in	O
the	O
WOMAC	O
function	O
scale	O
and	O
knee	O
strength	O
compared	O
with	O
the	O
control	O
group	O
.	O

NWB	Physical
exercise	Physical
alone	O
may	O
be	O
sufficient	O
enough	O
to	O
improve	O
function	O
and	O
muscle	O
strength	O
.	O

The	O
additional	O
benefit	O
of	O
WB	Physical
exercise	Physical
was	O
improved	O
position	O
sense	O
,	O
which	O
may	O
enhance	O
complex	O
walking	O
tasks	O
(	O
walking	O
on	O
figure	O
of	O
8	O
route	O
and	O
spongy	O
surface	O
)	O
.	O

Phytase	Pharmacological
and	O
1alpha-hydroxycholecalciferol	Pharmacological
supplementation	Pharmacological
of	O
broiler	O
chickens	O
during	O
the	O
starting	O
and	O
growing/finishing	O
phases	O
.	O

Supplemental	O
1alpha-hydroxycholecalciferol	O
(	O
1alpha-OHD3	O
)	O
has	O
been	O
shown	O
to	O
have	O
qualitatively	O
similar	O
and	O
quantitatively	O
additive	O
effects	O
to	O
exogenous	O
phytase	O
.	O

Two	O
experiments	O
were	O
conducted	O
from	O
0	O
to	O
35	O
d	O
in	O
floor	O
pens	O
to	O
determine	O
the	O
additive	O
effect	O
of	O
phytase	Pharmacological
and	O
1alpha-OHD3	Pharmacological
when	O
supplemented	O
to	O
Ca-	Pharmacological
and	Pharmacological
P-deficient	Pharmacological
diets	Pharmacological
.	O

In	O
both	O
experiments	O
,	O
at	O
least	O
4	O
replicates	O
per	O
treatment	O
(	O
50	O
chicks	O
per	O
replicate	O
)	O
were	O
used	O
.	O

Corn-soybean-meal-and	Other
soybean-oil-based	Other
diets	Other
were	O
fed	O
and	O
birds	O
were	O
raised	O
in	O
a	O
house	O
impervious	O
to	O
ultraviolet	O
light	O
.	O

During	O
the	O
starter	O
phase	O
(	O
ST	O
)	O
,	O
from	O
0	O
to	O
18	O
d	O
,	O
chicks	O
were	O
fed	O
a	O
23	O
%	O
CP	O
diet	O
containing	O
0.60	O
%	O
Ca	O
and	O
0.47	O
%	O
total	O
P	O
(	O
tP	O
)	O
.	O

During	O
the	O
grower/finisher	O
phase	O
(	O
GF	O
)	O
,	O
from	O
19	O
to	O
35	O
d	O
,	O
birds	O
were	O
fed	O
a	O
19	O
%	O
CP	O
diet	O
containing	O
0.30	O
%	O
Ca	O
and	O
0.37	O
%	O
tP	O
.	O

A	O
combination	O
of	O
1,000	O
phytase	O
units/kg	O
of	O
Natuphos	O
phytase	O
and	O
5	O
microg/kg	O
of	O
1alpha-OHD3	O
(	O
P+1A	O
)	O
was	O
supplemented	O
to	O
some	O
of	O
the	O
feed	O
during	O
the	O
ST	O
and	O
GF	O
.	O

Diets	O
containing	O
adequate	O
Ca	O
and	O
P	O
were	O
also	O
fed	O
during	O
the	O
ST	O
(	O
0.90	O
%	O
Ca	O
,	O
0.68	O
%	O
tP	O
)	O
and	O
GF	O
(	O
0.80	O
%	O
Ca	O
,	O
0.67	O
%	O
tP	O
)	O
.	O

Performance	O
characteristics	O
and	O
the	O
incidence	O
of	O
rickets	O
and	O
tibial	O
dyschondroplasia	O
were	O
measured	O
at	O
18	O
and	O
35	O
d.	O
In	O
experiment	O
1	O
,	O
unsupplemented	O
chicks	O
performed	O
well	O
but	O
had	O
considerable	O
leg	O
problems	O
.	O

Chicks	O
fed	O
P+1A	O
during	O
the	O
ST	O
or	O
GF	O
did	O
not	O
perform	O
as	O
well	O
as	O
birds	O
fed	O
P+1A	O
throughout	O
.	O

Birds	O
fed	O
P+1A	O
throughout	O
performed	O
as	O
well	O
birds	O
fed	O
the	O
adequate	O
diets	O
without	O
any	O
indication	O
of	O
leg	O
problems	O
.	O

In	O
experiment	O
2	O
,	O
unsupplemented	O
birds	O
performed	O
similarly	O
to	O
unsupplemented	O
birds	O
in	O
experiment	O
1	O
.	O

However	O
,	O
chicks	O
fed	O
the	O
supplements	O
or	O
the	O
control	O
diets	O
did	O
not	O
perform	O
as	O
well	O
or	O
accumulate	O
as	O
much	O
bone	O
ash	O
as	O
birds	O
in	O
experiment	O
1	O
,	O
although	O
the	O
diets	O
were	O
formulated	O
identically	O
in	O
both	O
experiments	O
.	O

Diets	O
with	O
as	O
little	O
as	O
0.30	O
%	O
Ca	O
and	O
0.37	O
%	O
tP	O
appear	O
to	O
be	O
adequate	O
for	O
broilers	O
older	O
than	O
18	O
d	O
if	O
supplemented	O
with	O
the	O
correct	O
amounts	O
of	O
phytase	O
and	O
1alpha-OHD3	O
.	O

However	O
,	O
there	O
are	O
unknown	O
variables	O
that	O
may	O
limit	O
the	O
potential	O
of	O
broilers	O
in	O
terms	O
of	O
bone	O
mineralization	O
and	O
bone	O
pathology	O
,	O
even	O
when	O
adequate	O
diets	O
are	O
fed	O
.	O

The	O
acute	O
effects	O
of	O
fluid	O
intake	O
on	O
urine	O
specific	O
gravity	O
and	O
fluid	O
retention	O
in	O
a	O
mildly	O
dehydrated	O
state	O
.	O

Many	O
athletes	O
arrive	O
at	O
training	O
sessions	O
and	O
competitions	O
in	O
a	O
mildly	O
hypohydrated	O
(	O
HYPO	O
)	O
state	O
and	O
are	O
instructed	O
to	O
drink	O
fluids	O
before	O
exercise	O
to	O
reach	O
a	O
euhydrated	O
(	O
HYD	O
)	O
state	O
.	O

Ten	O
recreational	O
athletes	O
(	O
6	O
women	O
,	O
4	O
men	O
;	O
71.9	O
?	O
4.6	O
kg	O
,	O
25.2	O
?	O
0.9	O
years	O
)	O
participated	O
in	O
the	O
studies	O
to	O
examine	O
(	O
a	O
)	O
the	O
day-to-day	O
variability	O
of	O
morning	O
urine	O
specific	O
gravity	O
(	O
USG	O
)	O
,	O
(	O
b	O
)	O
the	O
effects	O
of	O
consuming	O
600	Educational
ml	Educational
of	Educational
water	Educational
on	O
the	O
hydration	O
status	O
of	O
HYD	O
and	O
HYPO	O
(	O
USG	O
>	O
1.020	O
)	O
subjects	O
,	O
and	O
(	O
c	O
)	O
the	O
effects	O
of	O
consuming	O
water	Educational
(	Educational
W	Educational
)	Educational
,	O
salt-water	Educational
(	Educational
SW	O
,	O
40	O
mM	O
Na	O
)	O
,	O
a	O
carbohydrate-electrolyte	Educational
solution	Educational
with	Educational
3	Educational
%	Educational
or	Educational
light	Educational
carbohydrate	Educational
(	Educational
CES-L	O
,	O
20	O
mM	O
Na	O
)	O
or	O
a	O
CES	Educational
with	Educational
6	Educational
%	Educational
carbohydrate	Educational
(	Educational
CES	O
,	O
20	O
mM	O
Na	O
)	O
on	O
the	O
hydration	O
status	O
of	O
HYPO	O
subjects	O
.	O

The	O
hydration	O
status	O
was	O
assessed	O
with	O
USG	O
and	O
body	O
mass	O
measures	O
and	O
urine	O
volume	O
collections	O
.	O

The	O
day-to-day	O
variability	O
in	O
morning	O
USG	O
(	O
coefficient	O
of	O
variation	O
=	O
0.2	O
?	O
0.1	O
%	O
)	O
was	O
low	O
and	O
the	O
responses	O
to	O
600	O
ml	O
of	O
W	O
ingestion	O
were	O
repeatable	O
.	O

Pretrial	O
USG	O
was	O
1.022	O
?	O
0.001	O
in	O
the	O
HYPO	O
trial	O
and	O
decreased	O
<	O
1.020	O
by	O
45	O
minutes	O
(	O
1.013	O
?	O
0.003	O
)	O
.	O

In	O
the	O
CES	O
study	O
,	O
HYPO	O
subjects	O
reached	O
HYD	O
status	O
at	O
45	O
minutes	O
in	O
all	O
conditions	O
(	O
W	O
1.013	O
?	O
0.003	O
,	O
SW	O
1.013	O
?	O
0.003	O
,	O
CES-L	O
1.011	O
?	O
0.003	O
,	O
CES	O
1.017	O
?	O
0.004	O
)	O
because	O
salt	O
or	O
CES	O
ingestion	O
did	O
not	O
affect	O
fluid	O
retention	O
(	O
W	O
68	O
%	O
,	O
SW	O
72	O
%	O
,	O
CES-L	O
68	O
%	O
,	O
CES	O
76	O
%	O
)	O
.	O

This	O
study	O
demonstrated	O
that	O
mildly	O
HYPO	O
subjects	O
could	O
reach	O
euhydration	O
within	O
45	O
minutes	O
of	O
the	O
ingestion	O
of	O
600	O
ml	O
of	O
W	O
or	O
a	O
combination	O
of	O
salt	O
and	O
CES	O
solutions	O
.	O

Following	O
this	O
practice	O
will	O
minimize	O
the	O
incidence	O
of	O
starting	O
a	O
practice	O
or	O
competition	O
hypohydrated	O
.	O

Allogeneic	Pharmacological
marrow	Pharmacological
transplantation	Pharmacological
in	O
patients	O
with	O
chronic	O
myeloid	O
leukemia	O
in	O
the	O
chronic	O
phase	O
:	O
a	O
randomized	O
trial	O
of	O
two	O
irradiation	O
regimens	O
.	O

A	O
randomized	O
trial	O
was	O
performed	O
to	O
compare	O
two	O
regimens	O
of	O
total	Other
body	Other
irradiation	Other
in	O
patients	O
with	O
chronic	O
myeloid	O
leukemia	O
treated	O
by	O
allogeneic	Pharmacological
marrow	Pharmacological
transplantation	Pharmacological
while	O
in	O
the	O
chronic	O
phase	O
.	O

All	O
patients	O
received	O
cyclophosphamide	Pharmacological
120	O
mg/kg	O
followed	O
by	O
total	Other
body	Other
irradiation	Other
and	O
marrow	Pharmacological
from	Pharmacological
HLA-identical	Pharmacological
siblings	Pharmacological
.	O

Cyclosporine	Pharmacological
and	O
methotrexate	Pharmacological
were	O
used	O
for	O
prophylaxis	O
against	O
acute	O
graft-versus-host	O
disease	O
.	O

Fifty-seven	O
patients	O
were	O
randomized	O
to	O
receive	O
2.0	O
Gy	O
fractions	O
of	O
irradiation	Other
daily	O
for	O
6	O
days	O
and	O
59	O
were	O
randomized	O
to	O
receive	O
2.25	O
Gy	O
fractions	O
daily	O
for	O
7	O
days	O
.	O

The	O
probabilities	O
of	O
relapse	O
at	O
4	O
years	O
were	O
0.25	O
for	O
the	O
12.0	O
Gy	O
group	O
and	O
0.00	O
for	O
the	O
15.75	O
Gy	O
group	O
(	O
P	O
=	O
.008	O
)	O
.	O

The	O
actuarial	O
probabilities	O
of	O
survival	O
and	O
relapse-free	O
survival	O
at	O
4	O
years	O
were	O
0.60	O
and	O
0.58	O
among	O
the	O
patients	O
who	O
received	O
12.0	O
Gy	O
compared	O
with	O
0.66	O
and	O
0.66	O
for	O
those	O
who	O
received	O
15.75	O
Gy	O
.	O

The	O
4-year	O
probabilities	O
of	O
transplant-related	O
mortality	O
were	O
0.24	O
and	O
0.34	O
respectively	O
(	O
P	O
=	O
.13	O
)	O
while	O
the	O
probability	O
of	O
moderate	O
to	O
severe	O
acute	O
graft-versus-host	O
disease	O
was	O
0.33	O
for	O
the	O
12.0	O
Gy	O
group	O
and	O
0.44	O
for	O
the	O
15.75	O
Gy	O
group	O
(	O
P	O
=	O
.15	O
)	O
.	O

The	O
lower	O
relapse	O
probability	O
in	O
the	O
patients	O
receiving	O
the	O
higher	O
dose	O
of	O
total	Other
body	Other
irradiation	Other
did	O
not	O
result	O
in	O
improved	O
survival	O
because	O
mortality	O
from	O
causes	O
other	O
than	O
relapse	O
was	O
increased	O
.	O

Short-	O
and	O
long-term	O
effects	O
of	O
tactile	Physical
massage	Physical
on	O
salivary	O
cortisol	O
concentrations	O
in	O
Parkinson	O
's	O
disease	O
:	O
a	O
randomised	O
controlled	O
pilot	O
study	O
.	O

BACKGROUND	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
is	O
a	O
chronic	O
neurodegenerative	O
disorder	O
with	O
limited	O
knowledge	O
about	O
the	O
normal	O
function	O
and	O
effects	O
of	O
non-pharmacological	Other
therapies	Other
on	O
the	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
axis	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
analyse	O
the	O
basal	O
diurnal	O
and	O
total	O
secretion	O
of	O
salivary	O
cortisol	O
in	O
short-	O
and	O
long-term	O
aspects	O
of	O
tactile	Physical
massage	Physical
(	Physical
TM	Physical
)	Physical
.	Other

METHODS	O
DESIGN	O
Prospective	O
,	O
Controlled	O
and	O
Randomised	O
Multicentre	O
Trial	O
.	O

SETTING	O
AND	O
INTERVENTIONS	O
Forty-five	O
women	O
and	O
men	O
,	O
aged	O
50-79	O
years	O
,	O
were	O
recruited	O
.	O

Twenty-nine	O
of	O
them	O
were	O
blindly	O
randomised	O
to	O
tactile	Other
massage	Other
(	Other
TM	Other
)	Other
and	O
16	O
of	O
them	O
to	O
the	O
control	Control
group	O
,	O
rest	Control
to	Control
music	Control
(	Control
RTM	Control
)	Control
.	Control

Ten	O
interventions	O
were	O
given	O
during	O
8	O
weeks	O
followed	O
by	O
a	O
26	O
weeks	O
of	O
follow	O
up	O
.	O

Salivary	O
cortisol	O
was	O
collected	O
at	O
8	O
am	O
,	O
1	O
pm	O
,	O
8	O
pm	O
,	O
and	O
8	O
am	O
the	O
next	O
day	O
,	O
on	O
five	O
occasions	O
.	O

With	O
the	O
first	O
and	O
eighth	O
interventions	O
,	O
it	O
was	O
collected	O
immediately	O
before	O
and	O
after	O
intervention	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
The	O
primary	O
aim	O
was	O
to	O
assess	O
and	O
compare	O
cortisol	O
concentrations	O
before	O
and	O
immediately	O
after	O
intervention	O
and	O
also	O
during	O
the	O
follow-up	O
period	O
.	O

The	O
secondary	O
aim	O
was	O
to	O
assess	O
the	O
impact	O
of	O
age	O
,	O
gender	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
duration	O
and	O
severity	O
of	O
PD	O
,	O
effects	O
of	O
interventional	O
time-point	O
of	O
the	O
day	O
,	O
and	O
levodopa	O
doses	O
on	O
cortisol	O
concentration	O
.	O

RESULTS	O
The	O
median	O
cortisol	O
concentrations	O
for	O
all	O
participants	O
were	O
16.0	O
,	O
5.8	O
,	O
2.8	O
,	O
and	O
14.0	O
nmol/L	O
at	O
baseline	O
,	O
later	O
reproduced	O
four	O
times	O
without	O
significant	O
differences	O
.	O

Cortisol	O
concentrations	O
decreased	O
significantly	O
after	O
TM	Physical
intervention	O
but	O
no	O
change	O
in	O
diurnal	O
salivary	O
cortisol	O
pattern	O
was	O
found	O
.	O

The	O
findings	O
of	O
reduced	O
salivary	O
cortisol	O
concentrations	O
immediately	O
after	O
the	O
interventions	O
are	O
in	O
agreement	O
with	O
previous	O
studies	O
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
TM	Physical
and	O
control	O
groups	O
.	O

There	O
were	O
no	O
significant	O
correlations	O
between	O
cortisol	O
concentrations	O
and	O
age	O
,	O
gender	O
,	O
BMI	O
,	O
time-point	O
for	O
intervention	O
,	O
time	O
interval	O
between	O
anti-parkinson	O
pharmacy	O
intake	O
and	O
sampling	O
,	O
levodopa	O
doses	O
,	O
duration	O
,	O
or	O
severity	O
of	O
PD	O
.	O

CONCLUSIONS	O
Diurnal	O
salivary	O
cortisol	O
rhythm	O
was	O
normal	O
.	O

Salivary	O
cortisol	O
concentrations	O
were	O
significantly	O
reduced	O
after	O
the	O
TM	Physical
intervention	O
and	O
after	O
RTM	Control
,	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
and	O
no	O
sustained	O
long-term	O
effect	O
.	O

No	O
associations	O
were	O
seen	O
between	O
salivary	O
cortisol	O
concentration	O
and	O
clinical	O
and/or	O
pharmacological	O
characteristics	O
.	O

TRIAL	O
REGISTRATION	O
ClinicalTrial.gov	O
,	O
NCT01734876	O
and	O
FoU	O
Sweden	O
108881	O
.	O

Long-term	O
evaluation	O
of	O
tamsulosin	Pharmacological
in	O
benign	O
prostatic	O
hyperplasia	O
:	O
placebo-controlled	Control
,	O
double-blind	O
extension	O
of	O
phase	O
III	O
trial	O
.	O

Tamsulosin	O
Investigator	O
Group	O
.	O

OBJECTIVES	O
To	O
evaluate	O
the	O
long-term	O
efficacy	O
and	O
safety	O
of	O
once-daily	O
tamsulosin	Pharmacological
(	O
0.4	O
and	O
0.8	O
mg	O
)	O
,	O
a	O
unique	O
selective	O
alpha1A-adrenoceptor	O
antagonist	O
in	O
patients	O
with	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
.	O

METHODS	O
This	O
trial	O
extended	O
a	O
13-week	O
,	O
Phase	O
III	O
multicenter	O
placebo-controlled	O
,	O
double-blind	O
outpatient	O
trial	O
for	O
an	O
additional	O
40	O
weeks	O
.	O

Of	O
618	O
patients	O
,	O
418	O
(	O
68	O
%	O
)	O
continued	O
into	O
the	O
extension	O
phase	O
on	O
the	O
same	O
double-blind	O
medication	O
and	O
dose	O
.	O

The	O
primary	O
efficacy	O
parameters	O
were	O
total	O
American	O
Urological	O
Association	O
(	O
AUA	O
)	O
symptom	O
score	O
and	O
maximum	O
urinary	O
flow	O
(	O
Qmax	O
)	O
.	O

RESULTS	O
The	O
mean	O
changes	O
in	O
AUA	O
symptom	O
score	O
from	O
baseline	O
to	O
end	O
point	O
were	O
statistically	O
significant	O
in	O
all	O
groups	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Significant	O
improvements	O
were	O
observed	O
in	O
Qmax	O
for	O
both	O
tamsulosin	Pharmacological
groups	O
but	O
not	O
for	O
the	O
placebo	Control
group	O
.	O

The	O
statistically	O
significant	O
improvements	O
from	O
baseline	O
in	O
efficacy	O
parameters	O
observed	O
for	O
each	O
tamsulosin	Pharmacological
group	O
at	O
the	O
end	O
of	O
the	O
13-week	O
Phase	O
III	O
trial	O
were	O
maintained	O
during	O
the	O
long-term	O
extension	O
phase	O
.	O

Tamsulosin	O
at	O
both	O
dosages	O
was	O
well	O
tolerated	O
as	O
maintenance	O
therapy	O
.	O

Clinically	O
significant	O
orthostatic	O
hypotension	O
was	O
not	O
observed	O
.	O

Vital	O
sign	O
changes	O
in	O
either	O
hypertensive	O
or	O
normotensive	O
patients	O
were	O
not	O
clinically	O
significantly	O
different	O
across	O
the	O
three	O
groups	O
.	O

CONCLUSIONS	O
Tamsulosin	Pharmacological
once-daily	O
at	O
0.4	O
or	O
0.8	O
mg	O
was	O
shown	O
to	O
be	O
effective	O
,	O
safe	O
,	O
and	O
well	O
tolerated	O
in	O
the	O
target	O
BPH	O
population	O
during	O
long-term	O
use	O
.	O

A	O
randomized	O
,	O
evaluator-blind	O
,	O
multicenter	O
comparison	O
of	O
the	O
efficacy	O
and	O
tolerability	O
of	O
Perlane	Pharmacological
versus	O
Zyplast	Pharmacological
in	O
the	O
correction	O
of	O
nasolabial	O
folds	O
.	O

Bovine	Pharmacological
collagen	Pharmacological
is	O
widely	O
used	O
as	O
a	O
dermal	O
filler	O
for	O
facial	O
soft-tissue	O
augmentation	O
,	O
but	O
it	O
provides	O
only	O
temporary	O
cosmetic	O
improvement	O
.	O

Nonanimal	Pharmacological
stabilized	Pharmacological
hyaluronic	Pharmacological
acid	Pharmacological
has	O
reduced	O
potential	O
for	O
immunogenicity	O
and	O
hypersensitivity	O
and	O
may	O
provide	O
a	O
more	O
durable	O
aesthetic	O
result	O
.	O

Sixty-eight	O
patients	O
with	O
prominent	O
nasolabial	O
folds	O
were	O
randomized	O
to	O
intradermal	O
treatment	O
with	O
nonanimal	Pharmacological
stabilized	Pharmacological
hyaluronic	Pharmacological
acid	Pharmacological
gel	Pharmacological
(	Pharmacological
Perlane	Pharmacological
)	Pharmacological
and	O
bovine	Pharmacological
collagen	Pharmacological
(	Pharmacological
Zyplast	Pharmacological
)	Pharmacological
on	O
contralateral	O
sides	O
of	O
the	O
face	O
.	O

On	O
achievement	O
of	O
optimal	O
cosmetic	O
result	O
(	O
baseline	O
)	O
,	O
patients	O
were	O
followed	O
up	O
for	O
6	O
months	O
;	O
bilateral	O
retreatment	O
with	O
Perlane	Pharmacological
was	O
offered	O
at	O
6	O
or	O
9	O
months	O
after	O
baseline	O
.	O

Responses	O
were	O
evaluated	O
at	O
2	O
,	O
4	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
months	O
after	O
baseline	O
.	O

Investigator-based	O
and	O
patient-based	O
ratings	O
indicated	O
that	O
Perlane	Pharmacological
was	O
more	O
effective	O
than	O
Zyplast	Pharmacological
in	O
maintaining	O
cosmetic	O
correction	O
.	O

According	O
to	O
investigator-based	O
Wrinkle	O
Severity	O
Rating	O
Scale	O
assessments	O
at	O
6	O
and	O
9	O
months	O
after	O
baseline	O
,	O
Perlane	Pharmacological
was	O
superior	O
in	O
50.0	O
percent	O
and	O
48.8	O
percent	O
of	O
patients	O
,	O
respectively	O
,	O
whereas	O
Zyplast	Pharmacological
was	O
superior	O
in	O
10.3	O
percent	O
and	O
14.0	O
percent	O
of	O
patients	O
,	O
respectively	O
(	O
p	O
<	O
0.0004	O
)	O
.	O

Investigator-based	O
Global	O
Aesthetic	O
Improvement	O
Scale	O
assessment	O
at	O
9	O
months	O
after	O
baseline	O
indicated	O
that	O
Perlane	Pharmacological
was	O
superior	O
in	O
48.8	O
percent	O
of	O
patients	O
,	O
whereas	O
Zyplast	Pharmacological
was	O
superior	O
in	O
14.0	O
percent	O
of	O
patients	O
(	O
p	O
=	O
0.0025	O
)	O
.	O

Optimal	O
cosmetic	O
result	O
was	O
achieved	O
with	O
a	O
smaller	O
volume	O
of	O
Perlane	Pharmacological
than	O
Zyplast	Pharmacological
(	O
mean	O
,	O
1.2	O
ml	O
versus	O
2.1	O
ml	O
)	O
.	O

Local	O
injection-site	O
reactions	O
(	O
redness	O
,	O
swelling	O
,	O
pruritus	O
,	O
and	O
induration	O
)	O
were	O
less	O
frequent	O
with	O
Perlane	Pharmacological
than	O
with	O
Zyplast	Pharmacological
.	Pharmacological

Delayed-onset	O
reactions	O
were	O
rare	O
and	O
did	O
not	O
reoccur	O
after	O
Perlane	Pharmacological
retreatment	O
.	O

Perlane	Pharmacological
has	O
acceptable	O
long-term	O
safety	O
and	O
offers	O
a	O
longer-lasting	O
aesthetic	O
improvement	O
than	O
Zyplast	Pharmacological
.	Pharmacological

Perioperative	O
myocardial	O
infarctions	O
are	O
common	O
and	O
often	O
unrecognized	O
in	O
patients	O
undergoing	O
hip	O
fracture	O
surgery	O
.	O

BACKGROUND	O
The	O
aim	O
of	O
this	O
prospective	O
cohort	O
study	O
was	O
to	O
assess	O
the	O
incidence	O
and	O
characteristics	O
of	O
acute	O
myocardial	O
infarction	O
in	O
patients	O
undergoing	O
surgery	O
for	O
acute	O
hip	O
fracture	O
.	O

METHODS	O
A	O
consecutive	O
cohort	O
of	O
patients	O
(	O
n	O
=	O
200	O
,	O
68	O
men	O
)	O
referred	O
to	O
acute	Surgical
surgical	Surgical
correction	Surgical
of	Surgical
hip	Surgical
fracture	Surgical
was	O
studied	O
.	O

Troponin	Other
T	Other
(	Other
TnT	Other
)	Other
measurements	Other
and	O
electrocardiographic	Other
(	Other
ECG	Other
)	Other
recordings	Other
were	O
performed	O
at	O
admission	O
,	O
before	O
operation	O
,	O
and	O
on	O
the	O
first	O
and	O
2nd	O
postoperative	O
days	O
,	O
which	O
were	O
used	O
for	O
diagnosis	O
.	O

RESULTS	O
The	O
age	O
of	O
the	O
patients	O
ranged	O
from	O
32	O
to	O
98	O
years	O
(	O
mean	O
,	O
80.8	O
years	O
)	O
,	O
and	O
65	O
patients	O
had	O
a	O
history	O
of	O
coronary	O
artery	O
disease	O
.	O

A	O
significant	O
rise	O
in	O
TnT	O
as	O
a	O
sign	O
of	O
myocardial	O
infarction	O
was	O
observed	O
in	O
71	O
patients	O
(	O
35.5	O
%	O
)	O
,	O
and	O
25	O
of	O
them	O
had	O
a	O
TnT	O
elevation	O
exceeding	O
five	O
times	O
the	O
upper	O
normal	O
limit	O
.	O

TnT	O
elevation	O
was	O
observed	O
in	O
36	O
patients	O
(	O
51	O
%	O
)	O
already	O
before	O
surgery	O
.	O

Seven	O
patients	O
(	O
10	O
%	O
)	O
had	O
ST	O
elevation	O
myocardial	O
infarction	O
,	O
23	O
patients	O
(	O
32	O
%	O
)	O
had	O
new	O
ST	O
depressions	O
,	O
and	O
21	O
patients	O
(	O
30	O
%	O
)	O
had	O
no	O
new	O
ST	O
segment	O
changes	O
in	O
the	O
serial	O
electrocardiographic	O
recordings	O
.	O

In	O
40	O
patients	O
(	O
56	O
%	O
)	O
,	O
the	O
perioperative	O
myocardial	O
infarction	O
was	O
the	O
first	O
manifestation	O
of	O
coronary	O
artery	O
disease	O
.	O

Multivariate	O
logistic	O
regression	O
revealed	O
that	O
old	O
age	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
1.06	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.02-1.10	O
;	O
p	O
=	O
0.002	O
)	O
,	O
earlier	O
revascularization	O
(	O
OR	O
,	O
3.29	O
;	O
95	O
%	O
CI	O
1.12-9.73	O
;	O
p	O
=	O
0.03	O
)	O
,	O
and	O
heart	O
failure	O
(	O
OR	O
,	O
2.42	O
;	O
95	O
%	O
CI	O
1.04-5.61	O
;	O
p	O
=	O
0.04	O
)	O
were	O
independent	O
predictors	O
of	O
TnT	O
elevation	O
.	O

Majority	O
of	O
myocardial	O
infarctions	O
were	O
asymptomatic	O
or	O
unrecognized	O
.	O

Evidence-based	O
medications	O
of	O
myocardial	O
infarction	O
were	O
seldom	O
started	O
and	O
cardiologist	O
was	O
consulted	O
in	O
12	O
patients	O
(	O
16.9	O
%	O
)	O
.	O

CONCLUSION	O
Patients	O
with	O
hip	O
fracture	O
often	O
develop	O
asymptomatic	O
and	O
clinically	O
unrecognized	O
perioperative	O
myocardial	O
infarctions	O
.	O

Earlier	O
diagnosis	O
and	O
appropriate	O
treatment	O
of	O
cardiac	O
infarction	O
may	O
improve	O
survival	O
of	O
hip	O
fracture	O
patients	O
.	O

LEVEL	O
OF	O
EVIDENCE	O
Epidemiologic	O
study	O
,	O
level	O
III	O
.	O

Effect	O
of	O
testosterone	Pharmacological
and	O
a	O
nutritional	Pharmacological
supplement	Pharmacological
,	O
alone	O
and	O
in	O
combination	O
,	O
on	O
hospital	O
admissions	O
in	O
undernourished	O
older	O
men	O
and	O
women	O
.	O

BACKGROUND	O
In	O
older	O
people	O
,	O
undernutrition	O
is	O
associated	O
with	O
increased	O
hospitalization	O
rates	O
and	O
mortality	O
.	O

Because	O
weight	O
loss	O
in	O
older	O
people	O
often	O
reflects	O
a	O
disproportionate	O
reduction	O
of	O
skeletal	O
muscle	O
,	O
anabolic	O
treatments	O
may	O
be	O
beneficial	O
.	O

OBJECTIVE	O
Our	O
aim	O
was	O
to	O
evaluate	O
the	O
hypothesis	O
that	O
testosterone	Pharmacological
treatment	O
and	O
a	O
nutritional	Pharmacological
supplement	Pharmacological
have	O
additive	O
benefits	O
.	O

DESIGN	O
Oral	O
testosterone	Pharmacological
undecanoate	Pharmacological
(	O
40	O
mg	O
daily	O
for	O
women	O
,	O
80	O
mg	O
twice	O
daily	O
for	O
men	O
)	O
and	O
an	O
oral	O
nutritional	Pharmacological
supplement	Pharmacological
(	O
475	O
kcal/d	O
)	O
were	O
administered	O
,	O
alone	O
or	O
combined	O
,	O
for	O
1	O
y	O
to	O
49	O
community-dwelling	O
,	O
undernourished	O
people	O
[	O
Mini	O
Nutritional	O
Assessment	O
score	O
<	O
24	O
and	O
low	O
body	O
weight	O
(	O
body	O
mass	O
index	O
,	O
in	O
kg/m	O
(	O
2	O
)	O
:	O
<	O
22	O
)	O
or	O
recent	O
weight	O
loss	O
(	O
>	O
7.5	O
%	O
over	O
3	O
mo	O
)	O
]	O
aged	O
>	O
65	O
y	O
(	O
mean	O
age	O
:	O
77	O
y	O
;	O
26	O
women	O
and	O
23	O
men	O
)	O
.	O

Hospital	O
admissions	O
and	O
other	O
variables	O
were	O
assessed	O
.	O

RESULTS	O
In	O
subjects	O
receiving	O
combined	O
testosterone	Pharmacological
and	O
nutritional	Pharmacological
supplements	Pharmacological
(	O
n	O
=	O
11	O
)	O
,	O
there	O
were	O
no	O
hospital	O
admissions	O
,	O
whereas	O
there	O
were	O
9	O
admissions	O
(	O
2	O
elective	O
)	O
in	O
13	O
subjects	O
in	O
the	O
no-treatment	O
group	O
,	O
4	O
in	O
the	O
testosterone-treated	Pharmacological
group	O
(	O
n	O
=	O
12	O
)	O
,	O
and	O
5	O
in	O
the	O
supplement-treated	Pharmacological
group	O
(	O
n	O
=	O
13	O
)	O
;	O
P	O
=	O
0.06	O
with	O
no-treatment	O
compared	O
with	O
combined	O
treatment	O
.	O

When	O
compared	O
with	O
the	O
no-treatment	O
group	O
,	O
the	O
combined-treatment	Pharmacological
group	O
had	O
significantly	O
fewer	O
subjects	O
admitted	O
to	O
hospital	O
(	O
0	O
compared	O
with	O
5	O
,	O
P	O
=	O
0.03	O
)	O
,	O
fewer	O
days	O
in	O
hospital	O
(	O
0	O
compared	O
with	O
74	O
,	O
P	O
=	O
0.041	O
)	O
,	O
and	O
a	O
longer	O
time	O
to	O
hospital	O
admission	O
(	O
P	O
=	O
0.017	O
)	O
.	O

CONCLUSIONS	O
In	O
undernourished	O
older	O
people	O
,	O
combined	O
treatment	O
with	O
testosterone	Pharmacological
and	O
nutritional	Pharmacological
supplementation	Pharmacological
reduced	O
the	O
number	O
of	O
people	O
hospitalized	O
and	O
the	O
duration	O
of	O
hospital	O
admissions	O
,	O
which	O
are	O
important	O
endpoints	O
in	O
this	O
group	O
.	O

Larger	O
,	O
confirmatory	O
studies	O
are	O
now	O
needed	O
.	O

This	O
trial	O
was	O
registered	O
before	O
commencement	O
at	O
clinical	O
trials.gov	O
as	O
NCT00117000	O
.	O

Study	O
of	O
the	O
therapeutic	O
effects	O
of	O
a	O
hippotherapy	Physical
simulator	Physical
in	O
children	O
with	O
cerebral	O
palsy	O
:	O
a	O
stratified	O
single-blind	O
randomized	O
controlled	O
trial	O
.	O

OBJECTIVE	O
To	O
investigate	O
whether	O
hippotherapy	Physical
(	Physical
when	Physical
applied	Physical
by	Physical
a	Physical
simulator	Physical
)	Physical
improves	O
postural	O
control	O
and	O
balance	O
in	O
children	O
with	O
cerebral	O
palsy	O
.	O

DESIGN	O
Stratified	O
single-blind	O
randomized	O
controlled	O
trial	O
with	O
an	O
independent	O
assessor	O
.	O

Stratification	O
was	O
made	O
by	O
gross	O
motor	O
function	O
classification	O
system	O
levels	O
,	O
and	O
allocation	O
was	O
concealed	O
.	O

SUBJECTS	O
Children	O
between	O
4	O
and	O
18	O
years	O
old	O
with	O
cerebral	O
palsy	O
.	O

INTERVENTIONS	O
Participants	O
were	O
randomized	O
to	O
an	O
intervention	Physical
(	Physical
simulator	Physical
ON	Physical
)	Physical
or	O
control	Control
(	Control
simulator	Control
OFF	Control
)	Control
group	O
after	O
getting	O
informed	O
consent	O
.	O

Treatment	O
was	O
provided	O
once	O
a	O
week	O
(	O
15	O
minutes	O
)	O
for	O
10	O
weeks	O
.	O

MAIN	O
MEASURES	O
Gross	O
Motor	O
Function	O
Measure	O
(	O
dimension	O
B	O
for	O
balance	O
and	O
the	O
Total	O
Score	O
)	O
and	O
Sitting	O
Assessment	O
Scale	O
were	O
carried	O
out	O
at	O
baseline	O
(	O
prior	O
to	O
randomization	O
)	O
,	O
end	O
of	O
intervention	O
and	O
12	O
weeks	O
after	O
completing	O
the	O
intervention	O
.	O

RESULTS	O
Thirty-eight	O
children	O
participated	O
.	O

The	O
groups	O
were	O
balanced	O
at	O
baseline	O
.	O

Sitting	O
balance	O
(	O
measured	O
by	O
dimension	O
B	O
of	O
the	O
Gross	O
Motor	O
Function	O
Measure	O
)	O
improved	O
significantly	O
in	O
the	O
treatment	O
group	O
(	O
effect	O
size	O
=	O
0.36	O
;	O
95	O
%	O
CI	O
0.01-0.71	O
)	O
and	O
the	O
effect	O
size	O
was	O
greater	O
in	O
the	O
severely	O
disabled	O
group	O
(	O
effect	O
size	O
=	O
0.80	O
;	O
95	O
%	O
CI	O
0.13-1.47	O
)	O
.	O

The	O
improvements	O
in	O
sitting	O
balance	O
were	O
not	O
maintained	O
over	O
the	O
follow-up	O
period	O
.	O

Changes	O
in	O
the	O
total	O
score	O
of	O
the	O
Gross	O
Motor	O
Function	O
Measure	O
and	O
the	O
Sitting	O
Assessment	O
Scale	O
were	O
not	O
significant	O
.	O

CONCLUSION	O
Hippotherapy	Physical
with	O
a	O
simulator	O
can	O
improve	O
sitting	O
balance	O
in	O
cerebral	O
palsy	O
children	O
who	O
have	O
higher	O
levels	O
of	O
disability	O
.	O

However	O
,	O
this	O
did	O
not	O
lead	O
to	O
a	O
change	O
in	O
the	O
overall	O
function	O
of	O
these	O
children	O
(	O
Gross	O
Motor	O
Function	O
Classification	O
System	O
level	O
V	O
)	O
.	O

Randomized	O
,	O
double-blind	O
,	O
placebo-controlled	Control
trial	O
of	O
oral	O
sirolimus	O
for	O
restenosis	O
prevention	O
in	O
patients	O
with	O
in-stent	O
restenosis	O
:	O
the	O
Oral	O
Sirolimus	Pharmacological
to	O
Inhibit	O
Recurrent	O
In-stent	O
Stenosis	O
(	O
OSIRIS	O
)	O
trial	O
.	O

BACKGROUND	O
Despite	O
recent	O
advances	O
in	O
interventional	O
cardiology	O
,	O
including	O
the	O
introduction	O
of	O
drug-eluting	O
stents	O
for	O
de	O
novo	O
coronary	O
lesions	O
,	O
the	O
treatment	O
of	O
in-stent	O
restenosis	O
(	O
ISR	O
)	O
remains	O
a	O
challenging	O
clinical	O
issue	O
.	O

Given	O
the	O
efficacy	O
of	O
systemic	O
sirolimus	O
administration	O
to	O
prevent	O
neointimal	O
hyperplasia	O
in	O
animal	O
models	O
and	O
to	O
halt	O
and	O
even	O
reverse	O
the	O
progression	O
of	O
allograft	O
vasculopathy	O
,	O
the	O
aim	O
of	O
the	O
present	O
double-blind	O
,	O
placebo-controlled	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
of	O
a	O
10-day	O
oral	O
sirolimus	O
treatment	O
with	O
2	O
different	O
loading	O
regimens	O
for	O
the	O
prevention	O
of	O
recurrent	O
restenosis	O
in	O
patients	O
with	O
ISR	O
.	O

METHODS	O
AND	O
RESULTS	O
Three	O
hundred	O
symptomatic	O
patients	O
with	O
ISR	O
were	O
randomly	O
assigned	O
to	O
1	O
of	O
3	O
treatment	O
arms	O
:	O
placebo	Control
or	O
usual-dose	O
or	O
high-dose	O
sirolimus	Pharmacological
.	O

Patients	O
received	O
a	O
cumulative	O
loading	O
dose	O
of	O
0	O
,	O
8	O
,	O
or	O
24	O
mg	O
of	O
sirolimus	O
2	O
days	O
before	O
and	O
the	O
day	O
of	O
repeat	O
intervention	O
followed	O
by	O
maintenance	O
therapy	O
of	O
2	O
mg/d	O
for	O
7	O
days	O
.	O

Angiographic	O
restenosis	O
at	O
6-month	O
angiography	O
was	O
the	O
primary	O
end	O
point	O
of	O
the	O
study	O
.	O

Restenosis	O
was	O
significantly	O
reduced	O
from	O
42.2	O
%	O
to	O
38.6	O
%	O
and	O
to	O
22.1	O
%	O
in	O
the	O
placebo	O
,	O
usual-dose	O
,	O
and	O
high-dose	O
sirolimus	O
groups	O
,	O
respectively	O
(	O
P=0.005	O
)	O
.	O

Similarly	O
,	O
the	O
need	O
for	O
target	O
vessel	O
revascularization	O
was	O
reduced	O
from	O
25.5	O
%	O
to	O
24.2	O
%	O
and	O
to	O
15.2	O
%	O
in	O
the	O
placebo	O
,	O
usual-dose	O
,	O
and	O
high-dose	O
groups	O
,	O
respectively	O
(	O
P=0.08	O
)	O
.	O

The	O
sirolimus	O
blood	O
concentration	O
on	O
the	O
day	O
of	O
the	O
procedure	O
correlated	O
significantly	O
with	O
the	O
late	O
lumen	O
loss	O
at	O
follow-up	O
(	O
P	O
<	O
0.001	O
)	O
.	O

CONCLUSIONS	O
In	O
patients	O
with	O
ISR	O
,	O
an	O
oral	O
adjunctive	O
sirolimus	O
treatment	O
with	O
an	O
intensified	O
loading	O
regimen	O
before	O
coronary	O
intervention	O
resulted	O
in	O
a	O
significant	O
improvement	O
in	O
the	O
angiographic	O
parameters	O
of	O
restenosis	O
.	O

Comparison	O
of	O
neodymium-doped	Surgical
yttrium	Surgical
aluminum	Surgical
garnet	Surgical
laser	Surgical
treatment	Surgical
with	O
cold	Surgical
knife	Surgical
endoscopic	Surgical
incision	Surgical
of	O
urethral	O
strictures	O
in	O
male	O
patients	O
.	O

OBJECTIVE	O
To	O
assess	O
the	O
effectiveness	O
of	O
visual	Surgical
laser	Surgical
ablation	Surgical
treatment	Surgical
with	Surgical
neodymium-doped	Surgical
yttrium	Surgical
aluminum	Surgical
garnet	Surgical
(	Surgical
Nd	Surgical
:	Surgical
YAG	Surgical
)	Surgical
laser	O
in	O
male	O
patients	O
with	O
urethral	O
strictures	O
and	O
to	O
compare	O
the	O
effects	O
with	O
those	O
obtained	O
in	O
patients	O
treated	O
with	O
Sachse	O
's	O
optical	O
urethrotomy	O
.	O

MATERIALS	O
AND	O
METHODS	O
Fifty	O
patients	O
aged	O
22	O
to	O
83	O
(	O
mean	O
age	O
61.8	O
)	O
with	O
primary	O
(	O
n	O
=	O
26	O
,	O
52	O
%	O
)	O
and	O
recurrent	O
(	O
n	O
=	O
24	O
,	O
48	O
%	O
)	O
urethral	O
strictures	O
0.3	O
to	O
2.4	O
cm	O
long	O
qualified	O
for	O
the	O
study	O
.	O

The	O
patients	O
were	O
randomized	O
into	O
two	O
groups	O
:	O
30	O
men	O
treated	O
using	O
visual	Surgical
laser	Surgical
ablation	Surgical
of	Surgical
urethral	Surgical
strictures	Surgical
(	Surgical
VLASU	Surgical
)	Surgical
with	Surgical
Nd	Surgical
:	Surgical
YAGlaser	Surgical
and	O
20	O
men	O
treated	O
by	O
correction	O
of	O
urethral	O
strictures	O
using	O
Sachse	Surgical
's	Surgical
optical	Surgical
urethrotomy	Surgical
.	O

RESULTS	O
At	O
12-month	O
follow-up	O
,	O
seven	O
(	O
35	O
%	O
)	O
patients	O
who	O
underwent	O
optical	Surgical
urethrotomy	Surgical
and	O
21	O
(	O
70	O
%	O
)	O
in	O
the	O
VLASU	Surgical
group	O
did	O
not	O
require	O
repetition	O
of	O
the	O
procedure	O
.	O

The	O
choice	O
of	O
VLASU	Surgical
as	O
a	O
method	O
of	O
treatment	O
significantly	O
decreased	O
the	O
probability	O
of	O
therapeutic	O
failure	O
and	O
recurrence	O
of	O
urethral	O
strictures	O
(	O
p	O
=	O
0.02	O
)	O
.	O

CONCLUSION	O
VLASU	Surgical
can	O
be	O
used	O
as	O
a	O
method	O
of	O
treatment	O
of	O
this	O
disorder	O
.	O

It	O
is	O
an	O
effective	O
,	O
modern	O
,	O
low-invasive	O
,	O
and	O
repeatable	O
technique	O
and	O
is	O
technically	O
simple	O
and	O
easy	O
to	O
master	O
.	O

It	O
can	O
be	O
used	O
in	O
cases	O
in	O
which	O
introduction	O
of	O
a	O
22	O
Char	O
optical	O
urethrotome	O
into	O
the	O
stricture	O
site	O
is	O
impossible	O
,	O
as	O
well	O
as	O
for	O
treatment	O
of	O
multiple	O
strictures	O
during	O
one	O
procedure	O
.	O

Co-administration	O
of	O
pethidine	Pharmacological
and	O
clonidine	Pharmacological
:	O
a	O
spinal	O
anaesthetic	O
technique	O
for	O
total	Surgical
hip	Surgical
replacement	Surgical
.	Surgical

Co-administration	O
of	O
pethidine	Pharmacological
0.75	O
mg	O
kg-1	O
and	O
clonidine	Pharmacological
75	O
micrograms	O
intrathecally	O
provided	O
good	O
intraoperative	O
anaesthesia	O
for	O
total	Surgical
hip	Surgical
replacement	Surgical
,	O
similar	O
to	O
that	O
obtained	O
using	O
0.5	Pharmacological
%	Pharmacological
isobaric	Pharmacological
bupivacaine	Pharmacological
.	Pharmacological

Sensory	O
and	O
motor	O
block	O
were	O
of	O
shorter	O
duration	O
than	O
that	O
after	O
0.5	O
%	O
isobaric	Pharmacological
bupivacaine	Pharmacological
and	O
0.5	O
%	O
isobaric	Pharmacological
bupivacaine	Pharmacological
with	O
morphine	Pharmacological
0.5	O
mg	O
(	O
P	O
<	O
0.001	O
sensory	O
block	O
,	O
P	O
<	O
0.001	O
motor	O
block	O
)	O
.	O

Postoperative	O
morphine	Pharmacological
consumption	O
,	O
measured	O
using	O
a	O
patient-controlled	O
system	O
,	O
was	O
similar	O
to	O
that	O
in	O
patients	O
in	O
the	O
bupivacaine	Pharmacological
only	O
group	O
(	O
pethidine-clonidine	Pharmacological
:	O
median	O
39	O
mg/24	O
h	O
;	O
bupivacaine	Pharmacological
:	O
median	O
34	O
mg/24	O
h	O
)	O
but	O
greater	O
than	O
that	O
in	O
the	O
bupivacaine-morphine	Pharmacological
group	O
(	O
median	O
8	O
mg/24	O
h	O
)	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Visual	O
analogue	O
pain	O
scores	O
after	O
operation	O
were	O
similar	O
to	O
those	O
with	O
bupivacaine	Pharmacological
alone	Pharmacological
at	O
all	O
but	O
one	O
of	O
the	O
recording	O
times	O
but	O
were	O
greater	O
than	O
those	O
in	O
patients	O
who	O
received	O
bupivacaine	Pharmacological
and	O
morphine	Pharmacological
at	O
4	O
,	O
6	O
and	O
10	O
h	O
after	O
operation	O
(	O
P	O
<	O
0.001	O
,	O
P	O
<	O
0.04	O
,	O
P	O
<	O
0.02	O
)	O
.	O

The	O
combination	O
did	O
not	O
offer	O
any	O
major	O
advantage	O
over	O
conventional	O
agents	O
.	O

Effect	O
of	O
a	O
vitamin/mineral	Pharmacological
supplement	Pharmacological
on	O
children	O
and	O
adults	O
with	O
autism	O
.	O

BACKGROUND	O
Vitamin/mineral	Pharmacological
supplements	Pharmacological
are	O
among	O
the	O
most	O
commonly	O
used	O
treatments	O
for	O
autism	O
,	O
but	O
the	O
research	O
on	O
their	O
use	O
for	O
treating	O
autism	O
has	O
been	O
limited	O
.	O

METHOD	O
This	O
study	O
is	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	Control
three	O
month	O
vitamin/mineral	Pharmacological
treatment	Pharmacological
study	Pharmacological
.	Pharmacological

The	O
study	O
involved	O
141	O
children	O
and	O
adults	O
with	O
autism	O
,	O
and	O
pre	O
and	O
post	O
symptoms	O
of	O
autism	O
were	O
assessed	O
.	O

None	O
of	O
the	O
participants	O
had	O
taken	O
a	O
vitamin/mineral	Pharmacological
supplement	Pharmacological
in	O
the	O
two	O
months	O
prior	O
to	O
the	O
start	O
of	O
the	O
study	O
.	O

For	O
a	O
subset	O
of	O
the	O
participants	O
(	O
53	O
children	O
ages	O
5-16	O
)	O
pre	O
and	O
post	O
measurements	O
of	O
nutritional	O
and	O
metabolic	O
status	O
were	O
also	O
conducted	O
.	O

RESULTS	O
The	O
vitamin/mineral	Pharmacological
supplement	Pharmacological
was	O
generally	O
well-tolerated	O
,	O
and	O
individually	O
titrated	O
to	O
optimum	O
benefit	O
.	O

Levels	O
of	O
many	O
vitamins	O
,	O
minerals	O
,	O
and	O
biomarkers	O
improved/increased	O
showing	O
good	O
compliance	O
and	O
absorption	O
.	O

Statistically	O
significant	O
improvements	O
in	O
metabolic	O
status	O
were	O
many	O
including	O
:	O
total	O
sulfate	O
(	O
+17	O
%	O
,	O
p	O
=	O
0.001	O
)	O
,	O
S-adenosylmethionine	O
(	O
SAM	O
;	O
+6	O
%	O
,	O
p	O
=	O
0.003	O
)	O
,	O
reduced	O
glutathione	O
(	O
+17	O
%	O
,	O
p	O
=	O
0.0008	O
)	O
,	O
ratio	O
of	O
oxidized	O
glutathione	O
to	O
reduced	O
glutathione	O
(	O
GSSG	O
:	O
GSH	O
;	O
-27	O
%	O
,	O
p	O
=	O
0.002	O
)	O
,	O
nitrotyrosine	O
(	O
-29	O
%	O
,	O
p	O
=	O
0.004	O
)	O
,	O
ATP	O
(	O
+25	O
%	O
,	O
p	O
=	O
0.000001	O
)	O
,	O
NADH	O
(	O
+28	O
%	O
,	O
p	O
=	O
0.0002	O
)	O
,	O
and	O
NADPH	O
(	O
+30	O
%	O
,	O
p	O
=	O
0.001	O
)	O
.	O

Most	O
of	O
these	O
metabolic	O
biomarkers	O
improved	O
to	O
normal	O
or	O
near-normal	O
levels.The	O
supplement	Pharmacological
group	O
had	O
significantly	O
greater	O
improvements	O
than	O
the	O
placebo	Control
group	O
on	O
the	O
Parental	O
Global	O
Impressions-Revised	O
(	O
PGI-R	O
,	O
Average	O
Change	O
,	O
p	O
=	O
0.008	O
)	O
,	O
and	O
on	O
the	O
subscores	O
for	O
Hyperactivity	O
(	O
p	O
=	O
0.003	O
)	O
,	O
Tantrumming	O
(	O
p	O
=	O
0.009	O
)	O
,	O
Overall	O
(	O
p	O
=	O
0.02	O
)	O
,	O
and	O
Receptive	O
Language	O
(	O
p	O
=	O
0.03	O
)	O
.	O

For	O
the	O
other	O
three	O
assessment	O
tools	O
the	O
difference	O
between	O
treatment	O
group	O
and	O
placebo	O
group	O
was	O
not	O
statistically	O
significant.Regression	O
analysis	O
revealed	O
that	O
the	O
degree	O
of	O
improvement	O
on	O
the	O
Average	O
Change	O
of	O
the	O
PGI-R	O
was	O
strongly	O
associated	O
with	O
several	O
biomarkers	O
(	O
adj	O
.	O

R2	O
=	O
0.61	O
,	O
p	O
<	O
0.0005	O
)	O
with	O
the	O
initial	O
levels	O
of	O
biotin	O
and	O
vitamin	O
K	O
being	O
the	O
most	O
significant	O
(	O
p	O
<	O
0.05	O
)	O
;	O
both	O
biotin	O
and	O
vitamin	O
K	O
are	O
made	O
by	O
beneficial	O
intestinal	O
flora	O
.	O

CONCLUSIONS	O
Oral	O
vitamin/mineral	Pharmacological
supplementation	Pharmacological
is	O
beneficial	O
in	O
improving	O
the	O
nutritional	O
and	O
metabolic	O
status	O
of	O
children	O
with	O
autism	O
,	O
including	O
improvements	O
in	O
methylation	O
,	O
glutathione	O
,	O
oxidative	O
stress	O
,	O
sulfation	O
,	O
ATP	O
,	O
NADH	O
,	O
and	O
NADPH	O
.	O

The	O
supplement	Pharmacological
group	O
had	O
significantly	O
greater	O
improvements	O
than	O
did	O
the	O
placebo	Control
group	O
on	O
the	O
PGI-R	O
Average	O
Change	O
.	O

This	O
suggests	O
that	O
a	O
vitamin/mineral	Pharmacological
supplement	Pharmacological
is	O
a	O
reasonable	O
adjunct	O
therapy	O
to	O
consider	O
for	O
most	O
children	O
and	O
adults	O
with	O
autism	O
.	O

TRIAL	O
REGISTRATION	O
CLINICAL	O
TRIAL	O
REGISTRATION	O
NUMBER	O
NCT01225198	O
.	O

Combined	Pharmacological
typhoid	Pharmacological
fever	Pharmacological
and	Pharmacological
hepatitis	Pharmacological
A	Pharmacological
vaccine	Pharmacological
:	Pharmacological
comparison	O
of	O
immunogenicity	O
and	O
safety	O
to	O
concomitant	O
monovalent	O
vaccine	O
over	O
3	O
years	O
.	O

BACKGROUND	O
The	O
safety	O
and	O
immunogenicity	O
of	O
Viatim	Pharmacological
,	O
a	O
combined	Pharmacological
hepatitis	Pharmacological
A	Pharmacological
(	Pharmacological
HA	Pharmacological
)	Pharmacological
and	Pharmacological
typhoid	Pharmacological
fever	Pharmacological
(	Pharmacological
Vi	Pharmacological
)	Pharmacological
vaccine	Pharmacological
,	O
were	O
compared	O
with	O
the	O
monovalent	Pharmacological
component	Pharmacological
vaccines	Pharmacological
up	O
to	O
and	O
1	O
month	O
after	O
a	O
booster	O
dose	O
at	O
3	O
years	O
.	O

METHODS	O
Healthy	O
,	O
adult	O
volunteers	O
were	O
randomized	O
to	O
receive	O
Viatim	Pharmacological
(	O
group	O
A	O
,	O
n	O
=	O
179	O
)	O
or	O
separate	Pharmacological
HA	Pharmacological
and	Pharmacological
Vi	Pharmacological
vaccines	Pharmacological
(	O
group	O
B	O
,	O
n	O
=	O
181	O
)	O
;	O
subgroups	O
were	O
boosted	O
after	O
3	O
years	O
with	O
Viatim	Pharmacological
(	O
groups	O
C	O
and	O
D	O
,	O
n	O
=	O
56	O
and	O
46	O
,	O
respectively	O
)	O
.	O

Local	O
and	O
systemic	O
reactions	O
were	O
recorded	O
for	O
28	O
days	O
postvaccination	O
.	O

Seroconversion	O
and	O
seroprotection	O
rates	O
and	O
geometric	O
mean	O
antibody	O
concentrations	O
were	O
measured	O
at	O
14	O
and	O
28	O
days	O
,	O
1	O
,	O
2	O
,	O
and	O
3	O
years	O
postvaccination	O
,	O
and	O
28	O
days	O
after	O
the	O
booster	O
dose	O
.	O

RESULTS	O
Local	O
and	O
systemic	O
safety	O
profiles	O
were	O
equivalent	O
between	O
the	O
two	O
groups	O
.	O

Immediate	O
local	O
reactions	O
were	O
infrequent	O
(	O
1	O
in	O
group	O
A	O
and	O
2	O
in	O
group	O
B	O
)	O
.	O

Local	O
reactions	O
,	O
consisting	O
mostly	O
of	O
mild	O
or	O
moderate	O
pain	O
,	O
were	O
least	O
frequent	O
with	O
monovalent	O
HA	O
.	O

Antibody	O
concentrations	O
to	O
both	O
antigens	O
were	O
similar	O
in	O
groups	O
A	O
and	O
B	O
,	O
in	O
which	O
HA	O
seroprotection	O
rates	O
(	O
>	O
or	O
=	O
20	O
mIU/mL	O
)	O
were	O
respectively	O
,	O
98.7	O
%	O
and	O
100	O
%	O
at	O
day	O
28	O
,	O
and	O
99.1	O
%	O
and	O
99.0	O
%	O
after	O
3	O
years	O
,	O
achieving	O
100	O
%	O
after	O
the	O
booster	O
.	O

Vi	O
seroprotection	O
rates	O
(	O
>	O
or	O
=	O
1	O
microg/mL	O
)	O
of	O
85.2	O
%	O
and	O
84.9	O
%	O
after	O
28	O
days	O
fell	O
to	O
32.1	O
%	O
and	O
35.6	O
%	O
after	O
3	O
years	O
,	O
increasing	O
to	O
67.3	O
%	O
and	O
69.8	O
%	O
after	O
the	O
booster	O
dose	O
.	O

CONCLUSIONS	O
The	O
combined	Pharmacological
HA/Vi	Pharmacological
vaccine	Pharmacological
,	Pharmacological
Viatim	Pharmacological
,	O
had	O
equivalent	O
tolerability	O
and	O
safety	O
and	O
was	O
as	O
rapidly	O
immunogenic	O
as	O
its	O
component	O
monovalent	O
vaccines	O
when	O
given	O
concurrently	O
.	O

A	O
booster	O
dose	O
after	O
3	O
years	O
significantly	O
increased	O
antibody	O
levels	O
with	O
some	O
evidence	O
of	O
relative	O
hyporesponsiveness	O
of	O
the	O
typhoid	O
response	O
.	O

Menopausal	O
quality	O
of	O
life	O
:	O
RCT	O
of	O
yoga	Physical
,	O
exercise	Physical
,	O
and	O
omega-3	Pharmacological
supplements	Pharmacological
.	O

OBJECTIVE	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
efficacy	O
of	O
3	O
nonhormonal	O
therapies	O
for	O
the	O
improvement	O
of	O
menopause-related	O
quality	O
of	O
life	O
in	O
women	O
with	O
vasomotor	O
symptoms	O
.	O

STUDY	O
DESIGN	O
We	O
conducted	O
a	O
12-week	O
3	O
?	O
2	O
randomized	O
,	O
controlled	O
,	O
factorial	O
design	O
trial	O
.	O

Peri-	O
and	O
postmenopausal	O
women	O
,	O
40-62	O
years	O
old	O
,	O
were	O
assigned	O
randomly	O
to	O
yoga	Physical
(	O
n	O
=	O
107	O
)	O
,	O
exercise	O
(	O
n	O
=	O
106	O
)	O
,	O
or	O
usual	Control
activity	Control
(	O
n	O
=	O
142	O
)	O
and	O
also	O
assigned	O
randomly	O
to	O
a	O
double-blind	O
comparison	O
of	O
omega-3	Pharmacological
(	O
n	O
=	O
177	O
)	O
or	O
placebo	Control
(	O
n	O
=	O
178	O
)	O
capsules	O
.	O

We	O
performed	O
the	O
following	O
interventions	O
:	O
(	O
1	O
)	O
weekly	O
90-minute	O
yoga	O
classes	O
with	O
daily	O
at-home	O
practice	O
,	O
(	O
2	O
)	O
individualized	O
facility-based	O
aerobic	O
exercise	O
training	O
3	O
times/week	O
,	O
and	O
(	O
3	O
)	O
0.615	O
g	O
omega-3	Pharmacological
supplement	Pharmacological
,	O
3	O
times/day	O
.	O

The	O
outcomes	O
were	O
assessed	O
with	O
the	O
following	O
scores	O
:	O
Menopausal	O
Quality	O
of	O
Life	O
Questionnaire	O
(	O
MENQOL	O
)	O
total	O
and	O
domain	O
(	O
vasomotor	O
symptoms	O
,	O
psychosocial	O
,	O
physical	O
and	O
sexual	O
)	O
.	O

RESULTS	O
Among	O
355	O
randomly	O
assigned	O
women	O
who	O
average	O
age	O
was	O
54.7	O
years	O
,	O
338	O
women	O
(	O
95	O
%	O
)	O
completed	O
12-week	O
assessments	O
.	O

Mean	O
baseline	O
vasomotor	O
symptoms	O
frequency	O
was	O
7.6/day	O
,	O
and	O
the	O
mean	O
baseline	O
total	O
MENQOL	O
score	O
was	O
3.8	O
(	O
range	O
,	O
1-8	O
from	O
better	O
to	O
worse	O
)	O
with	O
no	O
between-group	O
differences	O
.	O

For	O
yoga	O
compared	O
to	O
usual	O
activity	O
,	O
baseline	O
to	O
12-week	O
improvements	O
were	O
seen	O
for	O
MENQOL	O
total	O
-0.3	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
-0.6	O
to	O
0	O
;	O
P	O
=	O
.02	O
)	O
,	O
vasomotor	O
symptom	O
domain	O
(	O
P	O
=	O
.02	O
)	O
,	O
and	O
sexuality	O
domain	O
(	O
P	O
=	O
.03	O
)	O
scores	O
.	O

For	O
women	O
who	O
underwent	O
exercise	Physical
and	O
omega-3	Pharmacological
therapy	Pharmacological
compared	O
with	O
control	O
subjects	O
,	O
improvements	O
in	O
baseline	O
to	O
12-week	O
total	O
MENQOL	O
scores	O
were	O
not	O
observed	O
.	O

Exercise	O
showed	O
benefit	O
in	O
the	O
MENQOL	O
physical	O
domain	O
score	O
at	O
12	O
weeks	O
(	O
P	O
=	O
.02	O
)	O
.	O

CONCLUSION	O
All	O
women	O
become	O
menopausal	O
,	O
and	O
many	O
of	O
them	O
seek	O
medical	O
advice	O
on	O
ways	O
to	O
improve	O
quality	O
of	O
life	O
;	O
little	O
evidence-based	O
information	O
exists	O
.	O

We	O
found	O
that	O
,	O
among	O
healthy	O
sedentary	O
menopausal	O
women	O
,	O
yoga	O
appears	O
to	O
improve	O
menopausal	O
quality	O
of	O
life	O
;	O
the	O
clinical	O
significance	O
of	O
our	O
finding	O
is	O
uncertain	O
because	O
of	O
the	O
modest	O
effect	O
.	O

Prophylactic	Pharmacological
vs	Pharmacological
therapeutic	Pharmacological
blood	Pharmacological
patch	Pharmacological
for	O
obstetric	O
patients	O
with	O
accidental	O
dural	O
puncture	O
--	O
a	O
randomised	O
controlled	O
trial	O
.	O

Epidural	Pharmacological
blood	Pharmacological
patch	Pharmacological
is	O
a	O
standard	O
treatment	O
for	O
obstetric	O
patients	O
experiencing	O
a	O
severe	O
post-dural	O
puncture	O
headache	O
.	O

Patients	O
who	O
sustained	O
an	O
accidental	O
dural	O
puncture	O
during	O
establishment	O
of	O
epidural	O
analgesia	O
during	O
labour	O
or	O
at	O
caesarean	O
delivery	O
were	O
randomly	O
assigned	O
to	O
receive	O
a	O
prophylactic	Pharmacological
epidural	Pharmacological
blood	Pharmacological
patch	Pharmacological
or	O
conservative	Pharmacological
treatment	Pharmacological
with	Pharmacological
a	Pharmacological
therapeutic	Pharmacological
epidural	Pharmacological
blood	Pharmacological
patch	Pharmacological
if	O
required	O
.	O

Eleven	O
of	O
60	O
(	O
18.3	O
%	O
)	O
patients	O
in	O
the	O
prophylactic	Pharmacological
epidural	Pharmacological
blood	Pharmacological
patch	Pharmacological
group	O
developed	O
a	O
post-dural	O
puncture	O
headache	O
compared	O
with	O
39	O
of	O
49	O
(	O
79.6	O
%	O
)	O
in	O
the	O
therapeutic	Pharmacological
epidural	Pharmacological
blood	Pharmacological
patch	Pharmacological
group	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

A	O
blood	O
patch	O
was	O
performed	O
in	O
36	O
(	O
73.4	O
%	O
)	O
of	O
patients	O
in	O
the	O
therapeutic	O
group	O
.	O

The	O
number	O
of	O
patients	O
who	O
needed	O
a	O
second	O
blood	O
patch	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
groups	O
:	O
6	O
(	O
10.0	O
%	O
)	O
for	O
prophylactic	Pharmacological
epidural	Pharmacological
blood	Pharmacological
patch	Pharmacological
and	O
4	O
(	O
11.1	O
%	O
)	O
for	O
therapeutic	Pharmacological
epidural	Pharmacological
blood	Pharmacological
patch	Pharmacological
.	Pharmacological

We	O
conclude	O
that	O
prophylactic	Pharmacological
epidural	Pharmacological
blood	Pharmacological
patch	O
is	O
an	O
effective	O
method	O
to	O
reduce	O
the	O
development	O
of	O
post-dural	O
puncture	O
headache	O
in	O
obstetric	O
patients	O
.	O

The	O
influence	O
of	O
breast	O
size	O
on	O
late	O
radiation	O
effects	O
and	O
association	O
with	O
radiotherapy	O
dose	O
inhomogeneity	O
.	O

A	O
prospective	O
assessment	O
of	O
late	O
changes	O
in	O
breast	O
appearance	O
in	O
559	O
patients	O
after	O
tumour	Surgical
excision	Surgical
and	O
radiotherapy	Physical
for	O
early	O
breast	O
cancer	O
noted	O
a	O
strong	O
association	O
with	O
breast	O
size	O
.	O

Only	O
3/48	O
(	O
6	O
%	O
)	O
patients	O
with	O
small	O
breasts	O
developed	O
moderate	O
or	O
severe	O
late	O
changes	O
compared	O
with	O
94/423	O
(	O
22	O
%	O
)	O
with	O
medium	O
sized	O
breasts	O
and	O
34/88	O
(	O
39	O
%	O
)	O
patients	O
with	O
large	O
breasts	O
(	O
p	O
<	O
0.001	O
)	O
.	O

One	O
possibility	O
is	O
that	O
greater	O
radiation	O
changes	O
are	O
related	O
to	O
greater	O
dose	O
inhomogeneity	O
in	O
women	O
with	O
large	O
breasts	O
.	O

To	O
explore	O
this	O
hypothesis	O
,	O
radiation	O
dose	O
distributions	O
were	O
assessed	O
in	O
a	O
separate	O
group	O
of	O
37	O
women	O
in	O
whom	O
three-level	O
transverse	O
computer	O
tomographic	O
images	O
of	O
the	O
breast	O
in	O
the	O
treatment	O
position	O
were	O
available	O
.	O

A	O
significant	O
correlation	O
was	O
found	O
between	O
breast	O
size	O
and	O
dose	O
inhomogeneity	O
which	O
may	O
account	O
for	O
the	O
marked	O
changes	O
in	O
breast	O
appearance	O
reported	O
in	O
women	O
with	O
large	O
breasts	O
.	O

Epirubicin	Pharmacological
and	O
cyclophosphamide	Pharmacological
versus	O
epirubicin	Pharmacological
and	O
docetaxel	Pharmacological
as	O
first-line	O
therapy	O
for	O
women	O
with	O
metastatic	O
breast	O
cancer	O
:	O
final	O
results	O
of	O
a	O
randomised	O
phase	O
III	O
trial	O
.	O

BACKGROUND	O
This	O
randomised	O
phase	O
III	O
trial	O
was	O
carried	O
out	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
epirubicin	Pharmacological
and	O
cyclophosphamide	Pharmacological
(	Pharmacological
EC	Pharmacological
)	Pharmacological
with	O
epirubicin	Pharmacological
and	O
docetaxel	Pharmacological
(	Pharmacological
Taxotere	Pharmacological
)	Pharmacological
(	Pharmacological
ED	Pharmacological
)	Pharmacological
as	O
first-line	O
chemotherapy	O
for	O
metastatic	O
breast	O
cancer	O
.	O

PATIENTS	O
AND	O
METHODS	O
Patients	O
(	O
n	O
=	O
240	O
)	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
ED	Pharmacological
(	Pharmacological
epirubicin	Pharmacological
75	O
mg/m	O
(	O
2	O
)	O
and	O
docetaxel	Pharmacological
75	O
mg/m	O
(	O
2	O
)	O
)	O
or	O
EC	Pharmacological
(	Pharmacological
epirubicin	Pharmacological
90	O
mg/m	O
(	O
2	O
)	O
and	O
cyclophosphamide	Pharmacological
600	O
mg/m	O
(	O
2	O
)	O
)	O
.	O

The	O
primary	O
end	O
point	O
was	O
objective	O
response	O
rate	O
(	O
ORR	O
)	O
.	O

Secondary	O
end	O
points	O
were	O
progression-free	O
survival	O
(	O
PFS	O
)	O
,	O
overall	O
survival	O
(	O
OS	O
)	O
,	O
and	O
safety	O
.	O

RESULTS	O
ORR	O
for	O
patients	O
randomly	O
assigned	O
to	O
receive	O
EC	Pharmacological
and	O
ED	Pharmacological
were	O
42	O
%	O
and	O
47	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0.63	O
)	O
.	O

Median	O
PFS	O
[	O
10.1	O
versus	O
10.3	O
months	O
;	O
hazard	O
ratio	O
(	O
HR	O
)	O
0.98	O
;	O
log-rank	O
P	O
=	O
0.38	O
]	O
and	O
OS	O
(	O
19.9	O
versus	O
30.0	O
months	O
;	O
HR	O
0.663	O
;	O
log-rank	O
P	O
=	O
0.21	O
)	O
were	O
comparable	O
in	O
both	O
arms	O
.	O

Although	O
grade	O
3/4	O
leucopenia	O
occurred	O
more	O
frequently	O
with	O
ED	Pharmacological
(	O
81	O
%	O
versus	O
73	O
%	O
;	O
P	O
=	O
0.01	O
)	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
incidence	O
of	O
febrile	O
neutropenia	O
and	O
grade	O
3/4	O
infections	O
.	O

Grade	O
3/4	O
non-haematologic	O
toxicity	O
was	O
infrequent	O
in	O
both	O
arms	O
.	O

Congestive	O
heart	O
failure	O
was	O
observed	O
in	O
one	O
patient	O
in	O
each	O
arm	O
.	O

CONCLUSION	O
In	O
this	O
randomised	O
trial	O
,	O
no	O
differences	O
in	O
the	O
efficacy	O
study	O
end	O
points	O
were	O
observed	O
between	O
the	O
two	O
treatment	O
arms	O
.	O

The	O
effect	O
of	O
body	O
positioning	O
upon	O
maximal	Pharmacological
oxygenation	Pharmacological
of	O
patients	O
with	O
unilateral	O
lung	O
pathology	O
.	O

A	O
quasi-experimental	O
,	O
repeated-measures	O
cross-over	O
design	O
study	O
on	O
the	O
effect	O
of	O
body	O
position	O
on	O
oxygenation	Pharmacological
(	Pharmacological
SaO2	Pharmacological
)	Pharmacological
blood	O
pressure	O
,	O
respiration	O
and	O
pulse	O
in	O
patients	O
with	O
unilateral	O
lung	O
pathology	O
was	O
conducted	O
.	O

Previous	O
research	O
strongly	O
suggests	O
that	O
positioning	O
with	O
the	O
healthy	O
(	O
unaffected	O
)	O
lung	O
in	O
the	O
dependent	O
lateral	O
(	O
down	O
)	O
position	O
is	O
related	O
to	O
improved	O
oxygenation	O
,	O
but	O
knowledge	O
about	O
whether	O
this	O
effect	O
is	O
maintained	O
over	O
time	O
is	O
lacking	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
determine	O
:	O
(	O
1	O
)	O
Is	O
positioning	O
with	O
the	O
unaffected	O
lung	O
in	O
the	O
dependent	O
lateral	O
position	O
related	O
to	O
increased	O
arterial	O
blood	O
saturation	O
levels	O
and	O
decreased	O
blood	O
pressure	O
,	O
pulse	O
and	O
respiration	O
?	O
(	O
2	O
)	O
What	O
is	O
the	O
relationship	O
between	O
the	O
dependent	O
variables	O
--	O
oxygenation	O
saturation	O
levels	O
,	O
blood	O
pressure	O
,	O
pulse	O
and	O
respiration	O
--	O
and	O
the	O
independent	O
variables	O
--	O
body	O
position	O
and	O
time	O
in	O
the	O
position	O
?	O
Thirty-nine	O
patients	O
with	O
unilateral	O
lung	O
pathology	O
were	O
positioned	O
on	O
their	O
sides	O
with	O
the	O
unaffected	O
lung	O
down	O
,	O
on	O
their	O
sides	O
with	O
the	O
affected	O
lung	O
down	O
,	O
and	O
also	O
in	O
semi-Fowler	O
's	O
position	O
.	O

Arterial	Physical
(	Physical
SaO2	Physical
)	Physical
blood	Physical
saturation	Physical
and	O
vital	Physical
signs	Physical
were	O
measured	O
at	O
baseline	O
0	O
,	O
15	O
and	O
30	O
minutes	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
relationship	O
between	O
oxygenation	O
level	O
or	O
systolic	O
blood	O
pressure	O
.	O

Diastolic	O
blood	O
pressure	O
,	O
respiration	O
and	O
pulse	O
did	O
vary	O
significantly	O
with	O
position	O
.	O

The	O
effects	O
of	O
physical	Psychological
and	Psychological
emotional	Psychological
status	Psychological
on	O
adherence	O
to	O
a	O
low-fat	Other
dietary	Other
pattern	Other
in	O
the	O
Women	O
's	O
Health	O
Initiative	O
.	O

OBJECTIVE	O
To	O
examine	O
whether	O
the	O
effects	O
of	O
physical	O
and	O
emotional	O
status	O
on	O
adherance	O
to	O
a	O
low-fat	Educational
(	Educational
20	Educational
%	Educational
energy	Educational
)	Educational
dietary	Educational
pattern	Educational
are	O
mediated	O
by	O
participation	O
in	O
an	O
intervention	Educational
program	Educational
(	Educational
attending	Educational
sessions	Educational
and	Educational
self-monitoring	Educational
)	Educational
.	Educational

DESIGN	O
The	O
Baron	O
and	O
Kenny	O
mediator	O
model	O
,	O
a	O
series	O
of	O
4	O
regression	O
analyses	O
,	O
was	O
used	O
to	O
evaluate	O
whether	O
:	O
a	O
)	O
physical	O
and	O
emotional	O
status	O
predicted	O
program	O
participation	O
,	O
b	O
)	O
program	O
participation	O
predicted	O
dietary	O
adherence	O
,	O
c	O
)	O
physical	O
and	O
emotional	O
status	O
factors	O
predicted	O
dietary	Other
adherence	Other
,	O
and	O
,	O
ultimately	O
d	O
)	O
the	O
effects	O
of	O
physical	O
and	O
emotional	O
status	O
on	O
dietary	O
adherence	O
were	O
mediated	O
by	O
program	O
participation	O
.	O

SUBJECTS/SETTING	O
Data	O
from	O
13,277	O
postmenopausal	O
women	O
randomly	O
assigned	O
to	O
the	O
low-fat	Educational
intervention	Educational
arm	O
of	O
the	O
Women	O
's	O
Health	O
Initiative	O
Dietary	O
Modification	O
Trial	O
.	O

INTERVENTION	O
The	O
nutrition	O
goals	O
for	O
women	O
randomly	O
assigned	O
to	O
the	O
low-fat	Educational
intervention	Educational
were	O
to	O
reduce	Educational
total	Educational
fat	Educational
intake	Educational
to	Educational
20	Educational
%	Educational
or	Educational
less	Educational
of	Educational
energy	Educational
from	Educational
fat	Educational
and	Educational
to	Educational
consume	Educational
5	Educational
or	Educational
more	Educational
fruit/vegetable	Educational
servings	Educational
daily	Educational
and	Educational
6	Educational
or	Educational
more	Educational
grain	Educational
servings	Educational
daily	Educational
.	Educational

MAIN	O
OUTCOME	O
MEASURES	O
Year	O
1	O
program	O
participation	O
(	O
degree	O
of	O
attending	O
group	O
sessions	O
and	O
submitting	O
fat	O
scores	O
)	O
and	O
adherence	O
to	O
the	O
low-fat	Educational
dietary	Educational
pattern	Educational
(	O
percent	O
energy	O
from	O
fat	O
)	O
as	O
predicted	O
by	O
baseline	O
physical	O
and	O
emotional	O
status	O
(	O
eight	O
SF-36	O
Health	O
Survey	O
subscales	O
)	O
.	O

RESULTS	O
Participating	O
in	O
the	O
dietary	Educational
intervention	Educational
program	Educational
reduced	O
(	O
mediated	O
)	O
the	O
negative	O
effect	O
of	O
poorer	O
mental	O
health	O
on	O
dietary	O
adherence	O
by	O
15	O
%	O
.	O

Additional	O
findings	O
included	O
that	O
a	O
10	O
%	O
increase	O
in	O
physical	O
functioning	O
increased	O
session	O
attendance	O
by	O
0.4	O
%	O
(	O
P	O
<	O
.001	O
)	O
and	O
a	O
10	O
%	O
increase	O
in	O
mental	O
health	O
predicted	O
a	O
decrease	O
in	O
percent	O
energy	O
from	O
fat	O
of	O
0.3	O
%	O
(	O
P	O
<	O
.001	O
)	O
.	O

Program	O
participation	O
had	O
a	O
marked	O
effect	O
on	O
dietary	O
adherence	O
:	O
a	O
10	O
%	O
increase	O
in	O
session	O
attendance	O
predicted	O
a	O
1.2	O
%	O
decrease	O
in	O
percent	O
energy	O
from	O
fat	O
(	O
P	O
<	O
.001	O
)	O
.	O

APPLICATIONS/CONCLUSIONS	O
Understanding	O
and	O
using	O
instruments	O
to	O
assess	O
the	O
physical	O
and	O
emotional	O
status	O
of	O
a	O
target	O
population	O
will	O
help	O
dietetic	O
professionals	O
promote	O
healthful	O
dietary	O
change	O
and	O
maintenance	O
.	O

Induction	Pharmacological
chemotherapy	Pharmacological
in	O
head	O
and	O
neck	O
cancer	O
:	O
results	O
of	O
a	O
phase	O
III	O
trial	O
.	O

Between	O
December	O
1982	O
and	O
October	O
1986	O
,	O
131	O
patients	O
with	O
stage	O
II-III-IV	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
oropharynx	O
or	O
oral	O
cavity	O
were	O
randomized	O
to	O
induction	O
chemotherapy	Pharmacological
,	O
consisting	O
of	O
bleomycin	Pharmacological
(	O
10	O
mg/m2/day	O
in	O
continuous	O
infusion	O
from	O
day	O
1	O
to	O
day	O
5	O
)	O
,	O
methotrexate	Pharmacological
(	O
120	O
mg/m2	O
on	O
day	O
2	O
)	O
followed	O
by	O
folinic	Pharmacological
acid	Pharmacological
,	O
5-fluorouracil	Pharmacological
(	O
5	O
FU	O
)	O
(	O
600	O
mg/m2	O
on	O
day	O
2	O
)	O
,	O
and	O
cisplatin	Pharmacological
(	O
120	O
mg/m2	O
on	O
day	O
4	O
)	O
every	O
4	O
weeks	O
for	O
a	O
total	O
of	O
three	O
cycles	O
followed	O
by	O
definitive	O
locoregional	O
treatment	O
versus	O
locoregional	O
treatment	O
alone	O
.	O

The	O
modalities	O
of	O
definitive	O
treatment	O
(	O
radiotherapy	Surgical
+/-	O
surgery	Surgical
)	O
were	O
chosen	O
prior	O
to	O
randomization	O
.	O

A	O
total	O
of	O
116	O
patients	O
were	O
evaluable	O
.	O

Of	O
55	O
patients	O
in	O
the	O
chemotherapy	Pharmacological
arm	O
,	O
four	O
(	O
7	O
%	O
)	O
had	O
a	O
complete	O
response	O
(	O
CR	O
)	O
and	O
23	O
(	O
42	O
%	O
)	O
a	O
partial	O
response	O
(	O
PR	O
)	O
following	O
the	O
induction	O
regimen	O
.	O

At	O
the	O
completion	O
of	O
locoregional	O
treatment	O
,	O
76	O
%	O
(	O
42	O
of	O
55	O
)	O
of	O
patients	O
in	O
the	O
experimental	O
group	O
were	O
in	O
CR	O
compared	O
to	O
89	O
%	O
(	O
54	O
of	O
61	O
)	O
in	O
the	O
control	O
group	O
.	O

There	O
was	O
no	O
difference	O
in	O
survival	O
,	O
cause-specific	O
survival	O
,	O
and	O
pattern	O
of	O
relapse	O
between	O
both	O
groups	O
.	O

The	O
median	O
survival	O
was	O
22	O
months	O
in	O
the	O
chemotherapy	O
group	O
and	O
29	O
months	O
in	O
the	O
control	O
group	O
.	O

Responders	O
to	O
chemotherapy	O
did	O
not	O
fare	O
better	O
than	O
nonresponders	O
.	O

Chemotherapy-related	O
toxicities	O
were	O
few	O
and	O
most	O
of	O
them	O
related	O
to	O
cisplatin	O
which	O
was	O
reduced	O
to	O
100	O
mg/m2	O
for	O
35	O
patients	O
.	O

There	O
were	O
no	O
treatment-related	O
deaths	O
and	O
,	O
in	O
the	O
experimental	O
arm	O
of	O
the	O
trial	O
,	O
no	O
increased	O
morbidity	O
from	O
locoregional	O
treatment	O
.	O

This	O
induction	O
regimen	O
does	O
not	O
offer	O
any	O
advantages	O
over	O
standard	O
treatment	O
.	O

Effect	O
of	O
upper	O
arm	O
brachial	O
basilic	O
and	O
prosthetic	O
forearm	O
arteriovenous	O
fistula	O
on	O
left	O
ventricular	O
hypertrophy	O
.	O

BACKGROUND	O
Creation	O
of	O
an	O
arteriovenous	O
fistula	O
(	O
AVF	O
)	O
may	O
increase	O
left	O
ventricular	O
hypertrophy	O
in	O
the	O
hemodialysis	O
population	O
.	O

Aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effects	O
of	O
a	O
brachial-basilic	Physical
(	Physical
BB	Physical
)	Physical
AVF	Physical
and	O
the	O
prosthetic	Physical
brachial-antecubital	Physical
forearm	Physical
loop	Physical
access	Physical
(	O
PTFE	O
)	O
on	O
cardiac	O
performance	O
.	O

METHODS	O
Patients	O
were	O
randomized	O
to	O
receive	O
BB-AVF	Physical
or	Physical
prosthetic	Physical
brachial-antecubital	Physical
forearm	Physical
loop	Physical
access	Physical
.	Physical

Before	O
and	O
three	O
months	O
after	O
AVF	O
creation	O
patients	O
underwent	O
an	O
echocardiographic	O
examination	O
.	O

Mann-Whitney	O
U-test	O
was	O
used	O
to	O
compare	O
relative	O
increase	O
between	O
the	O
measured	O
cardiac	O
parameters	O
for	O
the	O
two	O
groups	O
.	O

RESULTS	O
Twenty-seven	O
patients	O
participated	O
in	O
the	O
study	O
.	O

The	O
relative	O
increase	O
in	O
left	O
ventricular	O
parameters	O
was	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O

Only	O
left	O
ventricular	O
end-diastolic	O
diameter	O
tended	O
to	O
be	O
of	O
significance	O
.	O

Mean	O
blood	O
flow	O
through	O
the	O
brachial	O
artery	O
was	O
1680+/-156	O
and	O
1450+/-221	O
mL/min	O
three	O
months	O
after	O
surgery	O
for	O
the	O
PTFE	O
and	O
the	O
BB-AVF	O
group	O
,	O
respectively	O
.	O

CONCLUSION	O
After	O
three	O
months	O
of	O
follow-up	O
,	O
changes	O
in	O
cardiac	O
structure	O
were	O
comparable	O
between	O
patients	O
with	O
BB	O
and	O
PTFE	O
AVFs	O
.	O

Also	O
access	O
flow	O
was	O
comparable	O
at	O
this	O
time	O
.	O

In	O
general	O
,	O
the	O
effects	O
of	O
creation	O
of	O
a	O
fistula	O
on	O
LV	O
structure	O
were	O
limited	O
.	O

Longer	O
follow	O
up	O
time	O
may	O
be	O
needed	O
to	O
explore	O
the	O
long	O
term	O
effects	O
of	O
different	O
vascular	O
accesses	O
on	O
cardiac	O
function	O
.	O

Long	Surgical
pediatric	Surgical
colonoscope	Surgical
versus	O
intermediate	Surgical
length	Surgical
adult	Surgical
colonoscope	Surgical
for	O
colonoscopy	O
.	O

BACKGROUND	O
Controversy	O
exists	O
on	O
how	O
the	O
length	O
and	O
diameter	O
of	O
colonoscopes	O
affect	O
the	O
quality	O
of	O
colonoscopy	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
a	O
long	Surgical
pediatric	Surgical
colonoscope	Surgical
with	O
an	O
intermediate	Surgical
length	Surgical
adult	Surgical
colonoscope	Surgical
with	O
regards	O
to	O
completion	O
rate	O
and	O
cecal	O
intubation	O
time	O
.	O

Whether	O
either	O
scope	O
may	O
be	O
more	O
efficient	O
in	O
any	O
subgroups	O
was	O
also	O
investigated	O
.	O

METHODS	O
Asymptomatic	O
patients	O
admitted	O
to	O
the	O
physical	O
check-up	O
department	O
of	O
Buddhist	O
Dalin	O
Tzu	O
Chi	O
General	O
Hospital	O
were	O
included	O
.	O

A	O
single	O
endoscopist	O
performed	O
all	O
of	O
the	O
colonoscopic	Physical
examinations	Physical
under	O
sedation	O
.	O

Consecutive	O
patients	O
were	O
randomized	O
to	O
undergo	O
colonoscopy	Surgical
with	Surgical
either	Surgical
intermediate	Surgical
length	Surgical
adult	Surgical
colonoscope	Surgical
(	Surgical
CF-240I	Surgical
)	Surgical
or	O
long	Surgical
pediatric	Surgical
colonoscope	Surgical
(	Surgical
PCF-240L	Surgical
)	Surgical
.	O

The	O
success	O
rate	O
and	O
time	O
required	O
to	O
reach	O
cecum	O
were	O
compared	O
between	O
the	O
two	O
groups	O
.	O

RESULTS	O
Between	O
April	O
2005	O
and	O
February	O
2006	O
,	O
a	O
total	O
of	O
918	O
patients	O
were	O
enrolled	O
.	O

Incomplete	O
colonoscopy	O
occurred	O
in	O
21	O
(	O
2.3	O
%	O
)	O
cases	O
(	O
14	O
in	O
the	O
CF-240I	O
group	O
and	O
seven	O
in	O
the	O
PCF-240L	O
group	O
,	O
P	O
>	O
0.1	O
)	O
.	O

The	O
overall	O
cecal	O
mean	O
insertion	O
time	O
was	O
6.00	O
+/-	O
3.66	O
min	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
CF-240I	Surgical
and	O
PCF	Surgical
240L	Surgical
groups	O
with	O
regard	O
to	O
the	O
cecal	O
intubation	O
rate	O
(	O
96.9	O
%	O
vs	O
98.5	O
%	O
,	O
P	O
=	O
0.18	O
)	O
,	O
the	O
need	O
for	O
abdominal	O
pressure	O
(	O
71.7	O
%	O
vs	O
73.4	O
%	O
,	O
P	O
=	O
0.55	O
)	O
and	O
change	O
of	O
position	O
(	O
13.5	O
%	O
vs	O
11.5	O
%	O
,	O
P	O
=	O
0.37	O
)	O
.	O

However	O
,	O
the	O
cecal	O
intubation	O
time	O
was	O
shorter	O
in	O
the	O
CF-240I	O
group	O
(	O
5.75	O
+/-	O
3.18	O
vs	O
6.26	O
+/-	O
3.30	O
min	O
,	O
P	O
=	O
0.02	O
)	O
.	O

Subgroup	O
analysis	O
by	O
sex	O
,	O
age	O
,	O
and	O
body	O
mass	O
index	O
showed	O
comparable	O
outcomes	O
between	O
the	O
two	O
groups	O
except	O
that	O
the	O
cecal	O
intubation	O
times	O
were	O
significantly	O
shorter	O
in	O
the	O
CF-240I	O
group	O
when	O
only	O
men	O
(	O
4.78	O
+/-	O
2.57	O
vs	O
5.50	O
+/-	O
2.93	O
min	O
,	O
P	O
<	O
0.01	O
)	O
or	O
those	O
younger	O
than	O
50	O
years	O
(	O
5.50	O
+/-	O
2.90	O
vs	O
6.25	O
+/-	O
3.68	O
min	O
,	O
P	O
=	O
0.02	O
)	O
were	O
considered	O
.	O

CONCLUSION	O
Cecal	O
intubation	O
time	O
is	O
shorter	O
in	O
patients	O
examined	O
with	O
an	O
intermediate	Surgical
length	Surgical
adult	Surgical
colonoscope	Surgical
,	O
mainly	O
in	O
the	O
subgroups	O
of	O
men	O
and	O
those	O
younger	O
than	O
50	O
years	O
of	O
age	O
.	O

Migration	O
of	O
the	O
acetabular	O
component	O
:	O
effect	O
of	O
cement	Physical
pressurization	Physical
and	O
significance	O
of	O
early	O
radiolucency	O
:	O
a	O
randomized	O
5-year	O
study	O
using	O
radiostereometry	Other
.	Other

BACKGROUND	O
Cementing	O
technique	O
is	O
a	O
crucial	O
factor	O
in	O
prosthesis	O
fixation	O
.	O

No	O
randomized	O
studies	O
have	O
been	O
published	O
,	O
however	O
,	O
comparing	O
the	O
outcome	O
of	O
conventional	O
fingerpacking	O
with	O
the	O
outcome	O
of	O
pressurization	O
of	O
the	O
cement	O
prior	O
to	O
cup	O
insertion	O
.	O

PATIENTS	O
AND	O
METHODS	O
We	O
randomized	O
50	O
THAs	O
to	O
either	O
fingerpacking	Other
or	O
sequential	Physical
pressurization	Physical
(	Other
including	Other
individual	Other
pressurization	Other
of	Other
each	Other
anchorage	Other
hole	Other
)	Other
and	O
followed	O
the	O
patients	O
with	O
RSA	Other
for	O
5	O
years	O
.	O

The	O
penetration	O
of	O
cement	O
into	O
the	O
anchorage	O
holes	O
was	O
measured	O
on	O
digital	O
radiographs	O
.	O

Postoperative	O
radiolucent	O
lines	O
around	O
the	O
cup	O
were	O
correlated	O
to	O
later	O
RSA	O
results	O
.	O

For	O
clinical	O
evaluation	O
,	O
we	O
used	O
SF-36	O
and	O
HHS	O
.	O

RESULTS	O
The	O
pressurized	O
group	O
of	O
THAs	O
was	O
more	O
stable	O
regarding	O
changes	O
in	O
inclination	O
.	O

We	O
found	O
no	O
other	O
difference	O
in	O
the	O
migratory	O
behavior	O
.	O

The	O
cement	O
penetration	O
into	O
the	O
anchorage	O
holes	O
was	O
deeper	O
with	O
the	O
pressurization	O
technique	O
than	O
with	O
fingerpacking	O
.	O

For	O
the	O
whole	O
group	O
taken	O
together	O
,	O
there	O
was	O
a	O
strong	O
relation	O
between	O
the	O
presence	O
of	O
radiolucent	O
lines	O
as	O
measured	O
on	O
the	O
postoperative	O
radiograph	O
and	O
later	O
migration	O
observed	O
by	O
RSA	O
at	O
2	O
and	O
5	O
years	O
.	O

INTERPRETATION	O
Pressurization	O
of	O
the	O
cement	O
produced	O
better	O
cement	O
penetration	O
and	O
increased	O
the	O
cup	O
stability	O
in	O
terms	O
of	O
changes	O
in	O
inclination	O
.	O

Early	O
findings	O
of	O
radiolucent	O
lines	O
can	O
predict	O
later	O
unfavorable	O
cup	O
migration	O
.	O

B-domain	Pharmacological
deleted	Pharmacological
recombinant	Pharmacological
factor	Pharmacological
VIII	Pharmacological
preparations	Pharmacological
are	O
bioequivalent	O
to	O
a	O
monoclonal	O
antibody	O
purified	O
plasma-derived	O
factor	O
VIII	O
concentrate	O
:	O
a	O
randomized	O
,	O
three-way	O
crossover	O
study	O
.	O

BACKGROUND	O
Deletion	O
of	O
the	O
B-domain	O
of	O
recombinant	O
blood	O
coagulation	O
factor	O
VIII	O
(	O
BDDrFVIII	O
)	O
increases	O
the	O
manufacturing	O
yield	O
of	O
the	O
product	O
but	O
does	O
not	O
impair	O
in	O
vitro	O
or	O
in	O
vivo	O
functionality	O
.	O

BDDrFVIII	O
(	O
ReFacto	O
)	O
has	O
been	O
developed	O
with	O
the	O
additional	O
benefit	O
of	O
being	O
formulated	O
without	O
human	O
albumin	O
.	O

OBJECTIVE	O
The	O
primary	O
objective	O
of	O
this	O
three-way	O
crossover-design	O
study	O
was	O
to	O
compare	O
the	O
pharmacokinetic	O
(	O
PK	O
)	O
parameters	O
of	O
two	O
BDDrFVIII	Pharmacological
formulations	Pharmacological
(	O
one	O
reconstituted	O
with	O
5	O
mL	O
of	O
sterile	O
water	O
,	O
the	O
other	O
reconstituted	O
with	O
4	O
mL	O
sodium	O
chloride	O
0.9	O
%	O
USP	O
)	O
with	O
those	O
of	O
a	O
plasma-derived	O
,	O
full-length	Pharmacological
FVIII	Pharmacological
preparation	Pharmacological
(	Pharmacological
Hemofil	Pharmacological
M	Pharmacological
)	Pharmacological
in	O
patients	O
with	O
haemophilia	O
A	O
to	O
determine	O
bioequivalence	O
.	O

METHODS	O
A	O
series	O
of	O
blood	O
samples	O
were	O
collected	O
over	O
a	O
period	O
of	O
48	O
h	O
after	O
i.v	O
.	O

administration	O
of	O
each	O
of	O
the	O
FVIII	Pharmacological
preparations	Pharmacological
.	Pharmacological

Plasma	O
FVIII	O
activity	O
was	O
determined	O
using	O
a	O
validated	O
chromogenic	O
substrate	O
assay	O
.	O

Plasma	O
FVIII	O
activity	O
vs.	O
time	O
curves	O
was	O
characterized	O
for	O
a	O
standard	O
set	O
of	O
PK	O
parameter	O
estimates	O
.	O

Two	O
parameter	O
estimates	O
,	O
the	O
maximum	O
plasma	O
concentration	O
(	O
Cmax	O
)	O
and	O
the	O
area	O
under	O
plasma	O
concentration	O
vs.	O
time	O
curves	O
(	O
AUCs	O
)	O
,	O
were	O
used	O
to	O
evaluate	O
bioequivalence	O
.	O

The	O
two	O
preparations	O
were	O
considered	O
bioequivalent	O
if	O
the	O
90	O
%	O
confidence	O
intervals	O
for	O
the	O
ratio	O
of	O
geometric	O
means	O
for	O
Cmax	O
and	O
AUCs	O
fell	O
within	O
the	O
bioequivalence	O
window	O
of	O
80	O
%	O
to	O
125	O
%	O
.	O

RESULTS/CONCLUSION	O
Results	O
show	O
that	O
each	O
BDDrFVIII	Pharmacological
formulation	Pharmacological
is	O
bioequivalent	O
to	O
Hemofil	O
M	O
and	O
the	O
two	O
formulations	O
of	O
BDDrFVIII	O
are	O
bioequivalent	O
to	O
each	O
other	O
.	O

Short-term	O
studies	O
on	O
the	O
use	O
of	O
glycerol	Pharmacological
as	O
an	O
osmotic	O
agent	O
in	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
(	O
CAPD	O
)	O
.	O

The	O
use	O
of	O
glycerol	Pharmacological
as	O
an	O
osmotic	O
agent	O
in	O
two	O
different	O
concentrations	O
(	O
92	O
mmol/l	O
and	O
272	O
mmol/l	O
)	O
in	O
peritoneal	O
dialysis	O
fluid	O
was	O
investigated	O
over	O
3	O
days	O
in	O
six	O
patients	O
on	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
and	O
compared	O
with	O
two	O
concentrations	O
of	O
glucose	Control
(	O
76	O
mmol/l	O
and	O
215	O
mmol/l	O
)	O
in	O
the	O
same	O
patients	O
.	O

The	O
calorific	O
value	O
of	O
the	O
absorbed	O
osmotic	O
agent	O
was	O
lower	O
,	O
by	O
19	O
%	O
with	O
isotonic	O
and	O
22	O
%	O
with	O
hypertonic	O
solutions	O
,	O
when	O
glycerol	Pharmacological
was	O
used	O
in	O
place	O
of	O
glucose	Control
.	O

However	O
,	O
glycerol	O
provided	O
significantly	O
lower	O
total	O
ultrafiltration	O
than	O
glucose	O
at	O
each	O
concentration	O
,	O
despite	O
a	O
higher	O
initial	O
osmotic	O
pressure	O
of	O
the	O
glycerol-based	O
solutions	O
.	O

Thus	O
,	O
the	O
higher	O
concentration	O
of	O
glycerol	O
required	O
to	O
provide	O
equal	O
ultrafiltration	O
may	O
offset	O
any	O
calorific	O
advantage	O
.	O

Equilibration	O
of	O
creatinine	O
and	O
urea	O
was	O
slower	O
and	O
creatinine	O
clearance	O
lower	O
with	O
glycerol	Pharmacological
.	O

Solutions	O
containing	O
glycerol	Pharmacological
were	O
initially	O
less	O
acid	O
(	O
pH	O
6.5	O
)	O
than	O
those	O
containing	O
glucose	O
(	O
pH	O
5.1	O
)	O
.	O

Blood	O
glycerol	O
levels	O
,	O
which	O
were	O
in	O
the	O
physiological	O
range	O
with	O
glucose	O
as	O
the	O
osmotic	O
agent	O
,	O
reached	O
a	O
peak	O
80-fold	O
greater	O
at	O
4.3	O
+/-	O
0.8	O
mmol/l	O
during	O
dialysis	O
with	O
fluid	O
containing	O
glycerol	Pharmacological
at	O
272	O
mmol/l	O
and	O
eightfold	O
higher	O
at	O
0.42	O
+/-	O
0.09	O
mmol/l	O
with	O
glycerol	Pharmacological
at	O
92	O
mmol/l	O
.	O

There	O
was	O
no	O
evidence	O
of	O
haemolysis	O
or	O
other	O
toxic	O
effect	O
despite	O
these	O
levels	O
.	O

The	O
rise	O
in	O
blood	O
glucose	O
and	O
insulin	O
noted	O
during	O
the	O
use	O
of	O
glucose-based	O
solutions	O
was	O
not	O
found	O
with	O
glycerol	Pharmacological
.	O

Circulating	O
levels	O
of	O
lactate	O
,	O
pyruvate	O
,	O
alanine	O
,	O
non-esterified	O
fatty	O
acids	O
and	O
the	O
ketone	O
bodies	O
were	O
similar	O
with	O
the	O
two	O
agents	O
.	O

Although	O
these	O
short-term	O
studies	O
have	O
shown	O
no	O
conclusive	O
advantage	O
of	O
glycerol	Pharmacological
over	O
glucose	Control
,	O
long-term	O
effects	O
of	O
glycerol	Pharmacological
,	O
particularly	O
on	O
circulating	O
lipid	O
levels	O
,	O
will	O
determine	O
its	O
future	O
role	O
as	O
an	O
osmotic	O
agent	O
in	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
.	O

Motion	Physical
style	Physical
acupuncture	Physical
treatment	Physical
(	Physical
MSAT	Physical
)	Physical
for	O
acute	O
low	O
back	O
pain	O
with	O
severe	O
disability	O
:	O
a	O
multicenter	O
,	O
randomized	O
,	O
controlled	O
trial	O
protocol	O
.	O

BACKGROUND	O
Acupuncture	O
is	O
widely-used	O
to	O
treat	O
patients	O
with	O
low	O
back	O
pain	O
,	O
despite	O
insufficient	O
evidence	O
of	O
the	O
technique	O
's	O
efficacy	O
for	O
acute	O
back	O
pain	O
.	O

Motion	Physical
style	Physical
acupuncture	Physical
treatment	Physical
(	Physical
MSAT	Physical
)	Physical
is	O
a	O
non-traditional	O
acupuncture	O
treatment	O
requiring	O
a	O
patient	O
to	O
exercise	O
while	O
receiving	O
acupuncture	O
.	O

In	O
Korea	O
,	O
MSAT	O
is	O
used	O
to	O
reduce	O
musculoskeletal	O
pain	O
and	O
improve	O
functional	O
status	O
.	O

The	O
study	O
aims	O
to	O
evaluate	O
the	O
effect	O
of	O
MSAT	O
on	O
acute	O
low	O
back	O
pain	O
with	O
severe	O
disability	O
.	O

METHODS/DESIGN	O
This	O
study	O
is	O
a	O
multicenter	O
,	O
randomized	O
,	O
active-controlled	O
trial	O
with	O
two	O
parallel	O
arms	O
.	O

Participants	O
with	O
acute	O
low	O
back	O
pain	O
and	O
severe	O
functional	O
disability	O
,	O
defined	O
as	O
an	O
Oswestry	O
Disability	O
Index	O
(	O
ODI	O
)	O
value	O
>	O
60	O
%	O
,	O
will	O
be	O
randomly	O
allocated	O
to	O
the	O
acupuncture	Physical
group	O
and	O
the	O
nonsteroidal	Pharmacological
anti-inflammatory	Pharmacological
drug	Pharmacological
(	Pharmacological
NSAID	Pharmacological
)	Pharmacological
injection	Pharmacological
group	Pharmacological
.	O

The	O
acupuncture	O
group	O
will	O
receive	O
MSAT	Physical
and	O
the	O
NSAID	Pharmacological
injection	Pharmacological
group	Pharmacological
will	O
receive	O
an	O
intramuscular	O
injection	O
of	O
diclofenac	Pharmacological
.	Pharmacological

All	O
procedures	O
will	O
be	O
limited	O
to	O
one	O
session	O
and	O
the	O
symptoms	O
before	O
and	O
after	O
treatment	O
will	O
be	O
measured	O
by	O
assessors	O
blinded	O
to	O
treatment	O
allocation	O
.	O

The	O
primary	O
outcome	O
will	O
be	O
measured	O
at	O
30	O
minutes	O
after	O
treatment	O
using	O
the	O
numerical	O
rating	O
scale	O
(	O
NRS	O
)	O
of	O
low	O
back	O
pain	O
while	O
the	O
patient	O
is	O
moving	O
.	O

Secondary	O
outcomes	O
will	O
be	O
measured	O
at	O
30	O
minutes	O
after	O
treatment	O
using	O
the	O
NRS	O
of	O
leg	O
pain	O
,	O
ODI	O
,	O
patient	O
global	O
impression	O
of	O
change	O
,	O
range	O
of	O
motion	O
(	O
ROM	O
)	O
of	O
the	O
lumbar	O
spine	O
,	O
and	O
degrees	O
of	O
straight	O
leg	O
raising	O
(	O
SLR	O
)	O
.	O

Post-treatment	O
follow-up	O
will	O
be	O
performed	O
to	O
measure	O
primary	O
and	O
secondary	O
outcomes	O
with	O
the	O
exception	O
of	O
ROM	O
and	O
SLR	O
at	O
2	O
,	O
4	O
,	O
and	O
24	O
weeks	O
after	O
treatment	O
.	O

DISCUSSION	O
The	O
results	O
of	O
this	O
trial	O
will	O
be	O
discussed	O
.	O

TRIAL	O
REGISTRATION	O
ClinicalTrial.gov	O
NCT01315561	O
.	O

B-type	Other
natriuretic	Other
peptide	Other
in	O
the	O
evaluation	O
and	O
management	O
of	O
dyspnoea	O
in	O
primary	O
care	O
.	O

OBJECTIVES	O
The	O
rapid	O
and	O
accurate	O
diagnosis	O
of	O
heart	O
failure	O
in	O
primary	O
care	O
is	O
a	O
major	O
unmet	O
clinical	O
need	O
.	O

We	O
evaluated	O
the	O
additional	O
use	O
of	O
B-type	Other
natriuretic	Other
peptide	Other
(	Other
BNP	Other
)	Other
levels	O
.	O

DESIGN	O
A	O
randomized	O
controlled	O
trial	O
.	O

SETTING	O
Twenty-nine	O
primary	O
care	O
physicians	O
in	O
Switzerland	O
and	O
Germany	O
coordinated	O
by	O
the	O
University	O
Hospital	O
Basel	O
,	O
Switzerland	O
.	O

SUBJECTS	O
A	O
total	O
of	O
323	O
consecutive	O
patients	O
presenting	O
with	O
dyspnoea	O
.	O

INTERVENTIONS	O
Assignment	O
in	O
a	O
1	O
:	O
1	O
ratio	O
to	O
a	O
diagnostic	Other
strategy	Other
including	Other
point-of-care	Other
measurement	Other
of	Other
BNP	Other
(	O
n	O
=	O
163	O
)	O
or	O
standard	Control
assessment	Control
without	Control
BNP	Control
(	O
n	O
=	O
160	O
)	O
.	O

The	O
total	O
medical	O
cost	O
at	O
3	O
months	O
was	O
the	O
primary	O
end-point	O
.	O

Secondary	O
end-points	O
were	O
diagnostic	O
certainty	O
,	O
time	O
to	O
appropriate	O
therapy	O
,	O
functional	O
capacity	O
,	O
hospitalization	O
and	O
mortality	O
.	O

The	O
final	O
diagnosis	O
was	O
adjudicated	O
by	O
a	O
physician	O
blinded	O
to	O
the	O
BNP	O
levels	O
.	O

RESULTS	O
Heart	O
failure	O
was	O
the	O
final	O
diagnosis	O
in	O
34	O
%	O
of	O
patients	O
.	O

The	O
number	O
of	O
hospitalizations	O
,	O
functional	O
status	O
and	O
total	O
medical	O
cost	O
at	O
3	O
months	O
[	O
median	O
$	O
1655	O
,	O
interquartile	O
range	O
(	O
IQR	O
)	O
,	O
850-3331	O
vs.	O
$	O
1541	O
,	O
IQR	O
859-2827	O
;	O
P	O
=	O
0.68	O
]	O
were	O
similar	O
in	O
both	O
groups	O
.	O

BNP	O
increased	O
diagnostic	O
certainty	O
as	O
defined	O
by	O
the	O
need	O
for	O
further	O
diagnostic	O
work-up	O
(	O
33	O
%	O
vs.	O
45	O
%	O
;	O
P	O
=	O
0.02	O
)	O
and	O
accelerated	O
the	O
initiation	O
of	O
the	O
appropriate	O
treatment	O
(	O
13	O
days	O
vs.	O
25	O
days	O
;	O
P	O
=	O
0.01	O
)	O
.	O

The	O
area	O
under	O
the	O
receiver-operating	O
characteristics	O
curve	O
for	O
BNP	O
to	O
identify	O
heart	O
failure	O
was	O
0.87	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
0.81-0.93	O
)	O
.	O

CONCLUSIONS	O
The	O
use	O
of	O
BNP	Other
levels	Other
in	O
primary	O
care	O
did	O
not	O
reduce	O
total	O
medical	O
cost	O
,	O
but	O
improved	O
some	O
of	O
the	O
secondary	O
end-points	O
including	O
diagnostic	O
certainty	O
and	O
time	O
to	O
initiation	O
of	O
appropriate	O
treatment	O
.	O

[	O
Methodologic	O
comparison	O
of	O
the	O
polyfrequency	Physical
oscillation	Physical
method	Physical
,	O
transcutaneous	O
oxygen	O
pressure	O
measurement	O
and	O
body	O
plethysmography	O
in	O
bronchial	O
provocation	O
with	O
methacholine	Pharmacological
]	O
.	O

A	O
bronchial	O
provocation	O
challenge	O
test	O
was	O
conducted	O
with	O
30	O
subjects	O
using	O
metacholin	Pharmacological
.	Pharmacological

In	O
randomised	O
sequence	O
lung	O
function	O
analysis	O
tests	O
were	O
carried	O
out	O
with	O
the	O
bodyplethysmograph	Physical
(	O
Raw	O
,	O
FEV1	O
)	O
and	O
the	O
polyfrequent	O
oscillation	O
method	O
(	O
resistance	O
,	O
reactance	O
between	O
2	O
and	O
52	O
Hz	O
)	O
,	O
whereas	O
the	O
transcutaneous	Pharmacological
oxygen	Pharmacological
pressure	Pharmacological
(	O
tc-PO2	O
)	O
was	O
measured	O
continuously	O
.	O

Correlations	O
between	O
the	O
various	O
parameters	O
,	O
the	O
change	O
of	O
the	O
values	O
at	O
PD60	O
sGaw	O
in	O
relation	O
to	O
the	O
initial	O
values	O
,	O
the	O
interindividual	O
variability	O
and	O
the	O
reactivity	O
were	O
determined	O
.	O

Medium	O
correlations	O
were	O
found	O
for	O
the	O
oscillatory	O
parameters	O
and	O
Raw	O
,	O
whereas	O
for	O
tc-PO2	O
and	O
Raw	O
the	O
correlation	O
was	O
markedly	O
lower	O
.	O

In	O
terms	O
of	O
percentage	O
the	O
greatest	O
change	O
was	O
found	O
in	O
reactance	O
,	O
in	O
relation	O
to	O
the	O
initial	O
value	O
,	O
followed	O
by	O
Raw	O
and	O
FEV1	O
.	O

The	O
interindividual	O
variability	O
resulted	O
in	O
the	O
highest	O
values	O
for	O
the	O
reactance	O
,	O
followed	O
by	O
Raw	O
and	O
FEV1	O
.	O

Interindividual	O
variability	O
showed	O
the	O
highest	O
values	O
for	O
the	O
reactance	O
before	O
oscillatory	O
resistance	O
and	O
Raw	O
.	O

In	O
respect	O
of	O
reactivity	O
,	O
reactance	O
also	O
had	O
the	O
highest	O
values	O
.	O

Overall	O
evaluation	O
showed	O
that	O
bodyplethysmography	Physical
and	O
the	O
polyfrequent	Physical
oscillation	Physical
method	Physical
(	O
reactance	O
or	O
resonance	O
frequency	O
)	O
are	O
comparably	O
sensitive	O
.	O

Immunologic	O
response	O
after	O
laparoscopic	O
colon	O
cancer	O
operation	O
within	O
an	O
enhanced	O
recovery	O
program	O
.	O

OBJECTIVE	O
It	O
has	O
been	O
demonstrated	O
that	O
colon	O
operation	O
combined	O
with	O
fast-track	O
(	O
FT	O
)	O
surgery	O
and	O
laparoscopic	O
technique	O
can	O
shorten	O
the	O
length	O
of	O
hospital	O
stay	O
,	O
accelerate	O
recovery	O
of	O
intestinal	O
function	O
,	O
and	O
reduce	O
the	O
occurrence	O
of	O
post-operative	O
complications	O
.	O

However	O
,	O
there	O
are	O
no	O
reports	O
regarding	O
the	O
combined	O
effects	O
of	O
FT	O
colon	O
operation	O
and	O
laparoscopic	O
technique	O
on	O
humoral	O
inflammatory	O
cellular	O
immunity	O
.	O

METHODS	O
This	O
was	O
a	O
prospective	O
,	O
controlled	O
study	O
.	O

One	O
hundred	O
sixty-three	O
colon	O
cancer	O
patients	O
underwent	O
the	O
traditional	Surgical
protocol	Surgical
and	Surgical
open	Surgical
operation	Surgical
(	O
traditional	O
open	O
group	O
,	O
n=42	O
)	O
,	O
the	O
traditional	Surgical
protocol	Surgical
and	Surgical
laparoscopic	Surgical
operation	Surgical
(	O
traditional	O
laparoscopic	O
group	O
,	O
n=40	O
)	O
,	O
the	O
FT	Surgical
protocol	Surgical
and	Surgical
open	Surgical
operation	Surgical
(	O
FT	O
open	O
group	O
,	O
n=41	O
)	O
,	O
or	O
the	O
FT	Surgical
protocol	Surgical
and	Surgical
laparoscopic	Surgical
operation	Surgical
(	O
FT	O
laparoscopic	O
group	O
,	O
n=40	O
)	O
.	O

Blood	O
samples	O
were	O
taken	O
prior	O
to	O
operation	O
as	O
well	O
as	O
on	O
days	O
1	O
,	O
3	O
,	O
and	O
5	O
after	O
operation	O
.	O

The	O
number	O
of	O
lymphocyte	O
subpopulations	O
was	O
determined	O
by	O
flow	O
cytometry	O
,	O
and	O
serum	O
interleukin-6	O
and	O
C-reactive	O
protein	O
levels	O
were	O
measured	O
.	O

Post-operative	O
hospital	O
stay	O
,	O
post-operative	O
morbidity	O
,	O
readmission	O
rate	O
,	O
and	O
in-hospital	O
mortality	O
were	O
recorded	O
.	O

RESULTS	O
Compared	O
with	O
open	O
operation	O
,	O
laparoscopic	O
colon	O
operation	O
effectively	O
inhibited	O
the	O
release	O
of	O
post-operative	O
inflammatory	O
factors	O
and	O
yielded	O
good	O
protection	O
via	O
post-operative	O
cell	O
immunity	O
.	O

FT	O
surgery	O
had	O
a	O
better	O
protective	O
role	O
with	O
respect	O
to	O
the	O
post-operative	O
immune	O
system	O
compared	O
with	O
traditional	O
peri-operative	O
care	O
.	O

Inflammatory	O
reactions	O
,	O
based	O
on	O
interleukin-6	O
and	O
C-reactive	O
protein	O
levels	O
,	O
were	O
less	O
intense	O
following	O
FT	O
laparoscopic	O
operation	O
compared	O
to	O
FT	O
open	O
operation	O
;	O
however	O
,	O
there	O
were	O
no	O
differences	O
in	O
specific	O
immunity	O
(	O
CD3+	O
and	O
CD4+	O
counts	O
,	O
and	O
the	O
CD4+/CD8+	O
ratio	O
)	O
during	O
these	O
two	O
types	O
of	O
surgical	O
procedures	O
.	O

Post-operative	O
hospital	O
stay	O
in	O
patients	O
randomized	O
to	O
the	O
FT	O
laparoscopic	O
group	O
was	O
significantly	O
shorter	O
than	O
in	O
the	O
other	O
three	O
treatment	O
groups	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Post-operative	O
complications	O
in	O
patients	O
who	O
underwent	O
FT	O
laparoscopic	O
treatment	O
were	O
less	O
than	O
in	O
the	O
other	O
three	O
treatment	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
four	O
treatment	O
groups	O
regarding	O
readmission	O
rate	O
and	O
in-hospital	O
mortality	O
.	O

CONCLUSIONS	O
The	O
laparoscopic	O
technique	O
and	O
FT	O
surgery	O
rehabilitation	O
program	O
effectively	O
inhibited	O
release	O
of	O
post-operative	O
inflammatory	O
factors	O
with	O
a	O
reduction	O
in	O
peri-operative	O
trauma	O
and	O
stress	O
,	O
which	O
together	O
played	O
a	O
protective	O
role	O
on	O
the	O
post-operative	O
immune	O
system	O
.	O

Combining	O
two	O
treatment	O
measures	O
during	O
colon	O
operation	O
produced	O
better	O
protective	O
effects	O
via	O
the	O
immune	O
system	O
.	O

The	O
beneficial	O
clinical	O
effects	O
support	O
that	O
the	O
better-preserved	O
post-operative	O
immune	O
system	O
may	O
also	O
contribute	O
to	O
the	O
improvement	O
of	O
post-operative	O
results	O
in	O
FT	O
laparoscopic	O
patients	O
.	O

Enhancing	O
the	O
self-esteem	O
of	O
inpatient	O
alcoholics	O
.	O

This	O
study	O
examined	O
the	O
effect	O
of	O
pairing	O
inpatient	O
alcoholics	O
with	O
nursing	Other
home	Other
residents	Other
(	Other
NHRs	Other
)	Other
on	O
the	O
alcoholics	O
'	O
self-esteem	O
.	O

In	O
this	O
PALS	O
program	O
,	O
the	O
alcoholic	O
inpatients	O
assumed	O
a	O
helping-companion	O
relationship	O
with	O
the	O
NHRs	O
for	O
2	O
hr	O
per	O
day	O
during	O
their	O
last	O
2	O
weeks	O
of	O
treatment	O
.	O

Fifty	O
alcoholic	O
inpatients	O
were	O
randomly	O
assigned	O
to	O
the	O
PALS	Psychological
program	Psychological
(	O
n	O
=	O
25	O
)	O
or	O
to	O
the	O
library	Psychological
for	Psychological
free	Psychological
reading	Psychological
time	Psychological
(	O
n	O
=	O
25	O
)	O
.	O

The	O
Tennessee	O
Self-Concept	O
Scale	O
(	O
TSCS	O
)	O
was	O
administered	O
to	O
all	O
subjects	O
in	O
both	O
groups	O
before	O
and	O
after	O
the	O
interventions	O
.	O

Of	O
the	O
nine	O
TSCS	O
scales	O
,	O
the	O
improvement	O
on	O
the	O
Moral-Ethical	O
scale	O
was	O
significantly	O
greater	O
in	O
the	O
PALS	O
group	O
.	O

Because	O
the	O
alcoholic	O
inpatients	O
in	O
the	O
PALS	O
group	O
engaged	O
in	O
altruistic	O
(	O
moral	O
)	O
behavior	O
,	O
this	O
study	O
provides	O
a	O
logical	O
link	O
between	O
the	O
intervention	O
and	O
the	O
outcome	O
,	O
which	O
has	O
been	O
a	O
prevalent	O
weakness	O
in	O
previous	O
studies	O
of	O
self-esteem	O
in	O
alcoholics	O
.	O

Transurethral	Surgical
prostate	Surgical
resection	Surgical
and	O
bleeding	O
:	O
a	O
randomized	O
,	O
placebo	Control
controlled	O
trial	O
of	O
role	O
of	O
finasteride	Pharmacological
for	O
decreasing	O
operative	O
blood	O
loss	O
.	O

PURPOSE	O
Bleeding	O
associated	O
with	O
transurethral	O
prostate	O
resection	O
can	O
often	O
be	O
significant	O
and	O
lead	O
to	O
increased	O
morbidity	O
and	O
occasionally	O
mortality	O
.	O

It	O
has	O
been	O
shown	O
that	O
finasteride	Pharmacological
decreases	O
bleeding	O
in	O
patients	O
with	O
hematuria	O
of	O
prostatic	O
origin	O
.	O

We	O
hypothesized	O
that	O
bleeding	O
in	O
patients	O
undergoing	O
transurethral	O
prostate	O
resection	O
could	O
be	O
decreased	O
by	O
giving	O
finasteride	Pharmacological
for	O
2	O
weeks	O
before	O
surgery	O
.	O

MATERIALS	O
AND	O
METHODS	O
A	O
total	O
70	O
patients	O
scheduled	O
to	O
undergo	O
elective	O
transurethral	O
prostate	O
resection	O
were	O
randomized	O
to	O
receive	O
5	Pharmacological
mg.	Pharmacological
finasteride	Pharmacological
daily	Pharmacological
or	O
placebo	Control
for	O
2	O
weeks	O
before	O
surgery	O
.	O

Serum	O
hemoglobin	O
was	O
measured	O
before	O
and	O
after	O
surgery	O
,	O
and	O
the	O
following	O
day	O
.	O

The	O
volume	O
of	O
irrigation	O
fluid	O
used	O
and	O
its	O
hemoglobin	O
concentration	O
as	O
well	O
as	O
resected	O
prostate	O
weight	O
were	O
recorded	O
.	O

RESULTS	O
Of	O
the	O
68	O
patients	O
who	O
underwent	O
transurethral	O
prostate	O
resection	O
2	O
were	O
withdrawn	O
before	O
surgery	O
,	O
and	O
so	O
32	O
received	O
finasteride	Pharmacological
and	O
36	O
received	O
placebo	Control
.	O

There	O
was	O
significantly	O
less	O
mean	O
blood	O
loss	O
in	O
irrigation	O
fluid	O
in	O
the	O
finasteride	Pharmacological
group	O
than	O
in	O
the	O
control	O
group	O
(	O
43.6	O
versus	O
69.3	O
gm	O
.	O

hemoglobin	O
,	O
p	O
=	O
0.011	O
)	O
.	O

The	O
mean	O
difference	O
was	O
more	O
significant	O
when	O
blood	O
loss	O
per	O
gm	O
.	O

resected	O
prostate	O
was	O
calculated	O
(	O
2.65	O
versus	O
4.65	O
gm	O
.	O

hemoglobin	O
per	O
gm	O
.	O

prostate	O
,	O
p	O
<	O
0.01	O
)	O
.	O

CONCLUSIONS	O
This	O
study	O
shows	O
that	O
finasteride	Pharmacological
given	O
for	O
2	O
weeks	O
preoperatively	O
decreases	O
bleeding	O
in	O
patients	O
undergoing	O
transurethral	O
prostate	O
resection	O
.	O

Further	O
study	O
is	O
required	O
to	O
determine	O
the	O
optimal	O
timing	O
and	O
dose	O
duration	O
to	O
minimize	O
blood	O
loss	O
and	O
identify	O
how	O
relevant	O
such	O
a	O
decrease	O
in	O
bleeding	O
is	O
in	O
clinical	O
practice	O
.	O

Immunogenicity	O
and	O
safety	O
of	O
a	O
plasma-derived	Pharmacological
heat-inactivated	Pharmacological
hepatitis	Pharmacological
B	Pharmacological
vaccine	Pharmacological
(	Pharmacological
CLB	Pharmacological
)	Pharmacological
.	O

Studies	O
in	O
volunteers	O
at	O
a	O
low	O
risk	O
of	O
infection	O
with	O
hepatitis	O
B	O
virus	O
.	O

The	O
safety	O
and	O
immunogenicity	O
of	O
a	O
plasma-derived	Pharmacological
heat-inactivated	Pharmacological
hepatitis	Pharmacological
B	Pharmacological
vaccine	Pharmacological
(	Pharmacological
CLB	Pharmacological
)	Pharmacological
were	O
evaluated	O
in	O
471	O
healthy	O
human	O
volunteers	O
,	O
who	O
,	O
both	O
in	O
their	O
occupations	O
and	O
in	O
their	O
private	O
lives	O
,	O
had	O
been	O
at	O
minimal	O
risk	O
of	O
being	O
infected	O
with	O
hepatitis	O
B	O
virus	O
.	O

The	O
first	O
202	O
individuals	O
received	O
three	O
3-micrograms	O
doses	O
of	O
heat-inactivated	Pharmacological
hepatitis	Pharmacological
B	Pharmacological
surface	Pharmacological
antigen	Pharmacological
(	Pharmacological
HBsAg	Pharmacological
)	Pharmacological
at	O
one-month	O
intervals	O
(	O
trial	O
A	O
)	O
.	O

A	O
total	O
of	O
42	O
%	O
one	O
month	O
after	O
the	O
first	O
injection	O
,	O
84	O
%	O
after	O
two	O
months	O
,	O
and	O
93	O
%	O
after	O
five	O
months	O
had	O
become	O
anti-HBs	O
(	O
antibody	O
to	O
hepatitis	O
B	O
surface	O
antigen	O
)	O
positive	O
.	O

In	O
a	O
second	O
randomized	O
study	O
(	O
trial	O
B	O
)	O
,	O
the	O
immunogenicity	O
of	O
five	O
different	O
dosages	O
of	O
the	O
vaccine	O
was	O
compared	O
in	O
269	O
volunteers	O
.	O

When	O
the	O
dose	O
of	O
HBsAg	O
was	O
diminished	O
from	O
3	O
micrograms	O
to	O
1.5	O
,	O
0.6	O
,	O
and	O
0.25	O
microgram	O
,	O
no	O
decrease	O
of	O
the	O
anti-HBs	O
response	O
was	O
observed	O
.	O

However	O
,	O
when	O
the	O
dose	O
was	O
diminished	O
to	O
0.1	O
microgram	O
of	O
HBsAg	O
,	O
the	O
anti-HBs	O
response	O
dropped	O
significantly	O
to	O
63	O
%	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

In	O
the	O
recipients	O
of	O
all	O
five	O
vaccine	O
dosages	O
,	O
no	O
influence	O
of	O
sex	O
and	O
age	O
was	O
found	O
on	O
the	O
anti-HBs	O
conversion	O
rates	O
.	O

During	O
the	O
eight-month	O
observation	O
period	O
,	O
none	O
of	O
the	O
vaccinees	O
became	O
HBsAg	O
and/or	O
anti-HBc	O
(	O
antibody	O
to	O
hepatitis	O
B	O
core	O
antigen	O
)	O
positive	O
,	O
and	O
none	O
developed	O
antibodies	O
associated	O
with	O
autoimmune	O
liver	O
disease	O
.	O

No	O
serious	O
side	O
effects	O
were	O
observed	O
.	O

An	O
open	O
and	O
randomized	O
study	O
comparing	O
the	O
efficacy	O
of	O
standard	Pharmacological
danazol	Pharmacological
and	O
modified	Pharmacological
triptorelin	Pharmacological
regimens	Pharmacological
for	O
postoperative	O
disease	O
management	O
of	O
moderate	O
to	O
severe	O
endometriosis	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
efficacy	O
of	O
danazol	Pharmacological
and	O
triptorelin	Pharmacological
(	O
Decapeptyl	O
CR	O
,	O
Ferring	O
,	O
Kiel	O
,	O
Germany	O
)	O
in	O
the	O
management	O
of	O
moderate	O
and	O
severe	O
endometriosis	O
in	O
terms	O
of	O
symptom	O
control	O
and	O
revised	O
American	O
Fertility	O
Society	O
(	O
AFS	O
)	O
score	O
reduction	O
,	O
and	O
to	O
evaluate	O
the	O
hormonal	O
profile	O
of	O
patients	O
treated	O
with	O
triptorelin	Pharmacological
every	O
6	O
weeks	O
.	O

DESIGN	O
Open	O
and	O
randomized	O
trial	O
.	O

SETTING	O
Kwong	O
Wah	O
Hospital	O
,	O
a	O
large	O
public	O
hospital	O
in	O
an	O
urban	O
location	O
(	O
Hong	O
Kong	O
)	O
.	O

PATIENT	O
(	O
S	O
)	O
Forty	O
patients	O
after	O
their	O
first	O
conservative	O
operation	O
for	O
endometriosis	O
,	O
with	O
surgical	O
confirmation	O
of	O
revised	O
AFS	O
stage	O
III	O
or	O
IV	O
endometriosis	O
.	O

INTERVENTION	O
(	O
S	O
)	O
Postoperative	O
6	O
months	O
'	O
therapy	O
of	O
danazol	Pharmacological
or	O
triptorelin	Pharmacological
every	O
6	O
weeks	O
,	O
postmedical	O
therapy	O
second-look	O
laparoscopy	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
(	O
S	O
)	O
Symptom	O
control	O
and	O
patients	O
'	O
tolerance	O
during	O
medical	O
therapy	O
,	O
posttherapy	O
revised	O
AFS	O
score	O
,	O
hormonal	O
profile	O
during	O
triptorelin	O
therapy	O
.	O

RESULT	O
(	O
S	O
)	O
Pain	O
control	O
was	O
similar	O
between	O
danazol	Pharmacological
and	O
triptorelin	Pharmacological
therapy	O
.	O

There	O
was	O
less	O
breakthrough	O
bleeding	O
with	O
triptorelin	Pharmacological
.	Pharmacological

More	O
patients	O
failed	O
to	O
complete	O
the	O
whole	O
course	O
of	O
danazol	Pharmacological
because	O
of	O
its	O
side	O
effects	O
.	O

The	O
revised	O
AFS	O
score	O
at	O
second-look	O
laparoscopy	O
did	O
not	O
show	O
a	O
significant	O
difference	O
between	O
the	O
two	O
medications	O
.	O

Adequate	O
pituitary	O
suppression	O
was	O
observed	O
with	O
injection	O
of	O
triptorelin	Pharmacological
every	O
6	O
weeks	O
.	O

CONCLUSION	O
(	O
S	O
)	O
Lengthening	O
of	O
triptorelin	Pharmacological
administration	O
intervals	O
from	O
4	O
weeks	O
to	O
6	O
weeks	O
is	O
effective	O
in	O
maintaining	O
a	O
hypoestrogenic	O
state	O
.	O

Patients	O
were	O
more	O
compliant	O
with	O
triptorelin	Pharmacological
than	O
danazol	Pharmacological
.	Pharmacological

Thus	O
,	O
triptorelin	Pharmacological
injection	O
every	O
6	O
weeks	O
is	O
more	O
cost-effective	O
than	O
conventional	O
regimens	O
.	O

Comparison	O
of	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
release	O
of	O
digoxin	Pharmacological
from	O
four	O
different	O
soft	O
gelatin	O
capsule	Pharmacological
formulations	Pharmacological
.	Pharmacological

A	O
blinded	O
,	O
four-treatment	O
crossover	O
study	O
in	O
16	O
normal	O
adult	O
male	O
volunteers	O
compared	O
plasma	O
concentrations	O
and	O
urinary	O
excretion	O
of	O
digoxin	Pharmacological
,	O
measured	O
by	O
radioimmunoassay	O
,	O
after	O
oral	O
administration	O
of	O
soft	Pharmacological
gelatin	Pharmacological
capsule	Pharmacological
formulations	Pharmacological
of	Pharmacological
digoxin	Pharmacological
.	Pharmacological

Four	O
0.4-mg	O
formulations	O
with	O
different	O
in	O
vitro	O
burst	O
times	O
and	O
dissolution	O
rates	O
were	O
administered	O
,	O
with	O
2-week	O
intervals	O
between	O
treatments	O
.	O

The	O
two	O
capsules	O
with	O
lowest	O
in	O
vitro	O
burst	O
times	O
(	O
2.9	O
and	O
16	O
min	O
)	O
gave	O
comparable	O
in	O
vivo	O
results	O
.	O

The	O
other	O
two	O
capsules	O
,	O
with	O
in	O
vitro	O
burst	O
times	O
of	O
62	O
and	O
229	O
min	O
,	O
produced	O
significant	O
delays	O
in	O
digoxin	O
absorption	O
.	O

In	O
vitro-in	O
vivo	O
correlations	O
were	O
obtained	O
by	O
comparing	O
the	O
logarithm	O
of	O
the	O
in	O
vitro	O
burst	O
time	O
with	O
time	O
to	O
peak	O
plasma	O
level	O
and	O
the	O
time	O
to	O
the	O
first	O
measurable	O
plasma	O
level	O
(	O
>	O
or	O
=	O
0	O
.	O

05	O
ng/ml	O
)	O
.	O

Also	O
,	O
the	O
mean	O
time	O
to	O
peak	O
plasma	O
level	O
correlated	O
with	O
the	O
logarithm	O
of	O
the	O
time	O
required	O
to	O
release	O
either	O
50	O
%	O
or	O
85	O
%	O
of	O
the	O
digoxin	O
in	O
vitro	O
.	O

No	O
significant	O
changes	O
were	O
found	O
in	O
the	O
amount	O
of	O
digoxin	Pharmacological
absorbed	O
from	O
each	O
capsule	O
as	O
determined	O
by	O
urinary	O
excretion	O
or	O
AUC0-infinity	O
.	O

Transcutaneous	Physical
electrical	Physical
nerve	Physical
stimulation	Physical
following	O
appendicectomy	O
:	O
the	O
placebo	O
effect	O
.	O

A	O
controlled	O
trial	O
was	O
undertaken	O
to	O
compare	O
the	O
efficacy	O
of	O
transcutaneous	Physical
electrical	Physical
nerve	Physical
stimulation	Physical
(	Physical
TENS	Physical
)	Physical
with	O
standard	O
intramuscular	O
opiate	Pharmacological
analgesia	Pharmacological
in	O
the	O
management	O
of	O
postoperative	O
pain	O
following	O
appendicectomy	O
.	O

Consecutive	O
patients	O
undergoing	O
emergency	Surgical
appendicectomy	Surgical
were	O
randomised	O
into	O
control	O
,	O
sham	Physical
TENS	Physical
and	O
active	Physical
TENS	Physical
groups	Physical
.	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
pain	O
severity	O
and	O
analgesic	O
intake	O
in	O
both	O
active	Physical
and	Physical
sham	Physical
TENS	Physical
groups	O
when	O
compared	O
with	O
the	O
control	Control
group	Control
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

No	O
difference	O
was	O
demonstrated	O
in	O
pain	O
severity	O
between	O
active	Physical
and	Physical
sham	Physical
TENS	Physical
groups	O
but	O
the	O
active	Physical
TENS	Physical
group	O
required	O
slightly	O
less	O
analgesia	O
.	O

These	O
results	O
suggest	O
that	O
the	O
major	O
benefit	O
of	O
TENS	Physical
in	O
the	O
postappendicectomy	O
patient	O
is	O
due	O
to	O
its	O
'placebo	O
effect	O
'	O
and	O
its	O
use	O
in	O
this	O
situation	O
can	O
not	O
be	O
recommended	O
.	O

Concurrent	O
alcohol	Educational
dependence	Educational
among	O
methadone-maintained	O
cocaine	O
abusers	O
is	O
associated	O
with	O
greater	O
abstinence	O
.	O

Concurrent	Educational
alcohol	Educational
dependence	Educational
(	Educational
AD	Educational
)	Educational
among	O
polysubstance	O
abusers	O
has	O
been	O
associated	O
with	O
negative	O
consequences	O
,	O
although	O
it	O
may	O
not	O
necessarily	O
lead	O
to	O
poor	O
treatment	O
outcomes	O
.	O

One	O
of	O
the	O
most	O
efficacious	O
treatments	O
for	O
cocaine	O
abuse	O
is	O
contingency	Educational
management	Educational
(	Educational
CM	Educational
)	Educational
,	O
but	O
little	O
research	O
has	O
explored	O
the	O
impact	O
of	O
AD	Educational
on	O
abstinence	O
outcomes	O
,	O
particularly	O
among	O
patients	O
in	O
methadone	O
maintenance	O
.	O

Using	O
data	O
from	O
three	O
trials	O
of	O
CM	O
for	O
cocaine	O
use	O
,	O
we	O
compared	O
baseline	O
characteristics	O
and	O
posttreatment	O
and	O
follow-up	O
cocaine	O
outcomes	O
between	O
methadone-maintained	Pharmacological
,	O
cocaine-dependent	Pharmacological
patients	O
(	O
N	O
=	O
193	O
)	O
with	Educational
and	Educational
without	Educational
concurrent	Educational
AD	Educational
,	Educational
randomized	Educational
to	Educational
standard	Educational
care	Educational
(	Educational
SC	Educational
)	Educational
with	Educational
or	Educational
without	Educational
CM	Educational
.	Educational

Patients	O
with	Educational
and	Educational
without	Educational
concurrent	Educational
AD	Educational
had	O
similar	O
baseline	O
characteristics	O
,	O
with	O
the	O
exception	O
that	O
AD	Educational
patients	O
reported	O
more	O
alcohol	O
use	O
.	O

AD	Educational
patients	O
achieved	O
longer	O
durations	O
of	O
cocaine	O
abstinence	O
and	O
were	O
more	O
likely	O
to	O
submit	O
a	O
cocaine-negative	O
sample	O
at	O
follow-up	O
than	O
non-AD	Educational
patients	O
.	O

Patients	O
randomized	O
to	O
CM	Educational
achieved	O
better	O
outcomes	O
than	O
those	O
randomized	O
to	O
SC	Educational
,	O
but	O
there	O
was	O
no	O
interaction	O
between	O
treatment	O
condition	O
and	O
AD	Educational
status	O
.	O

These	O
findings	O
suggest	O
that	O
cocaine-using	O
methadone	O
patients	O
with	O
AD	Educational
achieve	O
greater	O
cocaine	O
abstinence	O
than	O
their	O
non-AD	Educational
counterparts	O
and	O
should	O
not	O
necessarily	O
be	O
viewed	O
as	O
more	O
difficult	O
to	O
treat	O
.	O

A	O
randomized	O
trial	O
of	O
radiation	Surgical
therapy	Surgical
compared	O
to	O
split	Surgical
course	Surgical
radiation	Surgical
therapy	Surgical
combined	O
with	O
mitomycin	Pharmacological
C	Pharmacological
and	O
5	Pharmacological
fluorouracil	Pharmacological
as	O
initial	O
treatment	O
for	O
advanced	O
laryngeal	O
and	O
hypopharyngeal	O
squamous	O
carcinoma	O
.	O

Two	O
hundred	O
and	O
twelve	O
patients	O
with	O
previously	O
untreated	O
advanced	O
squamous	O
carcinoma	O
of	O
the	O
larynx	O
or	O
hypopharynx	O
were	O
randomized	O
to	O
receive	O
initial	O
treatment	O
with	O
radiotherapy	Surgical
,	O
50	O
Gy	O
in	O
20	O
fractions	O
in	O
28	O
days	O
or	O
split	Surgical
course	Surgical
radiotherapy	Surgical
and	O
concurrent	Pharmacological
chemotherapy	Pharmacological
,	O
25	O
Gy	O
in	O
10	O
fractions	O
in	O
14	O
days	O
followed	O
by	O
a	O
4	O
week	O
rest	O
and	O
a	O
further	O
25	O
Gy	O
in	O
10	O
fractions	O
in	O
14	O
days	O
starting	O
on	O
day	O
43	O
;	O
Mitomycin	Pharmacological
C	Pharmacological
was	O
given	O
on	O
day	O
1	O
and	O
day	O
43	O
and	O
5FU	Pharmacological
continuous	O
infusions	O
on	O
days	O
1	O
--	O
4	O
and	O
days	O
43	O
--	O
46	O
.	O

Surgery	O
was	O
reserved	O
for	O
persistent	O
or	O
recurrent	O
disease	O
.	O

Two	O
hundred	O
and	O
nine	O
of	O
the	O
212	O
patients	O
randomized	O
were	O
included	O
in	O
the	O
analyses	O
.	O

Outcome	O
analyses	O
were	O
performed	O
at	O
a	O
median	O
follow-up	O
interval	O
of	O
4.4	O
years	O
.	O

No	O
patients	O
were	O
lost	O
to	O
follow-up	O
.	O

No	O
significant	O
difference	O
was	O
found	O
between	O
the	O
two	O
arms	O
for	O
the	O
end	O
points	O
of	O
local	O
relapse-free	O
rate	O
(	O
p	O
=	O
0.91	O
)	O
,	O
regional	O
relapse-free	O
rate	O
(	O
p	O
=	O
0.17	O
,	O
adjusted	O
)	O
or	O
overall	O
survival	O
(	O
p	O
=	O
0.86	O
)	O
.	O

Eight-eight	O
patients	O
had	O
attempted	O
surgical	O
resection	O
following	O
radiotherapy	Surgical
failure	O
.	O

The	O
contribution	O
of	O
salvage	O
surgery	O
to	O
overall	O
survival	O
was	O
similar	O
for	O
both	O
arms	O
of	O
the	O
study	O
as	O
was	O
the	O
surgical	O
complication	O
rate	O
.	O

Serious	O
late	O
radiation	O
toxicity	O
was	O
minimal	O
(	O
3	O
%	O
in	O
the	O
RT	O
group	O
,	O
0	O
%	O
in	O
the	O
radiation	O
therapy	O
plus	O
chemotherapy	O
group	O
)	O
.	O

The	O
result	O
of	O
the	O
trial	O
shows	O
no	O
advantage	O
in	O
terms	O
of	O
local	O
control	O
or	O
survival	O
for	O
the	O
experimental	O
treatment	O
arm	O
of	O
split	O
course	O
radiotherapy	Surgical
and	O
concurrent	Pharmacological
chemotherapy	Pharmacological
with	O
Mitomycin	Pharmacological
C	Pharmacological
and	O
5	Pharmacological
Fluorouracil	Pharmacological
compared	O
to	O
radiotherapy	O
alone	O
.	O

[	O
Dose-reduced	O
antihypertensive	Pharmacological
agents	Pharmacological
--	O
use	O
in	O
complex	O
nonmedicamentous	Pharmacological
therapy	O
of	O
hypertension	O
]	O
.	O

In	O
order	O
to	O
estimate	O
the	O
influence	O
of	O
a	O
non-medicamentous	Pharmacological
therapy	Pharmacological
(	Pharmacological
CNT	Pharmacological
)	Pharmacological
on	O
the	O
consumption	O
of	O
medicaments	O
and	O
coronary	O
risk	O
in	O
high	O
blood	O
pressure	O
73	O
hypertensives	O
of	O
a	O
medicamentously	O
stabilized	O
CNT-group	O
were	O
examined	O
in	O
comparison	O
to	O
a	O
group	O
of	O
the	O
same	O
size	O
of	O
patients	O
with	O
hypertension	O
who	O
were	O
managed	O
exclusively	O
medicamentously	O
for	O
behaviour	O
of	O
blood	O
pressure	O
,	O
need	O
of	O
antihypertensive	Pharmacological
drugs	Pharmacological
and	O
changes	O
of	O
hypertension-associated	O
risk	O
factors	O
.	O

After	O
an	O
exactly	O
controlled	O
6-month	O
treatment	O
hypertensives	O
with	O
additionally	O
recommended	O
far-reaching	O
CNT	O
showed	O
an	O
economization	O
of	O
medicaments	O
by	O
scarcely	O
the	O
half	O
in	O
comparison	O
to	O
the	O
reference	O
group	O
.	O

By	O
means	O
of	O
suitable	O
control	O
methods	O
a	O
causal	O
non-medicamentously	Pharmacological
conditioned	O
decrease	O
of	O
blood	O
pressure	O
could	O
be	O
excluded	O
.	O

A	O
different	O
need	O
of	O
antihypertensive	Pharmacological
drugs	Pharmacological
was	O
simulated	O
by	O
the	O
exacter	O
intake	O
of	O
medicaments	O
in	O
the	O
index-patients	O
.	O

Notwithstanding	O
the	O
metabolic	O
effects	O
of	O
the	O
additional	O
therapy	O
have	O
induced	O
a	O
positive	O
change	O
of	O
atherogenic	O
lipids	O
.	O

The	O
examinations	O
indicate	O
in	O
general	O
the	O
difficulty	O
of	O
the	O
judgement	O
of	O
efficacy	O
of	O
non-medicamentous	Pharmacological
therapeutic	Pharmacological
measures	O
in	O
connection	O
with	O
a	O
rational	O
dose-reduced	O
long-term	O
therapy	O
with	O
antihypertensive	O
drugs	O
.	O

The	O
influence	O
of	O
dietary	Pharmacological
fibre	Pharmacological
source	Pharmacological
and	O
gender	O
on	O
the	O
postprandial	O
glucose	O
and	O
lipid	O
response	O
in	O
healthy	O
subjects	O
.	O

BACKGROUND	O
Consumption	O
of	O
soluble	Pharmacological
dietary	Pharmacological
fibre	Pharmacological
is	O
correlated	O
with	O
decreased	O
postprandial	O
glucose	O
and	O
insulin	O
responses	O
and	O
hence	O
has	O
beneficial	O
effects	O
on	O
the	O
metabolic	O
syndrome	O
.	O

AIM	O
OF	O
THE	O
STUDY	O
To	O
investigate	O
the	O
effects	O
on	O
postprandial	O
glucose	O
,	O
insulin	O
and	O
triglyceride	O
concentrations	O
of	O
meals	O
enriched	O
with	O
soluble	O
dietary	O
fibres	O
from	O
oats	O
,	O
rye	O
bran	O
,	O
sugar	O
beet	O
fibre	O
or	O
a	O
mixture	O
of	O
these	O
three	O
fibres	O
.	O

METHODS	O
Thirteen	O
healthy	O
human	O
volunteers	O
(	O
6	O
men	O
and	O
7	O
women	O
,	O
aged	O
20-28	O
years	O
)	O
were	O
included	O
in	O
the	O
study	O
.	O

The	O
subjects	O
came	O
to	O
the	O
study	O
centre	O
once	O
a	O
week	O
after	O
an	O
overnight	O
fast	O
to	O
ingest	O
test	O
meals	Pharmacological
and	O
a	O
control	O
meal	O
in	O
random	O
order	O
.	O

The	O
meals	O
contained	O
either	O
oat	Pharmacological
powder	Pharmacological
(	O
62	O
g	O
,	O
of	O
which	O
2.7	O
soluble	O
fibre	O
)	O
,	O
rye	Pharmacological
bran	Pharmacological
(	O
31	O
g	O
,	O
of	O
which	O
1.7	O
g	O
soluble	O
fibre	O
)	O
,	O
sugar	Pharmacological
beet	Pharmacological
fibre	Pharmacological
(	O
19	O
g	O
,	O
of	O
which	O
5	O
g	O
soluble	O
fibre	O
)	O
,	O
a	O
mixture	Other
of	O
these	O
three	O
fibres	O
(	O
74	O
g	O
,	O
of	O
which	O
1.7	O
g	O
soluble	O
fibre	O
from	O
each	O
source	O
,	O
giving	O
5	O
g	O
soluble	O
fibre	O
)	O
or	O
no	O
added	Control
fibre	Control
(	Control
control	Control
)	Control
and	O
were	O
all	O
adjusted	O
to	O
contain	O
the	O
same	O
total	O
amount	O
of	O
available	O
carbohydrates	Other
.	Other

Blood	O
samples	O
were	O
drawn	O
before	O
and	O
every	O
30	O
min	O
up	O
to	O
180	O
min	O
after	O
the	O
meals	O
.	O

RESULTS	O
Meals	Pharmacological
with	Pharmacological
rye	Pharmacological
bran	Pharmacological
gave	O
a	O
lower	O
postprandial	O
glucose	O
peak	O
when	O
compared	O
with	O
the	O
control	O
meal	O
,	O
and	O
this	O
effect	O
was	O
more	O
pronounced	O
in	O
women	O
compared	O
to	O
men	O
.	O

Oat	Pharmacological
powder	Pharmacological
,	O
containing	O
a	O
low	O
amount	O
of	O
total	O
fibre	O
and	O
a	O
high	O
amount	O
of	O
carbohydrates	O
in	O
liquid	O
matrix	O
,	O
gave	O
a	O
higher	O
incremental	O
glucose	O
peak	O
concentration	O
compared	O
to	O
rye	O
bran	O
and	O
sugar	O
beet	O
fibre	O
and	O
higher	O
insulin	O
incremental	O
area	O
under	O
curve	O
compared	O
to	O
control	O
.	O

The	O
oat	Pharmacological
powder	Pharmacological
also	O
influenced	O
the	O
effects	O
of	O
the	O
mixed	O
meal	O
,	O
diminishing	O
the	O
glucose-lowering	O
effects	O
.	O

Postprandial	O
triglyceride	O
levels	O
tended	O
to	O
be	O
higher	O
after	O
all	O
fibre-rich	O
meals	O
,	O
but	O
only	O
significant	O
for	O
oat	O
powder	O
and	O
the	O
mixed	O
meal	Pharmacological
when	O
compared	O
with	O
the	O
control	O
meal	Control
.	Pharmacological

CONCLUSIONS	O
Postprandial	O
glucose	O
,	O
insulin	O
and	O
triglyceride	O
concentrations	O
are	O
influenced	O
by	O
dietary	Pharmacological
fibre-rich	Pharmacological
meals	Pharmacological
,	O
depending	O
on	O
fibre	O
source	O
,	O
dose	O
of	O
soluble	O
and	O
total	O
fibre	O
and	O
possibly	O
gender	O
.	O

Comparative	O
drug	O
effects	O
and	O
abuse	O
liability	O
of	O
lorazepam	Pharmacological
,	O
buspirone	Pharmacological
,	O
and	O
secobarbital	Pharmacological
in	O
nondependent	O
subjects	O
.	O

The	O
pharmacologic	O
effects	O
of	O
lorazepam	Pharmacological
(	O
2	O
mg	O
)	O
,	O
buspirone	Pharmacological
(	O
20	O
mg	O
,	O
10	O
mg	O
)	O
,	O
secobarbital	Pharmacological
(	O
100	O
mg	O
)	O
,	O
and	O
placebo	Control
were	O
compared	O
in	O
15	O
male	O
,	O
experienced	O
,	O
intermittent	O
nontherapeutic	O
drug	O
users	O
.	O

All	O
drugs	O
produced	O
a	O
drug	O
effect	O
,	O
however	O
,	O
buspirone	Pharmacological
20	O
mg	O
was	O
significantly	O
less	O
liked	O
than	O
were	O
lorazepam	Pharmacological
,	O
secobarbital	Pharmacological
,	O
or	O
buspirone	Pharmacological
10	O
mg	O
(	O
p	O
less	O
than	O
.05	O
)	O
but	O
not	O
placebo	Control
.	Control

Lorazepam	Pharmacological
was	O
liked	O
better	O
than	O
were	O
other	O
drugs	O
only	O
at	O
1	O
hour	O
and	O
only	O
compared	O
with	O
buspirone	Pharmacological
20	O
and	O
placebo	Control
.	Control

Compared	O
with	O
other	O
drugs	O
,	O
lorazepam	Pharmacological
drug	O
effects	O
were	O
greater	O
and	O
resulted	O
in	O
more	O
prolonged	O
impairment	O
of	O
a	O
motor	O
tracking	O
task	O
,	O
standing	O
steadiness	O
,	O
and	O
memory	O
.	O

Buspirone	Pharmacological
20	O
mg	O
significantly	O
impaired	O
memory	O
at	O
1	O
hour	O
compared	O
with	O
placebo	Pharmacological
.	Pharmacological

Subjects	O
were	O
more	O
likely	O
to	O
identify	O
buspirone	Pharmacological
as	O
unfamiliar	O
.	O

Because	O
buspirone	Pharmacological
20	O
mg	O
was	O
less	O
liked	O
than	O
were	O
other	O
drugs	O
,	O
dose	O
escalation	O
as	O
part	O
of	O
drug	O
abuse	O
is	O
not	O
likely	O
to	O
occur	O
.	O

Lorazepam	Pharmacological
also	O
was	O
not	O
particularly	O
liked	O
and	O
was	O
not	O
different	O
from	O
placebo	Control
on	O
most	O
subjective	O
abuse-relevant	O
measures	O
.	O

Effects	O
of	O
interaction	O
of	O
RRR-alpha-tocopheryl	Pharmacological
acetate	Pharmacological
and	O
fish	Pharmacological
oil	Pharmacological
on	O
low-density-lipoprotein	O
oxidation	O
in	O
postmenopausal	O
women	O
with	O
and	O
without	O
hormone-replacement	Pharmacological
therapy	Pharmacological
.	Pharmacological

We	O
evaluated	O
the	O
effects	O
of	O
RRR-alpha-tocpheryl	Pharmacological
acetate	Pharmacological
(	Pharmacological
alpha-tocopheryl	Pharmacological
acetate	Pharmacological
)	Pharmacological
and	O
hormone-replacement	Pharmacological
therapy	Pharmacological
(	Pharmacological
HRT	Pharmacological
)	Pharmacological
on	O
the	O
oxidative	O
susceptibility	O
of	O
low-density	O
lipoprotein	O
(	O
LDL	O
)	O
in	O
postmenopausal	O
women	O
consuming	O
a	O
fish	Pharmacological
oil	Pharmacological
supplement	Pharmacological
.	Pharmacological

The	O
independent	O
effect	O
of	O
fish	O
oil	O
was	O
also	O
assessed	O
.	O

Forty-eight	O
women	O
,	O
equally	O
divided	O
between	O
women	O
using	O
and	O
not	O
using	O
HRT	Pharmacological
,	O
participated	O
in	O
a	O
double-blind	O
crossover	O
trial	O
.	O

Each	O
of	O
the	O
four	O
periods	O
lasted	O
5	O
wk	O
and	O
was	O
followed	O
by	O
a	O
4-wk	O
washout	O
interval	O
.	O

During	O
each	O
period	O
all	O
subjects	O
were	O
given	O
a	O
15-g	O
supplement	O
of	O
fish	O
oil	O
and	O
either	O
0	O
(	O
placebo	Control
)	O
,	O
100	O
,	O
200	O
,	O
or	O
400	O
mg	O
alpha-tocopheryl	Pharmacological
acetate	Pharmacological
daily	O
.	O

LDL	O
resistance	O
to	O
oxidative	O
modification	O
was	O
assessed	O
by	O
calculating	O
lag	O
time	O
,	O
propagation	O
rate	O
,	O
and	O
maximum	O
production	O
of	O
conjugated	O
dienes	O
.	O

Supplementation	O
with	O
fish	O
oil	O
and	O
placebo	Control
shortened	O
lag	O
time	O
and	O
slowed	O
propagation	O
rate	O
in	O
women	O
both	O
using	O
and	O
not	O
using	O
HRT	O
.	O

After	O
subjects	O
consumed	O
fish	O
oil	O
,	O
supplementation	O
with	O
alpha-tocopheryl	O
acetate	O
increased	O
plasma	O
and	O
LDL	O
alpha-tocopherol	O
contents	O
significantly	O
and	O
lengthened	O
lag	O
time	O
(	O
at	O
even	O
the	O
lowest	O
concentration	O
)	O
but	O
had	O
no	O
significant	O
effect	O
on	O
propagation	O
rate	O
or	O
maximum	O
production	O
compared	O
with	O
values	O
measured	O
after	O
consumption	O
of	O
fish	O
oil	O
alone	O
.	O

Women	O
not	O
using	O
HRT	O
had	O
faster	O
propagation	O
rates	O
and	O
higher	O
maximum	O
production	O
than	O
women	O
using	O
HRT	O
;	O
after	O
supplementation	O
with	O
fish	O
oil	O
and	O
alpha-tocopheryl	Pharmacological
acetate	O
these	O
differences	O
prevailed	O
.	O

Supplements	O
as	O
low	O
as	O
100	O
mg	O
alpha-tocopheryl	O
acetate/d	O
increase	O
the	O
resistance	O
of	O
LDL	O
to	O
oxidation	O
when	O
fish	O
oil	O
supplements	O
are	O
used	O
.	O

HRT	O
and	O
fish	O
oil	O
supplements	O
may	O
independently	O
affect	O
LDL	O
oxidative	O
susceptibility	O
.	O

Failure	O
of	O
naltrexone	Pharmacological
hydrochloride	Pharmacological
to	O
reduce	O
self-injurious	O
and	O
autistic	O
behavior	O
in	O
mentally	O
retarded	O
adults	O
.	O

Double-blind	O
placebo-controlled	Control
studies	O
.	O

BACKGROUND	O
It	O
is	O
hypothesized	O
that	O
self-injurious	O
behavior	O
(	O
SIB	O
)	O
and	O
symptoms	O
of	O
autism	O
may	O
be	O
due	O
to	O
overactivity	O
in	O
some	O
opioid	O
systems	O
in	O
the	O
brain	O
.	O

We	O
examined	O
the	O
efficacy	O
and	O
safety	O
of	O
naltrexone	Pharmacological
hydrochloride	Pharmacological
,	O
an	O
opioid	O
antagonist	O
,	O
in	O
the	O
treatment	O
of	O
SIB	O
and	O
autism	O
in	O
mentally	O
retarded	O
adults	O
.	O

METHOD	O
Thirty-three	O
mentally	O
retarded	O
adults	O
with	O
autism	O
and/or	O
SIB	O
participated	O
in	O
double-blind	O
,	O
placebo-controlled	Control
crossover	O
studies	O
.	O

Active	O
treatment	O
was	O
first	O
a	O
single	O
100-mg	O
dose	O
of	O
naltrexone	Pharmacological
hydrochloride	Pharmacological
.	Pharmacological

Subsequently	O
,	O
19	O
subjects	O
were	O
treated	O
with	O
50	O
mg/d	O
and	O
14	O
with	O
150	O
mg/d	O
of	O
naltrexone	Pharmacological
hydrochloride	Pharmacological
for	O
4	O
weeks	O
.	O

The	O
outcome	O
was	O
assessed	O
by	O
means	O
of	O
direct	O
observations	O
(	O
n	O
=	O
11	O
)	O
and	O
on	O
the	O
basis	O
of	O
scores	O
on	O
a	O
list	O
of	O
target	O
behaviors	O
,	O
the	O
Aberrant	O
Behavior	O
Checklist	O
,	O
and	O
the	O
Clinical	O
Global	O
Impression	O
Scale	O
.	O

RESULTS	O
Thirty-two	O
subjects	O
(	O
seven	O
with	O
autism	O
,	O
16	O
with	O
autism	O
and	O
SIB	O
,	O
and	O
nine	O
with	O
SIB	O
)	O
completed	O
the	O
trial	O
.	O

Naltrexone	Pharmacological
treatment	O
failed	O
to	O
have	O
therapeutic	O
effects	O
on	O
SIB	O
and	O
autism	O
.	O

On	O
the	O
contrary	O
,	O
naltrexone	Pharmacological
increased	O
the	O
incidence	O
of	O
stereotypic	O
behavior	O
on	O
the	O
Aberrant	O
Behavior	O
Checklist	O
,	O
and	O
the	O
care	O
staff	O
evaluated	O
the	O
effect	O
of	O
the	O
50-mg/d	O
treatment	O
as	O
being	O
significantly	O
worse	O
than	O
that	O
of	O
the	O
placebo	O
treatment	O
as	O
measured	O
by	O
the	O
Clinical	O
Global	O
Impression	O
Scale	O
.	O

CONCLUSION	O
Our	O
findings	O
suggest	O
that	O
naltrexone	O
has	O
no	O
clinical	O
value	O
for	O
a	O
broad	O
group	O
of	O
mentally	O
retarded	O
subjects	O
with	O
SIB	O
and/or	O
autism	O
.	O

Junctional	O
ectopic	O
tachycardia	O
after	O
congenital	O
heart	O
surgery	O
in	O
the	O
current	O
surgical	O
era	O
.	O

To	O
determine	O
the	O
incidence	O
of	O
postoperative	O
junctional	O
ectopic	O
tachycardia	O
(	O
JET	O
)	O
in	O
a	O
modern	O
cohort	O
of	O
pediatric	O
patients	O
,	O
evaluate	O
possible	O
risk	O
factors	O
for	O
JET	O
,	O
and	O
examine	O
the	O
effects	O
of	O
JET	O
on	O
postoperative	O
morbidity	O
and	O
mortality	O
.	O

JET	O
is	O
common	O
after	O
congenital	O
heart	O
surgery	O
.	O

JET-related	O
mortality	O
has	O
been	O
a	O
rare	O
event	O
at	O
our	O
center	O
,	O
which	O
is	O
different	O
from	O
previous	O
reports	O
.	O

We	O
reviewed	O
records	O
for	O
pediatric	O
patients	O
who	O
had	O
postoperative	O
arrhythmias	O
between	O
January	O
2006	O
and	O
June	O
2010	O
at	O
a	O
large	O
tertiary-care	O
children	O
's	O
hospital	O
.	O

We	O
performed	O
a	O
matched	O
case-control	O
study	O
to	O
identify	O
risk	O
factors	O
for	O
JET	O
and	O
a	O
matched-cohort	O
study	O
to	O
compare	O
outcomes	O
between	O
patients	O
and	O
controls	O
.	O

Whenever	O
possible	O
,	O
each	O
JET	O
case	O
was	O
randomly	O
matched	O
to	O
two	O
controls	O
on	O
the	O
basis	O
of	O
lesion	O
,	O
repair	O
,	O
and	O
surgical	O
period	O
.	O

We	O
identified	O
54	O
patients	O
with	O
JET	O
(	O
incidence	O
=	O
1.4	O
%	O
)	O
.	O

After	O
multivariate	O
logistic	O
regression	O
analysis	O
,	O
low	O
operative	O
weight	O
,	O
cardiopulmonary	O
bypass	O
(	O
CPB	O
)	O
duration	O
>	O
100	O
min	O
,	O
and	O
immediate	O
postoperative	O
serum	O
lactic	O
acid	O
level	O
>	O
20	O
mg/dl	O
were	O
associated	O
with	O
increased	O
odds	O
of	O
developing	O
JET	O
.	O

Patients	O
with	O
JET	O
had	O
longer	O
mechanical	O
ventilation	O
time	O
,	O
cardiac	O
intensive	O
care	O
unit	O
(	O
CICU	O
)	O
stay	O
,	O
and	O
hospital	O
stay	O
.	O

There	O
was	O
only	O
one	O
death	O
in	O
JET	O
group	O
(	O
1.8	O
%	O
)	O
with	O
no	O
significant	O
difference	O
compared	O
with	O
the	O
control	O
group	O
.	O

JET	O
remains	O
a	O
relatively	O
common	O
postoperative	O
arrhythmia	O
,	O
but	O
it	O
is	O
less	O
frequent	O
than	O
previously	O
reported	O
.	O

JET	O
occurs	O
more	O
commonly	O
in	O
smaller	O
patients	O
with	O
longer	O
CPB	O
runs	O
and	O
significant	O
postoperative	O
lactic	O
acidosis	O
levels	O
.	O

Mortality	O
associated	O
with	O
JET	O
is	O
lower	O
than	O
historically	O
reported	O
,	O
but	O
morbidity	O
remains	O
high	O
.	O

Observer	O
variation	O
in	O
the	O
assessment	O
of	O
outcome	O
in	O
traumatic	O
brain	O
injury	O
:	O
experience	O
from	O
a	O
multicenter	O
,	O
international	O
randomized	O
clinical	O
trial	O
.	O

OBJECTIVE	O
Accurate	O
and	O
consistent	O
outcome	O
assessment	O
is	O
essential	O
to	O
randomized	O
clinical	O
trials	O
.	O

We	O
aimed	O
to	O
explore	O
observer	O
variation	O
in	O
the	O
assessment	O
of	O
outcome	O
in	O
a	O
recently	O
completed	O
trial	O
of	O
dexanabinol	Pharmacological
in	O
head	O
injury	O
and	O
to	O
consider	O
steps	O
to	O
reduce	O
such	O
variation	O
.	O

METHODS	O
Eight	O
hundred	O
sixty-one	O
patients	O
with	O
severe	O
traumatic	O
brain	O
injury	O
who	O
were	O
admitted	O
to	O
86	O
centers	O
were	O
included	O
in	O
a	O
multicenter	O
,	O
placebo-controlled	Control
,	O
Phase	O
III	O
trial	O
.	O

Outcome	O
was	O
assessed	O
at	O
3	O
and	O
6	O
months	O
postinjury	O
using	O
the	O
extended	O
Glasgow	O
Outcome	O
Scale	O
;	O
standardized	O
assessment	O
was	O
facilitated	O
by	O
the	O
use	O
of	O
a	O
structured	O
interview	O
.	O

Before	O
initiation	O
of	O
trial	O
centers	O
,	O
outcome	O
ratings	O
were	O
obtained	O
for	O
sample	O
cases	O
to	O
establish	O
initial	O
levels	O
of	O
agreement	O
.	O

Training	O
sessions	O
in	O
outcome	O
assessment	O
were	O
held	O
,	O
and	O
problems	O
in	O
assigning	O
outcome	O
were	O
investigated	O
.	O

During	O
the	O
trial	O
,	O
a	O
process	O
of	O
central	O
review	O
was	O
established	O
to	O
monitor	O
performance	O
.	O

Interobserver	O
variation	O
was	O
analyzed	O
using	O
the	O
kappa	O
statistic	O
.	O

RESULTS	O
Substantial	O
observer	O
variation	O
was	O
found	O
in	O
the	O
rating	O
of	O
sample	O
cases	O
(	O
weighted	O
kappa	O
,	O
0.72	O
;	O
confidence	O
interval	O
,	O
0.68-0.75	O
)	O
and	O
in	O
assigning	O
outcome	O
based	O
on	O
completed	O
structured	O
interviews	O
(	O
weighted	O
kappa	O
,	O
0.61	O
;	O
confidence	O
interval	O
,	O
0.57-0.64	O
)	O
.	O

In	O
the	O
early	O
stages	O
of	O
the	O
trial	O
,	O
a	O
relatively	O
large	O
number	O
of	O
discrepancies	O
(	O
29-37	O
%	O
)	O
were	O
identified	O
on	O
central	O
review	O
.	O

This	O
number	O
declined	O
as	O
the	O
trial	O
progressed	O
and	O
coincided	O
with	O
investigator	O
training	O
and	O
feedback	O
from	O
central	O
review	O
.	O

Centers	O
with	O
higher	O
enrollment	O
rates	O
showed	O
better	O
performance	O
.	O

CONCLUSION	O
Observer	O
variation	O
in	O
outcome	O
assessment	O
is	O
a	O
significant	O
problem	O
for	O
head	O
injury	O
trials	O
.	O

Consistency	O
can	O
be	O
improved	O
by	O
standardizing	O
procedures	O
,	O
training	O
assessors	O
,	O
and	O
monitoring	O
the	O
quality	O
of	O
assessments	O
and	O
providing	O
feedback	O
to	O
interviewers	O
.	O

Small	O
but	O
important	O
errors	O
in	O
cardiovascular	O
risk	O
calculation	O
by	O
practice	O
nurses	O
:	O
a	O
cross-sectional	O
study	O
in	O
randomised	O
trial	O
setting	O
.	O

BACKGROUND	O
Practice	O
nurses	O
play	O
an	O
increasingly	O
important	O
role	O
in	O
the	O
prevention	O
of	O
cardiovascular	O
diseases	O
but	O
we	O
do	O
not	O
have	O
evidence	O
about	O
the	O
accuracy	O
of	O
their	O
cardiovascular	O
risk	O
assessments	O
during	O
real	O
practice	O
consultations	O
.	O

OBJECTIVES	O
To	O
examine	O
how	O
nurses	O
perform	O
with	O
regard	O
to	O
absolute	O
10-year	O
cardiovascular	O
risk	O
assessment	O
in	O
actual	O
practice	O
.	O

DESIGN	O
Cross-sectional	O
study	O
.	O

SETTING	O
This	O
study	O
was	O
nested	O
in	O
the	O
IMPALA	O
study	O
,	O
a	O
clustered	O
randomised	O
controlled	O
trial	O
involving	O
24	O
general	O
practices	O
in	O
The	O
Netherlands	O
.	O

PARTICIPANTS	O
24	O
practice	O
nurses	O
,	O
trained	O
in	O
10-year	O
cardiovascular	O
risk	O
assessment	O
,	O
calculated	O
the	O
risk	O
of	O
a	O
total	O
of	O
421	O
patients	O
without	O
established	O
cardiovascular	O
diseases	O
but	O
eligible	O
for	O
cardiovascular	O
risk	O
assessment	O
.	O

METHODS	O
The	O
main	O
outcome	O
measure	O
was	O
the	O
accuracy	Other
of	Other
risk	Other
assessments	Other
,	O
defined	O
as	O
(	O
1	O
)	O
the	O
difference	O
between	O
the	O
10-year	O
cardiovascular	O
risk	O
percentage	O
calculated	O
by	O
nurses	Other
and	O
an	O
independent	O
assessor	O
,	O
and	O
(	O
2	O
)	O
the	O
agreement	O
between	O
the	O
treatment	O
categories	O
assigned	O
by	O
the	O
nurses	Other
(	O
low	O
,	O
moderate	O
or	O
high	O
risk	O
)	O
and	O
those	O
assigned	O
by	O
the	O
independent	O
assessor	O
.	O

RESULTS	O
Thirty-one	O
(	O
7.4	O
%	O
)	O
of	O
the	O
calculated	O
risk	O
percentages	O
differed	O
by	O
more	O
than	O
our	O
preset	O
limits	O
,	O
25	O
(	O
81	O
%	O
)	O
being	O
underestimations	O
.	O

Elderly	O
patients	O
(	O
OR	O
1.1	O
,	O
95	O
%	O
CI	O
1.0-1.1	O
)	O
,	O
male	O
patients	O
(	O
vs.	O
female	O
OR	O
3.1	O
,	O
95	O
%	O
CI	O
1.2-7.3	O
)	O
,	O
and	O
smoking	O
patients	O
(	O
vs.	O
non-smoking	O
OR	O
3.8	O
,	O
95	O
%	O
CI	O
1.7-8.9	O
)	O
were	O
more	O
likely	O
to	O
have	O
their	O
cardiovascular	O
risk	O
miscalculated	O
.	O

Ten	O
(	O
28	O
%	O
)	O
of	O
the	O
36	O
patients	O
who	O
should	O
be	O
assigned	O
to	O
the	O
high-risk	O
treatment	O
category	O
according	O
to	O
the	O
independent	O
calculation	O
,	O
were	O
missed	O
as	O
high-risk	O
patients	O
by	O
the	O
practice	O
nurses	O
.	O

CONCLUSIONS	O
The	O
overall	O
standard	O
of	O
accuracy	O
of	O
cardiovascular	Other
risk	Other
assessment	Other
by	O
trained	O
practice	O
nurses	O
in	O
actual	O
practice	O
is	O
high	O
.	O

However	O
,	O
a	O
significant	O
number	O
of	O
high-risk	O
patients	O
were	O
misclassified	O
,	O
with	O
the	O
probability	O
that	O
it	O
led	O
to	O
missed	O
opportunities	O
for	O
risk-reducing	O
interventions	O
.	O

As	O
cardiovascular	O
risk	O
assessments	O
are	O
frequently	O
done	O
by	O
nurses	O
in	O
general	O
practice	O
,	O
further	O
specific	O
training	O
should	O
be	O
considered	O
to	O
prevent	O
undertreatment	O
.	O

Cytokine	O
levels	O
and	O
systemic	O
toxicity	O
in	O
patients	O
undergoing	O
isolated	Pharmacological
limb	Pharmacological
perfusion	Pharmacological
with	O
high-dose	Pharmacological
tumor	Pharmacological
necrosis	Pharmacological
factor	Pharmacological
,	O
interferon	Pharmacological
gamma	Pharmacological
,	O
and	O
melphalan	Pharmacological
.	O

PURPOSE	O
Isolated	Pharmacological
limb	Pharmacological
perfusion	Pharmacological
(	Pharmacological
ILP	Pharmacological
)	Pharmacological
with	O
tumor	Pharmacological
necrosis	Pharmacological
factor	Pharmacological
(	Pharmacological
TNF	Pharmacological
)	Pharmacological
,	O
interferon	Pharmacological
gamma	Pharmacological
,	O
and	O
melphalan	Pharmacological
(	Pharmacological
M	Pharmacological
)	Pharmacological
has	O
been	O
reported	O
to	O
result	O
in	O
high	O
response	O
rates	O
for	O
extremity	O
melanoma	O
and	O
sarcoma	O
.	O

We	O
have	O
evaluated	O
the	O
relationship	O
of	O
systemic	O
TNF	O
exposure	O
to	O
induction	O
of	O
several	O
secondary	O
mediators	O
and	O
incidence	O
of	O
systemic	O
toxicity	O
.	O

PATIENTS	O
AND	O
METHODS	O
Nineteen	O
patients	O
with	O
extremity	O
melanoma	O
(	O
n	O
=	O
16	O
)	O
or	O
sarcoma	O
(	O
n	O
=	O
3	O
)	O
,	O
underwent	O
90-minute	O
ILP	Pharmacological
with	Pharmacological
TNF-alpha	Pharmacological
,	O
interferon	Pharmacological
gamma	Pharmacological
(	O
0.2	O
mg	O
)	O
,	O
and	O
M	Pharmacological
(	O
10	O
to	O
13	O
mg/L	O
of	O
limb	O
volume	O
)	O
(	Pharmacological
TNF/IFN/M	Pharmacological
)	Pharmacological
(	O
n	O
=	O
12	O
)	O
,	O
or	O
M	Pharmacological
alone	O
(	O
n	O
=	O
7	O
)	O
.	O

Continuous	O
intraoperative	O
monitoring	O
(	O
CIM	O
)	O
for	O
systemic	O
leak	O
from	O
the	O
perfusion	O
circuit	O
was	O
performed	O
using	O
radioactive	O
iodine-131	Pharmacological
albumin	Pharmacological
.	Pharmacological

Cytokine	O
levels	O
in	O
the	O
perfusate	O
and	O
systemic	O
circulation	O
during	O
and	O
after	O
ILP	O
were	O
measured	O
by	O
enzyme-linked	Pharmacological
immunosorbent	Pharmacological
assay	Pharmacological
.	Pharmacological

RESULTS	O
Systemic	O
leaks	O
>	O
or	O
=	O
1	O
%	O
from	O
the	O
perfusion	O
circuit	O
occurred	O
in	O
six	O
patients	O
who	O
received	O
TNF/IFN/M	O
and	O
in	O
four	O
who	O
received	O
M	O
alone	O
.	O

Hypotension	O
that	O
required	O
vasopressor	O
support	O
occurred	O
in	O
six	O
of	O
six	O
patients	O
with	O
evidence	O
of	O
a	O
leak	O
(	O
>	O
or	O
=	O
1	O
%	O
)	O
and	O
zero	O
of	O
six	O
patients	O
without	O
a	O
leak	O
(	O
<	O
1	O
%	O
)	O
.	O

These	O
six	O
patients	O
had	O
significantly	O
higher	O
peak	O
systemic	O
TNF	O
levels	O
during	O
and	O
after	O
perfusion	O
than	O
patients	O
without	O
a	O
leak	O
(	O
2.8	O
and	O
8.2	O
ng/mL	O
v	O
0.7	O
and	O
2.0	O
ng/mL	O
,	O
respectively	O
;	O
P	O
<	O
.05	O
)	O
.	O

All	O
patients	O
who	O
received	O
TNF/IFN/M	O
had	O
significantly	O
greater	O
increases	O
in	O
systemic	O
interleukin-6	O
(	O
IL-6	O
)	O
levels	O
than	O
in	O
patients	O
with	O
M	O
alone	O
(	O
12,395	O
+/-	O
10,374	O
pg/mL	O
v	O
79.4	O
+/-	O
7.2	O
pg/mL	O
,	O
respectively	O
;	O
P	O
<	O
.001	O
)	O
.	O

Intracellular	O
adhesion	O
molecule	O
(	O
ICAM	O
)	O
,	O
IL-8	O
,	O
and	O
TNF-R	O
levels	O
were	O
also	O
increased	O
after	O
ILP	O
with	O
TNF/IFN/M	O
.	O

CONCLUSION	O
ILP	O
with	O
TNF/IFN/M	O
can	O
be	O
safely	O
performed	O
,	O
as	O
I131	O
albumin	O
provides	O
a	O
sensitive	O
measure	O
of	O
systemic	O
leakage	O
from	O
the	O
perfusion	O
circuit	O
.	O

Patients	O
with	O
a	O
measured	O
leak	O
of	O
>	O
or	O
=	O
1	O
%	O
develop	O
mild	O
and	O
transient	O
postoperative	O
hypotension	O
with	O
significantly	O
higher	O
systemic	O
TNF	O
levels	O
and	O
lower	O
perfusate	O
TNF	O
levels	O
than	O
in	O
patients	O
without	O
leaks	O
.	O

Bitewing	O
film	O
quality	O
:	O
a	O
clinical	O
comparison	O
of	O
the	O
loop	Surgical
vs.	O
holder	Surgical
techniques	Surgical
.	O

OBJECTIVE	O
To	O
compare	O
in	O
vivo	O
bitewing	O
film	O
quality	O
using	O
the	O
holder	Surgical
versus	Surgical
the	Surgical
paper	Surgical
loop	Surgical
technique	Surgical
.	O

METHOD	O
AND	O
MATERIALS	O
Four	O
bitewing	O
films	O
were	O
taken	O
from	O
the	O
right	O
and	O
left	O
premolar	O
and	O
molar	O
regions	O
of	O
45	O
dental	O
students	O
using	O
both	O
the	O
bitewing	O
holder	Surgical
and	Surgical
paper	Surgical
loop	Surgical
techniques	Surgical
.	O

A	O
total	O
of	O
360	O
films	O
were	O
taken	O
and	O
assessed	O
by	O
an	O
experienced	O
practitioner	O
not	O
apprised	O
of	O
the	O
bitewing	Surgical
technique	Surgical
used	O
.	O

Of	O
interest	O
were	O
:	O
(	O
1	O
)	O
the	O
number	O
of	O
overlaps	O
and	O
the	O
percentage	O
of	O
teeth	O
showing	O
the	O
alveolar	O
crest	O
;	O
(	O
2	O
)	O
proper	O
film	O
positioning	O
;	O
and	O
(	O
3	O
)	O
the	O
percentage	O
of	O
cone	O
cutting	O
.	O

A	O
Poisson	O
regression	O
using	O
generalized	O
estimating	O
equations	O
(	O
GEEs	O
)	O
was	O
used	O
to	O
estimate	O
the	O
difference	O
in	O
overlap	O
between	O
the	O
two	O
techniques	O
.	O

For	O
proper	O
positioning	O
and	O
cone	O
cutting	O
,	O
logistic	O
regressions	O
using	O
GEEs	O
were	O
used	O
.	O

RESULTS	O
The	O
average	O
number	O
of	O
horizontal	O
overlaps	O
for	O
the	O
loop	Surgical
and	O
holder	Surgical
techniques	Surgical
at	O
the	O
right	O
premolar	O
,	O
right	O
molar	O
,	O
left	O
premolar	O
,	O
and	O
left	O
molar	O
were	O
1.64	O
,	O
2.11	O
,	O
2.16	O
,	O
2.78	O
,	O
and	O
1.64	O
,	O
2.00	O
,	O
2.00	O
,	O
2.18	O
,	O
respectively	O
.	O

The	O
loop	Surgical
technique	Surgical
was	O
1.11	O
times	O
more	O
likely	O
to	O
cause	O
overlapping	O
than	O
the	O
holder	Surgical
technique	Surgical
.	Surgical

The	O
highest	O
percentage	O
of	O
teeth	O
showing	O
the	O
alveolar	O
crest	O
by	O
the	O
loop	Surgical
technique	Surgical
was	O
97.8	O
%	O
in	O
the	O
mandibular	O
second	O
premolar	O
and	O
first	O
molar	O
.	O

With	O
respect	O
to	O
film	O
positioning	O
,	O
the	O
loop	Surgical
technique	Surgical
was	O
1.12	O
times	O
more	O
likely	O
to	O
cause	O
improper	O
positioning	O
than	O
the	O
holder	Surgical
technique	Surgical
.	Surgical

Both	O
techniques	O
demonstrated	O
minimal	O
cone	O
cutting	O
(	O
1	O
in	O
the	O
loop	O
versus	O
0	O
in	O
the	O
holder	O
)	O
.	O

CONCLUSION	O
The	O
quality	O
of	O
bitewing	O
films	O
taken	O
by	O
the	O
loop	Surgical
and	Surgical
holder	Surgical
techniques	Surgical
was	O
not	O
significantly	O
different	O
.	O

Smoking	O
cessation	O
with	O
smokeless	Other
tobacco	Other
and	O
group	Educational
therapy	Educational
:	Other
an	O
open	O
,	O
randomized	O
,	O
controlled	O
trial	O
.	O

Smokeless	Other
tobacco	Other
might	O
be	O
effective	O
as	O
an	O
adjunct	O
for	O
smoking	O
cessation	O
.	O

We	O
evaluated	O
the	O
efficacy	O
of	O
smokeless	Other
tobacco	Other
and	O
group	Educational
support	Educational
for	O
smoking	O
cessation	O
in	O
an	O
open	O
,	O
randomized	O
study	O
that	O
compared	O
smokeless	Other
tobacco	Other
plus	O
group	Educational
support	Educational
versus	O
group	Other
support	Other
only	Educational
.	O

The	O
study	O
enrolled	O
263	O
healthy	O
smokers	O
(	O
M	O
(	O
age	O
)	O
=	O
49	O
years	O
)	O
who	O
smoked	O
a	O
mean	O
of	O
24	O
cigarettes/day	O
,	O
with	O
a	O
mean	O
of	O
31	O
pack-years	O
.	O

Smokeless	Other
tobacco	Other
was	O
provided	O
for	O
7	O
weeks	O
(	O
or	O
up	O
to	O
12	O
)	O
,	O
combined	O
with	O
eight	O
group	Educational
support	Educational
visits	Educational
provided	Educational
by	Educational
nurses	Educational
.	O

The	O
control	Control
group	Control
received	O
group	Other
support	Other
only	Educational
.	O

Smoking	O
cessation	O
rates	O
were	O
statistically	O
significantly	O
better	O
in	O
the	O
smokeless	O
tobacco	O
group	O
than	O
in	O
the	O
control	O
group	O
during	O
the	O
first	O
7	O
weeks	O
.	O

Point-prevalence	O
abstinence	O
rates	O
at	O
7	O
weeks	O
were	O
36.4	O
%	O
versus	O
20.8	O
%	O
(	O
OR	O
=	O
2.52	O
,	O
p	O
=	O
.001	O
)	O
,	O
respectively	O
;	O
and	O
continuous	O
abstinence	O
rates	O
from	O
weeks	O
4	O
to	O
7	O
were	O
31.5	O
%	O
versus	O
19.2	O
%	O
(	O
OR	O
=	O
1.94	O
,	O
p	O
=	O
.023	O
)	O
,	O
respectively	O
.	O

The	O
primary	O
outcomes	O
(	O
i.e.	O
,	O
6-month	O
point	O
prevalence	O
)	O
were	O
23.1	O
%	O
versus	O
20.8	O
%	O
,	O
respectively	O
(	O
OR	O
=	O
1.31	O
,	O
ns	O
)	O
.	O

Smokeless	Other
tobacco	Other
was	O
relatively	O
well	O
tolerated	O
,	O
although	O
15	O
subjects	O
(	O
11.2	O
%	O
)	O
stopped	O
use	O
due	O
to	O
adverse	O
events	O
.	O

A	O
total	O
of	O
25	O
subjects	O
(	O
17.5	O
%	O
)	O
were	O
still	O
using	O
smokeless	O
tobacco	O
after	O
6	O
months	O
.	O

This	O
trial	O
demonstrated	O
short-term	O
efficacy	O
of	O
smokeless	Other
tobacco	Other
in	O
combination	O
with	O
group	O
support	O
for	O
smoking	O
cessation	O
but	O
no	O
long-term	O
efficacy	O
.	O

Efficacy	O
of	O
a	O
family	Educational
practice-based	Educational
lifestyle	Educational
intervention	Educational
program	Educational
to	O
increase	O
physical	O
activity	O
and	O
reduce	O
clinical	O
and	O
physiological	O
markers	O
of	O
vascular	O
health	O
in	O
patients	O
with	O
high	O
normal	O
blood	O
pressure	O
and/or	O
high	O
normal	O
blood	O
glucose	O
(	O
SNAC	O
)	O
:	O
study	O
protocol	O
for	O
a	O
randomized	O
controlled	O
trial	O
.	O

BACKGROUND	O
Previous	O
interventions	O
to	O
increase	O
physical	O
activity	O
and	O
reduce	O
cardiovascular	O
risk	O
factors	O
have	O
been	O
targeted	O
at	O
individuals	O
with	O
established	O
disease	O
;	O
less	O
attention	O
has	O
been	O
given	O
to	O
intervention	O
among	O
individuals	O
with	O
high	O
risk	O
for	O
disease	O
nor	O
has	O
there	O
been	O
determination	O
of	O
the	O
influence	O
of	O
setting	O
in	O
which	O
the	O
intervention	O
is	O
provided	O
.	O

In	O
particular	O
,	O
family	O
practice	O
represents	O
an	O
ideal	O
setting	O
for	O
the	O
provision	O
and	O
long-term	O
maintenance	O
of	O
lifestyle	O
interventions	O
for	O
patients	O
at	O
risk	O
(	O
ie	O
high-normal	O
blood	O
pressure	O
or	O
impaired	O
glucose	O
tolerance	O
)	O
.	O

METHODS/DESIGN	O
The	O
Staged	O
Nutrition	O
and	O
Activity	O
Counseling	O
(	O
SNAC	O
)	O
study	O
is	O
a	O
randomized	O
clustered	O
design	O
clinical	O
trial	O
that	O
will	O
investigate	O
the	O
effectiveness	O
and	O
efficacy	O
of	O
a	O
multi-component	Educational
lifestyle	Educational
intervention	Educational
on	O
cardiovascular	O
disease	O
risk	O
factors	O
and	O
vascular	O
function	O
in	O
patients	O
at	O
risk	O
in	O
primary	O
care	O
.	O

Patients	O
will	O
be	O
randomized	O
by	O
practice	O
to	O
either	O
a	O
standard	Educational
of	Educational
care	Educational
lifestyle	Educational
intervention	Educational
or	O
a	O
behaviourally-based	Educational
,	Educational
matched	Educational
prescriptive	Educational
physical	Educational
activity	Educational
and	Educational
diet	Educational
change	Educational
program	Educational
.	O

The	O
primary	O
goal	O
is	O
to	O
increase	O
physical	O
activity	O
and	O
improve	O
dietary	O
intake	O
according	O
to	O
Canada	O
's	O
Guides	O
to	O
Physical	O
Activity	O
Healthy	O
Eating	O
over	O
24	O
months	O
.	O

The	O
primary	O
intention	O
to	O
treat	O
analysis	O
will	O
compare	O
behavioral	O
,	O
physiological	O
and	O
metabolic	O
outcomes	O
at	O
6	O
,	O
12	O
and	O
24	O
months	O
post-randomization	O
including	O
estimation	O
of	O
incident	O
hypertension	O
and/or	O
diabetes	O
.	O

DISCUSSION	O
The	O
design	O
features	O
of	O
our	O
trial	O
,	O
and	O
the	O
practical	O
problems	O
(	O
and	O
solutions	O
)	O
associated	O
with	O
implementing	O
these	O
design	O
features	O
,	O
particularly	O
those	O
that	O
result	O
in	O
potential	O
delay	O
between	O
recruitment	O
,	O
baseline	O
data	O
collection	O
,	O
randomization	O
,	O
intervention	O
,	O
and	O
assessment	O
will	O
be	O
discussed	O
.	O

Results	O
of	O
the	O
SNAC	O
trial	O
will	O
provide	O
scientific	O
rationale	O
for	O
the	O
implementation	O
of	O
this	O
lifestyle	O
intervention	O
in	O
primary	O
care	O
.	O

TRIAL	O
REGISTRATION	O
ISRCTN	O
:	O
ISRCTN:42921300	O
.	O

Autism-Spectrum	Other
Quotient-Japanese	Other
version	O
and	O
its	O
short	O
forms	O
for	O
screening	O
normally	O
intelligent	O
persons	O
with	O
pervasive	O
developmental	O
disorders	O
.	O

A	O
Japanese	Other
version	Other
of	Other
the	Other
Autism	Other
Spectrum	Other
Quotient	Other
(	Other
AQ	Other
)	Other
,	Other
AQ-J	Other
was	O
administered	O
to	O
25	O
normally	O
intelligent	O
high-functioning	O
pervasive	O
developmental	O
disorder	O
(	O
HPDD	O
)	O
patients	O
(	O
mean	O
age	O
,	O
24.2	O
years	O
;	O
24	O
male	O
,	O
one	O
female	O
)	O
and	O
215	O
controls	O
(	O
mean	O
age	O
,	O
30.4	O
years	O
;	O
86	O
male	O
,	O
129	O
female	O
)	O
randomly	O
selected	O
from	O
the	O
general	O
population	O
.	O

The	O
AQ-J	Other
had	O
satisfactory	O
internal	O
consistency	O
reliability	O
(	O
Cronbach	O
's	O
alpha	O
>	O
0.70	O
in	O
the	O
two	O
groups	O
)	O
,	O
test-retest	O
reliability	O
,	O
and	O
discriminant	O
validity	O
[	O
i.e	O
.	O

the	O
AQ-J	O
score	O
was	O
significantly	O
higher	O
in	O
the	O
HPDD	O
(	O
mean	O
,	O
29.6	O
)	O
than	O
controls	O
(	O
mean	O
,	O
22.2	O
)	O
]	O
.	O

At	O
a	O
cut-off	O
of	O
26	O
,	O
the	O
AQ-J	Other
had	O
satisfactory	O
sensitivity	O
,	O
specificity	O
,	O
and	O
negative	O
predictive	O
value	O
,	O
but	O
it	O
had	O
low	O
positive	O
predictive	O
value	O
(	O
0.24	O
)	O
possibly	O
due	O
to	O
the	O
facts	O
that	O
the	O
25	O
mild	O
HPDD	O
patients	O
scored	O
lower	O
and	O
the	O
controls	O
scored	O
higher	O
on	O
the	O
AQ-J	Other
than	O
British	O
counterparts	O
on	O
the	O
AQ	O
.	O

The	O
AQ-J-21	Other
(	O
consisting	O
of	O
21	O
items	O
significantly	O
associated	O
with	O
HPDD	O
diagnosis	O
)	O
and	O
the	O
AQ-J-10	Other
(	O
consisting	O
of	O
10	O
of	O
the	O
21	O
items	O
with	O
an	O
effect	O
size	O
>	O
0.17	O
)	O
had	O
higher	O
,	O
although	O
not	O
satisfactory	O
,	O
positive	O
predictive	O
values	O
of	O
0.35	O
and	O
0.46	O
at	O
cut-offs	O
of	O
12	O
and	O
7	O
,	O
respectively	O
,	O
than	O
the	O
AQ-J	Other
.	Other

The	O
AQ-J	Other
and	O
two	O
short	O
forms	O
are	O
useful	O
not	O
to	O
predict	O
but	O
to	O
rule	O
out	O
mild	O
HPDD	O
,	O
the	O
most	O
difficult	O
part	O
of	O
HPDD	O
to	O
be	O
distinguished	O
from	O
non-PDD	O
conditions	O
,	O
in	O
persons	O
scoring	O
under	O
the	O
cut-offs	O
and	O
to	O
consider	O
professionals	O
'	O
examination	O
of	O
HPDD	O
in	O
persons	O
scoring	O
over	O
them	O
,	O
because	O
their	O
negative	O
predictive	O
values	O
were	O
satisfactory	O
.	O

Coagulation	Pharmacological
factor	Pharmacological
concentrate	Pharmacological
in	O
the	O
treatment	O
of	O
the	O
haemorrhagic	O
diathesis	O
of	O
fulminant	O
hepatic	O
failure	O
.	O

To	O
assess	O
the	O
value	O
of	O
clotting	Pharmacological
factor	Pharmacological
concentrate	Pharmacological
infusions	Pharmacological
in	O
fulminant	O
hepatic	O
failure	O
,	O
a	O
controlled	O
trial	O
was	O
performed	O
in	O
which	O
nine	O
patients	O
were	O
randomly	O
allocated	O
to	O
treatment	O
with	O
either	O
concentrate	Pharmacological
alone	Pharmacological
or	Pharmacological
concentrate	Pharmacological
plus	Pharmacological
heparin	Pharmacological
.	Pharmacological

The	O
five	O
patients	O
receiving	O
concentrate	Pharmacological
alone	O
all	O
died	O
,	O
with	O
major	O
bleeding	O
as	O
the	O
direct	O
cause	O
of	O
death	O
in	O
three	O
,	O
whereas	O
in	O
the	O
four	O
receiving	O
heparin	Pharmacological
as	O
well	O
there	O
was	O
only	O
one	O
instance	O
of	O
bleeding	O
and	O
one	O
patient	O
survived	O
.	O

Clinical	O
evidence	O
of	O
intravascular	O
coagulation	O
appeared	O
in	O
two	O
patients	O
treated	O
with	O
concentrate	Pharmacological
alone	O
and	O
the	O
laboratory	O
evidence	O
of	O
this	O
progressed	O
during	O
the	O
period	O
of	O
infusions	O
in	O
all	O
patients	O
in	O
both	O
treatment	O
groups	O
,	O
although	O
to	O
a	O
lesser	O
extent	O
in	O
those	O
receiving	O
heparin	Pharmacological
.	Pharmacological

Additional	O
evidence	O
for	O
intravascular	O
coagulation	O
came	O
from	O
the	O
changes	O
observed	O
in	O
factor	O
VIII	O
levels	O
which	O
,	O
although	O
initially	O
high	O
in	O
all	O
patients	O
,	O
fell	O
subsequently	O
,	O
particularly	O
in	O
those	O
given	O
concentrate	Pharmacological
alone	O
.	O

There	O
was	O
some	O
improvement	O
in	O
the	O
prothrombin	O
ratio	O
in	O
both	O
groups	O
of	O
patients	O
but	O
not	O
complete	O
correction	O
,	O
and	O
serial	O
assays	O
of	O
clotting	O
factors	O
showed	O
that	O
although	O
factor	O
II	O
rose	O
to	O
high	O
levels	O
during	O
treatment	O
,	O
factors	O
IX	O
and	O
X	O
showed	O
little	O
response	O
.	O

Thus	O
,	O
the	O
use	O
of	O
concentrate	O
of	O
factor	O
IX	O
in	O
this	O
trial	O
,	O
as	O
well	O
as	O
potentiating	O
intravascular	O
coagulation	O
,	O
was	O
inadequate	O
as	O
replacement	O
for	O
the	O
clotting	O
factor	O
deficiencies	O
.	O

Comparison	O
of	O
thiopentone/guaifenesin	Pharmacological
,	O
ketamine/guaifenesin	Pharmacological
and	O
ketamine/midazolam	Pharmacological
for	O
the	O
induction	O
of	O
horses	O
to	O
be	O
anaesthetised	O
with	O
isoflurane	O
.	O

Forty-eight	O
horses	O
subjected	O
to	O
elective	O
surgery	O
were	O
randomly	O
assigned	O
to	O
three	O
groups	O
of	O
16	O
horses	O
.	O

After	O
premedication	O
with	O
0.1	O
mg/kg	O
acepromazine	Pharmacological
intramuscularly	O
and	O
0.6	O
mg/kg	O
xylazine	Pharmacological
intravenously	O
,	O
anaesthesia	O
was	O
induced	O
either	O
with	O
2	O
g	O
thiopentone	Pharmacological
in	O
500	O
ml	O
of	O
a	O
10	O
per	O
cent	O
guaifenesin	Pharmacological
solution	O
,	O
given	O
intravenously	O
at	O
a	O
dose	O
of	O
1	O
ml/kg	O
(	O
group	O
TG	O
)	O
,	O
or	O
with	O
100	O
mg/kg	O
guaifenesin	Pharmacological
and	O
2.2	O
mg/kg	O
ketamine	Pharmacological
given	O
intravenously	O
(	O
group	O
KG	O
)	O
,	O
or	O
with	O
0.06	O
mg/kg	O
midazolam	Pharmacological
,	O
and	O
2.2	O
mg/kg	O
ketamine	Pharmacological
given	O
intravenously	O
(	O
group	O
KM	O
)	O
.	O

Anaesthesia	O
was	O
maintained	O
with	O
isoflurane	Pharmacological
.	Pharmacological

The	O
mean	O
(	O
sd	O
)	O
end	O
tidal	O
isoflurane	Pharmacological
concentration	O
(	O
per	O
cent	O
)	O
needed	O
to	O
maintain	O
a	O
light	O
surgical	O
anaesthesia	O
(	O
stage	O
III	O
,	O
plane	O
2	O
)	O
was	O
significantly	O
lower	O
in	O
group	O
KM	O
(	O
0.91	O
[	O
0.03	O
]	O
)	O
than	O
in	O
groups	O
TG	O
(	O
1.11	O
[	O
0.03	O
]	O
)	O
and	O
KG	O
(	O
1.14	O
[	O
0.03	O
]	O
)	O
.	O

The	O
mean	O
(	O
sd	O
)	O
arterial	O
pressure	O
(	O
mmHg	O
)	O
was	O
significantly	O
lower	O
in	O
group	O
KG	O
(	O
67.4	O
[	O
2.07	O
]	O
)	O
than	O
in	O
groups	O
TC	O
(	O
75.6	O
[	O
2.23	O
]	O
)	O
and	O
KM	O
(	O
81.0	O
[	O
2.16	O
]	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
logarithm	O
of	O
the	O
heart	O
rate	O
,	O
recovery	O
time	O
or	O
quality	O
of	O
recovery	O
between	O
the	O
three	O
induction	O
groups	O
.	O

However	O
,	O
pronounced	O
ataxia	O
was	O
observed	O
in	O
the	O
horses	O
of	O
group	O
KM	O
,	O
especially	O
after	O
periods	O
of	O
anaesthesia	O
lasting	O
less	O
than	O
75	O
minutes	O
.	O

Parents	O
'	O
state	O
and	O
trait	O
anxiety	O
:	O
relationships	O
with	O
anxiety	O
severity	O
and	O
treatment	O
response	O
in	O
adolescents	O
with	O
autism	O
spectrum	O
disorders	O
.	O

Comorbid	O
anxiety	O
is	O
common	O
among	O
children	O
with	O
Autism	O
Spectrum	O
Disorder	O
(	O
ASD	O
)	O
,	O
and	O
parents	O
of	O
children	O
with	O
ASD	O
are	O
more	O
likely	O
to	O
have	O
anxiety	O
disorders	O
.	O

This	O
study	O
investigated	O
the	O
relationship	O
between	O
parents	Psychological
'	Psychological
state	Psychological
and	Psychological
trait	Psychological
anxiety	Psychological
and	O
parent-reported	Educational
internalizing	Educational
and	Other
externalizing	Educational
symptoms	Educational
among	O
adolescents	O
(	O
n	O
=	O
30	O
)	O
with	O
ASD	O
,	O
as	O
well	O
as	O
the	O
relationship	O
of	O
parents	O
'	O
anxiety	O
symptoms	O
and	O
adolescent	O
treatment	O
response	O
in	O
the	O
context	O
of	O
a	O
randomized	O
controlled	O
trial	O
.	O

Parental	O
state	O
anxiety	O
correlated	O
with	O
severity	O
of	O
adolescent	O
anxiety	O
,	O
and	O
trait	O
anxiety	O
in	O
parents	O
correlated	O
with	O
parent-reported	O
adolescent	O
internalizing	O
and	O
externalizing	O
symptoms	O
.	O

Also	O
,	O
parents	O
of	O
adolescent	O
treatment	O
responders	O
experienced	O
a	O
decrease	O
in	O
their	O
own	O
trait	O
anxiety	O
.	O

Findings	O
highlight	O
the	O
importance	O
of	O
considering	O
parental	O
anxiety	O
when	O
targeting	O
anxiety	O
among	O
youth	O
with	O
ASD	O
.	O

Behavioral	O
effects	O
of	O
Org	Pharmacological
2766	Pharmacological
,	O
a	O
synthetic	O
analog	O
of	O
the	O
adrenocorticotrophic	O
hormone	O
(	O
4-9	O
)	O
,	O
in	O
14	O
outpatient	O
autistic	O
children	O
.	O

Fourteen	O
children	O
(	O
12	O
infantile	O
autism	O
full	O
syndrome	O
present	O
,	O
2	O
atypical	O
pervasive	O
developmental	O
disorder	O
)	O
between	O
5	O
and	O
13	O
years	O
of	O
age	O
participated	O
in	O
a	O
double-blind	O
placebo-controlled	O
cross-over	O
trial	O
.	O

Each	O
child	O
received	O
20	O
mg	O
Org	Pharmacological
2766	Pharmacological
(	O
synthetic	O
analog	O
of	O
ACTH	O
4-9	O
)	O
/day	O
during	O
4	O
weeks	O
,	O
or	O
placebo	O
in	O
a	O
randomly	O
assigned	O
sequence	O
.	O

Drug	O
effects	O
were	O
monitored	O
by	O
ethological	O
playroom	O
observation	O
and	O
by	O
Aberrant	O
Behavior	O
Checklist	O
ratings	O
by	O
parents	O
and	O
teachers	O
.	O

Data	O
of	O
the	O
playroom	O
observation	O
pointed	O
to	O
an	O
activating	O
influence	O
of	O
Org	O
2766	O
,	O
as	O
revealed	O
by	O
a	O
significant	O
decrease	O
of	O
stereotypic	O
behavior	O
and	O
significant	O
increases	O
in	O
change	O
toys	O
,	O
locomote	O
,	O
and	O
talk	O
.	O

Checklist	O
ratings	O
did	O
not	O
show	O
significant	O
changes	O
.	O

The	O
clinical	O
implications	O
of	O
these	O
findings	O
are	O
discussed	O
.	O

The	O
effects	O
of	O
hypoxemia	O
on	O
cardiac	O
output	O
.	O

A	O
dose-response	O
curve	O
.	O

To	O
establish	O
a	O
dose-response	O
curve	O
for	O
the	O
effects	O
of	O
isocapnic	O
hypoxemia	O
on	O
cardiac	O
output	O
(	O
CO	O
)	O
,	O
we	O
studied	O
20	O
healthy	O
men	O
,	O
aged	O
20	O
to	O
34	O
years	O
,	O
using	O
a	O
tight-fitting	Other
face	Other
mask	Other
and	Other
an	Other
isocapnic	Other
partial	Other
rebreathing	Other
system	Other
(	O
a	O
modified	O
anesthesia	O
machine	O
)	O
.	O

We	O
blended	O
oxygen	Other
and	O
hypoxic	Other
gas	Other
to	O
achieve	O
arterial	O
oxygen	O
saturations	O
(	O
SaO2	O
)	O
of	O
80	O
,	O
85	O
,	O
and	O
90	O
percent	O
;	O
subjects	O
also	O
breathed	O
100	Other
percent	Other
oxygen	Other
and	O
room	Other
air	Other
(	O
RA	O
)	O
.	O

Target	O
SaO2	O
and	O
end-tidal	O
carbon	O
dioxide	O
were	O
continuously	O
monitored	O
using	O
an	O
ear	O
oximeter	O
and	O
CO2	O
gas	O
analyzer	O
.	O

Subjects	O
experienced	O
the	O
five	O
SaO2	O
measurements	O
in	O
random	O
order	O
.	O

CO	O
was	O
measured	O
noninvasively	O
at	O
approximately	O
two-minute	O
intervals	O
,	O
using	O
continuous-wave	O
Doppler	O
echocardiography	O
.	O

Mean	O
cardiac	O
output	O
increased	O
with	O
increasing	O
hypoxemia	O
from	O
6.84	O
L/min	O
at	O
FIo2	O
1.0	O
to	O
8.44	O
L/min	O
at	O
SaO2	O
80	O
percent	O
(	O
p	O
less	O
than	O
0.0005	O
)	O
;	O
the	O
increase	O
was	O
entirely	O
due	O
to	O
increased	O
heart	O
rate	O
.	O

We	O
concluded	O
that	O
cardiac	O
output	O
increases	O
significantly	O
in	O
a	O
dose-response	O
manner	O
in	O
response	O
to	O
acute	O
isocapnic	O
hypoxemia	O
in	O
normal	O
persons	O
.	O

Is	O
chronic	Pharmacological
sildenafil	Pharmacological
therapy	Pharmacological
safe	O
and	O
clinically	O
beneficial	O
in	O
patients	O
with	O
systolic	O
heart	O
failure	O
?	O
Sildenafil	Pharmacological
is	O
a	O
selective	O
phosphodiesterase-5	O
inhibitor	O
and	O
causes	O
vasodilatation	O
,	O
particularly	O
in	O
pulmonary	O
circulation	O
.	O

Since	O
left	O
heart	O
failure	O
may	O
be	O
associated	O
with	O
pulmonary	O
hypertension	O
out	O
of	O
proportion	O
to	O
left	O
heart	O
disease	O
,	O
sildenafil	Pharmacological
may	O
have	O
beneficial	O
effect	O
in	O
such	O
patients	O
.	O

The	O
present	O
investigation	O
was	O
designed	O
as	O
a	O
12-week	O
,	O
single-center	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	Control
study	O
evaluating	O
the	O
effects	O
of	O
sildenafil	Pharmacological
on	O
mean	O
blood	O
pressure	O
(	O
primary	O
endpoint	O
)	O
in	O
patients	O
with	O
left	O
systolic	O
heart	O
failure	O
.	O

Secondary	O
endpoints	O
included	O
exercise	O
capacity	O
assessed	O
by	O
6-minute	O
walk	O
test	O
.	O

A	O
total	O
of	O
106	O
patients	O
were	O
randomized	O
1:1	O
to	O
sildenafil	Pharmacological
(	O
n=53	O
)	O
or	O
placebo	Control
(	O
n=53	O
)	O
.	O

Patients	O
received	O
sildenafil	Pharmacological
25	O
mg	O
twice	O
a	O
day	O
or	O
matching	O
placebo	Control
for	O
the	O
first	O
2	O
weeks	O
and	O
50	O
mg	O
3	O
times	O
a	O
week	O
for	O
the	O
remainder	O
of	O
the	O
trial	O
.	O

The	O
placebo-corrected	O
effect	O
on	O
mean	O
blood	O
pressure	O
was	O
1.16	O
mm	O
Hg	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
-1.6	O
to	O
5.1	O
,	O
P	O
>	O
.05	O
)	O
,	O
demonstrating	O
that	O
sildenafil	O
did	O
not	O
decrease	O
mean	O
blood	O
pressure	O
.	O

Compared	O
with	O
placebo	O
,	O
sildenafil	Pharmacological
increased	O
the	O
6-minute	O
walk	O
test	O
by	O
a	O
nonsignificant	O
treatment	O
effect	O
of	O
14	O
m	O
(	O
P=.67	O
)	O
.	O

Adverse	O
effects	O
occurred	O
in	O
a	O
comparable	O
proportion	O
of	O
patients	O
taking	O
sildenafil	Pharmacological
and	O
placebo	O
,	O
and	O
none	O
of	O
the	O
patients	O
needed	O
to	O
discontinue	O
therapy	O
.	O

Sildenafil	O
is	O
well	O
tolerated	O
in	O
left	O
heart	O
failure	O
patients	O
and	O
does	O
not	O
decrease	O
blood	O
pressure	O
.	O

It	O
can	O
be	O
safely	O
added	O
to	O
standard	O
heart	O
failure	O
therapy	O
.	O

The	O
aging	O
motor	O
system	O
as	O
a	O
model	O
for	O
plastic	O
changes	O
of	O
GABA-mediated	O
intracortical	O
inhibition	O
and	O
their	O
behavioral	O
relevance	O
.	O

Since	O
GABAA-mediated	O
intracortical	O
inhibition	O
has	O
been	O
shown	O
to	O
underlie	O
plastic	O
changes	O
throughout	O
the	O
lifespan	O
from	O
development	O
to	O
aging	O
,	O
here	O
,	O
the	O
aging	O
motor	O
system	O
was	O
used	O
as	O
a	O
model	O
to	O
analyze	O
the	O
interdependence	O
of	O
plastic	O
alterations	O
within	O
the	O
inhibitory	O
motorcortical	O
network	O
and	O
level	O
of	O
behavioral	O
performance	O
.	O

Double-pulse	Physical
transcranial	Physical
magnetic	Physical
stimulation	Physical
(	Physical
dpTMS	Physical
)	Physical
was	Physical
used	Physical
to	Physical
examine	Physical
inhibition	Physical
by	Physical
means	Physical
of	Physical
short-interval	Physical
intracortical	Physical
inhibition	Physical
(	Physical
SICI	Physical
)	Physical
of	Physical
the	Physical
contralateral	Physical
primary	Physical
motor	Physical
cortex	Physical
in	O
a	O
sample	O
of	O
64	O
healthy	O
right-handed	O
human	O
subjects	O
covering	O
a	O
wide	O
range	O
of	O
the	O
adult	O
lifespan	O
(	O
age	O
range	O
20-88	O
years	O
,	O
mean	O
47.6	O
?	O
20.7	O
,	O
34	O
female	O
)	O
.	O

SICI	O
was	O
evaluated	O
during	O
resting	O
state	O
and	O
in	O
an	O
event-related	O
condition	O
during	O
movement	O
preparation	O
in	O
a	O
visually	O
triggered	O
simple	O
reaction	O
time	O
task	O
.	O

In	O
a	O
subgroup	O
(	O
N	O
=	O
23	O
)	O
,	O
manual	O
motor	O
performance	O
was	O
tested	O
with	O
tasks	O
of	O
graded	O
dexterous	O
demand	O
.	O

Weak	O
resting-state	O
inhibition	O
was	O
associated	O
with	O
an	O
overall	O
lower	O
manual	O
motor	O
performance	O
.	O

Better	O
event-related	O
modulation	O
of	O
inhibition	O
correlated	O
with	O
better	O
performance	O
in	O
more	O
demanding	O
tasks	O
,	O
in	O
which	O
fast	O
alternating	O
activation	O
of	O
cortical	O
representations	O
are	O
necessary	O
.	O

Declining	O
resting-state	O
inhibition	O
was	O
associated	O
with	O
weakened	O
event-related	O
modulation	O
of	O
inhibition	O
.	O

Therefore	O
,	O
reduced	O
resting-state	O
inhibition	O
might	O
lead	O
to	O
a	O
subsequent	O
loss	O
of	O
modulatory	O
capacity	O
,	O
possibly	O
reflecting	O
malfunctioning	O
precision	O
in	O
GABAAergic	O
neurotransmission	O
;	O
the	O
consequence	O
is	O
an	O
inevitable	O
decline	O
in	O
motor	O
function	O
.	O

Effect	O
of	O
hydrochlorothiazide	Pharmacological
therapy	Pharmacological
on	O
cardiac	O
arrhythmias	O
in	O
African-American	O
men	O
with	O
systemic	O
hypertension	O
and	O
moderate	O
to	O
severe	O
left	O
ventricular	O
hypertrophy	O
.	O

The	O
effect	O
of	O
hydrochlorothiazide	Pharmacological
therapy	Pharmacological
on	O
ventricular	O
arrhythmias	O
was	O
studied	O
in	O
45	O
hypertensive	O
African-American	O
men	O
with	O
moderate	O
to	O
severe	O
left	O
ventricular	O
(	O
LV	O
)	O
hypertrophy	O
.	O

After	O
medication	O
washout	O
,	O
patients	O
were	O
treated	O
with	O
placebo	Control
followed	O
by	O
hydrochlorothiazide	Pharmacological
.	O

Clinical	O
,	O
biochemical	O
,	O
and	O
48-hour	O
ambulatory	O
electrocardiographic	O
data	O
was	O
collected	O
after	O
each	O
treatment	O
phase	O
.	O

Signal-averaged	O
electrocardiograms	O
were	O
recorded	O
in	O
a	O
subgroup	O
of	O
24	O
patients	O
.	O

Average	O
LV	O
posterior	O
wall	O
thickness	O
was	O
15	O
+/-	O
1.1	O
mm	O
,	O
septum	O
16	O
+/-	O
2	O
mm	O
,	O
LV	O
mass	O
420	O
+/-	O
90	O
g	O
,	O
and	O
LV	O
mass	O
index	O
212	O
=	O
51	O
g/m2	O
.	O

Systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
was	O
168	O
+/-	O
18	O
mm	O
Hg	O
after	O
the	O
placebo	O
phase	O
and	O
146	O
+/-	O
15	O
mm	O
Hg	O
after	O
hydrochlorothiazide	O
;	O
diastolic	O
BP	O
was	O
103	O
+/-	O
6	O
mm	O
Hg	O
and	O
89	O
+/-	O
9	O
mm	O
Hg	O
,	O
respectively	O
.	O

Serum	O
potassium	O
decreased	O
significantly	O
from	O
4.2	O
+/-	O
0.4	O
mmol/L	O
to	O
3.7	O
+/-	O
0.6	O
mmol/L	O
after	O
hydrochlorothiazide	Pharmacological
therapy	Pharmacological
.	Pharmacological

The	O
average	O
hourly	O
incidence	O
of	O
ventricular	O
premature	O
contractions	O
was	O
22	O
with	O
placebo	Control
and	O
25	O
with	O
hydrochlorothiazide	Pharmacological
.	Pharmacological

There	O
were	O
3	O
and	O
1	O
couplets	O
and	O
0.2	O
and	O
0.2	O
runs	O
of	O
ventricular	O
tachycardia	O
per	O
patient	O
per	O
hour	O
,	O
respectively	O
.	O

Variables	O
of	O
signal-averaged	O
electrocardiography	O
did	O
not	O
differ	O
between	O
the	O
2	O
treatments	O
.	O

Thus	O
,	O
in	O
hypertensive	O
African-American	O
men	O
with	O
moderate	O
to	O
severe	O
LV	O
hypertrophy	O
,	O
hydrochlorothiazide	Pharmacological
does	O
not	O
worsen	O
ventricular	O
arrhythmias	O
or	O
signal-averaged	O
electrocardiographic	O
variables	O
.	O

Reduced	O
platelet	O
thromboxane	O
formation	O
after	O
long-term	O
administration	O
of	O
a	O
dihydropyridine	Pharmacological
calcium	Pharmacological
channel	Pharmacological
blocker	Pharmacological
:	O
a	O
prospective	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
with	O
nitrendipine	Pharmacological
in	O
borderline	O
hypertensive	O
patients	O
with	O
IDDM-type	O
diabetes	O
mellitus	O
.	O

Twenty-nine	O
IDDM	O
patients	O
with	O
borderline	O
hypertension	O
were	O
randomly	O
allocated	O
to	O
placebo	Control
or	O
nitrendipine	Pharmacological
treatment	O
.	O

Nitrendipine	Pharmacological
was	O
given	O
orally	O
at	O
a	O
dosage	O
of	O
20	O
mg	O
once	O
daily	O
over	O
4	O
weeks	O
.	O

Stimulated	O
platelet	O
thromboxane	O
formation	O
at	O
rest	O
and	O
after	O
standardized	O
,	O
non	O
exhausting	O
exercise	O
was	O
measured	O
by	O
standard	O
methods	O
.	O

In	O
addition	O
,	O
plasma	O
levels	O
of	O
platelet	O
factor	O
4	O
and	O
aggregation	O
responses	O
to	O
collagen	O
and	O
ADP	O
were	O
determined	O
.	O

In	O
the	O
treatment	O
group	O
thromboxane	O
formation	O
after	O
stimulation	O
with	O
collagen	O
(	O
0.3	O
and	O
1.0	O
micrograms/ml	O
)	O
and	O
1	O
mM	O
arachidonic	O
acid	O
(	O
AA	O
)	O
was	O
reduced	O
in	O
the	O
resting	O
state	O
.	O

Exercise	O
induced	O
change	O
of	O
thromboxane	O
synthesis	O
in	O
response	O
to	O
1.0	O
micrograms/ml	O
collagen	O
was	O
significantly	O
lower	O
as	O
compared	O
to	O
placebo	Control
(	O
p	O
<	O
0.05	O
)	O
.	O

In	O
parallel	O
,	O
PF4	O
plasma	O
levels	O
were	O
significantly	O
lowered	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Whole	O
blood	O
aggregation	O
after	O
collagen	O
stimulation	O
(	O
1.0	O
micrograms/ml	O
)	O
was	O
reduced	O
after	O
4	O
weeks	O
of	O
nitrendipine	Pharmacological
treatment	O
,	O
but	O
ADP	O
(	O
5	O
microM	O
)	O
induced	O
aggregation	O
was	O
not	O
.	O

These	O
effects	O
of	O
nitrendipine	Pharmacological
were	O
not	O
seen	O
in	O
platelet	O
rich	O
plasma	O
.	O

In	O
conclusion	O
long-term	O
nitrendipine	Pharmacological
treatment	O
may	O
inhibit	O
collagen	O
dependent	O
platelet	O
activation	O
in	O
the	O
blood	O
of	O
diabetic	O
patients	O
with	O
borderline	O
hypertension	O
.	O

Effects	O
of	O
20	O
mg	O
rosuvastatin	Pharmacological
on	O
VLDL1-	O
,	O
VLDL2-	O
,	O
IDL-	O
and	O
LDL-ApoB	O
kinetics	O
in	O
type	O
2	O
diabetes	O
.	O

AIMS/HYPOTHESIS	O
In	O
addition	O
to	O
its	O
efficacy	O
in	O
reducing	O
LDL-cholesterol	O
,	O
rosuvastatin	Pharmacological
has	O
been	O
shown	O
to	O
significantly	O
decrease	O
plasma	O
triacylglycerol	O
.	O

The	O
use	O
of	O
rosuvastatin	Pharmacological
may	O
be	O
beneficial	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
,	O
who	O
usually	O
have	O
increased	O
triacylglycerol	O
levels	O
.	O

However	O
,	O
its	O
effects	O
on	O
the	O
metabolism	O
of	O
triacylglycerol-rich	O
lipoproteins	O
in	O
type	O
2	O
diabetic	O
patients	O
remains	O
unknown	O
.	O

METHODS	O
We	O
performed	O
a	O
randomised	O
double-blind	O
crossover	O
trial	O
of	O
6-week	O
treatment	O
with	O
placebo	Control
or	O
rosuvastatin	Pharmacological
20	O
mg	O
in	O
eight	O
patients	O
with	O
type	O
2	O
diabetes	O
who	O
were	O
being	O
treated	O
with	O
oral	O
glucose-lowering	O
agents	O
.	O

In	O
each	O
patient	O
,	O
an	O
in	O
vivo	O
kinetic	O
study	O
of	O
apolipoprotein	O
B	O
(	O
ApoB	O
)	O
-containing	O
lipoproteins	O
with	O
[	O
13C	O
]	O
leucine	O
was	O
performed	O
at	O
the	O
end	O
of	O
each	O
treatment	O
period	O
.	O

A	O
central	O
randomisation	O
centre	O
used	O
computer-generated	O
tables	O
to	O
allocate	O
treatments	O
.	O

Participants	O
,	O
caregivers	O
and	O
those	O
assessing	O
the	O
outcomes	O
were	O
blinded	O
to	O
group	O
assignment	O
.	O

RESULTS	O
Rosuvastatin	Pharmacological
20	O
mg	O
significantly	O
reduced	O
plasma	O
LDL-cholesterol	O
,	O
triacylglycerol	O
and	O
total	O
ApoB	O
.	O

It	O
also	O
significantly	O
reduced	O
ApoB	O
pool	O
sizes	O
of	O
larger	O
triacylglycerol-rich	O
VLDL	O
particles	O
(	O
VLDL1	O
;	O
p	O
=	O
0.011	O
)	O
,	O
smaller	O
VLDL	O
particles	O
(	O
VLDL2	O
;	O
p	O
=	O
0.011	O
)	O
,	O
intermediate	O
density	O
lipoprotein	O
(	O
IDL	O
;	O
p	O
=	O
0.011	O
)	O
and	O
LDL	O
(	O
p	O
=	O
0.011	O
)	O
.	O

This	O
reduction	O
was	O
associated	O
with	O
a	O
significant	O
increase	O
in	O
the	O
total	O
fractional	O
catabolic	O
rate	O
of	O
VLDL1-ApoB	O
(	O
6.70	O
+/-	O
3.24	O
vs	O
4.52	O
+/-	O
2.34	O
pool/day	O
,	O
p	O
=	O
0.049	O
)	O
,	O
VLDL2-ApoB	O
(	O
8.72	O
+/-	O
3.37	O
vs	O
5.36	O
+/-	O
2.64	O
,	O
p	O
=	O
0.011	O
)	O
,	O
IDL-ApoB	O
(	O
7.06	O
+/-	O
1.68	O
vs	O
4.21	O
+/-	O
1.51	O
,	O
p	O
=	O
0.011	O
)	O
and	O
LDL-ApoB	O
(	O
1.02	O
+/-	O
0.27	O
vs	O
0.59	O
+/-	O
0.13	O
,	O
p	O
=	O
0.011	O
)	O
.	O

Rosuvastatin	Pharmacological
did	O
not	O
change	O
the	O
production	O
rates	O
of	O
VLDL2-	O
,	O
IDL-	O
or	O
LDL-	O
,	O
but	O
did	O
reduce	O
VLDL1-ApoB	O
production	O
rate	O
(	O
12.4	O
+/-	O
4.5	O
vs	O
19.5	O
+/-	O
8.4	O
mg	O
kg	O
(	O
-1	O
)	O
day	O
(	O
-1	O
)	O
,	O
p	O
=	O
0.035	O
)	O
.	O

No	O
side	O
effects	O
of	O
rosuvastatin	O
were	O
observed	O
during	O
the	O
study	O
.	O

CONCLUSIONS/INTERPRETATION	O
In	O
type	O
2	O
diabetic	O
patients	O
rosuvastatin	Pharmacological
20	O
mg	O
not	O
only	O
induces	O
a	O
significant	O
increase	O
of	O
LDL-ApoB	O
catabolism	O
(	O
73	O
%	O
)	O
,	O
but	O
also	O
has	O
favourable	O
effects	O
on	O
the	O
catabolism	O
of	O
triacylglycerol-rich	O
lipoproteins	O
,	O
e.g	O
.	O

a	O
significant	O
increase	O
in	O
the	O
catabolism	O
of	O
VLDL1-ApoB	O
(	O
48	O
%	O
)	O
,	O
VLDL2-ApoB	O
(	O
63	O
%	O
)	O
and	O
IDL-ApoB	O
(	O
68	O
%	O
)	O
,	O
and	O
a	O
reduction	O
in	O
the	O
production	O
rate	O
of	O
VLDL1-ApoB	O
(	O
-36	O
%	O
)	O
.	O

The	O
effects	O
of	O
rosuvastatin	Pharmacological
on	O
the	O
metabolism	O
of	O
triacylglycerol-rich	O
lipoproteins	O
may	O
be	O
beneficial	O
for	O
prevention	O
of	O
atherosclerosis	O
in	O
type	O
2	O
diabetic	O
patients	O
.	O

How	O
does	O
Cash	Other
and	O
Counseling	Other
affect	O
costs	O
?	O
OBJECTIVE	O
To	O
test	O
the	O
effect	O
of	O
a	O
consumer-directed	O
model	O
(	O
Cash	Other
and	O
Counseling	Other
)	O
of	O
Medicaid	O
personal	O
care	O
services	O
(	O
PCS	O
)	O
or	O
home-	O
and	O
community-based	O
waiver	O
services	O
(	O
HCBS	O
)	O
on	O
the	O
cost	O
of	O
Medicaid	O
services	O
.	O

DATA	O
SOURCES/STUDY	O
SETTING	O
Medicaid	O
claims	O
data	O
were	O
collected	O
for	O
all	O
enrollees	O
in	O
the	O
Cash	O
and	O
Counseling	O
demonstration	O
.	O

Demonstration	O
enrollees	O
included	O
those	O
eligible	O
for	O
PCS	O
(	O
in	O
Arkansas	O
)	O
,	O
those	O
assessed	O
to	O
receive	O
such	O
services	O
(	O
in	O
New	O
Jersey	O
)	O
,	O
and	O
recipients	O
of	O
Medicaid	O
HCBS	O
(	O
in	O
Florida	O
)	O
.	O

Enrollment	O
occurred	O
from	O
December	O
1998	O
through	O
April	O
2001	O
.	O

The	O
follow-up	O
period	O
covered	O
up	O
to	O
24	O
months	O
after	O
enrollment	O
.	O

STUDY	O
DESIGN	O
Demonstration	O
volunteers	O
were	O
randomly	O
assigned	O
to	O
have	O
the	O
option	O
to	O
participate	O
in	O
Cash	Other
and	O
Counseling	Other
(	O
the	O
treatment	O
group	O
)	O
,	O
or	O
to	O
receive	O
Medicaid	Control
services	Control
as	Control
usual	Control
from	Control
an	Control
agency	Control
(	O
the	O
control	O
group	O
)	O
.	O

Ordinary	O
least	O
squares	O
regressions	O
were	O
used	O
to	O
estimate	O
the	O
effect	O
of	O
the	O
program	O
on	O
costs	O
for	O
Medicaid	O
PCS/waiver	O
services	O
and	O
other	O
Medicaid	O
services	O
,	O
while	O
controlling	O
for	O
consumers	O
'	O
preenrollment	O
characteristics	O
and	O
preenrollment	O
Medicaid	O
spending	O
.	O

Models	O
were	O
estimated	O
separately	O
for	O
nonelderly	O
and	O
elderly	O
adults	O
in	O
each	O
state	O
and	O
for	O
children	O
in	O
Florida	O
.	O

DATA	O
EXTRACTION	O
METHODS	O
Each	O
state	O
supplied	O
claims	O
data	O
for	O
demonstration	O
enrollees	O
.	O

PRINCIPAL	O
FINDINGS	O
Largely	O
because	O
the	O
program	O
increased	O
consumers	O
'	O
ability	O
to	O
get	O
the	O
authorized	O
amount	O
of	O
paid	O
care	O
,	O
expenditures	O
for	O
personal	O
care/waiver	O
services	O
were	O
higher	O
for	O
the	O
treatment	O
group	O
than	O
for	O
the	O
control	O
group	O
in	O
each	O
state	O
and	O
age	O
group	O
,	O
except	O
among	O
the	O
elderly	O
in	O
Florida	O
.	O

Higher	O
costs	O
for	O
personal	O
care/waiver	O
services	O
were	O
partially	O
offset	O
by	O
savings	O
in	O
other	O
Medicaid	O
services	O
,	O
particularly	O
those	O
related	O
to	O
long-term	O
care	O
.	O

During	O
year	O
1	O
,	O
total	O
Medicaid	O
costs	O
were	O
generally	O
higher	O
for	O
the	O
treatment	O
group	O
than	O
for	O
the	O
control	O
group	O
,	O
with	O
treatment-control	O
cost	O
differences	O
ranging	O
from	O
1	O
percent	O
(	O
and	O
statistically	O
insignificant	O
)	O
for	O
the	O
elderly	O
in	O
Florida	O
to	O
17	O
percent	O
for	O
the	O
elderly	O
in	O
Arkansas	O
.	O

In	O
year	O
2	O
,	O
these	O
cost	O
differences	O
were	O
generally	O
greater	O
than	O
in	O
year	O
1	O
.	O

Only	O
in	O
Arkansas	O
did	O
the	O
treatment-control	O
difference	O
in	O
total	O
cost	O
shrink	O
over	O
time-to	O
less	O
than	O
5	O
percent	O
(	O
and	O
statistically	O
insignificant	O
)	O
in	O
year	O
2	O
.	O

CONCLUSIONS	O
Medicaid	O
costs	O
were	O
generally	O
higher	O
under	O
Cash	Other
and	O
Counseling	Other
because	O
those	O
in	O
the	O
traditional	O
system	O
did	O
not	O
get	O
the	O
services	O
they	O
were	O
entitled	O
to	O
.	O

Compared	O
with	O
the	O
treatment	O
group	O
,	O
(	O
1	O
)	O
control	O
group	O
members	O
were	O
less	O
likely	O
to	O
receive	O
any	O
services	O
at	O
all	O
(	O
despite	O
being	O
authorized	O
for	O
them	O
)	O
,	O
and	O
(	O
2	O
)	O
service	O
recipients	O
received	O
a	O
lower	O
proportion	O
of	O
the	O
amount	O
of	O
care	O
that	O
was	O
authorized	O
.	O

In	O
addition	O
,	O
a	O
flaw	O
in	O
Florida	O
's	O
reassessment	O
procedures	O
led	O
to	O
treatment	O
group	O
members	O
receiving	O
more	O
generous	O
benefit	O
amounts	O
than	O
control	O
group	O
members	O
.	O

To	O
keep	O
total	O
Medicaid	O
costs	O
per	O
recipient	O
at	O
the	O
level	O
incurred	O
under	O
the	O
traditional	O
system	O
,	O
consumer-directed	O
programs	O
need	O
to	O
be	O
carefully	O
designed	O
and	O
closely	O
monitored	O
.	O

Comparing	O
the	O
effectiveness	O
of	O
peer	Educational
mentoring	Educational
and	O
student	Educational
mentoring	Educational
in	O
a	O
35-week	O
fitness	O
program	O
for	O
older	O
adults	O
.	O

To	O
investigate	O
the	O
applicability	O
and	O
effectiveness	O
of	O
a	O
peer-mentored	Physical
exercise	Physical
program	Physical
,	O
this	O
study	O
compared	O
the	O
retention	O
and	O
participation	O
rates	O
,	O
and	O
physical	O
improvements	O
of	O
older	O
adults	O
trained	O
by	O
peer	Physical
mentors	Physical
(	Physical
PM	Physical
)	Physical
to	O
a	O
group	O
trained	O
by	O
young	Physical
qualified	Physical
student	Physical
mentors	Physical
(	Physical
SM	Physical
)	Physical
.	O

A	O
group	O
of	O
older	O
adults	O
were	O
prepared	O
as	O
peer	O
mentors	O
through	O
a	O
30-week	O
preparation	O
program	O
.	O

Later	O
,	O
60	O
older	O
adults	O
(	O
mean	O
?	O
SD	O
age	O
:	O
68.7	O
?	O
6.1	O
years	O
)	O
were	O
recruited	O
and	O
randomly	O
assigned	O
to	O
either	O
the	O
PM	O
or	O
SM	O
group	O
.	O

Both	O
groups	O
completed	O
an	O
identical	O
35-week	O
fitness	O
program	O
.	O

Pre-	O
,	O
midterm-	O
and	O
post-training	O
assessments	O
of	O
fitness	O
were	O
completed	O
and	O
rates	O
of	O
participation	O
and	O
retention	O
were	O
documented	O
.	O

The	O
same	O
retention	O
rates	O
were	O
observed	O
in	O
the	O
two	O
groups	O
,	O
but	O
SM	O
group	O
had	O
higher	O
participation	O
.	O

Both	O
groups	O
improved	O
significantly	O
in	O
all	O
measures	O
of	O
fitness	O
and	O
there	O
were	O
no	O
significant	O
post-test	O
differences	O
between	O
the	O
groups	O
in	O
the	O
fitness	O
measures	O
.	O

Findings	O
suggest	O
that	O
the	O
peer	O
mentor	O
model	O
is	O
applicable	O
in	O
an	O
older	O
adult	O
exercise	O
program	O
and	O
may	O
be	O
as	O
effective	O
as	O
a	O
program	O
mentored	O
by	O
young	O
professionals	O
.	O

Comparison	O
of	O
rectal	O
midazolam	Pharmacological
and	O
diazepam	Pharmacological
for	O
premedication	O
in	O
pediatric	O
dental	O
patients	O
.	O

Rectally	O
administered	O
midazolam	Pharmacological
(	O
0.35	O
mg/kg	O
)	O
and	O
diazepam	Pharmacological
(	O
0.70	O
mg/kg	O
)	O
were	O
compared	O
with	O
each	O
other	O
and	O
with	O
placebo	Control
for	O
preanesthetic	O
medication	O
in	O
children	O
undergoing	O
dental	O
extractions	O
.	O

All	O
rectal	Pharmacological
medications	Pharmacological
were	O
very	O
well	O
accepted	O
,	O
but	O
mask	O
acceptance	O
,	O
improvement	O
in	O
anxiety	O
,	O
and	O
sedation	O
were	O
best	O
in	O
the	O
midazolam	Pharmacological
group	O
.	O

Improvement	O
in	O
anxiety	O
and	O
sedation	O
were	O
significantly	O
better	O
in	O
the	O
two	O
drug	O
groups	O
than	O
in	O
those	O
patients	O
who	O
had	O
received	O
placebo	Control
.	Control

Thirty	O
minutes	O
after	O
rectal	O
administration	O
of	O
midazolam	Pharmacological
,	O
patients	O
showed	O
a	O
decrease	O
in	O
both	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O

Although	O
these	O
decreases	O
differed	O
significantly	O
from	O
the	O
premedication	O
values	O
,	O
they	O
were	O
probably	O
of	O
little	O
clinical	O
importance	O
.	O

Only	O
minor	O
adverse	O
effects	O
were	O
observed	O
in	O
this	O
study	O
.	O

Overall	O
rectally	O
administered	O
midazolam	Pharmacological
appeared	O
to	O
be	O
somewhat	O
more	O
efficacious	O
than	O
diazepam	Pharmacological
.	Pharmacological

The	O
additional	O
value	O
of	O
a	O
night	Physical
splint	Physical
to	O
eccentric	Physical
exercises	Physical
in	O
chronic	O
midportion	O
Achilles	O
tendinopathy	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

AIM	O
To	O
assess	O
whether	O
the	O
use	O
of	O
a	O
night	Physical
splint	Physical
is	O
of	O
added	O
benefit	O
on	O
functional	O
outcome	O
in	O
treating	O
chronic	O
midportion	O
Achilles	O
tendinopathy	O
.	O

METHODS	O
This	O
was	O
a	O
single-blind	O
,	O
prospective	O
,	O
single	O
centre	O
,	O
randomised	O
controlled	O
trial	O
set	O
in	O
the	O
Sports	O
Medical	O
Department	O
,	O
The	O
Hague	O
Medical	O
Centre	O
,	O
The	O
Netherlands	O
.	O

Inclusion	O
criteria	O
were	O
:	O
age	O
18-70	O
years	O
,	O
active	O
participation	O
in	O
sports	O
,	O
and	O
tendon	O
pain	O
localised	O
at	O
2-7	O
cm	O
from	O
distal	O
insertion	O
.	O

Exclusion	O
criteria	O
were	O
:	O
insertional	O
disorders	O
,	O
partial	O
or	O
complete	O
ruptures	O
,	O
or	O
systemic	O
illness	O
.	O

70	O
tendons	O
were	O
included	O
and	O
randomised	O
into	O
one	O
of	O
two	O
treatment	O
groups	O
:	O
eccentric	Physical
exercises	Physical
with	Physical
a	Physical
night	Physical
splint	Physical
(	O
night	O
splint	O
group	O
,	O
n	O
=	O
36	O
)	O
or	O
eccentric	Physical
exercises	Physical
only	Physical
(	O
eccentric	O
group	O
,	O
n	O
=	O
34	O
)	O
.	O

INTERVENTIONS	O
Both	O
groups	O
completed	O
a	O
12-week	O
heavy-load	Physical
eccentric	Physical
training	Physical
programme	Physical
.	Physical

One	O
group	O
received	O
a	O
night	Physical
splint	Physical
in	O
addition	O
to	O
eccentric	Physical
exercises	Physical
.	O

At	O
baseline	O
and	O
follow-up	O
at	O
12	O
weeks	O
,	O
patient	O
satisfaction	O
,	O
Victorian	O
Institute	O
of	O
Sport	O
Assessment-Achilles	O
questionnaire	O
(	O
VISA-A	O
)	O
score	O
and	O
reported	O
compliance	O
were	O
recorded	O
by	O
a	O
single-blind	O
trained	O
researcher	O
who	O
was	O
blinded	O
to	O
the	O
treatment	O
.	O

RESULTS	O
After	O
12	O
weeks	O
,	O
patient	O
satisfaction	O
in	O
the	O
eccentric	O
group	O
was	O
63	O
%	O
compared	O
with	O
48	O
%	O
in	O
the	O
night	Physical
splint	Physical
group	O
.	O

The	O
VISA-A	O
score	O
significantly	O
improved	O
in	O
both	O
groups	O
;	O
in	O
the	O
eccentric	O
group	O
from	O
50.1	O
to	O
68.8	O
(	O
p	O
=	O
0.001	O
)	O
and	O
in	O
the	O
night	O
splint	O
group	O
from	O
49.4	O
to	O
67.0	O
(	O
p	O
<	O
0.001	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
in	O
VISA-A	O
score	O
(	O
p	O
=	O
0.815	O
)	O
and	O
patient	O
satisfaction	O
(	O
p	O
=	O
0.261	O
)	O
.	O

CONCLUSION	O
A	O
night	Physical
splint	Physical
is	O
not	O
beneficial	O
in	O
addition	O
to	O
eccentric	O
exercises	O
in	O
the	O
treatment	O
of	O
chronic	O
midportion	O
Achilles	O
tendinopathy	O
.	O

LNH-84	O
regimen	O
:	O
a	O
multicenter	O
study	O
of	O
intensive	O
chemotherapy	O
in	O
737	O
patients	O
with	O
aggressive	O
malignant	O
lymphoma	O
.	O

From	O
July	O
1984	O
to	O
September	O
1987	O
,	O
737	O
patients	O
with	O
aggressive	O
malignant	O
lymphoma	O
(	O
ML	O
)	O
were	O
treated	O
by	O
an	O
intensive	Pharmacological
regimen	Pharmacological
(	Pharmacological
LNH-84	Pharmacological
)	Pharmacological
comprising	O
three	O
or	O
four	O
courses	O
of	O
doxorubicin	Pharmacological
,	O
75	O
mg/m2	O
;	O
cyclophosphamide	Pharmacological
,	O
1,200	O
mg/m2	O
;	O
vindesine	Pharmacological
,	O
2	O
mg/m2	O
x	O
2	O
;	O
bleomycin	Pharmacological
,	O
10	O
mg	O
x	O
2	O
;	O
and	O
prednisolone	Pharmacological
,	O
60	O
mg/m2	O
x	O
5	O
(	O
ACVB	O
)	O
,	O
consolidation	O
with	O
high-dose	O
methotrexate	Pharmacological
,	O
ifosfamide	Pharmacological
,	O
etoposide	Pharmacological
,	O
asparaginase	Pharmacological
,	O
and	O
cytarabine	Pharmacological
,	O
and	O
a	O
randomized	O
late	O
intensification	O
with	O
two	O
courses	O
of	O
cytarabine	Pharmacological
,	O
cyclophosphamide	Pharmacological
,	O
teniposide	Pharmacological
,	O
bleomycin	Pharmacological
,	O
and	O
prednisone	Pharmacological
(	O
AraCVmB	O
)	O
.	O

Four	O
hundred	O
forty-two	O
patients	O
had	O
intermediate-grade	O
ML	O
,	O
221	O
highgrade	O
ML	O
,	O
and	O
74	O
unclassified	O
ML	O
.	O

Most	O
of	O
the	O
patients	O
had	O
advanced	O
disease	O
:	O
stage	O
IIE	O
(	O
23	O
%	O
)	O
,	O
III	O
(	O
13	O
%	O
)	O
,	O
or	O
IV	O
(	O
47	O
%	O
)	O
;	O
38	O
%	O
disseminated	O
nodes	O
;	O
38	O
%	O
two	O
or	O
more	O
extranodal	O
sites	O
;	O
and	O
41	O
%	O
a	O
tumoral	O
mass	O
greater	O
than	O
10	O
cm	O
.	O

Five	O
hundred	O
fifty-three	O
patients	O
(	O
75	O
%	O
)	O
went	O
into	O
complete	O
remission	O
(	O
CR	O
)	O
,	O
63	O
(	O
9	O
%	O
)	O
into	O
partial	O
remission	O
,	O
62	O
(	O
8	O
%	O
)	O
failed	O
to	O
respond	O
,	O
and	O
59	O
(	O
8	O
%	O
)	O
died	O
during	O
ACVB	O
courses	O
,	O
17	O
of	O
them	O
from	O
progression	O
of	O
the	O
disease	O
.	O

With	O
a	O
median	O
follow-up	O
of	O
23	O
months	O
,	O
the	O
estimated	O
2-year	O
overall	O
survival	O
time	O
to	O
failure	O
(	O
TTF	O
)	O
,	O
and	O
time	O
to	O
relapse	O
(	O
TTR	O
)	O
survival	O
are	O
67	O
%	O
,	O
56	O
%	O
,	O
and	O
67	O
%	O
,	O
respectively	O
.	O

Patients	O
receiving	O
a	O
late	O
intensification	O
had	O
the	O
same	O
relapse	O
rate	O
as	O
the	O
other	O
patients	O
.	O

A	O
persistent	O
fibronecrotic	O
mass	O
was	O
found	O
in	O
150	O
patients	O
(	O
20	O
%	O
)	O
and	O
did	O
not	O
influence	O
the	O
relapse	O
rate	O
.	O

Toxicity	O
was	O
mainly	O
neutropenia	O
and	O
infection	O
during	O
the	O
ACVB	O
courses	O
,	O
with	O
40	O
patients	O
(	O
5	O
%	O
)	O
dying	O
from	O
septic	O
complications	O
while	O
responding	O
to	O
treatment	O
.	O

Fifty-three	O
percent	O
of	O
the	O
patients	O
had	O
a	O
neutropenia	O
less	O
than	O
0.500	O
x	O
10	O
(	O
9	O
)	O
/L	O
,	O
58	O
%	O
fever	O
(	O
6	O
%	O
grade	O
4	O
)	O
,	O
and	O
49	O
%	O
a	O
documented	O
infection	O
(	O
8	O
%	O
grade	O
4	O
)	O
.	O

These	O
results	O
obtained	O
with	O
the	O
LNH-84	O
regimen	O
demonstrate	O
that	O
this	O
therapeutic	O
scheme	O
is	O
an	O
effective	O
treatment	O
for	O
aggressive	O
ML	O
.	O

Randomized	O
trial	O
of	O
tailored	O
skin	O
cancer	O
prevention	O
for	O
children	O
:	O
the	O
Project	O
SCAPE	O
family	O
study	O
.	O

This	O
study	O
evaluated	O
a	O
tailored	Educational
intervention	Educational
to	O
promote	Physical
sun	Physical
protection	Physical
in	O
parents	O
and	O
their	O
children	O
,	O
hypothesizing	O
that	O
the	O
tailored	O
intervention	O
would	O
lead	O
to	O
improved	O
skin	O
cancer	O
prevention	O
behaviors	O
compared	O
to	O
generic	O
materials	O
.	O

Families	O
were	O
recruited	O
through	O
schools	O
and	O
community	O
centers	O
and	O
were	O
included	O
if	O
there	O
was	O
1	O
child	O
in	O
Grades	O
1-3	O
at	O
moderate	O
to	O
high	O
risk	O
for	O
skin	O
cancer	O
.	O

Participants	O
were	O
randomized	O
into	O
one	O
of	O
two	O
intervention	O
groups	O
:	O
a	O
tailored	Educational
intervention	Educational
,	Educational
in	Educational
which	Educational
they	Educational
received	Educational
personalized	Educational
skin	Educational
cancer	Educational
education	Educational
through	Educational
the	Educational
mail	Educational
;	Educational
or	Educational
a	Educational
control	Educational
group	Educational
who	Educational
received	Educational
generic	Educational
skin	Educational
cancer	Educational
information	Educational
materials	Educational
.	Educational

Before	O
and	O
after	O
intervention	O
,	O
parents	O
completed	O
questionnaires	O
about	O
their	O
and	O
their	O
children	O
's	O
skin	O
cancer	O
risk	O
and	O
prevention	O
knowledge	O
and	O
behaviors	O
.	O

Parents	O
also	O
completed	O
4-day	O
sun	O
exposure	O
and	O
protection	O
diaries	O
for	O
their	O
child	O
and	O
themselves	O
.	O

Tailored	O
group	O
participants	O
demonstrated	O
significantly	O
greater	O
positive	O
changes	O
in	O
prevention	O
behavior	O
after	O
the	O
intervention	O
,	O
including	O
children	O
's	O
use	O
of	O
sunscreen	O
,	O
shirts	O
,	O
and	O
hats	O
,	O
and	O
parents	O
'	O
use	O
of	O
shade	O
,	O
and	O
skin	O
examinations	O
.	O

Effect	O
sizes	O
were	O
small	O
and	O
perceived	O
benefits	O
and	O
social	O
norms	O
mediated	O
intervention	O
effects	O
.	O

Findings	O
from	O
this	O
study	O
support	O
the	O
efficacy	O
of	O
focusing	O
tailored	O
communications	O
to	O
families	O
in	O
order	O
to	O
change	O
skin	O
cancer	O
prevention	O
practices	O
in	O
young	O
children	O
.	O

Chemotherapy	O
of	O
large	O
bowel	O
carcinoma	O
--	O
fluorouracil	Pharmacological
(	Pharmacological
FU	Pharmacological
)	Pharmacological
+	O
hydroxyurea	Pharmacological
(	Pharmacological
HU	Pharmacological
)	Pharmacological
vs.	O
methyl-CCNU	Pharmacological
,	O
oncovin	Pharmacological
,	O
fluorouracil	Pharmacological
,	O
and	O
streptozotocin	Pharmacological
(	Pharmacological
MOF-Strep	Pharmacological
)	Pharmacological
.	O

An	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
study	O
.	O

In	O
this	O
prospective	O
randomized	O
study	O
of	O
initial	O
chemotherapy	O
for	O
advanced	O
measurable	O
metastatic	O
large	O
bowel	O
carcinoma	O
,	O
the	O
response	O
rate	O
was	O
6/32	O
(	O
19	O
%	O
)	O
for	O
FU	O
+	O
HU	O
and	O
5/32	O
(	O
16	O
%	O
)	O
for	O
MOF-Strep	O
;	O
the	O
estimated	O
median	O
survival	O
is	O
43	O
weeks	O
for	O
both	O
treatments	O
.	O

Patients	O
who	O
received	O
MOF-Strep	O
experienced	O
substantially	O
greater	O
vomiting	O
and	O
hematologic	O
toxicity	O
than	O
patients	O
who	O
received	O
FU	O
+	O
HU	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

Mechanical	O
efficiency	O
and	O
propulsion	O
technique	O
after	O
7	O
weeks	O
of	O
low-intensity	O
wheelchair	O
training	O
.	O

BACKGROUND	O
To	O
evaluate	O
the	O
effect	O
of	O
a	O
7-week	O
low-intensity	O
hand	O
rim	O
wheelchair	O
training	O
on	O
the	O
submaximal	O
metabolic	O
cost	O
,	O
mechanical	O
efficiency	O
and	O
propulsion	O
technique	O
in	O
able-bodied	O
participants	O
.	O

METHODS	O
Participants	O
were	O
randomly	O
divided	O
over	O
an	O
experimental	O
group	O
(	O
n=14	O
)	O
and	O
a	O
control	O
group	O
(	O
n=7	O
)	O
.	O

The	O
experimental	O
group	O
received	O
7	O
weeks	O
wheelchair	Physical
training	Physical
(	O
3	O
week	O
(	O
-1	O
)	O
,	O
70	O
min	O
)	O
at	O
a	O
low	O
intensity	O
(	O
30	O
%	O
of	O
the	O
heart	O
rate	O
reserve	O
)	O
,	O
whereas	O
the	O
control	Educational
group	O
did	Educational
not	Educational
receive	Educational
training	Educational
.	O

During	O
pre-	O
and	O
post-tests	O
,	O
submaximal	O
exercise	O
was	O
performed	O
on	O
a	O
stationary	O
wheelchair	Physical
ergometer	O
at	O
fixed	O
levels	O
of	O
power	O
output	O
.	O

Mechanical	O
efficiency	O
,	O
oxygen	O
uptake	O
,	O
heart	O
rate	O
,	O
timing	O
parameters	O
and	O
stroke	O
angles	O
were	O
measured	O
.	O

Video	O
recordings	O
were	O
made	O
to	O
determine	O
the	O
stroke	O
pattern	O
.	O

FINDINGS	O
Mechanical	O
efficiency	O
increased	O
and	O
metabolic	O
cost	O
decreased	O
significantly	O
in	O
the	O
experimental	O
group	O
compared	O
to	O
the	O
control	O
group	O
.	O

Push	O
time	O
increased	O
and	O
cycle	O
frequency	O
decreased	O
as	O
a	O
result	O
of	O
training	O
.	O

The	O
stroke	O
angle	O
increased	O
in	O
the	O
experimental	O
group	O
during	O
the	O
training	O
period	O
.	O

The	O
experimental	O
group	O
preferred	O
double-looping	O
over	O
propulsion	O
,	O
while	O
the	O
control	O
group	O
mainly	O
used	O
single-looping	O
over	O
propulsion	O
patterns	O
during	O
the	O
post-test	O
.	O

INTERPRETATION	O
A	O
low-intensity	O
,	O
7-week	O
training	O
protocol	O
has	O
a	O
beneficial	O
effect	O
on	O
the	O
mechanical	O
efficiency	O
and	O
metabolic	O
cost	O
of	O
wheelchair	O
propulsion	O
in	O
able-bodied	O
participants	O
.	O

The	O
improved	O
mechanical	O
efficiency	O
seems	O
to	O
be	O
the	O
result	O
of	O
changes	O
in	O
propulsion	O
technique	O
that	O
were	O
found	O
.	O

Differential	O
effects	O
of	O
amino	O
acid	O
and	O
ketoacid	O
on	O
protein	O
metabolism	O
in	O
humans	O
.	O

We	O
examined	O
the	O
effects	O
of	O
insulin	O
,	O
amino	O
acid	O
(	O
AA	O
)	O
,	O
and	O
branched-chain	O
ketoacid	O
(	O
KA	O
)	O
availability	O
on	O
leucine	O
kinetics	O
in	O
eight	O
healthy	O
volunteers	O
(	O
age	O
=	O
22	O
+/-	O
2	O
y	O
,	O
body	O
mass	O
index	O
=	O
24	O
+/-	O
1	O
kg	O
)	O
by	O
using	O
the	O
euglycemic	Surgical
insulin	Surgical
clamp	Surgical
and	Surgical
[	Surgical
1-14C	Surgical
]	Surgical
leucine	Surgical
turnover	Surgical
techniques	Surgical
.	Surgical

Four	O
experimental	O
conditions	O
were	O
studied	O
:	O
study	O
I	O
,	O
hyperinsulinemia	O
;	O
study	O
II	O
,	O
hyperinsulinemia	O
with	O
maintenance	O
of	O
basal	O
plasma	O
AA	O
and	O
branched-chain	O
KA	O
concentrations	O
;	O
study	O
III	O
,	O
hyperinsulinemia	O
with	O
hyperaminoacidemia	O
and	O
basal	O
plasma	O
branched-chain	O
KA	O
concentrations	O
;	O
and	O
study	O
IV	O
,	O
hyperinsulinemia	O
plus	O
basal	O
plasma	O
AA	O
concentrations	O
and	O
elevated	O
branched-chain	O
KA	O
levels	O
.	O

Basal	O
endogenous	O
leucine	O
flux	O
(	O
ELF	O
)	O
averaged	O
1.20	O
+/-	O
0.05	O
(	O
mumol.kg-1.min-1	O
,	O
mean	O
+/-	O
SE	O
)	O
;	O
basal	O
leucine	O
oxidation	O
(	O
LOX	O
)	O
was	O
0.25	O
+/-	O
0.01	O
;	O
and	O
basal	O
non-oxidative	O
leucine	O
disposal	O
(	O
NOLD	O
)	O
was	O
0.95	O
+/-	O
0.04	O
.	O

ELF	O
significantly	O
decreased	O
in	O
study	O
I	O
(	O
0.77	O
+/-	O
0.06	O
mumol.kg-1.min-1	O
,	O
P	O
<	O
0.01	O
versus	O
basal	O
)	O
.	O

When	O
plasma	O
AA	O
and	O
branched-chain	O
KA	O
were	O
either	O
maintained	O
at	O
their	O
basal	O
levels	O
(	O
study	O
II	O
)	O
or	O
increased	O
above	O
baseline	O
values	O
(	O
studies	O
III	O
and	O
IV	O
)	O
,	O
ELF	O
declined	O
further	O
(	O
0.64	O
+/-	O
0.05	O
,	O
0.66	O
+/-	O
0.02	O
,	O
and	O
0.66	O
+/-	O
0.03	O
mumol.kg-1.min-1	O
,	O
respectively	O
;	O
all	O
Ps	O
<	O
0.01	O
versus	O
basal	O
and	O
P	O
<	O
0.01	O
versus	O
study	O
I	O
)	O
.	O

LOX	O
declined	O
in	O
study	O
I	O
(	O
0.12	O
+/-	O
0.02	O
mumol.kg-1.min-1	O
,	O
P	O
<	O
0.01	O
versus	O
basal	O
)	O
but	O
increased	O
significantly	O
in	O
studies	O
II	O
,	O
III	O
,	O
and	O
IV	O
(	O
0.31	O
+/-	O
0.04	O
,	O
0.37	O
+/-	O
0.03	O
,	O
and	O
0.40	O
+/-	O
0.03	O
mumol.kg-1.min-1	O
,	O
respectively	O
,	O
all	O
Ps	O
<	O
0.01	O
versus	O
basal	O
,	O
P	O
<	O
0.05	O
study	O
IV	O
versus	O
study	O
II	O
,	O
and	O
P	O
<	O
0.05	O
study	O
III	O
versus	O
study	O
II	O
)	O
.	O

NOLD	O
declined	O
in	O
study	O
I	O
(	O
0.65	O
+/-	O
0.05	O
mumol/kg.min	O
,	O
P	O
<	O
0.01	O
versus	O
basal	O
)	O
,	O
whereas	O
neither	O
the	O
maintenance	O
of	O
basal	O
plasma	O
AA/branched-chain	O
KA	O
levels	O
(	O
study	O
II	O
;	O
0.89	O
+/-	O
0.2	O
mumol.kg-1.min-1	O
)	O
nor	O
the	O
elevation	O
of	O
plasma	O
branched-chain	O
KA	O
concentration	O
(	O
study	O
IV	O
;	O
0.96	O
+/-	O
0.1	O
mumol.kg-1.min-1	O
)	O
increased	O
NOLD	O
above	O
baseline	O
level	O
.	O

A	O
stimulation	O
of	O
NOLD	O
was	O
observed	O
only	O
when	O
plasma	O
AA	O
levels	O
were	O
increased	O
(	O
study	O
III	O
;	O
1.23	O
+/-	O
0.03	O
mumol/kg.min	O
,	O
P	O
<	O
0.01	O
versus	O
basal	O
)	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
data	O
do	O
not	O
support	O
the	O
concept	O
of	O
a	O
direct	O
anabolic	O
action	O
of	O
ketoanalogs	O
but	O
do	O
provide	O
additional	O
evidence	O
for	O
the	O
pivotal	O
role	O
of	O
AA	O
availability	O
in	O
the	O
stimulation	O
of	O
whole-body	O
protein	O
synthesis	O
.	O

Effect	O
of	O
patient	O
withdrawal	O
on	O
a	O
study	O
evaluating	O
pharmacist	Other
management	Other
of	Other
hypertension	Other
.	O

STUDY	O
OBJECTIVES	O
To	O
examine	O
potential	O
threats	O
to	O
internal	O
and	O
external	O
study	O
validity	O
caused	O
by	O
differential	O
patient	O
withdrawal	O
from	O
a	O
randomized	O
controlled	O
trial	O
evaluating	O
pharmacist	O
management	O
of	O
hypertension	O
,	O
to	O
compare	O
the	O
characteristics	O
of	O
patients	O
who	O
withdrew	O
with	O
those	O
of	O
patients	O
who	O
completed	O
the	O
study	O
,	O
and	O
to	O
identify	O
characteristics	O
that	O
predispose	O
patients	O
to	O
withdraw	O
from	O
hypertension	O
management	O
.	O

DESIGN	O
Prospective	O
,	O
randomized	O
,	O
comparative	O
study	O
.	O

SETTING	O
Network	O
of	O
primary	O
care	O
clinics	O
.	O

PATIENTS	O
Four	O
hundred	O
sixty-three	O
patients	O
with	O
a	O
diagnosis	O
of	O
hypertension	O
and	O
a	O
last	O
documented	O
systolic	O
blood	O
pressure	O
of	O
160	O
mm	O
Hg	O
or	O
greater	O
and/or	O
diastolic	O
blood	O
pressure	O
of	O
100	O
mm	O
Hg	O
or	O
greater	O
.	O

INTERVENTION	O
Patients	O
were	O
randomly	O
allocated	O
to	O
the	O
pharmacist	Other
intervention	Other
or	O
usual-care	Control
(	Control
control	Control
)	Control
group	Other
.	O

Those	O
in	O
the	O
pharmacist	O
intervention	O
group	O
were	O
collaboratively	O
managed	Other
by	Other
a	Other
primary	Other
care	Other
clinical	Other
pharmacy	Other
specialist	Other
and	Other
their	Other
primary	Other
care	Other
provider	Other
.	O

Patients	O
in	O
the	O
control	O
group	O
received	O
usual	Control
care	Control
from	O
only	O
their	O
primary	Other
care	Other
provider	Other
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
Of	O
the	O
463	O
patients	O
,	O
191	O
(	O
41	O
%	O
)	O
withdrew	O
from	O
the	O
study	O
after	O
randomization	O
and	O
272	O
(	O
59	O
%	O
)	O
completed	O
the	O
study	O
.	O

Patients	O
who	O
withdrew	O
from	O
the	O
pharmacist	Other
intervention	Other
group	O
were	O
similar	O
to	O
patients	O
who	O
withdrew	O
from	O
the	O
usual-care	O
group	O
with	O
respect	O
to	O
age	O
,	O
sex	O
,	O
insurance	O
status	O
,	O
and	O
chronic	O
conditions	O
.	O

Patients	O
who	O
smoked	O
or	O
had	O
commercial	O
insurance	O
were	O
more	O
likely	O
to	O
withdraw	O
from	O
the	O
study	O
than	O
the	O
other	O
participants	O
.	O

However	O
,	O
multivariate	O
analysis	O
of	O
all	O
variables	O
,	O
when	O
adjusted	O
for	O
the	O
effect	O
of	O
the	O
intervention	O
,	O
revealed	O
that	O
insurance	O
status	O
was	O
the	O
only	O
variable	O
associated	O
with	O
a	O
heightened	O
probability	O
of	O
withdrawal	O
(	O
p=0.002	O
)	O
.	O

CONCLUSION	O
Although	O
this	O
study	O
had	O
a	O
high	O
withdrawal	O
rate	O
,	O
between-group	O
patient	O
characteristics	O
remained	O
balanced	O
.	O

Therefore	O
,	O
internal	O
validity	O
was	O
preserved	O
,	O
and	O
outcomes	O
from	O
the	O
study	O
groups	O
could	O
be	O
reliably	O
compared	O
.	O

A	O
lack	O
of	O
significant	O
differences	O
between	O
patients	O
who	O
withdrew	O
versus	O
those	O
who	O
completed	O
,	O
with	O
the	O
exception	O
of	O
insurance	O
status	O
,	O
suggests	O
that	O
external	O
validity	O
was	O
not	O
jeopardized	O
.	O

Effectiveness	O
and	O
safety	O
of	O
the	O
Levitan	Physical
FPS	Physical
Scope?	Physical
for	O
tracheal	O
intubation	O
under	O
general	O
anesthesia	O
with	O
a	O
simulated	O
difficult	O
airway	O
.	O

PURPOSE	O
Studies	O
show	O
that	O
the	O
Levitan	Physical
FPS	Physical
(	Physical
first	Physical
pass	Physical
success	Physical
)	Physical
Scope?	Physical
(	Physical
LFS	Physical
)	Physical
is	O
analogous	O
to	O
a	O
bougie	O
in	O
simulated	O
difficult	O
airways	O
with	O
comparable	O
tracheal	O
intubation	O
success	O
rates	O
.	O

In	O
this	O
study	O
,	O
the	O
efficacy	O
and	O
safety	O
of	O
tracheal	O
intubation	O
with	O
the	O
LFS	O
was	O
compared	O
with	O
that	O
of	O
the	O
Macintosh	O
laryngoscope	O
utilizing	O
manual	O
in-line	O
stabilization	O
(	O
MILS	O
)	O
to	O
simulate	O
difficult	O
airways	O
.	O

METHODS	O
Ninety-four	O
subjects	O
successfully	O
completed	O
the	O
trial	O
.	O

Manual	O
in-line	O
stabilization	O
of	O
the	O
cervical	O
spine	O
was	O
applied	O
and	O
the	O
initial	O
laryngoscopy	O
was	O
performed	O
using	O
either	O
the	O
Macintosh	Physical
or	O
the	O
LFS	Physical
in	O
conjunction	O
with	O
the	O
Macintosh	O
.	O

Following	O
the	O
initial	O
grading	O
,	O
a	O
second	O
laryngoscopy	O
was	O
repeated	O
using	O
the	O
second	O
randomized	O
technique	O
.	O

Cormack-Lehane	O
grades	O
,	O
percentage	O
of	O
glottic	O
opening	O
(	O
POGO	O
)	O
scores	O
,	O
time	O
to	O
intubate	O
,	O
number	O
of	O
intubation	O
attempts	O
,	O
and	O
the	O
use	O
of	O
alternate	O
techniques	O
were	O
recorded	O
.	O

The	O
anesthesiologist	O
rated	O
the	O
subjective	O
difficulty	O
in	O
using	O
each	O
technique	O
with	O
a	O
numeric	O
rating	O
scale	O
and	O
a	O
visual	O
rating	O
scale	O
.	O

RESULTS	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
primary	O
outcome	O
good	O
laryngoscopic	O
views	O
(	O
Cormack-Lehane	O
grade	O
1	O
and	O
2	O
)	O
compared	O
with	O
poor	O
laryngoscopic	O
views	O
(	O
Cormack-Lehane	O
grade	O
3	O
and	O
4	O
)	O
between	O
the	O
LFS	O
and	O
the	O
Macintosh	O
.	O

There	O
were	O
higher	O
POGO	O
scores	O
with	O
the	O
LFS	O
compared	O
with	O
the	O
Macintosh	O
(	O
80	O
%	O
vs	O
20	O
%	O
,	O
respectively	O
;	O
P	O
<	O
0.0001	O
)	O
,	O
but	O
this	O
did	O
not	O
translate	O
to	O
easier	O
intubations	O
,	O
as	O
documented	O
by	O
the	O
need	O
for	O
an	O
alternate	O
intubation	O
technique	O
or	O
time	O
to	O
intubate	O
(	O
<	O
30	O
and	O
<	O
60	O
sec	O
,	O
respectively	O
)	O
.	O

The	O
incidence	O
of	O
mucosal	O
trauma	O
,	O
sore	O
throat	O
,	O
and	O
hemodynamic	O
responses	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
techniques	O
.	O

CONCLUSION	O
The	O
LFS	O
in	O
conjunction	O
with	O
the	O
Macintosh	Physical
laryngoscope	O
does	O
not	O
improve	O
the	O
efficacy	O
or	O
safety	O
of	O
tracheal	O
intubation	O
in	O
a	O
simulated	O
difficult	O
airway	O
.	O

Enhanced	Educational
small	Educational
group	Educational
instruction	Educational
using	Educational
choral	Educational
responding	Educational
and	Educational
student	Educational
interaction	Educational
for	O
children	O
with	O
autism	O
and	O
developmental	O
disabilities	O
.	O

The	O
use	O
of	O
effective	Educational
instructional	Educational
strategies	Educational
in	O
small	O
groups	O
was	O
investigated	O
to	O
determine	O
learning	O
effects	O
for	O
24	O
elementary	O
age	O
students	O
with	O
autism	O
and	O
developmental	O
disabilities	O
.	O

Effective	O
strategies	O
included	O
(	O
a	O
)	O
the	Educational
use	Educational
of	Educational
choral	Educational
responding	Educational
;	Educational
(	O
b	O
)	O
the	Educational
use	Educational
of	Educational
student-to-student	Educational
responding	Educational
;	Educational
(	O
c	O
)	O
the	Educational
rotation	Educational
of	Educational
materials	Educational
every	Educational
5	Educational
minutes	Educational
during	Educational
the	Educational
30-minute	Educational
group	Educational
while	Educational
teaching	Educational
2	Educational
to	Educational
3	Educational
concepts	Educational
;	Educational
and	Educational
(	O
d	O
)	O
the	Educational
use	Educational
of	Educational
random	Educational
,	Educational
unpredictable	Educational
trials	Educational
for	Educational
student	Educational
responding	Educational
.	Educational

Thirty-minute	O
language	O
groups	O
were	O
targeted	O
to	O
teach	O
receptive	O
and	O
expressive	O
skills	O
using	O
pictures	O
and	O
common	O
objects	O
across	O
five	O
categories	O
(	O
e.g.	O
,	O
household	O
items	O
,	O
foods	O
)	O
.	O

Results	O
showed	O
increased	O
opportunities	O
to	O
respond	O
,	O
increased	O
levels	O
of	O
responding	O
and	O
academic	O
engagement	O
,	O
higher	O
gains	O
on	O
weekly	O
criterion-referenced	O
pre-	O
and	O
posttests	O
,	O
and	O
decreased	O
passive	O
and	O
inappropriate	O
student	O
behavior	O
during	O
interventions	O
.	O

Immunological	O
changes	O
after	O
minimally	Surgical
invasive	Surgical
or	O
conventional	Surgical
esophageal	Surgical
resection	Surgical
for	O
cancer	O
:	O
a	O
randomized	O
trial	O
.	O

BACKGROUND	O
This	O
study	O
was	O
performed	O
as	O
a	O
substudy	O
analysis	O
of	O
a	O
randomized	O
trial	O
comparing	O
conventional	Surgical
open	Surgical
esophagectomy	Surgical
[	O
open	O
surgical	O
technique	O
(	O
OE	O
)	O
]	O
by	O
thoracotomy	Surgical
and	O
laparotomy	Surgical
with	O
minimally	Surgical
invasive	Surgical
esophagectomy	Surgical
[	O
minimally	O
invasive	O
procedure	O
(	O
MIE	O
)	O
]	O
by	O
thoracoscopy	Surgical
and	O
laparoscopy	Surgical
.	O

This	O
additional	O
analysis	O
focuses	O
on	O
the	O
immunological	O
changes	O
and	O
surgical	O
stress	O
response	O
in	O
these	O
two	O
randomized	O
groups	O
of	O
a	O
single	O
center	O
.	O

METHODS	O
Patients	O
with	O
a	O
resectable	O
esophageal	O
cancer	O
were	O
randomized	O
to	O
OE	O
(	O
n	O
=	O
13	O
)	O
or	O
MIE	O
(	O
n	O
=	O
14	O
)	O
.	O

All	O
patients	O
received	O
neoadjuvant	Pharmacological
chemoradiotherapy	Pharmacological
.	Pharmacological

The	O
immunological	O
response	O
was	O
measured	O
by	O
means	O
of	O
leukocyte	O
counts	O
,	O
HLA-DR	O
expression	O
on	O
monocytes	O
,	O
the	O
acute-phase	O
response	O
by	O
means	O
of	O
C-reactive	O
protein	O
(	O
CRP	O
)	O
,	O
interleukin-6	O
(	O
IL-6	O
)	O
,	O
and	O
interleukin-8	O
(	O
IL-8	O
)	O
,	O
and	O
the	O
stress	O
response	O
was	O
measured	O
by	O
cortisol	O
,	O
growth	O
hormone	O
,	O
and	O
prolactin	O
.	O

All	O
parameters	O
were	O
determined	O
at	O
baseline	O
(	O
preoperatively	O
)	O
and	O
24	O
,	O
72	O
,	O
96	O
,	O
and	O
168	O
h	O
postoperatively	O
.	O

RESULTS	O
Significant	O
differences	O
between	O
the	O
two	O
groups	O
were	O
seen	O
in	O
favor	O
of	O
the	O
MIE	O
group	O
with	O
regard	O
to	O
leukocyte	O
counts	O
,	O
IL-8	O
,	O
and	O
prolactin	O
at	O
168	O
h	O
(	O
1	O
week	O
)	O
postoperatively	O
.	O

For	O
HLA-DR	O
expression	O
,	O
IL-6	O
,	O
and	O
CRP	O
levels	O
,	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
,	O
although	O
there	O
was	O
a	O
clear	O
rise	O
in	O
levels	O
upon	O
operation	O
in	O
both	O
groups	O
.	O

CONCLUSION	O
In	O
this	O
substudy	O
of	O
a	O
randomized	O
trial	O
comparing	O
minimally	O
invasive	O
and	O
conventional	O
open	O
esophagectomies	O
for	O
cancer	O
,	O
significantly	O
better	O
preserved	O
leukocyte	O
counts	O
and	O
IL-8	O
levels	O
were	O
observed	O
in	O
the	O
MIE	O
group	O
compared	O
to	O
the	O
open	O
group	O
.	O

Both	O
findings	O
can	O
be	O
related	O
to	O
fewer	O
respiratory	O
infections	O
found	O
postoperatively	O
in	O
the	O
MIE	O
group	O
.	O

Moreover	O
,	O
significant	O
differences	O
in	O
the	O
prolactin	O
levels	O
at	O
168	O
h	O
after	O
surgery	O
imply	O
that	O
the	O
stress	O
response	O
is	O
better	O
preserved	O
in	O
the	O
MIE	Surgical
group	O
.	O

These	O
findings	O
indicate	O
that	O
less	O
surgical	O
trauma	O
could	O
lead	O
to	O
better	O
preserved	O
acute-phase	O
and	O
stress	O
responses	O
and	O
fewer	O
clinical	O
manifestations	O
of	O
respiratory	O
infections	O
.	O

Treatment	O
with	O
metformin	Pharmacological
of	O
non-diabetic	O
men	O
with	O
hypertension	O
,	O
hypertriglyceridaemia	O
and	O
central	O
fat	O
distribution	O
:	O
the	O
BIGPRO	O
1.2	O
trial	O
.	O

BACKGROUND	O
In	O
the	O
BIGPRO	O
1	O
trial	O
,	O
one	O
year	O
of	O
treatment	O
with	O
metformin	Pharmacological
in	O
non-diabetic	O
obese	O
subjects	O
with	O
a	O
central	O
fat	O
distribution	O
had	O
no	O
significant	O
effect	O
on	O
fasting	O
plasma	O
triglyceride	O
concentration	O
or	O
on	O
blood	O
pressure	O
despite	O
a	O
decrease	O
in	O
weight	O
,	O
fasting	O
plasma	O
insulin	O
and	O
glucose	O
concentrations	O
.	O

To	O
re-evaluate	O
the	O
effect	O
of	O
metformin	Pharmacological
on	O
fasting	O
triglyceride	O
concentration	O
and	O
on	O
blood	O
pressure	O
,	O
the	O
BIGPRO	O
1.2	O
trial	O
included	O
non-diabetic	O
men	O
(	O
n=168	O
)	O
with	O
a	O
fasting	O
plasma	O
triglyceride	O
concentration	O
>	O
or	O
=1.7	O
and	O
<	O
or	O
=6.5	O
mmol/l	O
,	O
high	O
blood	O
pressure	O
(	O
systolic	O
>	O
or	O
=140	O
and	O
<	O
or	O
=180	O
and/or	O
diastolic	O
>	O
or	O
=90	O
and	O
<	O
or	O
=105	O
mmHg	O
,	O
or	O
treatment	O
for	O
hypertension	O
)	O
and	O
a	O
waist-to-hip	O
ratio	O
>	O
or	O
=0.95	O
.	O

METHODS	O
A	O
randomised	O
double-blind	O
trial	O
comparing	O
metformin	Pharmacological
treatment	O
(	O
850	O
mg	O
bid	O
)	O
with	O
placebo	Control
.	O

RESULTS	O
Metformin	Pharmacological
had	O
no	O
significant	O
effect	O
either	O
on	O
blood	O
pressure	O
or	O
plasma	O
triglyceride	O
concentration	O
.	O

In	O
comparison	O
with	O
the	O
placebo	Control
group	O
,	O
fasting	O
plasma	O
insulin	O
(	O
p	O
<	O
0.04	O
)	O
,	O
total	O
cholesterol	O
(	O
p	O
<	O
0.05	O
)	O
and	O
Apo	O
B	O
(	O
p	O
<	O
0.008	O
)	O
concentrations	O
decreased	O
more	O
in	O
the	O
metformin	O
group	O
in	O
the	O
BIGPRO	O
1	O
.	O

2	O
trial	O
,	O
confirming	O
most	O
of	O
the	O
previous	O
results	O
of	O
the	O
BIGPRO	O
1	O
trial	O
.	O

Tissue	O
plasminogen	O
activator	O
antigen	O
concentration	O
decreased	O
significantly	O
(	O
p	O
<	O
0.01	O
)	O
only	O
in	O
the	O
metformin	Pharmacological
group	O
,	O
but	O
this	O
was	O
not	O
significantly	O
different	O
from	O
the	O
placebo	Control
group	O
(	O
p	O
<	O
0.12	O
)	O
;	O
further	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
change	O
in	O
plasminogen	O
activator	O
inhibitor	O
1	O
.	O

CONCLUSIONS	O
The	O
consistency	O
of	O
the	O
two	O
BIGPRO	O
trials	O
supports	O
the	O
conclusion	O
that	O
metformin	Pharmacological
affects	O
several	O
cardiovascular	O
risk	O
factors	O
favourably	O
in	O
non-diabetic	O
subjects	O
with	O
a	O
central	O
fat	O
distribution	O
.	O

Psychoeducational	Educational
group	Educational
intervention	Educational
for	O
wives	O
of	O
men	O
with	O
prostate	O
cancer	O
.	O

OBJECTIVE	O
The	O
effects	O
of	O
a	O
6-week	O
psychoeducational	Educational
group	Educational
intervention	Educational
on	O
the	O
distress	O
,	O
coping	O
,	O
personal	O
growth	O
,	O
and	O
marital	O
communication	O
of	O
wives	O
of	O
men	O
diagnosed	O
with	O
prostate	O
cancer	O
were	O
evaluated	O
using	O
a	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
Sixty	O
wives	O
completed	O
measures	O
prior	O
to	O
random	O
assignment	O
to	O
either	O
the	O
psychoeducational	Control
group	Control
intervention	Control
or	O
a	O
no-treatment	Control
control	Control
group	Control
,	O
and	O
1	O
month	O
after	O
completion	O
of	O
the	O
group	O
.	O

RESULTS	O
No	O
differences	O
with	O
regard	O
to	O
wives	O
'	O
general	O
distress	O
or	O
cancer-specific	O
distress	O
were	O
noted	O
.	O

In	O
comparison	O
with	O
the	O
control	O
group	O
,	O
participants	O
receiving	O
the	O
intervention	O
perceived	O
that	O
having	O
a	O
spouse	O
with	O
prostate	O
cancer	O
had	O
made	O
positive	O
contributions	O
to	O
their	O
lives	O
,	O
reported	O
gains	O
in	O
the	O
use	O
of	O
positive	O
reappraisal	O
coping	O
and	O
reductions	O
in	O
denial	O
coping	O
.	O

CONCLUSION	O
Although	O
the	O
psychoeducational	Educational
intervention	Educational
did	O
not	O
result	O
in	O
changes	O
in	O
psychological	O
distress	O
,	O
improvements	O
in	O
adaptive	O
coping	O
and	O
indicators	O
of	O
psychological	O
growth	O
were	O
found	O
.	O

The	O
utility	O
of	O
group	O
interventions	O
for	O
spouses	O
of	O
men	O
with	O
prostate	O
cancer	O
is	O
discussed	O
.	O

Clinically	O
relevant	O
improvement	O
of	O
recurrence-free	O
survival	O
with	O
5-aminolevulinic	Pharmacological
acid	Pharmacological
induced	O
fluorescence	O
diagnosis	O
in	O
patients	O
with	O
superficial	O
bladder	O
tumors	O
.	O

PURPOSES	O
Fluorescence	O
diagnosis	O
induced	O
by	O
5-aminolevulinic	Pharmacological
acid	Pharmacological
enables	O
more	O
thorough	O
transurethral	O
resection	O
of	O
superficial	O
bladder	O
carcinoma	O
compared	O
with	O
conventional	O
white	O
light	O
.	O

We	O
performed	O
a	O
prospective	O
,	O
single	O
institution	O
,	O
randomized	O
trial	O
to	O
investigate	O
whether	O
the	O
residual	O
tumor	O
rate	O
and	O
long-term	O
tumor	O
recurrence	O
can	O
be	O
decreased	O
by	O
fluorescence	O
diagnosis	O
.	O

MATERIALS	O
AND	O
METHODS	O
A	O
total	O
of	O
301	O
patients	O
underwent	O
transurethral	Surgical
resection	Surgical
of	O
bladder	O
tumors	O
with	O
white	O
light	O
or	O
fluorescence	O
diagnosis	O
.	O

Transurethral	Surgical
resection	Surgical
was	O
repeated	O
5	O
to	O
6	O
weeks	O
later	O
to	O
evaluate	O
the	O
residual	O
tumor	O
rate	O
.	O

To	O
determine	O
recurrence-free	O
survival	O
patient	O
followup	O
was	O
performed	O
every	O
3	O
months	O
by	O
white	O
light	O
cystoscopy	O
and	O
urine	O
cytology	O
.	O

Recurrence-free	O
survival	O
was	O
analyzed	O
via	O
Kaplan-Meier	O
methods	O
and	O
multivariable	O
Cox	O
regression	O
analysis	O
.	O

RESULTS	O
A	O
total	O
of	O
191	O
patients	O
with	O
superficial	O
bladder	O
carcinoma	O
were	O
available	O
for	O
efficacy	O
analysis	O
.	O

The	O
residual	O
tumor	O
rate	O
was	O
25.2	O
%	O
in	O
the	O
white	O
light	O
arm	O
versus	O
4.5	O
%	O
in	O
the	O
fluorescence	O
diagnosis	O
arm	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

Median	O
followup	O
in	O
the	O
white	O
light	O
arm	O
in	O
103	O
cases	O
was	O
21.2	O
months	O
(	O
range	O
4	O
to	O
40	O
)	O
compared	O
with	O
20.5	O
(	O
range	O
3	O
to	O
40	O
)	O
in	O
the	O
88	O
in	O
the	O
fluorescence	O
diagnosis	O
arm	O
.	O

Recurrence-free	O
survival	O
in	O
the	O
fluorescence	O
diagnosis	O
group	O
was	O
89.6	O
%	O
after	O
12	O
and	O
24	O
months	O
compared	O
with	O
73.8	O
%	O
and	O
65.9	O
%	O
,	O
respectively	O
,	O
in	O
the	O
white	O
light	O
group	O
(	O
p	O
=	O
0.004	O
)	O
.	O

This	O
superiority	O
proved	O
to	O
be	O
independent	O
of	O
risk	O
group	O
.	O

The	O
adjusted	O
hazard	O
ratio	O
of	O
fluorescence	O
diagnosis	O
versus	O
white	O
light	O
transurethral	O
resection	O
was	O
0.33	O
(	O
95	O
%	O
confidence	O
interval	O
0.16	O
to	O
0.67	O
)	O
.	O

CONCLUSIONS	O
Fluorescence	O
diagnosis	O
is	O
significantly	O
superior	O
to	O
conventional	O
white	O
light	O
transurethral	O
resection	O
with	O
respect	O
to	O
the	O
residual	O
tumor	O
rate	O
and	O
recurrence-free	O
survival	O
.	O

The	O
differences	O
in	O
recurrence-free	O
survival	O
imply	O
that	O
fluorescence	O
diagnosis	O
is	O
a	O
clinically	O
relevant	O
procedure	O
for	O
decreasing	O
the	O
number	O
of	O
tumor	O
recurrences	O
.	O

The	O
relationship	O
between	O
repetitive	O
behaviors	O
and	O
growth	O
hormone	O
response	O
to	O
sumatriptan	Pharmacological
challenge	O
in	O
adult	O
autistic	O
disorder	O
.	O

Autism	O
is	O
heterogeneous	O
with	O
respect	O
to	O
clinical	O
symptoms	O
and	O
etiology	O
.	O

To	O
sort	O
out	O
this	O
heterogeneity	O
in	O
autism	O
,	O
we	O
investigated	O
whether	O
specific	O
neurobiological	O
markers	O
vary	O
in	O
parallel	O
to	O
core	O
symptomatology	O
.	O

Specifically	O
,	O
we	O
assessed	O
growth	O
hormone	O
response	O
to	O
the	O
5-HT	Pharmacological
1d	Pharmacological
agonist	Pharmacological
,	Pharmacological
sumatriptan	Pharmacological
,	O
and	O
linked	O
this	O
measure	O
of	O
serotonergic	O
function	O
to	O
the	O
severity	O
of	O
repetitive	O
behaviors	O
in	O
adult	O
autistic	O
patients	O
.	O

Eleven	O
adult	O
patients	O
with	O
autism	O
or	O
Asperger	O
's	O
disorder	O
were	O
randomized	O
to	O
single	O
dose	O
sumatriptan	Pharmacological
(	O
6	O
mg	O
SQ	O
)	O
and	O
placebo	Control
challenges	O
,	O
separated	O
by	O
a	O
one-week	O
interval	O
.	O

In	O
adult	O
autistic	O
disorders	O
,	O
severity	O
of	O
repetitive	O
behaviors	O
at	O
baseline	O
,	O
as	O
measured	O
by	O
YBOCS-compulsion	O
score	O
,	O
significantly	O
positively	O
correlated	O
with	O
both	O
peak	O
delta	O
growth	O
hormone	O
response	O
and	O
area	O
under	O
the	O
curve	O
growth	O
hormone	O
response	O
to	O
sumatriptan	Pharmacological
.	Pharmacological

Thus	O
,	O
the	O
severity	O
of	O
a	O
specific	O
behavioral	O
dimension	O
in	O
autism	O
(	O
repetitive	O
behaviors	O
)	O
parallels	O
the	O
sensitivity	O
of	O
the	O
5-HT	Pharmacological
1d	Pharmacological
receptor	Pharmacological
,	O
as	O
manifest	O
by	O
sumatriptan	Pharmacological
elicited	O
GH	O
response	O
.	O

Anxiety	O
sensitivity	O
as	O
an	O
incremental	O
predictor	O
of	O
later	O
anxiety	O
symptoms	O
and	O
syndromes	O
.	O

Although	O
anxiety	O
sensitivity	O
(	O
AS	O
)	O
has	O
been	O
shown	O
to	O
predict	O
anxiety	O
symptoms	O
and	O
panic	O
,	O
this	O
literature	O
is	O
limited	O
in	O
regard	O
to	O
evaluating	O
AS	O
as	O
an	O
incremental	O
predictor	O
of	O
anxiety	Psychological
psychopathology	Psychological
relative	O
to	O
other	O
established	O
risk	O
factors	O
including	O
sex	O
and	O
negative	O
affect	O
.	O

The	O
present	O
report	O
prospectively	O
evaluated	O
whether	O
AS	O
was	O
predictive	O
of	O
later	O
changes	O
in	O
anxiety	O
symptoms	O
after	O
controlling	Other
for	Other
potential	Other
confounding	Other
factors	Other
.	Other

Consistent	O
with	O
hypothesis	O
,	O
AS	O
was	O
found	O
to	O
be	O
a	O
significant	O
,	O
incremental	O
predictor	O
of	O
anxiety	O
symptoms	O
over	O
time	O
,	O
even	O
after	O
controlling	O
for	O
sex	O
and	O
negative	O
affectivity	O
.	O

These	O
data	O
provide	O
novel	O
evidence	O
for	O
the	O
unique	O
association	O
between	O
AS	O
of	O
the	O
development	O
of	O
anxiety	O
symptoms	O
.	O

A	O
double-blind	O
randomized	O
clinical	O
evaluation	O
of	O
enamel	Pharmacological
matrix	Pharmacological
derivative	Pharmacological
proteins	Pharmacological
for	O
the	O
treatment	O
of	O
proximal	O
class-II	O
furcation	O
involvements	O
.	O

OBJECTIVE	O
The	O
aim	O
of	O
the	O
present	O
randomized	O
,	O
double-blind	O
study	O
was	O
to	O
evaluate	O
the	O
clinical	O
response	O
of	O
proximal	O
furcations	O
treated	O
with	O
enamel	Pharmacological
matrix	Pharmacological
derivative	Pharmacological
proteins	Pharmacological
(	Pharmacological
EMD	Pharmacological
)	Pharmacological
.	Pharmacological

MATERIAL	O
AND	O
METHODS	O
Fifteen	O
patients	O
,	O
each	O
with	O
a	O
pair	O
of	O
contralateral	O
class-II	O
proximal	O
furcation	O
involvements	O
,	O
presenting	O
probing	O
depths	O
(	O
PDs	O
)	O
>	O
/=5	O
mm	O
and	O
bleeding	O
on	O
probing	O
(	O
BOP	O
)	O
were	O
selected	O
.	O

The	O
patients	O
were	O
randomly	O
assigned	O
to	O
:	O
control	Control
group	Control
(	O
n=15	O
)	O
-	O
open	Control
flap	Control
debridement	Control
(	Control
OFD	Control
)	Control
+24	Control
%	Control
ethylenediaminetetraacetic	Control
acid	Control
(	Control
EDTA	Control
)	Control
conditioning	Control
;	Pharmacological
test	O
group	O
(	O
n=15	O
)	O
-	O
OFD+24	Pharmacological
%	Pharmacological
EDTA	Pharmacological
conditioning+EMD	Pharmacological
application	Pharmacological
.	Pharmacological

Plaque	O
index	O
(	O
PI	O
)	O
,	O
BOP	O
,	O
PD	O
,	O
gingival	O
margin	O
position	O
(	O
GMP	O
)	O
,	O
relative	O
vertical	O
and	O
horizontal	O
clinical	O
attachment	O
level	O
(	O
RVCAL	O
and	O
RHCAL	O
)	O
,	O
vertical	O
and	O
horizontal	O
bone	O
level	O
(	O
VBL	O
and	O
HBL	O
)	O
and	O
furcation	O
closure	O
were	O
evaluated	O
immediately	O
before	O
and	O
2	O
,	O
4	O
and	O
6	O
months	O
after	O
the	O
surgeries	O
.	O

RESULTS	O
At	O
6	O
months	O
,	O
the	O
RVCAL	O
gains	O
of	O
the	O
control	O
and	O
test	O
group	O
were	O
0.39	O
+/-	O
1.00	O
and	O
0.54	O
+/-	O
0.95	O
mm	O
,	O
while	O
the	O
RHCAL	O
gains	O
were	O
1.21	O
+/-	O
2.28	O
and	O
1.36	O
+/-	O
1.26	O
mm	O
(	O
p	O
>	O
0.05	O
)	O
.	O

The	O
VBL	O
and	O
HBL	O
gains	O
of	O
the	O
control	O
group	O
were	O
1.04	O
+/-	O
1.12	O
and	O
1.00	O
+/-	O
1.79	O
mm	O
,	O
and	O
0.82	O
+/-	O
1.82	O
and	O
1.17	O
+/-	O
1.38	O
mm	O
for	O
the	O
test	O
group	O
(	O
p	O
>	O
0.05	O
)	O
.	O

In	O
addition	O
,	O
a	O
statistical	O
difference	O
was	O
observed	O
in	O
the	O
number	O
of	O
the	O
remaining	O
class-II	O
furcations	O
between	O
the	O
test	O
and	O
control	O
groups	O
(	O
p	O
<	O
0.05	O
)	O
in	O
this	O
period	O
.	O

CONCLUSION	O
It	O
may	O
be	O
concluded	O
that	O
the	O
use	O
of	O
EMD	Pharmacological
in	O
proximal	O
furcations	O
did	O
not	O
promote	O
a	O
superior	O
reduction	O
in	O
PD	O
or	O
a	O
gain	O
in	O
clinical	O
and	O
osseous	O
attachment	O
levels	O
,	O
but	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
class-II	O
to	O
class-I	O
furcation	O
conversion	O
.	O

Psychosocial	Psychological
nursing	Psychological
therapy	Psychological
following	O
sudden	O
cardiac	O
arrest	O
:	O
impact	O
on	O
two-year	O
survival	O
.	O

BACKGROUND	O
Although	O
psychosocial	Psychological
therapy	Psychological
has	O
been	O
shown	O
to	O
reduce	O
mortality	O
after	O
myocardial	O
infarction	O
,	O
it	O
is	O
unknown	O
whether	O
the	O
benefits	O
of	O
psychosocial	Psychological
therapy	Psychological
on	O
mortality	O
reduction	O
extend	O
to	O
out-of-hospital	O
sudden	O
cardiac	O
arrest	O
,	O
a	O
main	O
cause	O
of	O
cardiovascular	O
mortality	O
.	O

OBJECTIVE	O
Describe	O
efficacy	O
of	O
psychosocial	Psychological
therapy	Psychological
on	O
two-year	O
cardiovascular	O
mortality	O
in	O
sudden	O
cardiac	O
arrest	O
survivors	O
.	O

METHOD	O
Survivors	O
of	O
out-of-hospital	O
ventricular	O
fibrillation	O
or	O
asystole	O
(	O
N	O
=	O
129	O
)	O
,	O
documented	O
by	O
electrocardiograms	O
from	O
registries	O
of	O
a	O
citywide	O
Medic	O
One	O
unit	O
and	O
two	O
countywide	O
emergency	O
units	O
,	O
were	O
randomized	O
into	O
a	O
two	O
group	O
,	O
experimental	O
,	O
longitudinal	O
design	O
.	O

The	O
intervention	O
consisted	O
of	O
11	O
individual	O
sessions	O
,	O
implementing	O
three	O
components	O
:	O
physiologic	O
relaxation	O
with	O
biofeedback	O
training	O
focused	O
on	O
altering	O
autonomic	O
tone	O
;	O
cognitive	Psychological
behavioral	Psychological
therapy	Psychological
aimed	O
at	O
self-management	O
and	O
coping	O
strategies	O
for	O
depression	O
,	O
anxiety	O
,	O
and	O
anger	O
;	O
and	O
cardiovascular	O
health	O
education	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
cardiovascular	O
mortality	O
.	O

RESULTS	O
Risk	O
of	O
cardiovascular	O
death	O
was	O
significantly	O
reduced	O
86	O
%	O
by	O
psychosocial	O
therapy	O
,	O
p	O
=	O
.03	O
.	O

Six	O
of	O
the	O
seven	O
cardiovascular	O
deaths	O
in	O
the	O
control	O
group	O
were	O
caused	O
by	O
ventricular	O
arrhythmias	O
.	O

The	O
cardiovascular	O
death	O
in	O
the	O
therapy	O
group	O
was	O
due	O
to	O
stroke	O
.	O

Controlling	O
for	O
depression	O
,	O
previous	O
myocardial	O
infarction	O
,	O
low	O
ejection	O
fraction	O
,	O
decreased	O
heart	O
rate	O
variability	O
,	O
and	O
ventricular	O
ectopic	O
beats	O
had	O
little	O
impact	O
on	O
estimated	O
treatment	O
effect	O
.	O

The	O
risk	O
of	O
all-cause	O
mortality	O
was	O
reduced	O
by	O
62	O
%	O
in	O
the	O
therapy	O
group	O
,	O
p	O
=	O
.13	O
.	O

There	O
were	O
a	O
total	O
of	O
three	O
deaths	O
in	O
the	O
therapy	O
group	O
and	O
eight	O
deaths	O
in	O
the	O
control	Control
group	O
.	O

CONCLUSIONS	O
Psychosocial	Psychological
therapy	Psychological
significantly	O
reduced	O
the	O
risk	O
of	O
cardiovascular	O
death	O
in	O
sudden	O
cardiac	O
arrest	O
survivors	O
.	O

